=== МЕТАДАННЫЕ ===
{
  "original_filename": "eurheartj_40_2_87.pdf",
  "converted_date": "2026-01-31T14:51:08.960033",
  "file_size_bytes": 5439132,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/eurheartj_40_2_87.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC/EACTS GUIDELINES
EuropeanHeartJournal(2019)40,87–165
doi:10.1093/eurheartj/ehy394
2018 ESC/EACTS Guidelines on myocardial
revascularization
The Task Force on myocardial revascularization of the European
Society of Cardiology (ESC) and European Association for
Cardio-Thoracic Surgery (EACTS)
Developed with the special contribution of the European
Association for Percutaneous Cardiovascular Interventions (EAPCI)
Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson)
(Germany), Miguel Sousa-Uva*1 (EACTS Chairperson) (Portugal), Anders Ahlsson1
(Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto1
(UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk1
(Germany), Stuart J. Head1 (The Netherlands), Peter Ju¨ni (Canada),
Adnan Kastrati (Germany), Akos Koller (Hungary), Steen D. Kristensen (Denmark),
Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferovi(cid:2)c (Serbia),
Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker
(Switzerland), Rashmi Yadav1 (UK), Michael O. Zembala1 (Poland)
DocumentReviewers:WilliamWijns(ESCReviewCo-ordinator)(Ireland),DavidGlineur1(EACTSReview
Co-ordinator)(Canada),VictorAboyans(France),StephanAchenbach(Germany),StefanAgewall
(Norway),FelicitaAndreotti(Italy),EmanueleBarbato(Italy),AndreasBaumbach(UK),JamesBrophy
(Canada),He´ctorBueno(Spain),PatrickA.Calvert(UK),DavideCapodanno(Italy),PirozeM.Davierwala1
*Correspondingauthors.Franz-JosefNeumann,DepartmentofCardiologyandAngiologyII,UniversityHeartCentreFreiburg-BadKrozingen,Suedring15,79189BadKrozingen,
Germany.Tel:þ4976334022000,Fax:þ4976334022009,Email:franz-josef.neumann@universitaets-herzzentrum.de.MiguelSousa-Uva,CardiacSurgeryDepartment,Hospital
SantaCruz,AvenueProfReynaldodosSantos,2790-134Carnaxide,Portugal.Tel:þ351210433163,Fax:þ351214241388,CardiovascularResearchCentre,Departmentof
SurgeryandPhysiology,FacultyofMedicine-UniversityofPorto,AlamedaProfHernaniMonteiro,4200-319Porto,PortugalEmail:migueluva@gmail.com.
ESCCommitteeforPracticeGuidelines(CPG),EACTSClinicalGuidelinesCommittee,andNationalCardiacSocietiesdocumentreviewers:listedintheAppendix.
1RepresentingtheEuropeanAssociationforCardio-ThoracicSurgery(EACTS).
ESCentitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AcuteCardiovascularCareAssociation(ACCA),EuropeanAssociationofPreventiveCardiology(EAPC),EuropeanAssociationofCardiovascularImaging
(EACVI),EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),EuropeanHeartRhythmAssociation(EHRA),HeartFailureAssociation(HFA).
Councils:CouncilonCardiovascularNursingandAlliedProfessions,CouncilforCardiologyPractice,CouncilonCardiovascularPrimaryCare,CouncilonStroke,Councilon
ValvularHeartDisease
WorkingGroups:AortaandPeripheralVascularDiseases,CardiovascularPharmacotherapy,CoronaryPathophysiologyandMicrocirculation,Thrombosis.
Disclaimer.TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavail-
ableatthetimeoftheirdating.TheESCisnotresponsibleintheeventofanycontradiction,discrepancyand/orambiguitybetweentheESCGuidelinesandanyotherofficialrec-
ommendationsorguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsare
encouragedtotaketheESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgmentaswellasinthedeterminationandtheimplementationofpreventive,diagnostic
ortherapeuticmedicalstrategies.However,theESCGuidelinesdonotoverrideinanywaywhatsoevertheindividualresponsibilityofhealthprofessionalstomakeappropriate
andaccuratedecisionsinconsiderationofeachpatient’shealthconditionandinconsultationwiththatpatientandthepatient’scaregiverwhereappropriateand/ornecessary.
NordotheESCGuidelinesexempthealthprofessionalsfromtakingcarefulandfullconsiderationoftherelevantofficialupdatedrecommendationsorguidelinesissuedbythe
competentpublichealthauthoritiesinordertomanageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobliga-
tions.Itisalsothehealthprofessional’sresponsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
Thisarticlehasbeenco-publishedwithpermissionintheEuropeanHeartJournalandEuropeanJournalofCardio-ThoracicSurgery.Allrightsreserved.VC 2018EuropeanSocietyof
Cardiology.Thearticlesareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournal’sstyle.Eithercitationcanbeusedwhencitingthisarticle.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 2 ---
88 ESC/EACTSGuidelines
(Germany),VictoriaDelgado(TheNetherlands),DariuszDudek(Poland),NickFreemantle1(UK),
ChristianFunck-Brentano(France),OliverGaemperli(Switzerland),StephanGielen(Germany),Martine
Gilard(France),BulentGorenek(Turkey),JoergHaasenritter(Germany),MichaelHaude(Germany),
BorjaIbanez(Spain),BernardIung(France),AndersJeppsson1(Sweden),DemosthenesKatritsis(Greece),
JuhaniKnuuti(Finland),PhilippeKolh1(Belgium),AdelinoLeite-Moreira1(Portugal),LarsH.Lund
(Sweden),FrancescoMaisano(Switzerland),JulindaMehilli(Germany),BernhardMetzler(Austria),Gilles
Montalescot(France),DomenicoPagano1(UK),AnnaSoniaPetronio(Italy),MassimoFrancescoPiepoli
(Italy),BogdanA.Popescu(Romania),RafaelSa(cid:2)daba1(Spain),EvgenyShlyakhto(Russia),SigmundSilber
(Germany),IainA.Simpson(UK),DavidSparv(Sweden),GiuseppeTavilla1(TheNetherlands),Holger
Thiele(Germany),PetrTousek(CzechRepublic),EricVanBelle(France),PascalVranckx(Belgium),Adam
Witkowski(Poland),JoseLuisZamorano(Spain),MarcoRoffi(ESCCPGSupervisor)(Switzerland)
ThedisclosureformsofallexpertsinvolvedinthedevelopmentoftheseGuidelinesareavailableonthe
ESCwebsitewww.escardio.org/guidelines
Onlinepublish-ahead-of-print25August2018
...................................................................................................................................................................................................
Keywords Acutecoronarysyndromes • Antithrombotictherapy • Bare-metalstents • Coronaryarterybypass
grafting • Coronaryarterydisease • Drug-elutingstents • Guidelines • HeartTeam • Myocardial
infarction • Myocardialischaemia • Myocardialrevascularization • Medicaltherapy • Percutaneouscoronary
intervention • Recommendation • Revascularization • Riskstratification • Stents • Stableangina • Stable
coronaryarterydisease • ST-segmentelevationmyocardialinfarction • SYNTAXscore
.
Table of contents .. 4.1Patientinformationandinformedconsent .....................98
.
.
. 4.2Multidisciplinarydecision-making(HeartTeam) ................99
.
.
Abbreviationsandacronyms ........................................90 . 4.3Timingofrevascularization ....................................99
.
.
1Preamble .........................................................93 . 5Revascularizationforstablecoronaryarterydisease ...............101
.
.
2Introduction ......................................................94 . 5.1Rationaleforrevascularization................................101
.
.
2.1Whatisnewinthe2018Guidelines?...........................95 . 5.2Evidencebasisforrevascularization...........................101
.
.
3Diagnostictoolstoguidemyocardialrevascularization..............96 . 5.2.1Revascularizationwiththeuseofpercutaneouscoronary
.
.
3.1Non-invasivediagnostictools .................................96 . intervention ..................................................102
.
. 3.1.1Assessmentofmyocardialischaemia.......................96 .. 5.2.2Revascularizationwiththeuseofcoronaryarterybypass
. 3.1.2Assessmentofmyocardialviabilityinpatientswithheart .. grafting.......................................................102
.
failureandcoronaryarterydisease .............................96 .. 5.3Percutaneouscoronaryinterventionvs.coronaryartery
.
3.2Invasivediagnostictools.......................................96 .. bypassgrafting ..................................................102
.
3.2.1Pressure-derivedfractionalflowreserve...................96 .. 5.3.1Criteriafordecisionmaking..............................102
.
3.2.1.1Useoffractionalflowreserveinpatientswith .. 5.3.1.1Predictedsurgicalmortality ..........................104
.
intermediate-gradecoronarystenosisincludingleftmain .. 5.3.1.2Anatomicalcomplexityofcoronaryarterydisease ......104
.
stenosis ...................................................96 .. 5.3.1.3Completenessofrevascularization....................106
.
3.2.1.2Useoffractionalflowreservetoidentifylesions .. 5.3.2Isolatedproximalleftanteriordescendingcoronary
.
requiringrevascularizationinpatientswithmultivessel .. arterydisease.................................................109
.
coronaryarterydiseaseundergoingpercutaneouscoronary .. 5.3.3Leftmaincoronaryarterydisease ........................109
.
intervention................................................97 .. 5.3.4Multivesselcoronaryarterydisease.......................109
.
.
3.2.1.3Fractionalflowreserve-guidedmanagementvs.medical . 5.4Gapsintheevidence.........................................110
.
.
therapyinpatientswithcoronaryarterydisease................97 . 6Revascularizationinnon-ST-elevationacutecoronarysyndrome...110
.
.
3.2.2Otherpressure-derivedindices ...........................97 . 6.1Earlyinvasivevs.conservativestrategy ........................110
.
.
3.2.3Useoffractionalflowreserveandpressure-derived . 6.2Timingofangiographyandintervention .......................110
.
.
indicesinpatientswithsevereaorticstenosis ...................98 . 6.3Typeofrevascularization.....................................110
.
.
3.2.4Useofintravascularimagingfordiagnosticassessment . 6.3.1Percutaneouscoronaryintervention .....................110
.
.
ofstenosis.....................................................98 . 6.3.1.1Technicalaspects ..................................110
.
.
3.3Gapsintheevidence..........................................98 . 6.3.1.2Revascularizationstrategiesandoutcomes ............111
.
.
4Processfordecision-makingandpatientinformation................98 . 6.3.2Coronaryarterybypassgrafting ..........................111
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 3 ---
ESC/EACTSGuidelines 89
.
.
6.3.3Percutaneouscoronaryinterventionvs.coronaryartery . 13.4.1Restenosis...........................................125
.
.
bypassgrafting................................................111 . 13.4.2Diseaseprogression .................................126
.
.
6.4Gapsintheevidence.........................................112 . 13.4.3Stentthrombosis ....................................126
.
.
7RevascularizationinST-segmentelevationmyocardialinfarction ...112 . 14Arrhythmias....................................................127
.
.
7.1Timedelays .................................................112 . 14.1Ventriculararrhythmias.....................................127
.
.
7.2Selectionofreperfusionstrategy .............................112 . 14.1.1Revascularizationforthepreventionofsuddencardiac
.
.
7.3Primarypercutaneouscoronaryintervention .................113 . deathinpatientswithstablecoronaryarterydiseaseand
.
.
7.4Percutaneouscoronaryinterventionafterthrombolysis . reducedleftventricularfunction ............................127
.
.
andinpatientswithlatediagnosis ................................114 .. 14.1.2Revascularizationforthetreatmentofelectricalstorm 128
.
7.5Gapsintheevidence.........................................114 .. 14.1.3Revascularizationafterout-of-hospitalcardiacarrest ..128
.
8Myocardialrevascularizationinpatientswithheartfailure ..........116 .. 14.2Atrialarrhythmias ..........................................128
.
8.1Chronicheartfailure.........................................116 .. 14.2.1Atrialfibrillationcomplicatingpercutaneouscoronary
.
8.1.1Recommendationsformyocardialrevascularizationin .. intervention................................................128
.
patientswithchronicheartfailure .............................116 .. 14.2.2Atrialfibrillationcomplicatingcoronaryarterybypass
.
8.1.2Ventricularreconstructionandaneurysmresection .......116 .. grafting ....................................................128
.
8.2Acuteheartfailureandcardiogenicshock.....................117 .. 14.2.3Postoperativeatrialfibrillationandstrokerisk .........128
.
8.2.1Revascularization........................................117 .. 14.3Gapsintheevidence........................................129
.
8.2.2Mechanicalcirculatorysupport...........................117 .. 15Proceduralaspectsofcoronaryarterybypassgrafting ............129
. 8.2.2.1Intra-aorticballoonpump ...........................117 .. 15.1Surgicaltechniques .........................................129
.
8.2.2.2Extracorporealmembraneoxygenation...............117 .. 15.1.1Completenessofrevascularization....................129
.
.
8.2.2.3Percutaneousleftventricularassistdevices ............118 . 15.1.2Conduitselection....................................130
.
.
8.2.2.4Surgicallyimplantedleftventricularassistdevices.......118 . 15.1.3Mammaryarteryharvesting ..........................130
.
.
8.3Gapsintheevidence.........................................119 . 15.1.4Radialarteryharvesting ..............................130
.
.
9Revascularizationinpatientswithdiabetes ........................119 . 15.1.5Saphenousveinharvesting ...........................130
.
.
9.1Evidenceformyocardialrevascularization.....................119 . 15.1.6Constructionofcentralanastomosis..................131
.
.
9.2Typeofmyocardialrevascularization .........................119 . 15.1.7Intraoperativequalitycontrol.........................131
.
.
9.2.1.Randomizedclinicaltrials................................119 . 15.1.8On-pumpandoff-pumpprocedures ..................131
.
.
9.2.2Meta-analysisofcoronaryarterybypassgraftingvs. . 15.1.9Minimallyinvasiveandhybridprocedures .............131
.
.
percutaneouscoronaryinterventioninpatientswithdiabetes...120 . 15.2Reportingperioperativeoutcomes ..........................131
.
.
9.3Revascularizationwiththeuseofpercutaneouscoronary . 15.3Gapsintheevidence........................................131
.
.
intervention.....................................................120 .. 16Proceduralaspectsofpercutaneouscoronaryintervention .......133
.
9.4Antithromboticpharmacotherapy............................120 .. 16.1Percutaneouscoronaryinterventiondevices.................133
.
9.5Metformin...................................................120 .. 16.1.1Balloonangioplasty ..................................133
.
9.6Gapsintheevidence.........................................121 .. 16.1.2Choiceofcoronarystents............................133
.
10Revascularizationinpatientswithchronickidneydisease .........121 .. 16.1.3Bioresorbablescaffolds ..............................134
.
10.1Evidencebaseforrevascularizationandrecommendations ...121 .. 16.1.4Drug-coatedballoons................................134
.
10.2Preventionofcontrast-inducednephropathy ................121 .. 16.1.5Devicesforlesionpreparation........................134
.
10.3Gapsintheevidence........................................121 .. 16.2Invasiveimagingtoolsforproceduralguidance ...............134
.
11Revascularizationinpatientsrequiringvalveinterventions ........122 .. 16.2.1Intravascularultrasound..............................134
.
11.1Primaryindicationforvalveinterventions....................122 .. 16.2.2Opticalcoherencetomography ......................135
.
11.2Primaryindicationformyocardialrevascularization...........122 .. 16.3Specificlesionsubsets ......................................135
.
11.2.1Aorticvalvedisease..................................122 .. 16.3.1Bifurcationstenosis ..................................135
.
.
11.2.2Mitralvalvedisease ..................................122 . 16.3.2Chronictotalcoronaryocclusion.....................135
. .
11.3Gapsintheevidence........................................122 . 16.3.3Ostiallesions ........................................136
.
.
12Associatedperipheralarterydiseases............................123 . 16.4Vascularaccess.............................................136
.
.
12.1Preventionofstrokeassociatedwithcarotidartery . 17Antithrombotictreatments .....................................137
.
.
diseaseandmyocardialrevascularization .........................123 . 17.1Percutaneouscoronaryinterventioninstablecoronary
.
.
12.2Associatedcoronaryandperipheralarterydiseases ..........123 . arterydisease ...................................................138
.
.
13Repeatrevascularization ........................................124 . 17.1.1Choiceoftreatmentandpre-treatment...............138
.
.
13.1Earlygraftfailure............................................124 . 17.1.2Peri-interventionaltreatment.........................138
.
.
13.2Acutepercutaneouscoronaryinterventionfailure ...........125 . 17.1.3Post-interventionalandmaintenancetreatment .......139
.
.
13.3Diseaseprogressionandlategraftfailure ....................125 . 17.2Non-ST-segmentelevationacutecoronarysyndrome........141
.
.
13.3.1Redocoronaryarterybypassgraftingorpercutaneous .. 17.2.1Choiceoftreatmentandpre-treatment...............141
.
coronaryintervention ......................................125 .. 17.2.2Peri-interventionaltreatment.........................141
.
13.3.2Percutaneouscoronaryinterventionforsaphenousvein .. 17.2.3Post-interventionalandmaintenancetreatment .......141
.
graftlesions ................................................125 .. 17.3ST-segmentelevationmyocardialinfarction..................144
.
13.4Repeatpercutaneouscoronaryintervention.................125 . 17.3.1Choiceoftreatmentandpre-treatment...............144
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 4 ---
90 ESC/EACTSGuidelines
.
17.3.2Peri-interventionaltreatment.........................144 .. ARCTIC AssessmentbyaDoubleRandomizationofa
.
17.3.3Post-interventionalandmaintenancetreatment .......144 .. ConventionalAntiplateletStrategyversusa
.
17.4Coronaryarterybypassgrafting .............................145 .. Monitoring-guidedStrategyforDrug-Eluting
.
17.5Specialconditions ..........................................145 .. StentImplantationandofTreatment
.
17.5.1Antithrombotictherapyafterpercutaneous .. InterruptionversusContinuationOneYear
.
coronaryinterventioninpatientsrequiringoral .. afterStenting
.
anticoagulation.............................................145 .. ART ArterialRevascularizationTrial
.
17.5.2Revascularizationinpatientswithrenalfailure .........148 .. AS Aorticstenosis
.
17.5.3Monitoringofantiplateletdrugs(plateletfunction .. ASE AmericanSocietyofEchocardiography
.
testingandgenotyping) .....................................148 ... ATLANTIC AdministrationofTicagrelorintheCathLab
17.5.4Surgeryinpatientsondualantiplatelettherapy ........148 ... orintheAmbulanceforNewST-Elevation
17.6Gapsintheevidence........................................148 ... MyocardialInfarctiontoOpentheCoronary
18Volume–outcomerelationshipforrevascularization ... Artery
.
procedures........................................................149 .. ATLAS-ACS Anti-XaTherapytoLowercardiovascular
.
18.1Coronaryarterybypassgrafting .............................149 .. 2–TIMI51 eventsinAdditiontoStandardtherapyin
.
18.2Percutaneouscoronaryintervention ........................149 .. subjectswithAcuteCoronary
.
18.3Trainingincardiacsurgeryandinterventionalcardiology .. Syndrome–ThrombolysisInMyocardial
.
formyocardialrevascularization .................................149 .. Infarction51
.
19Medicaltherapy,secondaryprevention,andstrategiesfor .. ATOLL AcuteSTEMITreatedwithprimaryPCIand
.
follow-up..........................................................151 .. intravenousenoxaparinOrUFHtoLower
.
19.1Gapsintheevidence........................................152 .. ischaemicandbleedingeventsatshort-and
.
20Keymessages...................................................152 .. Long-termfollow-up
.
21Evidence-based0todo0and0nottodo0messagesfromthe ..
AWESOME AnginaWithExtremelySeriousOperative
.
Guidelines.........................................................152 .. MortalityEvaluation
.
22Appendix ......................................................156 .. BARC BleedingAcademicResearchConsortium
.
23References .....................................................157 .. BARI-2D BypassAngioplastyRevascularization
.
.
. Investigation2Diabetes
.
.
. BES Biolimus-elutingstent
.
Abbreviations and acronyms .. BEST RandomisedComparisonofCoronary
.
.
. ArteryBypassSurgeryandEverolimus-Eluting
.
ABC Age,Biomarkers,ClinicalHistory .. StentImplantationintheTreatmentof
.
ABSORBII ABioresorbableEverolimus-ElutingScaffold ... PatientswithMultivesselCoronaryArtery
.
VersusaMetallicEverolimus-ElutingStentII .. Disease
.
AIDA AmsterdamInvestigator-InitiatedAbsorb .. b.i.d. Bisindie(twicedaily)
.
StrategyAll-Comers .. BIMA Bilateralinternalmammaryartery
.
ACCOAST ComparisonofPrasugrelattheTimeof .. BMS Bare-metalstent
.
PercutaneousCoronaryInterventionoras .. BRAVE BavarianReperfusionAlternativesEvaluation
.
PretreatmentattheTimeofDiagnosisin .. BRS Bioresorbablescaffolds
.
PatientswithNon-STElevationMyocardial .. BVS Bioresorbablevascularscaffold
.
Infarction .. CABG Coronaryarterybypassgrafting
.
ACS Acutecoronarysyndrome .. CAD Coronaryarterydisease
.
ACUITY AcuteCatheterizationandUrgent .. CARDia CoronaryArteryRevascularizationin
.
InterventionTriagestrategy .. Diabetes
.
ADAPT-DES AssessmentofDualAntiplateletTherapy .. CCS CanadianCardiovascularSociety
.
WithDrug-ElutingStents .. CEA Carotidendarterectomy
.
AF Atrialfibrillation .. CHA DS -VASc CardiacCongestiveheartfailure,
. 2 2
ALPHEUS AssessmentofLoadingWiththeP2Y 12- ... Hypertension,Age>_75[Doubled],Diabetes
InhibitorTicagrelororClopidogreltoHalt .. mellitus,priorStrokeortransientischaemic
.
IschemicEventsinPatientsUndergoing .. attackorthromboembolism[Doubled]–
.
ElectiveCoronaryStenting .. Vasculardisease,Age65–74andSex
.
AMI Acutemyocardialinfarction .. category[Female]
.
AMACING AMaastrichtContrast-Induced .. CHAMPION CangrelorversusStandardTherapyto
.
NephropathyGuideline .. AchieveOptimalManagementofPlatelet
.
ANTARCTIC Plateletfunctionmonitoringtoadjust ... Inhibition
.
antiplatelettherapyinelderlypatients .. CI Confidenceinterval
.
stentedforanacutecoronarysyndrome . CIN Contrast-inducednephropathy
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 5 ---
ESC/EACTSGuidelines 91
.
CKD Chronickidneydisease .. EUROMAX EuropeanAmbulanceAcuteCoronary
.
CMR Cardiacmagneticresonance .. SyndromeAngiography
.
COMPASS RivaroxabanforthePreventionofMajor .. EXCEL EvaluationofXIENCEVersusCoronary
.
CardiovascularEventsinCoronaryor .. ArteryBypassSurgeryforEffectivenessof
.
PeripheralArteryDisease .. LeftMainRevascularization
.
COURAGE ClinicalOutcomesUtilizingRevascularization .. FAME FractionalFlowReserveversusAngiography
.
andAggressiveDrugEvaluation .. forMultivesselEvaluation
.
CPG ESCCommitteeforPracticeGuidelines .. FDG-PET Fluorodeoxyglucosepositronemission
.
CT Computedtomography .. tomography
.
.
CT-FFR CT-derivedfractionalflowreserve . FFR Fractionalflowreserve
.
.
CTO Chronictotalocclusion . FITT-STEMI FeedbackInterventionandTreatment
.
.
CTSN CardiothoracicSurgicalTrialNetwork . TimesinST-ElevationMyocardial
.
.
CULPRIT-SHOCK CulpritLesionOnlyPCIversusMultivessel . Infarction
.
.
PCIinCardiogenicShock . FMC Firstmedicalcontact
.
.
CVA Cerebrovascularaccident . FREEDOM FutureRevascularizationEvaluationin
.
.
CvLPRIT CompleteVersusLesion-OnlyPrimaryPCITrial . PatientswithDiabetesMellitus
.
.
DANAMI3-DEFER TheThirdDANishStudyofOptimalAcute . GLOBAL Long-termticagrelormonotherapyversus
.
.
TreatmentofPatientswithST-segment . LEADERS standarddualantiplatelettherapyfollowedby
. .
ElevationMyocardialInfarction:DEFERred . aspirinmonotherapyinpatientsundergoing
.
.
stentimplantationinconnectionwith .. biolimus-elutingstentimplantation
.
primaryPCI .. GPIIb/IIIa GlycoproteinIIb/IIIa
.
DANAMI-3- TheThirdDANishStudyofOptimalAcute .. GRAVITAS GaugingResponsivenesswithA
.
PRIMULTI TreatmentofPatientswithST-segment .. VerifyNowassay-ImpactonThrombosis
.
ElevationMyocardialInfarction:PRImaryPCI .. AndSafety
.
inMULTIvesselDisease .. HAS-BLED Hypertension,Abnormalrenal/liverfunction,
.
DAPT Dualantiplatelettherapy .. Stroke,Bleedinghistoryorpredisposition,
.
DCB Drug-coatedballoon .. LabileINR,Elderly,Drugs/alcohol
.
DEFINE-FLAIR DefineFunctionalLesionAssessmentof .. HEAT-PPCI HowEffectiveareAntithromboticTherapies
.
IntermediateStenosistoGuide .. inprimaryPCI
.
Revascularization .. HF Heartfailure
.
DES Drug-elutingstents .. HFrEF Heartfailurewithreducedejectionfraction
.
.
DUS Duplexultrasound . HORIZONS HarmonizingOutcomeswith
.
.
EACTS EuropeanAssociationforCardio-Thoracic . RevascularizationandStentsinAcute
.
.
Surgery . MyocardialInfarction
.
.
EAPCI EuropeanAssociationforPercutaneous . HPR Highplateletreactivity
.
.
CardiovascularInterventions . HR Hazardratio .
.
EBCTWO EuropeanBifurcationCoronaryTWO . i.v. Intravenous .
.
ECG Electrocardiogram . IABP Intra-aorticballoonpump
.
.
ECLS Extracorporeallifesupport . IABP-SHOCKII IntraaorticBalloonPumpinCardiogenic
.
. ECMO Extracorporealmembraneoxygenation . ShockIITrial
.
. EES Everolimus-elutingstent . ICD Implantablecardioverterdefibrillator
.
.
EF Ejectionfraction .. iwFR Instantaneouswave-freeratio
.
EMS Emergencymedicalservice .. IMA Internalmammaryartery
.
EROA Effectiveregurgitantorificearea .. IMR Ischaemicmitralregurgitation
.
ENTRUST-AF-PCI Evaluationofthesafetyandefficacyofan .. INR Internationalnormalizedratio
.
edoxaban-basedantithromboticregimenin .. IRA Infarct-relatedartery
.
patientswithatrialfibrillationfollowing .. ISAR-CABG IsDrug-Eluting-StentingAssociatedwith
.
successfulpercutaneouscoronaryintervention .. ImprovedResultsinCoronaryArteryBypass
.
ESC EuropeanSocietyofCardiology .. Grafts
.
EUROCTO RandomizedMulticentreTrialtoCompare .. ISAR-REACT IntracoronaryStentingandAntithrombotic
.
RevascularizationWithOptimalMedical .. RegimenRapidEarlyActionforCoronary
.
TherapyfortheTreatmentofChronicTotal .. Treatment
.
Occlusions .. ISCHEMIA InternationalStudyofComparativeHealth
.
.
EuroSCORE EuropeanSystemforCardiacOperativeRisk . EffectivenessWithMedicalandInvasive
.
.
Evaluation . Approaches
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 6 ---
92 ESC/EACTSGuidelines
.
.
IVUS Intravascularultrasoundimaging . PIONEER PreventionofbleedinginpatientswithAF
.
.
LAA Leftatrialappendage . undergoingPCI
.
.
LAD Leftanteriordescending . PLATFORM ProspectiveLongitudinAlTrialofFFRct:
.
.
LEAD Lowerextremityarterydisease . OutcomeandResourceImpacts,
.
.
LGE-CMR Lategadoliniumenhancementcardiac . PLATO StudyofPlateletInhibitionandPatient
.
.
magneticresonance .. Outcomes
.
LIMA Leftinternalmammaryartery .. pLVAD Percutaneousleftventricularassistdevice
.
LM/LMS Leftmain/leftmainstem .. p.o. Peros(orally)
.
LMWH Low-molecular-weightheparin .. POSEIDON PreventionofContrastRenalInjurywith
.
LPR Lowplateletreactivity .. DifferentHydrationStrategies
.
LV Leftventricle/leftventricular .. PPI Protonpumpinhibitor
.
LVAD Leftventricularassistdevice, .. PRAGUE-18 ComparisonofPrasugrelandTicagrelorin
.
LVEF Leftventricularejectionfraction .. theTreatmentofAcuteMyocardialInfarction
.
MACCE Majoradversecardiacandcerebrovascular .. PRAMI PreventiveAngioplastyinAcuteMyocardial
.
events .. Infarction
.
MACE Majoradversecardiacevents .. PRECISE-DAPT PREdictingbleedingComplicationsIn
.
MADITII MulticenterAutomaticDefibrillator .. patientsundergoingStentimplantationand
.
.
ImplantationTrialII . subsEquentDualAntiPlateletTherapy
.
.
MATRIX MinimizingAdverseHaemorrhagicEventsby . PRECOMBAT PremierofRandomisedComparisonof
.
.
TransradialAccessSiteandSystemic . BypassSurgeryversusAngioplastyUsing
.
.
ImplementationofAngioX . Sirolimus-ElutingStentinPatientswithLeft
.
.
MCS Mechanicalcirculatorysupport . MainCoronaryArteryDisease
.
.
MI Myocardialinfarction . PRESERVE PreventionofSeriousAdverseEvents
.
.
MINOCA Myocardialinfarctionwithnon-obstructive . FollowingAngiography
.
.
coronaryarteries . q.d. Quaquedie(oncedaily)
.
.
MLA Minimalluminalarea . RCT Randomizedcontrolledtrial
.
.
MR Mitralregurgitation . RE-DUAL RandomisedEvaluationofDual
.
.
MSCT Multi-slicecomputedtomography .. AntithromboticTherapywithDabigatran
.
MT Medicaltherapy .. versusTripleTherapywithWarfarinin
.
MVD Multivesselcoronaryarterydisease .. PatientswithNonvalvularAtrialFibrillation
.
MVO Microvascularobstruction .. UndergoingPercutaneousCoronary
.
NAC N-acetylcysteine .. Intervention
.
NNT Numberneededtotreat .. REMEDIALII RenalInsufficiencyAfterContrastMedia
.
NOAC Non-vitaminKantagonistoralanticoagulant .. AdministrationII
.
NOBLE Nordic-Baltic-BritishLeftMain .. REPLACE-2 TheRandomisedEvaluationinPCILinking
.
RevascularizationStudy .. AngiomaxtoReducedClinicalEvents2
.
NSTE-ACS Non-ST-segmentelevationacutecoronary .. RIVAL Radialversusfemoralaccessforcoronary
.
syndrome .. angiographyandinterventioninpatients
.
NSTEMI Non-ST-segmentelevationmyocardial .. withacutecoronarysyndromes
.
. infarction . ROMA RandomizationofSinglevs.MultipleArterial
.
. NYHA NewYorkHeartAssociation . Grafts
.
.
OAC Oralanticoagulation . RR Relativerisk
.
.
OASIS-5 OptimalAntiplateletStrategyfor . SASSICAIA ComparisonofLoadingStrategiesWith
.
.
Interventions-5 . AntiplateletDrugsinPatientsUndergoing
.
.
OCT Opticalcoherencetomography . ElectiveCoronaryIntervention
.
.
OR Oddsratio . SAVR Surgicalaorticvalvereplacement
.
.
ORBITA ObjectiveRandomisedBlindedInvestigation . s.c. Subcutaneous
.
.
withoptimalmedicalTherapyofAngioplasty . SCAD Stablecoronaryarterydisease
.
.
instableangina . SCD-HEFT SuddenCardiacDeathinHeartFailureTrial
.
.
PARR-2 PETandRecoveryfollowing .. SES Sirolimus-elutingstent
.
Revascularization .. SHOCK ShouldWeEmergentlyRevascularize
.
PCI Percutaneouscoronaryintervention .. OccludedCoronariesforCardiogenicShock
.
Pd/Pa Distalcoronarytoaorticpressure .. SIMA Singleinternalmammaryartery
.
PES Paclitaxel-elutingstent .. SMART-DATE SmartAngioplastyResearchTeam-safetyof
.
PET Positronemissiontomography .. 6-monthdurationofDualAntiplatelet
.
PF Plateletfunction . Therapyafterpercutaneouscoronary
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 7 ---
ESC/EACTSGuidelines 93
.
.
interventioninpatientswithacutecoronary .. foranindividualpatientwitha givencondition,taking intoaccount
.
syndromes .. theimpactonoutcomeaswellastherisk–benefitratioofparticular
.
SPECT Single-photonemissioncomputedtomography .. diagnosticortherapeutic means.Clinical practiceguidelinesare no
.
SR Sinusrhythm .. substitutes for textbooks, but complement them, and cover the
.
STEEPLE SafetyandEfficacyofIntravenous .. EuropeanSocietyofCardiology(ESC)CoreCurriculumtopics.As
.
EnoxaparininElectivePercutaneous .. suchtheyshouldhelpphysicianstomakedecisionsintheirdailyprac-
.
CoronaryInterventionRandomised .. tice.However,finaldecisionsshouldbeindividualizedbyresponsible
.
Evaluation .. physiciansandthepatient.
.
STEMI ST-segmentelevationmyocardialinfarction .. Agreatnumberofclinicalpracticeguidelineshavebeenissuedin
.
STICH SurgicalTreatmentforIschemicHeartFailure .. recentyearsbothbytheESCaswellasbyothersocietiesandorgani-
.
STICHES STICHExtensionStudy .. zations.Becauseoftheimpactonclinicalpractice,qualitycriteriafor
.
STS SocietyofThoracicSurgeons .. the development of guidelines have been established in order to
.
SVG Saphenousveingraft .. makealldecisionstransparenttotheuser.Therecommendationsfor
.
SVR Surgicalventricularreconstruction .. formulatingandissuingESCandjointsocietyguidelinescanbefound
.
SWEDEHEART SwedishWeb-systemforEnhancementand .. on the ESC website (https://www.escardio.org/Guidelines/Clinical-
.
DevelopmentofEvidence-basedcarein .. Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines).
.
HeartdiseaseEvaluatedAccordingto ... These Guidelines represent the official position of the ESC and the
RecommendedTherapies ... European Association for Cardio-Thoracic Surgery (EACTS) on this
SYNTAX SynergybetweenPercutaneousCoronary ... giventopicandwillberegularlyupdated.
InterventionwithTAXUSandCardiacSurgery ... MembersofthisTaskForcewereselectedbytheESCandEACTS
.
TAP Tandprotrusion .. torepresentprofessionalsinvolvedwiththemedicalcareofpatients
.
TAVI Transcatheteraorticvalveimplantation .. withthispathology.Selectedexpertsinthefieldundertookacom-
.
TIA Transientischaemicattack .. prehensivereviewofthepublishedevidencefordiagnosis,manage-
.
TIMI ThrombolysisinMyocardialInfarction .. ment (including treatment) and/or prevention of a given condition
.
TLR Targetlesionrevascularization .. accordingtotheESCCommitteeforPracticeGuidelines(CPG)and
.
TOTAL TrialofRoutineAspirationThrombectomywith .. EACTSpolicy.Acriticalevaluationofdiagnosticandtherapeuticpro-
.
PCIversusPCIAloneinPatientswithSTEMI .. cedures was performed including assessment of the risk–benefit
.
TRIGGER-PCI TestingplateletReactivityInpatients .. ratio.Estimatesofexpectedhealthoutcomesforlargerpopulations
.
underGoingelectivestentplacementon .. were included, where data exist. The level of evidence and the
.
clopidogreltoGuidealternativethErapy .. strength of recommendation of particular treatment options were
.
withpRasugrel .. weighed and graded according to predefined scales, as outlined in
.
TRITON-TIMI38 TRialtoAssessImprovementinTherapeutic .. Tables1and2.
.
OutcomesbyOptimizingPlateletInhibitioN .. Theexpertsofthewritingandreviewingpanelscompleteddecla-
.
withPrasugrel–ThrombolysisInMyocardial .. rations of interest forms on what might be perceived as real or
.
Infarction .. potentialsourcesofconflictsofinterest.Theseformswerecompiled
.
TROPICAL-ACS Testingresponsivenesstoplateletinhibition .. into one file and can be found on the ESC and EACTS websites .
onchronicantiplatelettreatmentforacute .. http://www.escardio.org/guidelines and http://www.eacts.org). Any .
coronarysyndromes .. changesindeclarationsofinterestthatariseduringthewritingperiod
.
TVR Targetvesselrevascularization ... must be notified to the ESC and EACTS and updated. The Task
TWILIGHT TicagrelorWithAspirinorAloneinHigh- ... ForcereceiveditsentirefinancialsupportfromtheESCandEACTS
RiskPatientsAfterCoronaryIntervention ... withoutanyinvolvementfromthehealthcareindustry.
UFH Unfractionatedheparin ... TheCPG-ESCandEACTSsupervisedandcoordinatedtheprepa-
.
VA Veno-arterial .. ration of these new Guidelines produced by the joint Task Force.
.
VACARDS VeteransAffairsCoronaryArtery .. Theseentitiesarealsoresponsiblefortheendorsementprocessof
.
RevascularizationinDiabetesStudy .. theseGuidelines.TheESC/EACTSGuidelinesunderwentextensive
.
VALIDATE BivalirudinversusHeparininST-Segment .. reviewbyawidepanelofrelevantexternalexperts.Afterappropri-
.
andNon–ST-SegmentElevationMyocardial .. aterevisionsitwasapprovedbyalltheexpertsinvolvedintheTask
.
InfarctioninPatientsonModernAntiplatelet .. Force.ThefinalizeddocumentwasapprovedbytheESCCPGand
.
Therapy .. EACTS for joint publication in the European Heart Journal and the
.
VKA VitaminKantagonist .. EuropeanJournalofCardio-ThoracicSurgery.
.
. Thetaskofdevelopingclinicalpracticeguidelinescoversnotonly
.
.
. theintegrationofthemostrecentresearch,butalsothecreationof
.
.
1 Preamble . educational tools and implementation programmes for the recom-
.
.
.. mendations.Toimplementtheguidelines,condensedpocketguide-
.
Clinicalpracticeguidelinessummarizeandevaluateallavailableevi- .. lines, summary slides, booklets with essential messages, and an
.
denceatthetimeofthewritingprocessonaparticularissuewiththe .. electronicversionfordigitalapplications(smartphones,etc.)arepro-
.
aimofassistingphysiciansinselectingthebestmanagementstrategies . duced.Theseversionsareabridgedand,thus,ifneeded,oneshould
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 8 ---
94 ESC/EACTSGuidelines
Table1 Classesofrecommendations
Classes of Definition Suggested wording to use
recommendations
Class I Evidence and/orgeneralagreement Is recommended/is
that a given treatmentorprocedure is indicated
beneficial, useful, effective.
Class II Conflicting evidence and/or a
divergence of opinion about the
usefulness/efficacy of the given
treatment or procedure.
Class IIa Weight of evidence/opinion is in favour Should be considered
of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that Is not recommended
the given treatment or procedure is
not useful/effective, and in some cases
may be harmful.
.
.. circumstances of the individual patients, in consultation with that
.
Table2 Levelsofevidence .. patient,andwhereappropriateandnecessarythepatient’sguardian
.
.. orcarer.Itisalsothehealthprofessional’sresponsibilitytoverifythe
.
.. rulesandregulationsapplicabletodrugsanddevicesatthetimeof
.
.
. prescription.
.
.
.
.
.
.
.
.. 2 Introduction
.
.
.
.
.
. TheseGuidelinesrepresentthethirdtimethattheESCandEACTS
.
. . have broughttogethercardiologistsand cardiacsurgeons ina joint
.
. . TaskForcetoreviewtheever-increasingbodyofevidence,withthe
.
.
. missionofdraftingbalanced,patient-centredpracticeGuidelineson
.
.
. myocardialrevascularization.Summariesofthekeychangesincom-
. .
. parisonwiththepreviousGuidelinesareprovidedinFigures1and2.
. .
. Thereisconsiderableoverlapofthecurrentdocumentwithother
.
.
alwaysrefertothefulltextversion,whichisfreelyavailableonthe . Guidelines,specificallythoseonstablecoronaryarterydisease,non-
.
.
ESC and EACTS websites. The National Societies of the ESC are . ST-elevation myocardial infarction, ST-elevation myocardial infarc- .
.
encouraged to endorse, translate, and implement the ESC . tion,heartfailure,valvularheartdiseaseandtheFocusedUpdateon
.
.
Guidelines.Implementationprogrammesareneededbecauseithas . Dual Antiplatelet Therapy. Unless supported by new evidence, we
.
.
been shown that the outcome of disease may be favourably influ- .. followedtherecommendationsoftheseGuidelineswherepertinent
.
encedbythethoroughapplicationofclinicalrecommendations. .. toourGuidelines,andreferthereadertotherespectivesectionsin
.
Surveysandregistriesareneededtoverifythatreal-lifedailyprac- .. thosedocumentsfordetaileddiscussion.Wereservemorein-depth
.
ticeisinkeepingwithwhatisrecommendedintheguidelines,thus .. discussionfortopicsthatarespecifictoissuespertainingtomyocar-
.
completingtheloopbetweenclinicalresearch,writingofguidelines, .. dial revascularization that are not covered in other Guidelines. To
.
andimplementingtheminclinicalpractice. .. keep the current document concise and reader-friendly, we also
.
Theguidelinesdonot,however,overridetheindividualresponsi- .. moved some of the detailed descriptions of study results to the
.
bilityofhealthcareprofessionalstomakeappropriatedecisionsinthe . onlineSupplementaryData.
8102CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 9 ---
ESC/EACTSGuidelines 95
2.1 What is new in the 2018 Guidelines?
Calculation of the Syntax Score, if left Completeness of revascularization Routine non-invasive imaging
main or multivessel revascularization prioritized, when considering CABG surveillance in high-risk patients
is considered vs PCI 6 months after revascularization
Radial access as standard approach Double-kissing crush technique
NOAC preferred over VKA in patients
for coronary angiography and PCI preferred over provisional T-stenting
with non-valvular AF requiring
in true left main bifurcations.
DES for any PCI anticoagulation and antiplatelet
treatment Cangrelor in P2Y -inhibitor naïve
Systematic re-evaluation of patients 12
patients undergoing PCI
after myocardial revascularization No-touch vein technique, if open vein
Stabilised NSTE-ACS patients: harvesting for CABG GP IIb/IIIa inhibitors for PCI in P2Y 12-
revascularization strategy according inhibitor naïve patients with ACS
Annual operator volume for left main
to principles for SCAD undergoing PCI
PCI of at least 25 cases per year
Use of the radial artery grafts over Dabigatran 150-mg dose preferred
saphenous vein grafts in patients with Pre- and post-hydration with isotonic over 110-mg dose when combined with
saline in patients with moderate or high-degree stenosis single antiplatelet therapy after PCI
severe CKD if the expected contrast
Myocardial revascularization in volume is >100 mL De-escalation of P2Y inhibitor guided
12
patients with CAD, heart failure, and by platelet function testing in ACS
LVEF ≤35% Class I Class IIa patients
CABG preferred
Class IIb Class III
Routine revascularization of non-IRA
PCI as alternative to CABG
lesions in myocardial infarction with
cardiogenic shock
The figure does not show changes Current generation BRS for clinical use
compared with the 2014 version of outside clinical studies
the Myocardial Revascularization
Guidelines that were due to updates for
consistency with other ESC Guidelines
published since 2014.
ACS = acute coronary syndromes; AF = atrial fibrillation; BRS = bioresorbable scaffolds; CABG = coronary artery bypass grafting; CAD = coronary artery disease;
CKD = chronic kidney disease; DES = drug-eluting stents; FFR = fractional flow reserve; GP = glycoprotein; IRA = infarct-related artery; LVEF = left ventricular
ejection fraction; NOAC = non-vitamin K oral anticoagulants; NSTEMI = non-ST-elevation; PCI = percutaneous coronary intervention; SCAD = stable coronary
artery disease; VKA = vitamin K antagonists.
Figure1Newrecommendations.
UPGRADES DOWNGRADES
For PCI of bifurcation lesions, stent implantation in Distal protection devices for PCI of SVG lesions
the main vessel only, followed by provisional balloon
Bivalirudin for PCI in NSTE-ACS
angioplasty with or without stenting of the side branch
Bivalirudin for PCI in STEMI
Immediate coronary angiography and revascularization,
<
if appropriate, in survivors of out-of-hospital cardiac arrest PCI for MVD with diabetes and SYNTAX score 23
and an ECG consistent with STEMI
Platelet function testing to guide antiplatelet therapy
Assess all patients for the risk of interruption in patients undergoing cardiac surgery
contrast-induced nephropathy
EuroSCORE II to assess in-hospital mortality after CABG
OCT for stent optimization
Class I Class IIa
Class IIb Class III
The figure does not show changes compared with the 2014
version of the Myocardial Revascularization Guidelines
that were due to updates for consistency with other ESC
Guidelines published since 2014.
CABG = coronary artery bypass grafting; MVD = multivessel coronary artery disease; NSTE-ACS = non-ST-elevation acute coronary syndromes; OCT = optical
coherence tomography; PCI = percutaneous coronary interventions; STEMI = ST-elevation myocardial infarction,
SVG = saphenous vein grafts;
Figure2Changesinclassofrecommendation.
8102
CSE©
8102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 10 ---
96 ESC/EACTSGuidelines
.
3 Diagnostic tools to guide .. contractilereserve.1,5Assessmentofischaemiaprovidesincremental
.
.
myocardial revascularization
.. benefitoverviabilityinmildtomoderateCAD,butwithextensive
.
.. CADviabilityassessmentmaybesufficient.6Patientswithadvanced
.
The use of diagnostic imaging and functional testing modalities to
... HF and viable myocardium should first undergo revascularization
detectpatients withcoronaryartery disease (CAD) isdiscussed in
... withcoronaryarterybypassgrafting(CABG)orpercutaneouscoro-
detail in the clinical practice Guidelines for patients with SCAD.1 ... naryintervention(PCI)beforebeingconsideredformechanicalcircu-
Further diagnostic assessment of patients with obstructive CAD is
... latorysupport(MCS)orhearttransplantation.7,8
criticalinordertoidentifypatientsandselectspecificlesionsthatare
... ThePARR-2(PETandRecoveryfollowingRevascularization)trial
likelytobenefitfrommyocardialrevascularization,inadditiontoopti-
... includedpatientswithsevereleftventricular(LV)dysfunctionbeing
malmedicaltherapy.
... consideredforrevascularizationorHF/transplantationworkups,and
.. randomized them to management assisted by fluorodeoxyglucose
.
.. PET(FDG-PET)orstandardcare.6Theprimaryoutcomeofcardiac
3.1 Non-invasive diagnostic tools .
.. death,myocardialinfarction(MI),orrecurrenthospitalstayforcar-
3.1.1Assessmentofmyocardialischaemia ..
. diac cause at 1 year was not improved in the group managed by
.
Non-invasivediagnosticassessmentofpatientswithCADbeingcon- .
. FDG-PET [relative risk (RR) 0.82, 95% confidence interval (CI)
.
sideredformyocardialrevascularizationcomprisestheassessmentof .
. 0.59–1.14,P=0.16],thoughtherateofcompliancewiththetreat-
.
ischaemiaandtheevaluationofviabilityinpatientswithregionalwall .
. mentrecommendedbyFDG-PETwasvariable. .
motionabnormalitiesorreducedejectionfraction(EF). .
. The viability substudy of the STICH (Surgical Treatment for
.
Functionaltestingtoassessischaemiaiscriticalfortheassessment .
. Ischemic Heart Failure) trial found viable myocardium in 487/601
.
ofstablepatientswithCAD.Documentationofischaemiausingfunc- .. patients(81%)andnonein114(19%).9Therewasasignificantassoci-
.
tionaltestingbeforeelectiveinvasiveproceduresforCADisthepre- .
. ationbetweenmyocardialviabilityandoutcomebyunivariateanaly-
.
ferredapproach.Itmayalsohavearoleintheassessmentofsome .
. sis,butnotonmultivariableanalysis.Thelackofcorrelationbetween
.
patientspresentingwithacutecoronarysyndrome(ACS).Becauseof .
. myocardialviabilityandbenefitfromrevascularizationindicatesthat
.
thelowsensitivityofexerciseelectrocardiogram(ECG)testinginthe .
.. thisstrategyshouldnotbetheonlytestwhenselectingtheoptimal
assessmentofpatientswithsymptomsofangina,non-invasiveimaging ...
therapy.
isrecommendedasthefirst-linetest.1Detectionofalargeareaof
myocardial ischaemia by functional imaging is associated with
impaired prognosis of patients and identifies patients who should Recommendationsfornon-invasiveimaginginpatients
withcoronaryarterydiseaseandheartfailurewith
undergorevascularization(seesection5).
reducedejectionfraction
In patients undergoing coronary computed tomography (CT),
bothCT-derivedfractionalflowreserve(CT-FFR)andCTperfusion
representpossibleapproachestoevaluatelesion-specificischaemia. Recommendations Classa Levelb
Althoughtheevidenceforbothislimitedatpresent,therearecon-
Non-invasivestressimaging(CMR,stress
siderablymoredatafromclinicalinvestigationsofCT-FFR.Anumber
echocardiography,SPECT,orPET)maybe
of trials have shown that correlation between CT-derived FFR
consideredfortheassessmentofmyocar-
and invasive FFR is high.2,3 The non-randomized PLATFORM
dialischaemiaandviabilityinpatientswith IIb B
(Prospective LongitudinAl Trial of FFRct: Outcome and Resource
HFandCAD(consideredsuitableforcoro-
Impacts)studyshowedthatinpatientsreferredforinvasiveangiogra-
naryrevascularization)beforethedecision
phyduetochestpain(predominantlyatypicalangina)andintermedi- onrevascularization.9–11
ate pre-test probability of CAD, assessment with CT and CT-FFR
reducedthenumber ofpatientswith subsequentlynormalinvasive
CAD=coronaryarterydisease;CMR=cardiacmagneticresonance;HF=heart
coronaryangiogramscomparedwithstandardcare.4Currently,clini-
failure;PET=positronemissiontomography;SPECT=single-photonemission
caltrialdatawithCT-FFRareinsufficienttomakearecommendation computedtomography.
foritsuseinclinicalpractice. aClassofrecommendation.
bLevelofevidence.
3.1.2Assessmentofmyocardialviabilityinpatientswith
heartfailureandcoronaryarterydisease
Inpatientswithregionalwallmotionabnormalitiesorventriculardys-
3.2 Invasive diagnostic tools
function,heartfailure(HF)canbecausedbystunnedorhibernating
myocardiumandmaybereversedbyrevascularization.Assessment 3.2.1Pressure-derivedfractionalflowreserve
ofmyocardialviabilitymaybedoneinordertoselectpatientsthat 3.2.1.1Useoffractionalflowreserveinpatientswithintermediate-grade
aremorelikelytobenefitfrommyocardialrevascularizationandcan coronarystenosisincludingleftmainstenosis
be achieved with several imaging modalities: myocardial contrast Coronarypressure-derivedFFRis thecurrentstandard of care for
echocardiography, single-photon emission CT (SPECT), and late the functional assessment of lesion severity in patients with
gadoliniumenhancementcardiacmagneticresonance(LGE-CMR)all intermediate-grade stenosis (typically around 40–90% stenosis)
assess cellular integrity; positron emission tomography (PET) without evidence of ischaemia in non-invasive testing, or in those
assesses cellular metabolism; and dobutamine techniques assess withmultivesseldisease.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 11 ---
ESC/EACTSGuidelines 97
.
MultiplestudieshaveshownthatPCIcanbesafelydeferredifFFR .. been shown in an observational study.28 Of the 627 patients with
.
is >0.75.12–15 TheDEFER trialenrolled 325patients scheduled for .. intermediate stenosisthatwereevaluated,429hadbypasswithout
.
PCI of an intermediate stenosis.15 If FFR was >_0.75, patients were .. FFRand198hadbypasswithFFR;inthelattergroup,theproportion
.
.
randomlyassignedtodeferral(defergroup;n=91)orperformance . ofpatientswiththree-vesseldiseasewasreclassifiedfrom94to86%.
.
.
(performgroup;n=90)ofPCI.Thecompositerateofcardiacdeath . Outcomesweresimilarinbothgroupsat3years[hazardratio(HR)
.
.
andacuteMI(AMI)inthedeferandperformgroupswas3.3vs.7.9% . for death/MI/target vessel revascularization (TVR) = 1.03, 95% CI
.
.
(P=0.21). . 0.67–1.69],thoughthegroupwithFFRguidancewasassociatedwith
.
.
However,mostcontemporarystudiesuseanFFRcut-offof0.80. . alowernumberofgraftanastomosesandalowerrateofon-pump
.
.
A recent large-scale observational study supports the use of FFR .. surgerycomparedwithangiography-guidedCABGsurgery.
.
>0.80ratherthan0.75asacut-off.16Indeed,thetwolargeststudies ..
.
inthisfield,DEFINE-FLAIR(DefineFunctionalLesionAssessmentof .. 3.2.1.2Useoffractionalflowreservetoidentifylesionsrequiringrevascu-
.
Intermediate Stenosis to Guide Revascularization DES drug-eluting .. larizationinpatientswithmultivesselcoronaryarterydiseaseundergoing
.
stent)17 and iFR-SWEDEHEART (Swedish Web-system for .. percutaneouscoronaryintervention
.
EnhancementandDevelopmentofEvidence-basedcareinHeartdis- .. FFRmayalsobeusefulfortheselectionoflesionsrequiringrevascula-
.
easeEvaluatedAccordingtoRecommendedTherapies),18usedthe .. rizationinpatientswithmultivesselCAD.TheFAMEtrialshowedthat
.
0.80cut-offforlesionselectionbyFFR,withfavourableeventratesat .. inpatientswithmultivesseldiseaserandomizedtoanFFR-guidedPCI
.
1year.Thus,0.80istheacceptedFFRthresholdfordefininghaemo- .. strategy(usingacut-off<_0.80toindicaterequirementforPCI),out-
.
dynamicallyrelevantlesions. .. comesat12monthsintermsofdeath,non-fatalMI,andrepeatrevas-
. Haemodynamic relevance, as defined by FFR <_0.80, correlates .. cularization were superior compared with angiography-guided PCI
.
poorly with diameter stenosis by visual assessment. In the FAME .. andutilizedfewerresources.29Inaddition,the2yearcompositerisk
.
.
(Fractional Flow Reserve versus Angiography for Multivessel . ofdeathorMIwassignificantlylowerwiththeFFR-guidedPCIstrat-
.
Evaluation)trial,only35%ofthe50–70%stenoseswerehaemody- .. egy.30Long-termfollow-upat5yearsshowedbroadlyconsistentfind-
.
.
namicallyrelevantand,ofthe71–90%stenoses,20%werenot.Only . ings,althoughdifferencesbetweengroupsinrelationtotheprimary
.
anestimateddiameterstenosis>90%predictedhaemodynamicrele- .. endpointwerenolongersignificant.31ThissuggeststhatFFR-guided
.
.
vancewithhighaccuracy(96% correctclassification).Anumber of . PCIshouldbethepreferredmanagementstrategyinthesepatients.
.
.
studieshaveshownthatutilizationofanFFR-basedassessmentstrat- .
.
.
egyatthetimeofangiographyresultsinreclassificationoftherevas- . 3.2.1.3Fractionalflowreserve-guidedmanagementvs.medicaltherapy
.
.
cularization strategy (PCI, bypass surgery, or medical therapy) in a . inpatientswithcoronaryarterydisease
.
.
highproportionofpatientswithintermediate-gradelesions(>40%of . InpatientswithSCADandatleastonestenosiswithFFR<_0.80,the
.
.
patientsarereclassified).19–22Inaddition,separateandpooledanaly- . FAME2trialshowedthatPCIusingdrug-elutingstent(DES)implan-
.
.
sesofthepatientsincludedinthosestudieshaveshownthattheend .. tation improved the primary endpoint of death, non-fatal MI, or
.
results of ‘FFR-based reclassification’ in patients investigated at the .. urgentrevascularizationwithin2yearscomparedwithmedicaltreat-
.
time ofdiagnostic angiographyisneutral overallforthe number of .. mentalone,whichwasdrivenbyalowerneedforurgentrevasculari-
.
patientsindicatedforrevascularization.23 .. zation.32 The advantage of FFR-guided PCI over medical therapy
.
Apatient-levelandstudy-levelmeta-analysisof9173lesionsdem- .. alonewasmaintainedat3years.33
.
onstratedthatwithlesionswithFFR<0.75,revascularizationreduced ..
.
the1yearriskofmajoradversecardiacevents(MACE),includinga .. 3.2.2Otherpressure-derivedindices .
reduction in the composite risk of death and MI.24 Thus, the FFR .. FFRevaluationrequiresmaximalandstablehyperaemia,whichisusu-
.
thresholdof0.75isusedtodefinemoresevereischaemiathatisof .. ally obtained by the administration of intravenous (i.v.) adenosine.
.
prognosticrelevance. .. Recently,therehasbeenrenewedinterestinrestingindicesderived
.
Thepresenceofintermediategradeleftmainstem(LMS)diseaseis .. fromrestinggradientsalone[distalcoronarytoaorticpressure(Pd/
.
not infrequent and angiographic evaluation may be challenging. .. Pa)orinstantaneouswave-freeratio(iwFR)].Tworecentlarge-scale
.
.
Assessmentusingpressure-derivedFFRismorechallengingincompar- . randomizedtrialsshowedbroadlycomparableresultsbetweenFFR-
. .
isonwithnon-LMSstenosisduetotherequirementfordisengagement . guidedandiwFR-guidedrevascularizationstrategiesinpatientswith
.
of the guiding catheter and an inability to administer intracoronary .. intermediate-grade stenosis.17,18 Revascularization was indicated in
.
.
adenosine.SomeobservationaldataexisttosupporttheuseofFFRin . both trials if FFR was<_0.80orif iwFRwas <_0.89. In the DEFINE-
.
ordertodecideifrevascularizationshouldbedeferredorperformed.25 .. FLAIR trial, the primary endpoint of MACE at 1 year occurred in
.
.
In the largest study, which included 230 patients with intermediate- . 6.8% in patients randomized to iwFR-guided revascularization vs.
.
.
gradeLMSstenosis,only23%showedanFFR<0.80.Treatmentwas . 7.0% in patients randomized to FFR-guided revascularization (P
.
.
deferredinpatientswithanFFR>_0.80andbypasssurgerywasdonein .. <0.001fornon-inferiority;HR0.95,95%CI0.68–1.33,P=0.78).17In
patientswithanFFR<0.80.26Clinicaloutcomesat5yearsweresimilar ... theiFR-SWEDEHEARTtrial,theprimaryendpointofdeathfromany
.
inbothgroups.However,itisimportanttoconsiderthepotentialinflu- .. cause,non-fatalMI,orunplannedrevascularizationwas6.7% inthe
.
ence of any untreated downstream disease in the left anterior .. iwFRgroupand6.1%intheFFRgroup(P=0.007fornon-inferiority;
.
descending(LAD)orleftcircumflexarteries,whichmaybeassociated .. HR1.12,95%CI0.79–1.58,P=0.53).18Inthistrial,17.5%ofpatients
.
withanincreasedriskofafalsenegativeFFR.27 .. hadACSatthetimeofpresentation.Therewasnointeractionwith
.
ThevalueofFFRtoevaluateintermediatestenosisandguideselec- .. outcomes.Bothtrialsarelimitedbyhavingafollow-updurationof
.
tionoflesionsforrevascularizationatthetimeofbypasssurgeryhas . only1year.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 12 ---
98 ESC/EACTSGuidelines
.
TheSYNTAXIIstudy(SynergybetweenPercutaneousCoronary .. IVUSevaluationofintermediate-gradeLMSdiseaseinpatientsbeing
.
Intervention with TAXUS and Cardiac Surgery), a single-arm, pro- .. considered for bypass surgery or PCI is supported by data from a
.
spective study in patients with multivessel disease incorporating a .. numberofobservationalstudies.35–38 In a multicentre, prospective
.
management strategy including combined iwFR/FFR assessment of .. study, revascularization was mainly deferred if the minimal luminal
.
stenosis severity in addition to intravascular ultrasound (IVUS)- .. area (MLA) was >_6 mm2 and performed in cases of an MLA <6
.
guided stent implantation and guideline-directed medical therapy, .. mm2.37Aftera2yearfollow-up,cardiacdeath-freesurvivalwassimi-
.
.
showed encouraging outcomes compared with a historical cohort . lar in both groups (98 and 95%, respectively). Another study sug-
.
enrolledintheSYNTAXtrial.34 .. gestedthatdeferralofinterventionin131patientswithanMLA>_7.5
.
Randomized trials comparing iwFR-guided revascularization with .. mm2showedfavourableclinicaloutcomes.36InAsianpatientswith
.
.
angiography-guided revascularization or medical therapy are not . generally smaller heart sizes, studies have suggested that an IVUS
.
available. iwFRhasnotbeen extensivelyvalidated for patients with .. MLAof4.5–4.8mm2maybethemostappropriate.38
.
.
LMSstenosis. .
Thereisnoadequaterandomizedcontrolledtrial(RCT)datato
Recommendationsonfunctionaltestingandintravascu-
support the use of whole-cardiac cycle Pd/Pa for the guidance of
larimagingforlesionassessment
revascularizationdecisions.
3.2.3Useoffractionalflowreserveandpressure-derived Recommendations Classa Levelb
indicesinpatientswithsevereaorticstenosis
Whenevidenceofischaemiaisnotavail-
In patients with intermediate coronary stenosis and concomitant
able,FFRoriwFRarerecommendedto
severeaorticstenosis,althoughsomeobservationalstudiesexist(see I A
assessthehaemodynamicrelevanceof
section11),therearenoadequateRCTdatatosupporttheuseof
intermediate-gradestenosis.15,17,18,39
FFRoriwFRfortheguidanceofrevascularizationdecisions.
FFR-guidedPCIshouldbeconsideredin
3.2.4Useofintravascularimagingforthediagnostic patientswithmultivesseldiseaseunder- IIa B
assessmentofstenosis goingPCI.29,31
IVUSisanultrasound-basedmodalityofintravascularimagingwithan
IVUSshouldbeconsideredtoassessthe
axial resolution of about 150 mm. IVUS imaging allows real-time
severityofunprotectedleftmain IIa B
tomographicassessmentofvesselsize,lumenarea,andplaquecom-
lesions.35–37
positionandvolume.Incomparisonwithopticalcoherencetomogra-
phy (OCT), it has more limited spatial resolution, but better
FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; IVUS =
penetrationdepthandpotentialadvantagesintermsofvesselsizing.
intravascularultrasound;PCI=percutaneouscoronaryintervention.
OCT is a light-based modality of intravascular imaging with higher aClassofrecommendation.
axialresolutioncomparedwithIVUS(15vs.150mm).Thedisadvan- bLevelofevidence.
tagesofOCTimagingarethatitrequirescompletebloodclearance
fromthelumenforimagingandthatithasmorelimitedpenetration,
whichcanlimittheassessmentofcompleteplaqueburdenandmay 3.3 Gaps in the evidence
impairaccuratevesselsizing. Furtherstudiesinvestigatingtheroleofnovel,combined,non-inva-
Potentialclinicalusesofintravascularimagingfordiagnosticassess-
siveanatomicalandfunctionalimagingareneeded,suchasrandom-
ment in patients being considered for myocardial revascularization
izedclinicaltrialswithCT-FFRinpatientswithsuspectedandknown
aretheevaluationofstenosisseverityinlesionswithintermediate-
CAD,aswellasfurtherclinicalinvestigationofperfusionCT.
gradestenosis,evaluationoflesionmorphologyinlesionsambiguous
RandomizedtrialscomparingiwFR-basedmanagementofpatients
with angiographic assessment, and the characterization of plaque
withintermediate-gradestenosiscomparedwithmedicaltherapyare
composition. The majority of the existing data from clinical trials
missing.Furtherstudyofwhole-cardiaccyclePd/Pafortheguidanceof
relatetotheuseofintravascularimagingguidanceduringPCIandare
revascularization in the setting of randomized clinical trials is also
discussedinsection16.Theuseofintravascularimagingtoevaluate
required.
patientswithstentfailureisdiscussedinsection13.
Further studies includingrandomized trialsare needed to assess
Regardingtheassessmentofintermediate-gradestenosis,anum-
thevalueoffunctionalvs.anatomicalguidanceforCABG.
berofstudieshaveevaluated theoptimalcut-off of minimallumen
areafortheidentificationofhaemodynamicallyrelevantlesions.One
prospectiveregistryshowedoverallmoderatecorrelationofminimal 4 Process for decision-making and
lumenareawithFFRvalues,withcut-offvaluesfordetectinghaemo-
patient information
dynamicallyrelevantstenosis(<2.4,<2.7,and<3.6mm2)dependent
on vessel size (reference vessel diameters <3.0, 3.0–3.5, and >3.5
4.1 Patient information and informed
mm,respectively).34aGenerally,haemodynamicassessmentwithFFR
consent
shouldbepreferredforthisindication.
Thepresenceofintermediate-gradeLMSdiseaseisnotinfrequent Informedconsentrequirestransparency,especiallyifthereisdebate
and angiographic assessment may be challenging. Assessment using over various treatment options. Active patient participation in the
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 13 ---
ESC/EACTSGuidelines 99
.
.
decision-makingprocessshouldbeencouraged.Patientinformation . patientswith CAD44 and (ii) inappropriate use of revascularization
.
.
needstobeunbiased,evidence-based,up-to-date,reliable,accessible, .. strategieswithalackofcasediscussions.45Themarkedvariabilityin
.
relevant,andconsistentwithlegalrequirements.Useofterminology .. PCI-to-CABG ratios between European countries (ranging from
.
that the patient understands is essential. Short-term procedure- .. 2.4–7.6 in 2013, for example) has raised concerns regarding the
.
related and long-termrisks and benefits—such assurvival, relief of .. appropriateselectionofrevascularizationstrategies.46Ratesforthe
.
angina,qualityoflife,thepotentialneedforlatereintervention,the .. inappropriate use of PCI (10–15%)43,47,48 and CABG (1–2%) are
.
needforpreventionmeasures,anduncertaintiesassociatedwithdif- .. reported.Multidisciplinarydecision-makinginaHeartTeamcanmini-
.
ferent treatment strategies—should be thoroughly discussed. .. mize specialty bias and prevent self-referral from interfering with
.
Althoughcurrentrecommendationsaremostlybasedontheability .. optimalpatientcare.49
.
oftreatmentstoreduceadverseeventsincludingmortality,thereis .. Several reports from different centres have established that the
.
growinginterestinpatient-reportedoutcomemeasures.40,41Patients .. treatmentrecommendations made in multidisciplinaryHeart Team
.
are not only interested to know how recommended treatment .. discussionsarereproducibleandimplementedinthevastmajorityof
.
impactsonprognosisbutalsoontheirqualityoflifeinthewaythey .. cases(93–95%).50,51
.
.
perceiveit.Awrittenevidence-basedpatientinformationdocument . Interdisciplinary institutional protocols should be developed
.
.
shouldbeprovided,potentiallywithdecisionaids. . forcommoncasescenariostoavoidtheneedforsystematiccase-
.
.
Patientsmusthavethetimetoreflectonthetrade-offsimposed . by-case review of all diagnostic angiograms. However, complex
.
.
bytheoutcomeestimates.Inordertoseekasecondopinionorto . cases—defined by the protocols—should be discussed individu- .
.
discuss the findings and consequences with referring physicians, . ally.Inthesecases,revascularizationshouldnotbeperformedat
.
.
enoughtimeshouldbeallowed—uptoseveraldays,asrequired— . the time of diagnostic angiography, to allow sufficient time to
.
.
betweendiagnosticcatheterizationandintervention.Theserecom- . assessallavailableinformationandclearlyexplainanddiscussthe
.
.
mendationspertaintopatientsinastablecondition,forwhomvari- . findingswiththepatient.Therationaleforadecisionandconsen-
.
.
oustreatmentoptions existandwhocanmake adecisionwithout . sus on the optimal revascularization treatment should be docu-
.
.
the constraints of an urgent or emergent situation (Table 3). The . mented on the patient’s chart. In institutions without an on-site
.
.
patient’srighttodeclinethetreatmentoptionrecommendedbythe .. cardiac surgery unit, collaboration with an external cardiac sur-
.
HeartTeamhastoberespected.Patientrefusalofarecommended .. geryunitisrequiredtodesignprotocolsthatdefinewhenHeart
.
treatmentshouldbeacknowledgedinawrittendocumentafterthe .. Teamdiscussionisneeded.
.
patienthas receivedthenecessary informationby theHeartTeam ..
.
members.Inthiscase,thepatientmaybeofferedanalternativetreat- ..
mentoptionbytheHeartTeam.
... 4.3 Timing of revascularization
.
The patient has the right to obtain information on the level of .. Patientsrequiringmyocardialrevascularization maybe atincreased
.
expertise oftheoperator,theworkloadofthecentre,whether all .. risk of adverse events during the waiting period.52 A recent meta-
.
treatment options—including surgery—are available on-site, and .. analysisofobservationalstudiescalculatedthatawaitingperiodof3
.
localresultsintheperformanceofpercutaneousandsurgicalmyo- .. months forsurgicalmyocardialrevascularizationmaybeassociated
.
cardialrevascularizationprocedures.Patientsconsideredforrevascu- .. withtheriskof1deathamong80patients.53Table3showsthepre-
.
larizationshouldalsobeclearlyinformedofthecontinuingneedfor .. ferredtimingofrevascularizationdependingontheclinicalpresenta-
.
medicaltherapy,aswellaslifestylemodificationandothersecondary .. tionandtheextentandlocalizationofCAD.54Sections7and8show
.
preventionstrategies(seesection19).42 .. additional and more specific information in this regard for patients
.
.
. withACS.
.
.
. Ad hoc PCI is defined as a therapeutic intervention performed 4.2 Multidisciplinary decision-making ..
. withinthesameprocedureasthediagnosticcoronaryangiography.
.
(Heart Team) . . AdhocPCIisconvenient,oftencost-effectiveandsafe,andisassoci-
.
.
TheHeartTeam—comprising clinical ornon-invasivecardiologists, . atedwithfeweraccesssitecomplicationsandlowerradiationexpo-
.
cardiacsurgeons, and interventional cardiologists, as wellas anaes- .. sure.55,56However,intheUSA,upto30%ofpatientsundergoingad
. thetistsandotherspecialistsifdeemednecessary—shouldprovidea .. hocPCIarepotentialcandidatesforCABG.56Thisnumbermaybe
.
balanced, multidisciplinary decision-making process.43 Additional .. lowerinEurope.45AlthoughitisnotadvisableforadhocPCItorep-
.
.
inputmaybeneededfromotherspecialtiesinvolvedinthecareof . resentthedefaultapproachforcomplexSCAD,itmaybejustifiedifa
.
.
thepatient.TheHeartTeamshouldmeetonaregularbasistoana- .. full diagnostic work-up, including functional testing, is available and
.
lyse and interpret the available diagnostic evidence, determine the .. thepatientisadequatelyinformedonbothpercutaneousandsurgical
.
needformyocardialrevascularization,andassesstherelativeshort- .. myocardial revascularization options (see section 4.1). Institutional
.
andlong-termsafetyandeffectivenessofthepercutaneousandsurgi- .. protocolsdevelopedbytheHeartTeaminaccordancewithcurrent
.
caloptions.AdhocmeetingsoftheHeartTeamshouldfacilitateand .. Guidelinesshoulddefinespecificanatomicalcriteriaandclinicalsub-
.
supportefficientclinicalworkflows. .. setsthatmaybe—orshouldnotbe—treatedadhoc.Stablepatients
.
Theneedforaninterdisciplinaryapproachisunderlinedbyreports .. withcomplexCAD,asreflectedbyahighSYNTAXscore,shouldin
.
on (i) the underuse of revascularization procedures in 18–40% of . generalbediscussedbytheHeartTeamandnotbetreatedadhoc.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 14 ---
100 ESC/EACTSGuidelines
noitaziralucsaverfognimitdna,tnesnocdemrofnitneitap,syawhtapnoisicedyranilpicsiditluM
3elbaT
SCA
ICPcohdahtiwDACS
ICPcohdatuohtiwDACS
SCA-ETSN
IMETS
kcohS
otgnidroccanoitacidni
traeHotgnidroccanoitacidni
locotorpmaeTtraeH
locotorpmaeT
deriuqertoN
deriuqeR
etucaehtgnirudyrotadnamtoN
etucaehtgnirudyrotadnamtoN
etucaehtgnirudyrotadnamtoN
yranilpicsiditluM
-mocer,noitazilibatsretfa;esahp
esahp
-pusyrotalucriclacinahcem;esahp
gnikam-noisiced
DACSnisadednem
maeTtraeHotgnidroccatrop
locotorp
atnesnocdemrofninettirW
atnesnocdemrofninettirW
ni;atnesnocdemrofninettirW
-nocdemrofnilabrevdessentiW
-nocdemrofnilabrevdessentiW
tnesnocdemrofnI
labrevdessentiwsesacycnegreme
-tirwsselnutneicfifusebyamtnes
elbissopfitnesnocylimafrotnes
tneicfifusebyamtnesnocdemrofni
deriuqeryllagelsitnesnocnet
yaledtuohtiw
cohdA
ksir-hgihrofskeew2nihtiW
h27nihtiwoth2nihtiw:ycnegrU
yaledon:ycnegremE
yaledon:ycnegremE
otemiT
llarofskeew6nihtiwdnabstneitap
airetircksirehtnognidneped
noitaziralucsaver
stneitaprehto
noitnevretnihtiwdeecorP
-gaidmorfemithguonerofwollA
desabnoitnevretnihtiwdeecorP
desabnoitnevretnihtiwdeecorP
desabnoitnevretnihtiwdeecorP
erudecorP
lanoitutitsniotgnidrocca
noedicedotnoitaziretehtaccitson
-noN.ytilibaliava/ecnedivetsebno
-noN.ytilibaliava/ecnedivetsebno
cohdA.ytilibaliava/ecnedivetsebno
traeHybdenfiedlocotorp
.noitnevretnietairporppaeht
otgnidroccadetaertsnoiseltirpluc
otgnidroccadetaertsnoiseltirpluc
degats,noiseltirplucfotnemtaert
.maeT
traeHrolocotorplanoitutitsni
traeHrolocotorplanoitutitsni
snoiseltirpluc-nonfotnemtaert
.noisicedmaeT
.noisicedmaeT
locotorplanoitutitsniotgnidrocca
.noisicedmaeTtraeHro
yranorocetucanoitaveletnemges-TS-non=SCA-ETSN;yregruScicarohT-oidraCrofnoitaicossAnaeporuE=STCAE;ygoloidraCfoyteicoSnaeporuE=CSE;yteicoSralucsavoidraCnaidanaC=SCC;semordnysyranorocetuca=SCA
.noitcrafnilaidracoymnoitaveletnemges-TS=IMETS;esaesidyretrayranorocelbats=DACS;noitnevretniyranorocsuoenatucrep=ICP;emordnys
.serudecorpnoitaziralucsaverllaroftnesnoctneitapfonoitatnemucodehtetacovdaSTCAEdnaCSEehT.tnesnocdemrofninettirwrofksaotderiuqeryllageltoneratahtseirtnuocotylppatonyamsihTa
.noitcnufralucirtnevdesserpedro,)yretragnidnecsedroiretnatfellamixorproesaesidlessev-eerht,tnelaviuqeroesaesidniamtfel(ymotana,)3ssalcSCC(smotpmysereveSb
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 15 ---
ESC/EACTSGuidelines 101
Recommendationsfordecision-makingandpatientinformationintheelectivesetting
Recommendations Classa Levelb
Itisrecommendedthatpatientsundergoingcoronaryangiographyareinformedaboutbenefitsandrisks,aswellaspotential
I C
therapeuticconsequences,aheadoftheprocedure.
Itisrecommendedthatpatientsareadequatelyinformedaboutshort-andlong-termbenefitsandrisksoftherevascularization
I C
procedurewithinformationaboutlocalexperience,andallowedenoughtimeforinformeddecision-making.
ItisrecommendedthatinstitutionalprotocolsaredevelopedbytheHeartTeamtoimplementtheappropriaterevasculariza-
I C
tionstrategyinaccordancewithcurrentGuidelines.
InPCIcentreswithouton-sitesurgery,itisrecommendedthatinstitutionalprotocolsareestablishedwithpartnerinstitutions
I C
providingcardiacsurgery.
PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence.
.
5 Revascularization for stable .. (-0.09,95%CI-0.15to-0.04,P=0.001).ORBITAraisestheissueof
.
coronary artery disease ... whether the symptom relief of PCI in the specific setting of stable
.. single-vesselCADmayberelatedatleastinparttoaplaceboeffect.
.
5.1 Rationale for revascularization
... Limitations of the study, as acknowledged by the investigators and
.. outlinedelsewhere,includetheshortobservationperiod(6weeks),
The indications for revascularization in patients with SCAD who ...
the inclusion of patients with mild symptoms pre-randomization
receive guideline-recommended medical treatment are the persis- ...
(CCSclass0-Iin25%ofpatients),thegroupimbalanceinostialand
tenceofsymptomsdespitemedicaltreatmentand/ortheimprove- ..
. proximallesions(37vs.57%,P=0.005),losstofollow-upafterran-
mentofprognosis.1 ...
domization,andtheinsufficientpowertodetectatruedifference.64
Several studies have shown that myocardial revascularization by ..
. This precludes definite conclusions at this stage. Nevertheless, the
PCI or CABG more effectively relieves angina, reduces the use of ..
. ORBITAstudyunderlinesthevalueofoptimalmedicaltherapyinthe
anti-anginaldrugs,andimprovesexercisecapacityandqualityoflife ..
. managementofSCAD.
comparedwithastrategyofmedicaltherapyaloneduringshort-and ..
. Three year follow-up of the FAME 2 study indicated yearly and
long-termfollow-up(SupplementaryTable1).32,33,57–62Recently,the ..
. sustainedimprovementofangina(10.2vs.28.5%at1monthand5.2
.
ORBITA(ObjectiveRandomisedBlindedInvestigationwithoptimal .
. vs.9.7%at3years)infavourofFFR-guidedPCI,despiteconsiderable .
medicalTherapyofAngioplastyinstableangina)trialrandomlycom- .. crossoverinthemedicaltherapyarm.33Amongpatientswithmulti-
.
pared PCI with placebo (sham procedure) in patients with SCAD .
. vesseldisease,theassessmentoffrequencyofanginaandqualityof
.
duetosingle-vesselCAD(diameterstenosis>70%)andpreserved .
. lifemeasuresintheSYNTAX,FREEDOM(FutureRevascularization
.
LV function in the presence of moderate symptoms of angina .
.. EvaluationinPatientswithDiabetesMellitus),andEXCEL(Evaluation
[CanadianCardiovascularSociety(CCS)classIIin59% ofpatients, .
duration9months]forthefirsttime.63After6weeksofmedication
... ofXIENCEVersusCoronaryArteryBypassSurgeryforEffectiveness
.. ofLeftMainRevascularization)trialsconsistentlyshowedearlyand
optimization(meannumberofanti-anginaldrugs:3)andbaselinecar- .
.. sustainedimprovementforbothPCIandCABGduringlong-termfol-
diopulmonaryexercisetesting,200patientswererandomized(105 .
.. low-up.65–67
PCIand95placebo).Followinga6-weekpost-randomizationperiod, .
.
.
theprimaryendpointofincrementinexercisetimewasnotsignifi- .
.
cantly different, but estimates were imprecise (PCI minus placebo ... 5.2 Evidence basis for revascularization
.
16.6sec,95%CI–8.9to42.0,P=0.20).Thedobutaminestressecho- .. Theindicationsforrevascularizationinpatientswithstableanginaor
.
cardiographypeakstresswallmotionscoreindeximprovedwithPCI . silentischaemiaaresummarizedintherecommendationtable.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 16 ---
102 ESC/EACTSGuidelines
Indicationsforrevascularizationinpatientswithstableanginaorsilentischaemia
ExtentofCAD(anatomicaland/orfunctional) Classa Levelb
For Leftmaindiseasewithstenosis>50%.c68–71 I A
prognosis
ProximalLADstenosis>50%.c62,68,70,72 I A
Two-orthree-vesseldiseasewithstenosis>50%withimpairedLVfunction(LVEF<_35%).c61,62,68,70,73–83 I A
Largeareaofischaemiadetectedbyfunctionaltesting(>10%LV)orabnormalinvasiveFFR.d24,59,84–90 I B
Singleremainingpatentcoronaryarterywithstenosis>50%.c I C
Forsymptoms Haemodynamicallysignificantcoronarystenosiscinthepresenceoflimitinganginaoranginaequivalent,
I A
withinsufficientresponsetooptimizedmedicaltherapy.e24,63,91–97
CAD=coronaryarterydisease;FFR=fractionalflowreserve;iwFR=instantaneouswave-freeratio;LAD=leftanteriordescendingcoronaryartery;LV=leftventricular;
LVEF=leftventricularejectionfraction.
aClassofrecommendation.
bLevelofevidence.
cWithdocumentedischaemiaorahaemodynamicallyrelevantlesiondefinedbyFFR<_0.80oriwFR<_0.89(seesection3.2.1.1),or>90%stenosisinamajorcoronaryvessel.
dBasedonFFR<0.75indicatingaprognosticallyrelevantlesion(seesection3.2.1.1).
eInconsiderationofpatientcomplianceandwishesinrelationtotheintensityofanti-anginaltherapy.
.
.
5.2.1Revascularizationwiththeuseofpercutaneous . with SCAD and left main (LM) orthree-vessel disease,particularly
.
.
coronaryintervention . whentheproximalLADcoronaryarterywasinvolved,andhasbeen
.
Severalmeta-analysescomparingastrategyofPCIwithinitialmedical .. corroboratedinmorerecentstudies.100,101Anetworkmeta-analysis
.
.
therapyamongpatientswithSCADfoundnooronlymodestbene- . of100trialswith93553patientscomparingastrategyofinitialmedi-
.
.
fits in terms of survival or MI for an invasive strategy, taking into . cal therapy with revascularization reported improved survival (RR
.
.
account the fact that up to 40% of patients crossed over after to . 0.80,95%CI0.63–0.99)andareducedriskofMI(RR0.79,95%CI
.
revascularization during longer-term follow-up.91,98,99 A network .. 0.83–0.99)amongpatientsundergoingCABGcomparedwithinitial
.
meta-analysisof100trialswith93553patientsand262090patient- .. medicaltreatment.100
.
.
years of follow-up comparing a strategy of initial medical therapy .. In the STICH trial, 1212 patients with CAD and an LV ejection
.
with revascularization reported improved survival using PCI with .. fraction(LVEF)<_35%wererandomizedtoinitialmedicaltherapyor
.
new-generationDES(everolimus:rateratio0.75,95%CI0.59–0.96; .. CABG.Theextended10yearfollow-upoftheSTICHtrialreported
.
zotarolimus:rateratio0.65,95%CI0.42–1.00)comparedwithinitial .. a significant reduction in all-cause (59 vs. 66%; HR 0.84, 95% CI
.
medicaltreatment.100 .. 0.73–0.97; P ¼ 0.02)and cardiovascularmortality (41 vs.49%; HR
.
IntheFAME2trial,32patientswithSCADandatleastonefunc- .. 0.79,95%CI0.66–0.93;P¼0.006).81Foranoverviewofstudies,see
.
tionally significant stenosis (invasive FFR <_0.80) were randomly .. SupplementaryTable2.
.
assignedtomedicaltherapyormedicaltherapyplusFFR-guidedPCI ..
.
using new-generation DES. The 3 year report of the FAME 2 trial .. 5.3 Percutaneous coronary intervention
.
reportedalowerincidenceoftheprimarycompositeendpointsof ...
vs. coronary artery bypass grafting
death, MI, and urgent revascularization (10.1 vs. 22.0%; P <0.001), ..
driven by a lower incidence of urgent revascularization in the PCI
... The recommendations for thetype ofrevascularization (CABG or
.. PCI)inpatientswithSCADwithsuitablecoronaryanatomyforboth
group(4.3vs.17.2%;P<0.001)andwithoutsignificantdifferencesin .
theratesofdeathandMI.33At2yearsoffollow-up,therateofdeath
... procedures and low predicted surgical mortality are summarized
.. below.TheHeartTeamshouldtakeintoconsiderationtheindividual
orMIwaslowerinthePCIthanthemedicaltherapygroup(4.6vs. .
.. cardiacandextracardiaccharacteristics,inadditiontopatientprefer-
8.0%; HR 0.56, 95% CI 0.32–0.97, P = 0.04) in a landmark analysis .
.. ence,intheoveralldecision-makingprocess(Figure3).Asummaryof
between8daysand2yearsoffollow-up,whereaseventrateswere .
.. trialscomparingtheoutcomesofpatientstreatedwithangioplastyvs.
higherduringdays 0-7 dueto periprocedural MI (foroverview of .
studiesseeSupplementaryTable2).97
... CABG and bare-metal stent (BMS) vs. CABG is shown in
.
. SupplementaryTable3,andofstudiescomparingDESandCABGin
.
.
. Table4.
.
.
.
5.2.2Revascularizationwiththeuseofcoronaryartery ..
.
bypassgrafting .. 5.3.1Criteriafordecision-making
.
ThesuperiorityofCABG over a strategyofinitial medicaltherapy .. Predictedsurgicalmortality,theanatomicalcomplexityofCAD,and
.
wasestablishedinameta-analysisofsevenRCTs68morethantwo .. theanticipatedcompletenessofrevascularizationareimportantcri-
.
decades ago, demonstrating a survival benefit of CABG in patients . teriafordecision-makingwithrespecttothetypeofrevascularization
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 17 ---
ESC/EACTSGuidelines 103
noitaziralucsaverlacigrus.svstnetsgnitule-gurdhtiwnoitnevretniyranorocsuoenatucrepgnirapmocslairtlacinilcdezimodnaR
4elbaT
astniopdneyradnoceS
atniopdneyramirP
scitsiretcarahcenilesaB
N
ydutS
epyttnetS foraeydna
ekortS
csaveR
IM
htaeD
Y
stluseR
Y
noitinfieD
)%(FE
esaesidVM
setebaiD
nemoW
egA
noitacilbup
)%(
)%(
)%(
)y(
SED
%7.3.sv4.2
.sv9.52
*%8.3.sv7.9
%4.11.sv9.31
5
%4.21.sv8.71
1
,ekorts,IM,htaeD
-
93ML16VM
52
22
56
0081
201XATNYS
9002SEP
*%7.31
csavertaeperro
-
%9.5.sv41
%3.sv3
%5.sv2
1
%91.sv9.31
1
ro,IM,htaeD
56
001ML
63
52
86
102
301toirduoB
1102SES
csavertaeper
%7.0.sv4.0
*%2.4.sv0.9
%0.1.sv7.1
%4.3.sv4.2
2
b%7.6.sv7.8
1
,ekorts,IM,htaeD
16
001ML
23
42
26
006
401TABMOCERP
1102SES
RVTro
%3.3.sv9.2
%6.6.sv4.31
%7.2sv8.4
%0.5.sv6.6
5
%9.7.sv0.11
2
RVTro,IM,htaeD
06
001VM
14
92
46
088
501TSEB
5102SEE
%7.1.sv9.4
*%4.01.sv2.61
c*%9.1.sv9.6
%5.9.sv6.11
5
%2.7.sv4.51
5
RVTro,IM,htaeD
06
001ML
51
22
66
1021
601ELBON
6102SEB
%9.2.sv3.2
*%6.6.sv4.31
%3.8.sv0.8
%9.5.sv2.8
3
b%7.41.sv4.51
3
ekortsro,IM,htaeD
75
001ML
03
42
66
5091
701LECXE
6102SEE
.snaemsadetropereraFEdnaegA
.50.0<P*
;stnetsgnitule-gurd=SED;esaesiDyretrAyranoroClessevitluMhtiwstneitaPfotnemtaerTehtninoitatnalpmItnetSgnitulE-sumilorevEdnayregruSssapyByretrAyranoroCfonosirapmoCdesimodnaR=TSEB;stnetsgnitule-sumiloib=SEB -crafnilaidracoym=IM;esaesidyretrayranorocniamtfel=ML;noitaziralucsaveRniaMtfeLfossenevitceffErofyregruSssapyByretrAyranoroCsusreVECNEIXfonoitaulavE=LECXE;noitcarfnoitceje=FE;tnetsgnitule-sumiloreve=SEE ytsalpoignAsusrevyregruSssapyBfonosirapmoCdesimodnaRforeimerP=TABMOCERP;stnetsgnitule-lexatilcap=SEP;ydutSnoitaziralucsaveRniaMtfeLhsitirB-citlaB-cidroN=ELBON;esaesidyretrayranoroclessevitlum=VM;noit caidraCdnaSUXAThtiwnoitnevretnIyranoroCsuoenatucrePneewtebygrenyS=XATNYS;stnetsgnitule-sumiloris=SES;noitaziralucsaver=csaveR;esaesiDyretrAyranoroCniaMtfeLhtiwstneitaPnitnetSgnitulE-sumiloriSgnisU
.sraey=Y;noitaziralucsaverlessevtegrat=RVT;yregruS
.gnitfargssapybyretrayranoroc.svnoitnevretniyranorocsuoenatucrepsadetropererastluseRa
.temytiroirefni-noNb
.)IMlarudecorpirepfonoisulcxe(IMlarudecorp-noNc
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 18 ---
104 ESC/EACTSGuidelines
(CABG or PCI). Whether conservative therapy, PCI, or CABG is
Table5 LogisticEuroSCOREsinmajorrandomized
preferredshoulddependontherisk-benefitratiosofthesetreatment
trialscomparingpercutaneouscoronaryintervention
strategies,weighinguptherisksofperiproceduralcomplications(e.g. withcoronaryarterybypassgrafting
cerebrovascularevents,bloodtransfusions,renalfailure,newonset
arrhythmias, or wound infections) against improvements in health-
Trial EuroSCOREPCI EuroSCORECABG
relatedqualityoflife,aswellaslong-termfreedomfromdeath,MI,or
repeatrevascularization. SYNTAX 3.8±2.6 3.8±2.7
BEST 2.9±2.0 3.0±2.1
5.3.1.1Predictedsurgicalmortality
Toassessthepredictedsurgicalmortality,theEuropeanSystemfor FREEDOM 2.7±2.4 2.8±2.5
CardiacOperativeRiskEvaluation(EuroSCOREII)(www.euroscore.
PRECOMBAT 2.7±1.8 2.8±1.9
org/calc.html) and the Society of Thoracic Surgeons (STS) score
(http://riskcalc.sts.org)werebothdevelopedbasedonclinicalvaria- EXCEL Notreported Notreported
bles to estimate the operative in-hospital or 30 day mortality
risk108–110(SupplementaryTable4).Bothscoreshavedemonstrated NOBLE 2(2–4) 2(2–4)
their value in specific cohorts of patients undergoing CABG.111
CalibrationoftheSTSscoreisupdatedonaregularbasis.Ithasbeen Numbersarepresentedasmean±SDormedian(interquartilerange).
BEST = Randomised Comparison of Coronary Artery Bypass Surgery and
suggestedthattheSTSscoreoutperformstheEuroSCOREIIwhen
Everolimus-Eluting Stent Implantation in the Treatment of Patients with compareddirectlyinacohortofCABGpatients,112althoughother
MultivesselCoronaryArteryDisease;CABG=coronaryarterybypassgrafting;
studieshavefoundcomparableperformanceofbothmodels.113,114 EuroSCORE=EuropeanSystemforCardiacOperativeRiskEvaluation;EXCEL
= Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for
Therearenoestablishedcut-offsforlowpredictedsurgicalmor-
EffectivenessofLeftMainRevascularization;NOBLE=Nordic-Baltic-BritishLeft
talitybasedontheEuroSCOREIIorSTSscore.Thus,individualized Main Revascularization Study; PCI = percutaneous coronary intervention;
treatmentdecisionsareneeded.Thesedecisionsshouldrespectthe PRECOMBAT=PremierofRandomisedComparisonofBypassSurgeryversus
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary
rangeofpredictedsurgicalrisksinthemajorRCTsthatinformthe
Artery Disease; SYNTAX = Synergy between Percutaneous Coronary
choice of revascularization modality (Table 5). In these studies, InterventionwithTAXUSandCardiacSurgery.
thepredictedsurgicalriskwasassessedbythelogisticEuroSCORE.
Compared with the more recent EuroSCORE II, the logistic
EuroSCORE has similar discrimination but poorer calibration and,
thus,overestimatessurgicalmortalitybyroughlytwo-fold.115 ... complexityofcoronarylesionsinpatients withLMorthree-vessel
.
Despite theusefulness ofthese scores, thereis not a single risk .. disease (Table 6 and Supplementary Table 4).116 In the cohort of
.
modelthatprovidesperfectriskassessmentbecausethescoresare .. the SYNTAXtrial,andsubsequentlyinexternalvalidationcohorts,
.
limitedby(i)thespecificdefinitionsusedorthemethodologyapplied, .. the SYNTAX score was found to be an independent predictor of
.
(ii)theabsenceofimportantvariablessuchasfrailty,(iii)thepractic- .. long-term major adverse cardiac and cerebrovascular events
.
abilityofcalculation,(iv)afailuretoreflectallrelevantmortalityand .. (MACCE) and of death in patients treated with PCI but not
.
morbidity endpoints, and (v) limited external validation. Decision- .. CABG.117–120
.
makingshouldnotbesolelydependentonriskscores.Thesescores .. Inthe SYNTAXtrial, tertilesofSYNTAXscore withlow,inter-
.
should be used as a guide within the multidisciplinary Heart Team .. mediate,andhighanatomicalcomplexitystratifiedpatientsintothose .
discussion. .. whohadsimilaroutcomeswithbothPCIandCABGandthosewho
.
Tocombineclinicalandanatomicalriskestimation,theSYNTAXII .. derived significant benefit from CABG.121–123 In subsequent RCTs,
.
scorewasretrospectivelyderivedfromtheSYNTAXcohort127and .. theinteractionofthestrataofSYNTAXscorewiththeeffectofthe
.
subsequentlyexternallyvalidated.120,128,129Nevertheless,compared .. randomizedtreatmentwaslesspronouncedanddidnotreachstatis-
.
with the SYNTAX score, its value in assigning patients to PCI or .. ticalsignificance.105–107However,inarecentcollaborativeindividual
.
.
CABGislesswellinvestigated.ThefactthattheSYNTAXIIscore . patient pooled analysis of randomized trials including 11518
. failed to predict the outcome of the EXCEL trial raises additional .. patients,124 the test for trend across the ordered tertiles of the
.
concern.130 .. SYNTAX score of the SYNTAX study was positive at P = 0.0011
.
.
. (unpublishedanalysis),confirmingthestrataoftheSYNTAXscoreas
.
.
5.3.1.2Anatomicalcomplexityofcoronaryarterydisease .. aneffectmodifiertobeconsidered.Thereisconcernaboutbiasand
.
The SYNTAX score (http://www.syntaxscore.com) was prospec- .. inter-individual variability in calculating the SYNTAX score.125 This
.
tively developed for the SYNTAX trial to grade the anatomical . shouldbeminimizedbyadequatetraining.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 19 ---
ESC/EACTSGuidelines 105
Table6 GuideforcalculatingtheSYNTAXscore
Steps Variableassessed Description
Step1 Dominance Theweightofindividualcoronarysegmentsvariesaccordingtocoronaryarterydominance(rightorleft).Co-
dominancedoesnotexistasanoptionintheSYNTAXscore.
Step2 Coronarysegment Thediseasedcoronarysegmentdirectlyaffectsthescoreaseachcoronarysegmentisassignedaweightdepend-
ingonitslocation,rangingfrom0.5(i.e.theposterolateralbranch)to6(i.e.leftmainincaseofleftdominance).
Step3 Diameterstenosis Thescoreofeachdiseasedcoronarysegmentismultipliedbytwoincaseofastenosis50–99%andbyfivein
caseoftotalocclusion.
Incaseoftotalocclusion,additionalpointswillbeaddedasfollows:
• Age>3monthsorunknown þ1
• Bluntstump þ1
• Bridging þ1
• Firstsegmentvisibledistally þ1pernon-visiblesegment
• Sidebranchattheocclusion þ1if<1.5mmdiameter
þ1ifboth<1.5mmand>_1.5mmdiameter
þ0if>_1.5mmdiameter(i.e.bifurcationlesion)
Step4 Trifurcationlesion Thepresenceofatrifurcationlesionaddsadditionalpointsbasedonthenumberofdiseasedsegments:
(cid:2)1segment þ3
(cid:2)2segments þ4
(cid:2)3segments þ5
(cid:2)4segments þ6
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 20 ---
106 ESC/EACTSGuidelines
Step5 Bifurcationlesion Thepresenceofabifurcationlesionaddsadditionalpointsbasedonthetypeofbifurcationaccordingtothe
Medinaclassification:126
• Medina1,0,0–0,1,0–1,1,0 þ1
• Medina1,1,1–0,0,1–1,0,1–0,1,1 þ2
Moreover,thepresenceofabifurcationangle<70(cid:3)addsoneadditionalpoint
Step6 Aorto-ostiallesion Thepresenceofaorto-ostiallesionsegmentsaddsoneadditionalpoint
Step7 Severetortuosity Thepresenceofseveretortuosityproximalofthediseasedsegmentaddstwoadditionalpoints
Step8 Lesionlength Lesionlength>20mmaddsoneadditionalpoint
Step9 Calcification Thepresenceofheavycalcificationaddstwoadditionalpoints
Step10 Thrombus Thepresenceofthrombusaddsoneadditionalpoint
Step11 Diffusedisease/ Thepresenceofdiffuselydiseasedandnarrowedsegmentsdistaltothelesion(i.e.whenatleast75%ofthe
smallvessels lengthofthesegmentdistaltothelesionhasavesseldiameter<2mm)addsonepointpersegmentnumber
SYNTAX=SynergybetweenPercutaneousCoronaryInterventionwithTAXUSandCardiacSurgery.
.
5.3.1.3Completenessofrevascularization .. BEST(RandomisedComparisonofCoronaryArteryBypassSurgery
.
The aim of myocardial revascularization is to minimize residual .. and Everolimus-Eluting Stent Implantation in the Treatment of
.
ischaemia. In support of this concept, the nuclear substudy of the .. Patients with Multivessel Coronary Artery Disease), and
.
COURAGE (Clinical Outcomes Utilizing Revascularization and .. PRECOMBAT (Premier of Randomised Comparison of Bypass
.
AggressiveDrugEvaluation)trialdemonstratedanincrementalbene- .. SurgeryversusAngioplastyUsingSirolimus-ElutingStentinPatients
.
fitinreducingthe riskofdeathand MIbyreducingresidualstress- .. withLeftMainCoronaryArteryDisease)trials.136AmeanSYNTAX
.
inducedischaemiafrom>10%ofthemyocardiumto<_5%.86 .. score of 27 and an LVEF of 59% were obtained. In a propensity-
.
.
In theSYNTAXtrial, anatomical complete revascularization was . matchedanalysis,mortalityandthecompositeriskofdeath,MI,and
.
.
defined as PCI or bypass of all epicardial vessels with a diameter . stroke were significantly lower after PCI with complete vs. incom-
.
.
exceeding>_1.5mmandaluminalreductionof>_50%inatleastone . plete revascularization. After PCI with complete revascularization,
.
angiographicview.131Ameta-analysisof89883patientsenrolledin .. theriskofdeathorofthecompositeofdeath,MI,orstrokewasnot
.
.
RCTsandobservationalstudiesrevealedalowerlong-termmortality . significantlydifferentfromthatafterCABGwithcompleterevascula-
.
.
(RR 0.71, 95% CI 0.65–0.77, P <0.001), MI (RR 0.78, 95% CI . rization(adjustedHR1.16,95%CI0.83–1.63,P=0.39,and1.14,95%
.
.
0.68–0.90;P= 0.001),andrepeatmyocardialrevascularization(RR . CI0.87–1.48,P=0.35,respectively),whereastheserisksweresignifi-
.
.
0.74, 95% CI 0.65–0.83; P <0.001) by complete revascularization . cantlyelevatedafterPCIwithincompleterevascularization.
.
. (basedonanatomicaldefinitionin87%ofthepatients)ascompared .. Functionalcompleterevascularizationisachievedwhenalllesions
. withincompleterevascularization.132Thebenefitofcompleterevas- .. causingrestingorstress-inducedischaemiaarebypassedortreated
.
cularization was independent of the treatment modality. A more .. byPCI.Giventhelimitationsofnon-invasiveimagingtechniques(see
.
recent meta-analysis suggested enhanced benefit when complete .. section3),theselesionsareidentifiedbyFFRoriwFRduringdiagnos-
.
revascularization is performed with state-of-the-art techniques in .. tic angiography. For PCI, the FAME study demonstrated that the
.
high-riskpatients.133Likewise,inaposthocanalysisoftheSYNTAX .. more restrictive selection of target lesions by functional guidance
.
trial, anatomical incomplete revascularization was associated with .. conferredsuperiorlong-termoutcomescomparedwithanatomically
.
inferiorlong-termoutcomesafterbothCABGandPCI.131Aresidual .. guidedlesionselection(seesection3).31Incontrast,leavingfunction-
.
SYNTAXscore>8afterPCIwasassociatedwithsignificantincreases .. allyrelevantlesionsuntreatedresultedinahighrateofreinterven-
.
in the5-year risk ofdeath and ofthe composite of death, MI, and .. tions in the FAME 2 study.33 Based on the data of the FAME and
.
stroke,andanyresidualSYNTAXscore>0wasassociatedwiththe .. FAME2studies,completerevascularizationbasedonthefunctional
.
risk of repeat intervention.134 In an observational study from the .. definitionisthepreferredstrategyforPCI.
.
NewYorkStateregistrythatcomparedCABGwithPCIusingnew- .. TheroleoffunctionalguidanceforCABGislessclear.28,137One
.
.
generation DES [everolimus-eluting stent (EES)] in 9223 pairs of . ofthepotentialbenefitsofCABGisprotectionagainstdiseasepro-
.
.
propensity-matchedpatientswithmultivesselCAD,thesignificantly . gressioninproximalsegments,whichmaybediminishedbyrestrict-
.
.
higherriskofMIassociatedwithPCIascomparedwithCABGwas . ingthebypasstargetstofunctionallyrelevantlesions.Thishastobe
.
.
notseenamongmatchedpairsofpatientsinwhichthePCIgrouphad . weighedagainsttheriskofbypassclosurewhennativevesselflowis
.
completerevascularization(P =0.02).135Consistentfindings .. high. Thus, for ambiguous lesions, functional testing may also help
interaction .
.
wereobtainedinapooledanalysisof3212patientsoftheSYNTAX, . guidethesurgicalrevascularizationstrategy.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 21 ---
Recommendationsoncriteriaforthechoicebetweencoronaryarterybypassgraftingandpercutaneouscoronary
intervention
Recommendations Classa Levelb
Assessmentofsurgicalriskc
ItisrecommendedthattheSTSscoreiscalculatedtoassessin-hospitalor30daymortality,andin-hospitalmorbidity
I B
afterCABG.112,114,138
CalculationoftheEuroSCOREIIscoremaybeconsideredtoassessin-hospitalmortalityafterCABG.112 IIb B
AssessmentofCADcomplexity
InpatientswithLMormultivesseldisease,itisrecommendedthattheSYNTAXscoreiscalculatedtoassesstheana-
I B
tomicalcomplexityofCADandthelong-termriskofmortalityandmorbidityafterPCI.117–124
WhenconsideringthedecisionbetweenCABGandPCI,completenessofrevascularizationshouldbeprioritized.131,132,134–136 IIa B
EuroSCORE=EuropeanSystemforCardiacOperativeRiskEvaluation;CABG=coronaryarterybypassgrafting;CAD=coronaryarterydisease;LM=leftmain;PCI=percu-
taneouscoronaryintervention;STS=SocietyofThoracicSurgeons;SYNTAX=SynergybetweenPercutaneousCoronaryInterventionwithTAXUSandCardiacSurgery.
aClassofrecommendation.
bLevelofevidence.
cLevelofevidencereferstopredictionofoutcomes.
Recommendationforthetypeofrevascularizationinpatientswithstablecoronaryarterydiseasewithsuitablecoro-
naryanatomyforbothproceduresandlowpredictedsurgicalmortalityd
RecommendationsaccordingtoextentofCAD CABG PCI
Classa Levelb Classa Levelb
One-vesselCAD
WithoutproximalLADstenosis. IIb C I C
WithproximalLADstenosis.68,101,139–144 I A I A
Two-vesselCAD
WithoutproximalLADstenosis. IIb C I C
WithproximalLADstenosis.68,70,73 I B I C
LeftmainCAD
LeftmaindiseasewithlowSYNTAXscore(0-22).69,121,122,124,145–148 I A I A
LeftmaindiseasewithintermediateSYNTAXscore(23-32).69,121,122,124,145–148 I A IIa A
LeftmaindiseasewithhighSYNTAXscore(>_33).c69,121,122,124,146–148 I A III B
Three-vesselCADwithoutdiabetesmellitus
Three-vesseldiseasewithlowSYNTAXscore(0-22).102,105,121,123,124,135,149 I A I A
Three-vesseldiseasewithintermediateorhighSYNTAXscore(>22).c102,105,121,123,124,135,149 I A III A
Three-vesselCADwithdiabetesmellitus
Three-vesseldiseasewithlowSYNTAXscore0–22.102,105,121,123,124,135,150–157 I A IIb A
Three-vesseldiseasewithintermediateorhighSYNTAXscore(>22).c102,105,121,123,124,135,150–157 I A III A
SYNTAXscorecalculationinformationisavailableathttp://www.syntaxscore.com.
CABG=coronaryarterybypassgrafting; CAD=coronaryarterydisease;LAD=leftanteriordescendingcoronaryartery; PCI=percutaneouscoronaryintervention;
SYNTAX=SynergybetweenPercutaneousCoronaryInterventionwithTAXUSandCardiacSurgery.
aClassofrecommendation.
bLevelofevidence.
cPCIshouldbeconsiderediftheHeartTeamisconcernedaboutthesurgicalriskorifthepatientrefusesCABGafteradequatecounsellingbytheHeartTeam.
dForexample,absenceofpreviouscardiacsurgery,severemorbidities,frailty,orimmobilityprecludingCABG(alsoseeTable5).
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 22 ---
108 ESC/EACTSGuidelines
PCI CABG
Left internal thoracic
artery to left anterior
descending
Left coronary artery
Right internal thoracic
artery or radial artery
Right coronary Circumflex
artery coronary artery
Sequential anastomosis
Left anterior to obtuse marginal
descending
1 and 3
coronary
artery
Distal right
coronary
artery
FAVOURS PCI FAVOURS CABG
Clinical characteristics Clinical characteristics
Presence of severe co-morbidity (not adequately reflected Diabetes
by scores) Reduced LV function (EF ≤35%)
Advanced age/frailty/reduced life expectancy Contraindication to DAPT
Restricted mobility and conditions that affect the Recurrent diffuse in-stent restenosis
rehabilitation process
Anatomical and technical aspects
Anatomical and technical aspects
MVD with SYNTAX score ≥23
MVD with SYNTAX score 0–22
Anatomy likely resulting in incomplete revascularization
Anatomy likely resulting in incomplete revascularization with PCI
with CABG due to poor quality or missing conduits
Severely calcified coronary artery lesions limiting lesion
Severe chest deformation or scoliosis expansion
Sequelae of chest radiation
Need for concomitant interventions
Porcelain aortaa
Ascending aortic pathology with indication for surgery
Concomitant cardiac surgery
CABG = coronary artery bypass grafting; Cx = circumflex; DAPT = dual antiplatelet therapy; EF = ejection fraction; LAD = left anterior descending
coronary artery; LIMA = left internal mammary artery; LV= left ventricular; MVD = multivessel coronary artery disease; PCI = percutaneous
coronary intervention; PDA = posterior descending artery; RA = radial artery; RIMA = right internal mammary artery; SYNTAX = Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
aConsider no-touch off-pump CABG in case of porcelain aorta.
Figure 3 AspectstobeconsideredbytheHeartTeamfordecision-makingbetweenpercutaneouscoronaryinterventionandcoronaryartery
bypassgraftingamongpatientswithstablemultivesseland/orleftmaincoronaryarterydisease.
8102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 23 ---
ESC/EACTSGuidelines 109
.
.
5.3.2Isolatedproximalleftanteriordescendingcoronary . anatomical complexity, the number of patients studied in RCTs is
.
.
arterydisease . lowduetoexclusioncriteria;theriskestimatesandCIsareimpre-
.
.
Comparing CABG and PCI among patients with isolated proximal . cise, but suggest a trend towards better survival with CABG.
.
.
LAD disease, the available evidence suggests similar outcomes in . Therefore,PCIinthissettingcannotbeendorsedasreflectedbya
.
.
termsofdeath,MI,andstroke,butahigherriskofrepeatrevasculari- . classIIIrecommendation.ForPCIinLMwithintermediateanatomical
.
zationwithPCI.68,70,73,101,139–144 .. complexity,thepreviousclassIIarecommendationwasmaintainedin
.
.
. viewoftheincomplete5yearfollow-upofthetwolargestRCTsin
.
.
5.3.3Leftmaincoronaryarterydisease .. thissetting.
.
The available evidence from RCTs and meta-analyses comparing ..
.
CABGwithPCIusingDESamongpatientswithLMdiseasesuggests .. 5.3.4Multivesselcoronaryarterydisease
.
equivalentresultsforthesafetycompositeofdeath,MI,andstroke .. TheobservationofasurvivaladvantageofCABGoverPCIhasbeen
.
upto 5 years offollow-up.148 A significant interaction with time is .. consistentamongpatientswithseverethree-vesselCAD(intermedi-
.
notable, providing early benefit for PCI in terms of MI and peri- .. atetohighSYNTAXscore),andhasbeenattributedatleastinpart
.
interventionalstroke,whichissubsequentlyoffsetbyahigherriskof .. totheplacementofbypassgraftstothemidcoronaryvesselsprovid-
.
spontaneous MI during long-term follow-up. The need for repeat .. ingprophylaxisagainstthedevelopmentofnewproximaldisease.
.
revascularizationishigherwithPCIthanwithCABG. .. TheBESTtrial,comparingCABGwithPCIusingnew-generation
.
.
TheEXCELtrialcomparedCABGwithPCIusingnew-generation . DES(EES)amongpatientswithmultivesselCAD(77%three-vessel
.
DES(EES)among1905patientswithsignificantLMdisease.107At3 .. CADand23%two-vesseldisease,meanSYNTAXscore24),prema-
. .
years of follow-up, the primary endpoint of death, stroke, or MI . turelystoppedenrolmentaftertheinclusionof880patientsdueto
.
occurredwithsimilarfrequencyintheCABGandPCIgroup(14.7vs. .. slow recruitment.105 At a median follow-up of 4.6 years, PCI was
.
.
15.4%;HR1.00,95%CI0.79–1.26,P=0.98).Thepre-plannedland- . associated with a higher incidence ofthe primary endpoint (death,
.
.
markanalysisfrom30daysto3yearsshowedasignificantdifference . MI,andTVR)(15.3vs.10.6%;HR1.47,95%CI1.01–2.13,P=0.04)
.
.
fortheprimaryendpointinfavourofCABG(7.9vs.11.5%,P=0.02). . thanCABG.Theriskofdeath,MI,andstrokewasnotstatisticallydif-
.
.
The NOBLE (Nordic-Baltic-British Left Main Revascularization . ferentbetweenthe twotreatmentgroups(11.9vs.9.5%; HR1.26,
.
.
Study) trial compared CABG with PCI using new-generation DES . 95%CI0.84–1.89,P=0.26),whereasrepeatrevascularizationofany
.
.
[biolimus-eluting stents (BES)]among1201patients withsignificant . vessel(11.0vs.5.4%;HR2.1,95%CI1.28–3.41,P=0.003)butnot
.
.
LMdisease(meanSYNTAXscoreof23).106Atamedianfollow-up .. target lesion revascularization (5.7 vs. 3.8%; HR 1.51, 95% CI
.
of 3.1 years, the primary endpoint of death, non-procedural MI, .. 0.82–2.80, P = 0.19) was more frequent in the PCI group. CABG
.
stroke,andrepeatrevascularizationoccurredmorefrequentlyinthe .. resulted in more complete revascularization (71.5 vs. 50.9%;
.
PCIthantheCABGgroup(29vs.19%;HR1.48,95%CI1.11–1.96, .. P<0.001)andalowerincidenceofrevascularizationfornewlesions
.
P=0.007). .. (5.5vs.2.3%;HR2.47,95%CI1.18–5.17,P=0.01).
.
A recent collaborative individual patient pooled analysis of .. Consistentwithfindingsintheoverallcohort(seesection5.3.3),
.
randomized trials including 11 518 patients reviewed the currently .. thecollaborativeindividualpatientpooledanalysisfoundthatin7040
.
availableevidencefromrandomizedtrialscomparingCABGwithPCI .. patientswithmultivesseldisease,thoseassignedtoCABGhadsignifi-
.
forLMormultivesseldisease.124Theprimaryoutcomewasall-cause .. cantly lower 5 year all-cause mortality than those assigned to PCI
.
mortality.Intheoverallcohort,CABGwasassociatedwithasignifi- .. (PCI11.5vs.CABG8.9%;HR1.28,95%CI1.09–1.49,P=0.0019).124
.
cant survivalbenefitduring a meanfollow-upof3.8± 1.4years (5 .. Outcomesfortheendpointall-causemortalityweremodifiedbytwo .
year all-cause mortality 11.2% after PCI vs. 9.2% after CABG; HR .. variables, diabetes and disease complexity, as assessed by the
.
.
1.20, 95% CI 1.06–1.37, P = 0.0038).There was a linear trend for . SYNTAX score. Compared with patients without diabetes (8.7 vs.
.
.
HRsofdeathincreasingwithincreasingSYNTAXtertiles[P=0.0011 . 8.0%;HR1.08,95%CI0.86–1.36,P=0.49),mortalitywashigherafter
.
. for trend (unpublished analysis)]. However, among 4478 patients . PCIthanCABGinpatientswithdiabetes(15.5vs.10.0%;HR1.48,
.
.
withLMdisease,those randomlyassigned toCABGorPCIwith a . 95%CI1.19–1.84,P=0.0004,P =0.045).Therewasagra-
. interaction
.
meanfollow-upof3.4±1.4yearsreportedsimilarrisksforthepri- . dientofriskwithastepwiseincreaseinmortalityforPCIaccording
. .
mary outcome all-cause mortality (PCI 10.7 vs. CABG 10.5%; HR . toSYNTAXscoretertile(SYNTAXscore0-22:10.5vs.8.4%;HR
.
.
1.07,95%CI0.87–1.33,P=0.52)at5years.Therewerenosignifi- . 1.11, 95% CI 0.77–1.62, P = 0.57; SYNTAX score 23-32: 14.0 vs.
.
.
cant differences in mortality between PCI and CABG in subgroup . 9.5%;HR1.50,95%CI1.09–2.08,P=0.0129;SYNTAXscore>32:
.
.
analyses according to SYNTAX scores. Nevertheless, in patients . 19.2vs.11.2%;HR1.70,95%CI1.13–2.55,P=0.0094).
.
.
with a high SYNTAX score, a trend towards better survival was . AnindividualpatientdatapooledanalysisofSYNTAXandBEST,
.
.
notedwithCABG.TheproportionofpatientswithahighSYNTAX . comparingCABGwithPCIusingDESamong1275patientswithmul-
.
.
scorewaslimitedinviewoftheinclusioncriteriaoftherespective .. tivesseldiseaseintheabsenceofdiabetes(89% three-vesselCAD,
.
studies. .. mean SYNTAX score 26), reported a lower risk of death (6.0 vs.
.
CurrentevidenceindicatesthatPCIisanappropriatealternative .. 9.3%;HR0.65,95%CI0.43–0.98,P=0.04)andMI(3.3vs.8.3%;HR
.
to CABG in LM disease and low-to-intermediate anatomical com- .. 0.40,95%CI0.24–0.65,P<0.001)intheCABGgroupatamedian
.
plexity. Amongpatients with LMdisease and low anatomicalcom- .. follow-upof61months.149Theriskofdeathwasnotsignificantlydif-
.
plexity,thereisevidencethattheoutcomeswithrespecttomajor .. ferent among patients with a low (0-22) SYNTAX score (6.0 vs.
.
clinicalendpointsaresimilarforPCIandCABG,resultinginaclassI .. 7.5%,P=0.66),whereasthebenefitofCABGoverPCIwasgreater
.
recommendation. Among patients with LM disease and high . inpatientswithanintermediate-to-high(>22)SYNTAXscore(7.1
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 24 ---
110 ESC/EACTSGuidelines
.
.
vs.11.6%,P=0.02).Anotherindividualpatientdatapooledanalysis . 6.1 Early invasivevs. conservative
.
.
ofSYNTAXandBEST,comparingCABGwithPCIusingDESamong .. strategy
.
1166 patients with multivessel disease involving the proximal LAD .
.. An invasivestrategyhas become the standard ofcare for high-risk
(88%three-vesselCAD,meanSYNTAXscore28),reportedahigher .
.. patients.158Thisapproachallowspromptdiagnosisoftheunderlying
riskofthecomposite of death,MI, and stroke(16.3vs.11.5%; HR .
.. CAD,identificationoftheculpritlesion,guidanceforantithrombotic
1.43,95%CI1.05–1.96,P=0.02),cardiacdeath,MI,andrepeatrevas- .
cularizationinthePCIgroupat5yearsoffollow-up.147Ofnote,out-
... management,andtheassessmentofthesuitabilityofcoronaryanat-
.. omyforPCIorCABG.Numerousfactorsinterplayinthedecision-
comes were not significantly different for CABG and PCI for any .
.. making process, including clinical presentation, comorbidities, risk
endpoint except for MI among the subgroup of patients with low ...
stratification(Figure4),andhigh-riskfeaturesspecificforarevasculari-
SYNTAXscore(0-22). ...
zationmodalitysuchasfrailty,cognitivestatus,estimatedlifeexpect-
TheavailableevidencesuggeststhatinmultivesselCADwithout ...
ancy,andthefunctionalandanatomicalseverityofCAD.
diabetesandlowanatomicalcomplexity,PCIandCABGachievesim- ...
Upto40%ofNSTE-ACSpatientswithobstructiveCADpresent
ilarlong-termoutcomeswithrespecttosurvivalandthecomposite ...
with multiple complex plaques159–162 and 25% with an acute
ofdeath,MI,andstroke,justifyingaclassIrecommendationforPCI. ...
occluded coronary artery,163 so that identification of the culprit
InpatientswithmultivesselCADandintermediate-to-highanatomi- ..
. lesion may be challenging. Correlation with ECG or echo changes
calcomplexity,thetwolargetrialsusingDES,SYNTAXandBEST, ..
. andtheuseofOCTinthe25%ofNSTE-ACSpatientswithangio-
foundasignificantlyhighermortalityandahigherincidenceofdeath, ... graphicallynormalepicardialcoronaryarteries164–166maybehelpful
MI,andstrokewithPCIintheabsenceofdiabetes.Consistentresults ..
. foridentifyingtheculpritlesion,orruleoutothermechanismssuch werealsoobtainedforpatientswithmultivesselCADintherecent ..
. as dissection or haematomas [MI with non-obstructive coronary
individual patient-level meta-analysis.124 Thus, the previous class III ...
arteries(MINOCA)].167–169
.
recommendation for PCI in multivessel CAD and intermediate-to- .
. A routine invasive strategy in NSTE-ACS has been shown to
.
highcomplexitywasmaintained. .. improve clinical outcomes,170 and benefit was mainly confined to
.
.
. biomarker-positivepatients171andpatientswithotherhigh-riskfea-
.
5.4 Gaps in the evidence .
.. tures as defined in Figure 4. Of importance, the use of a radial
.
It remains to be determined whether revascularization by PCI ... approach,new-generationDES,andmoreeffectiveP2Y 12-inhibitors
improves prognosis in patients with SCAD. The ISCHEMIA .. werenotavailableorbroadlyimplementedinthesetrials,andledto
.
(International Study of Comparative Health Effectiveness With .. amagnifiedbenefitinfrailACSpopulations.172,173
.
MedicalandInvasiveApproaches)study(NCT01471522)iscurrently .
.
.
recruiting 5000 patients withSCAD and evidence ofmoderate-to- .. 6.2 Timing of angiographyand
.
severeischaemiadetectedbynon-invasiveimaging,whoarerandom- .. intervention
.
izedbeforecoronaryangiographytomedicaltherapyoraninvasive ..
. Thecurrentrecommendationsonthetimingofangiographyandinter-
strategytodetectdifferencesintheprimaryendpointofdeathorMI. ..
. vention,asdefinedinFigure4,arebasedonevidencediscussedindetail
Currenttechniquesrelyoncoronaryangiographyandthedetection ...
bythepriorGuidelinesonNSTE-ACS.158Specifically,areductionin
ofischaemia-producinglesions.However,futureadverseeventsare ..
. recurrent or refractory ischaemia and length of hospital stay was
relatedatleastinparttonon-flowlimiting,vulnerableplaques.Better ...
foundwithearlyintervention.174,175Morerecently,anupdatedcollab-
identificationofvulnerableplaquesandthedevelopmentofappropri- ..
. orative meta-analysis on individual published and unpublished data
ate treatmentstrategies is needed.Along thesamelines,thecom- ..
. (n= 5324patients with a medianfollow-up of 180days) suggested
pleteness and timing of revascularization are not well defined, and ..
. thatearlyinterventionmightalsobeassociatedwithdecreasedmor-
neitheraretherolesofresidualischaemiaandlesions.Moreover,we ...
tality.176 This meta-analysis showed a statistical trend towards needmoreresearchontheuseoftheSYNTAXandotherscoresfor ..
. decreasedmortalitywithanearlyinvasivestrategycomparedwitha informingtreatmentallocation,aswellasdedicatedtrialsinspecific ..
. delayedinvasivestrategyinunselectedpatientswithNSTE-ACS(HR
subsets.Verylong-term,extendedfollow-up(10years)oftrialscom- ..
.. 0.81,95%CI0.64–1.03,P=0.088).Thesurvivalbenefitoftheearly
paringPCIandCABG,particularlyinthesettingofLMdisease,will . .. invasive strategy appeared more pronounced in high-risk subsets,
providefurtherinsightsintotherelativemeritsofbothrevasculariza- .
.. including elevated cardiac biomarkers at baseline (HR 0.76, 95% CI
tiontechniques. .
.. 0.58–0.996),diabetes(HR0.67,95%CI0.45–0.99),aGlobalRegistry
.
.. of Acute Coronary Events risk score >140 (HR 0.70, 95% CI
.
6 Revascularization in
... 0.52–0.95),andage75yearsorolder(HR0.65,95%CI0.46–0.93),
.. althoughtestsforinteractionwereinconclusive.
.
non-ST-elevation acute coronary .
.
.
syndrome .. 6.3 Type of revascularization
.
.
.. 6.3.1Percutaneouscoronaryintervention
.
Myocardialrevascularizationinpatientswithnon-ST-segmenteleva- .. 6.3.1.1Technicalaspects
.
tion ACS (NSTE-ACS) is addressed by prior Guidelines that are .. Implantationofnew-generationDESisthestandardtreatmentstrat-
.
endorsedbythecurrentTaskForce.158InthepresentGuidelines,we .. egyevenwhendualantiplatelettherapy(DAPT)cannotbesustained
.
discussnewevidencewherepreviousrecommendationsrequirean .. beyond 1 month post-intervention173,177–179 (see section 17),
.
update. . and the radial approach has also become the standard of care.172
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 25 ---
ESC/EACTSGuidelines 111
.
DAPT is recommended for 12 months irrespective of stent type, .. incidenceoftheprimaryoutcome—thecompositeofdeath,MI,or
.
while in patients at high ischaemic risk not experiencing bleeding .. stroke—wassignificantlylowerwithCABGthanwithPCI(13.4vs.
.
events, DAPT may be extended (see section 17). There is no evi- .. 18%, P= 0.036).Thefindingsofthis meta-analysis wereconsistent
.
denceforanyadditionalbenefitofthrombectomyinpatientsunder- .. with the main findings of the studies included, thus supporting the
.
goingPCI in the settingofNSTE-ACS.180 While FFR isconsidered .. concept that the principles of SCAD should apply to stabilized
.
the invasive gold standard for the functional assessment of lesion .. patientswithNSTE-ACSaswell.
.
severityinSCAD,ithasbeenshowntobefeasible,reliable,safe,and .. For complex cases, Heart Team discussion and use of the
.
effectiveinNSTE-ACSpatientswithmultivesseldisease,althoughits .. SYNTAX score are recommended,195 given its ability to predict
.
prognosticvalueisunclear.22,137,181 .. death,MI,andrevascularizationinpatientswithNSTE-ACSandmul-
.
.
. tivesseldiseaseundergoingPCI.Inpatientswithmultivesseldisease
.
.
6.3.1.2Revascularizationstrategiesandoutcomes . anddiabetesinparticular,recentevidencesuggestsagreaterbenefit
.
Completerevascularizationofsignificantlesionsshouldbeattempted .. ofCABGvs.PCI.196
.
.
inmultivesseldiseaseNSTE-ACSpatients,giventhatitwasmandated . .
intrialstestingearlyvs.lateintervention171,182,183andthattheprog- ..
.
nosis of patients with incomplete revascularization is known to be
worse.131,184Inaddition,itseemsthatcompleteone-stagerevascula- Recommendationsforinvasiveevaluationand
rization is associated with better clinical outcome than multistage revascularizationinnon-ST-elevationacutecoronary
PCI.185TheriskofperiproceduralcomplicationsofPCIdefinedasMI syndrome
ormyocardialinjury,aswellasthatoflong-termischaemia,remains
higherinNSTE-ACSthaninstablepatients.186,187ForACSpatients Recommendations Classa Levelb
who have undergone PCI, revascularization procedures represent
Urgentcoronaryangiography(<2h)isrec-
themostfrequent,mostcostly,andearliestcausesforrehospitaliza-
ommendedinpatientsatveryhighischae- I C
tion.188,189AsinST-elevationmyocardialinfarction(STEMI),routine
micrisk(Figure4).197
treatmentofnon-culpritlesionsduringtheprimaryinterventionby
PCI is harmful in NSTE-ACS patients with cardiogenic shock, as Anearlyinvasivestrategy(<24h)isrecom-
shownbytherecentlypublishedCULPRIT-SHOCK(CulpritLesion mendedinpatientswithatleastonehigh- I A
OnlyPCIversusMultivesselPCIinCardiogenicShock)trial(seesec- riskcriterion(Figure4).164,174,176
tion7.3).190
Aninvasivestrategy(<72hafterfirst
presentation)isindicatedinpatients
6.3.2Coronaryarterybypassgrafting
withatleastoneintermediate-riskcrite- I A
Approximately5–10%ofNSTE-ACSpatientsrequireCABG,191and
rion(Figure4)orrecurrent
theyrepresentachallengingsubgroupgiventheirhigh-riskcharacter-
symptoms.170,171
istics compared with patients undergoing elective CABG.192 In the
absenceofrandomizeddata,optimaltimingfornon-emergentCABG Itisrecommendedtobasetherevasculari-
inNSTE-ACSpatientsshouldbedeterminedindividually.Theriskof zationstrategy(adhocculpritlesionPCI/
ischaemiceventspossiblyrelatedtosuboptimalantiplatelettherapy multivesselPCI/CABG)ontheclinicalstatus
whileawaitingsurgeryis<0.1%,whilethatofperioperativebleeding andcomorbidities,aswellasthedisease
I B
complications associated with platelet inhibitors is >10%.193 In severity[i.e.thedistributionandangio-
patientswithongoingischaemiaorhaemodynamicinstabilitywithan graphiclesioncharacteristics(e.g.SYNTAX
indicationforCABG,emergencysurgeryshouldbeperformedand score)],accordingtotheprinciplesfor
notpostponedasaconsequenceofantiplatelettreatmentexposure. SCAD.c194
Incardiogenicshock,routinerevasculariza-
6.3.3Percutaneouscoronaryinterventionvs.coronary tionofnon-IRAlesionsisnotrecommended III B
arterybypassgrafting duringprimaryPCI.190
ThereisnorandomizedcomparisonofPCIvs.CABGinthespecific
settingofNSTE-ACS.Thecurrentlyavailableevidenceindirectlysug-
CABG=coronaryarterybypassgrafting;IRA=infarct-relatedartery;NSTE-ACS
gests that the criteria applied to patients with SCAD to guide the
= non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary
choiceofrevascularizationmodalityshouldbe applied to stabilized intervention; SCAD = stable coronary artery disease; SYNTAX = Synergy
patientswithNSTE-ACS.100,121,150,194Recentindividual-patientsdata BetweenPercutaneousCoronaryInterventionwithTAXUSandCardiacSurgery.
aClassofrecommendation.
analysisfromtheBEST,PRECOMBAT,andSYNTAXstudiescom- bLevelofevidence.
paredtheoutcomeofCABGwiththatofPCIin1246patientswith cMayapplytostabilizedNSTE-ACSpatients.
stabilized NSTE-ACS and multivesselorLMdisease.194 The 5 year
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 26 ---
112 ESC/EACTSGuidelines
Figure4Selectionofnon-ST-elevationacutecoronarysyndrometreatmentstrategyandtimingaccordingtoinitialriskstratification.
.
6.4 Gaps in the evidence .. shockorout-of-hospitalcardiacarrest.199Inshockwithoutout-of-
.
.
. hospital cardiac arrest, every 10 min treatment delay between
InthesettingofNSTE-ACS,therearenodedicatedprospectivestud- .
.
. 60–180minfromthefirstmedicalcontactresultedin3.3additional
iesontherevascularizationstrategywithmultivessel disease. Thus, .
.
. deathsper100PCI-treatedpatients,andin1.3additionaldeathsafter
currentrecommendationsonthechoiceoflesionstobetreatedand .
.
. out-of-hospital cardiac arrest without cardiogenic shock. In stable
treatmentmodality(PCIorCABG)arebasedonananalogytofind- .
.
. STEMIpatients,timedelaysweresubstantiallylessrelevant(0.3addi-
ings obtained in SCAD or STEMI. Likewise, the prognostic role of .
.
FFRandiwFRinguidingmyocardialrevascularizationneedsadditional
.. tional deaths per 100 PCI-treated patients for every 10 min delay
.
clarification.
.. between60–180minfromthefirstmedicalcontact).Thus,high-risk
.
.. STEMI patients with cardiogenic shock or out-of-hospital cardiac
.
.. arrestarethose who benefitmostfromexpeditingall steps of the
.
7 Revascularization in ST-segment .. carepathway.
. .
.
elevation myocardial infarction .. 7.2 Selection of reperfusion strategy
.
.
.
. Primary PCI, defined as percutaneous catheter intervention in the
MyocardialrevascularizationinpatientswithSTEMIisaddressedby ..
. settingofSTEMIwithoutpreviousfibrinolysis,isthepreferredreper-
the2017ESCGuidelinesonSTEMI.Afterreviewingthesubsequent ..
. fusionstrategy.IthasreplacedfibrinolysisinpatientswithSTEMI,pro-
.
literature,thecurrentTaskForceendorsesmostrecommendations .
. vided it can be performed in a timely manner in high-volume PCI
oftheseGuidelines.198 ..
. centreswithexperiencedoperatorsand24h/7daysaweekcatheter-
.
.. ization laboratory activation.198,200,201 In settings where primary
.
7.1 Time delays ..
PCIcannotbeperformedina timelyfashion,fibrinolysisshouldbe
.
.
Delaysinthetimelyimplementationofreperfusiontherapyarekey .. administered as soon as possible. If first medical contact (FMC) is
.
issuesinthemanagementofSTEMI.Detailedrecommendationson .. out-of-hospital,lysisshouldbeimplementedpre-hospital(e.g.inthe
.
timelines,logistics,andpre-hospitalmanagementhavebeenprovided .. ambulance) (Figure 5).202–206 It should be followed by transfer to
.
intherecentESCSTEMIGuidelines(Figure5).198 .. PCI-capablecentresforroutinecoronaryangiographyinallpatients,
.
A recent analysis of 12 675 STEMI patients in the FITT-STEMI .. andshouldbeperformedwithoutdelayforrescuePCIinthecaseof
.
(Feedback Intervention and Treatment Times in ST-Elevation .. unsuccessful fibrinolysis or within 2–24 h after bolus administra-
.
Myocardial Infarction) trial emphasizes the strong impact of time .. tion.198 Emergency CABG may be indicated in selected STEMI
.
delays on mortality, particularly in STEMI patients with cardiogenic . patientsunsuitableforPCI.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 27 ---
ESC/EACTSGuidelines 113
Figure5Modesofpatient’smedicalcontact,componentsofischaemiatime,andflowchartforreperfusionstrategyselection.
7.3 Primary percutaneous coronary .
.. Four major randomized trials-PRAMI (Preventive Angioplasty in
intervention ... AcuteMyocardialInfarction),211CvLPRIT(CompleteVersusLesion-
.
Keypoints for optimizing and guiding primary PCIare summarized .. Only Primary PCI trial),212 DANAMI-3-PRIMULTI (The Third
.
below. .. DANish Study of Optimal Acute Treatment of Patients with ST-
.
The infarct-related artery (IRA) should be systematically treated .. segment Elevation Myocardial Infarction: PRImary PCI in
.
duringtheinitialintervention.PatientswithextensiveCADinvessels .. MULTIvessel Disease),213 and Compare-Acute214-have consistently
.
remote fromthe IRA have anadverse prognosisfollowingprimary .. shownabenefitofcompleterevascularization(performedimmedi-
.
PCI.207StagedPCIinpatientswithmultivesseldiseaseandnohaemo- .. ately or staged) as compared with IRA-only PCI in patients with
.
.
dynamic compromise is an independent predictor of survival, and . STEMI and multivessel disease (for details see the Supplementary
.
.
more frequent ischaemic events have been reported in direct vs. . Data).Arecentmeta-analysisof10trialshasshownthatcomplete
.
.
staged revascularization of STEMI patients with multivessel . revascularizationwasassociatedwithalowerriskofMACE(RR0.57,
.
disease.208–210 .. 95% CI 0.42–0.77),dueto a lower riskofurgentrevascularization
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 28 ---
114 ESC/EACTSGuidelines
.
(RR0.44,95%CI0.30–0.66),withnosignificantdifferenceinmortal- .. median follow-up of 42 months.221 Routine deferred stenting was
.
.
ity (RR 0.76, 95% CI 0.52–1.12) or MI (RR 0.54, 95% CI . associatedwithahigherriskofTVR.
.
0.23–1.27).215 This meta-analysis did not include Compare-Acute. .. Thrombusaspirationhasbeenproposedasanadjunctduringpri-
.
.
Yet,similartoearlierstudies,thebenefitofcompleterevasculariza- . maryPCItofurtherimproveepicardialandmyocardialreperfusion
.
.
tionoverculprit-onlyrevascularizationseeninCompare-Acutewas . bythepreventionofdistalembolizationofthromboticmaterialand
.
driven by a lower need for unplanned reintervention, whereasthe .. plaquedebris.222TwolandmarkRCTs,whichwereadequatelypow-
.
.
incidencesofdeathandrecurrentMIweresimilarbetweenthetwo . eredtodetectthesuperiorityofroutinemanualthrombusaspiration
.
.
strategies.214 .. vs.conventionalPCI,showednobenefitonclinicaloutcomesofthe
.
Mostofthestudiessupporttheconceptoffullrevascularization .. routineaspirationstrategyoverallorinanysubgroupofpatientsindi-
.
either during the initial hospital stay for STEMI or a staged admis- .. cating high thrombotic risk.223–226 A safety concern emerged in
.
sion,215butitremainstobedeterminedhowclinicianscanidentify .. TOTAL(TrialofRoutineAspirationThrombectomywithPCIversus
.
lesionsthatshouldberevascularizedbeyond the culpritlesion and .. PCIAloneinPatientswithSTEMI)trialwithanincreaseintheriskof
.
whethercompleterevascularizationshouldbeperformedinsingle- .. stroke.225,227Takentogether,theseresultssuggestthattheroutine
.
ormulti-stageprocedures.Moreover,thereisalackofevidenceon .. useofthrombusaspirationisnotindicated.Inthehigh-thrombusbur-
.
the optimal timing of staged procedures. In most of the studies, .. densubgroup,thetrendtowardsreducedcardiovasculardeathand
.
stagedprocedureswereperformedduringtheinitialhospitalstay.At .. increasedstroke/transientischaemicattack(TIA)providesarationale
.
present,one-stagemultivesselPCIduringSTEMIwithoutcardiogenic .. forfuturetrialsofimprovedthrombusaspirationtechnologiesinthis
.
shockshouldbeconsideredinpatientsinthepresenceofmultiple, .. high-risksubgroup (althoughstatisticaltestsdidnotsupportsignifi-
. criticalstenosesorhighlyunstablelesions(angiographicsignsofpos- .. cantsubgroupinteraction).228
.
.
siblethrombusorlesiondisruption),andifthereispersistentischae- .
.
.
miaafterPCIonthesupposedculpritlesion. . 7.4 Percutaneous coronary intervention
.
.
In patients with multivessel disease and AMI with cardiogenic .. after thrombolysis and in patients with
.
shock,therecentlypublishedCULPRIT-SHOCKtrialshowedthata .
.. late diagnosis
strategywithPCIoftheculpritlesiononlywithpossiblestagedrevas- .
.
. Thebenefitsofearly,routinePCIafterthrombolysiswereseeninthe
cularizationdeterminedalower30dayriskofthecompositeofall- .
.
. absence of an increased risk of adverse events (stroke or major
cause mortality or severe renal failure compared with immediate .
.
multivesselPCI.190Thiswasdrivenbyasignificantriskreductionin .. bleeding).Basedondatafromthefourmostrecenttrials,allofwhich
.
30 day all-cause mortality by the culprit lesion-only strategy com-
.. hadamediandelaybetweenthestartofthrombolysisandangiogra-
.
paredwithimmediatemultivesselPCI(43.3vs.51.6%;HR0.84,95%
.. phyof2–6h,atimeframeof2–24haftersuccessfullysisisrecom-
.
CI0.72–0.98,P=0.03).Thesefindingsneedtobeinterpretedinlight
... mended.206,229–231Incasesoffailedfibrinolysis,orifthereisevidence
ofalow12.5%(43outof344patients)crossoverratefromculprit
... ofre-occlusionorreinfarctionwithrecurrenceofST-segmenteleva-
lesion-onlytoimmediatemultivesselPCIbasedonphysicians’judg-
... tion, the patient should undergo immediate coronary angiography
ment. Based on these findings, culprit lesion-only PCI is recom-
... andrescuePCI.232Patientspresentingbetween12and48hafterthe
mendedasthedefaultstrategyinpatientswithAMIwithcardiogenic
... onsetofsymptoms,evenifpainfreeandwithstablehaemodynamics,
shock.Amoredetaileddiscussionoftherevascularizationstrategyin
... may still benefit from early coronary angiography and possibly
MI patients with cardiogenic shock is found in the Supplementary
... PCI.233,234 In patients presenting days after the acute event with a
Data.
... completed MI, only those with recurrent angina or documented
In patients with STEMI, DES (in particular new-generation DES)
... residualischaemia—andprovenviabilityonnon-invasiveimagingina
.
havedemonstratedbetterefficacyascomparedwithBMSandshould .. largemyocardialterritory—maybeconsideredforrevascularization
.
beusedasthedefaultstrategyinSTEMIpatients,evenwhenDAPT .. whentheinfarctarteryisoccluded.RoutinelatePCIofanoccluded
.
cannot be sustained beyond 1 month.177,178,216–218 (see section .. IRAafterMIinstablepatientshasnoincrementalbenefitovermedi-
.. caltherapy.235
16.1.2).Asdiscussedinsection16.4,radialaccessispreferredover .
.
.
femoralaccess. .
. DelayingstentinginprimaryPCIhasbeeninvestigatedasanoption .. 7.5 Gaps in the evidence
.
.
toreducemicrovascularobstruction(MVO)andpreservemicrocir- . Patientsundergoingprimary PCI benefit fromfullrevascularization,
.
culatory function in two small trials with conflicting results.219,220 ... buttheoptimaltimingoftreatmentofthenon-culpritlesionisnot
.
Morerecently,inthelargerdeferredvs.conventionalstentimplanta- .. known.Morestudiesevaluatingtheassessmentofnon-culpritlesions
.
tion in patients with STEMI [The Third DANish Study of Optimal .. by FFR or iwFR at the time of acute PCI, and studies investigating
.
AcuteTreatmentofPatientswithST-segmentElevationMyocardial .. whetherintravascularimagingguidanceofprimaryPCIcanimprove
.
Infarction:DEFERredstentimplantationinconnectionwithprimary .. the outcomes of STEMI patients, are needed. Future trials of
.
PCI(DANAMI3-DEFER)]trialin1215STEMIpatients,therewasno .. improvedthrombusaspirationtechnologiesmayaddresstheroleof
.
effectontheprimaryclinicaloutcome(compositeofdeath,non-fatal .. thisstrategyinpatientswithhigh-riskfeatures,suchaslargethrombus
.
MI,orischaemia-drivenrevascularizationofnon-IRAlesions)overa . burden.228
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 29 ---
ESC/EACTSGuidelines 115
PrimarypercutaneouscoronaryinterventionformyocardialreperfusioninST-elevationmyocardialinfarction:indica-
tionsandlogistics
Recommendations Classa Levelb
Indication
Reperfusiontherapyisindicatedinallpatientswithtimefromsymptomonset<12hdurationandpersistentST-seg-
I A
mentelevation.200,201,236
IntheabsenceofST-segmentelevation,aprimaryPCIstrategyisindicatedinpatientswithsuspectedongoing
ischaemicsymptomssuggestiveofMIandatleastoneofthefollowingcriteriapresent:
• haemodynamicinstabilityorcardiogenicshock
• recurrentorongoingchestpainrefractorytomedicaltreatment
I C
• life-threateningarrhythmiasorcardiacarrest
• mechanicalcomplicationsofMI
• acuteheartfailure
• recurrentdynamicST-segmentorT-wavechanges,particularlywithintermittentST-segmentelevation.
AprimaryPCIstrategyisrecommendedoverfibrinolysiswithintheindicatedtimeframes.200,201,237,238 I A
Inpatientswithtimefromsymptomonset>12h,aprimaryPCIstrategyisindicatedinthepresenceofongoing
I C
symptomsorsignssuggestiveofischaemia,haemodynamicinstability,orlife-threateningarrhythmias.
AroutineprimaryPCIstrategyshouldbeconsideredinpatientspresentinglate(12–48h)aftersymptom
IIa B
onset.233,234,239
Logistics
Itisrecommendedthatthepre-hospitalmanagementofSTEMIpatientsshouldbebasedonregionalnetworksthat
aredesignedtodeliverreperfusiontherapyeffectivelyinatimelyfashion,andtoofferprimaryPCItoasmany I B
patientsaspossible.240,241
ItisrecommendedthatallEMS,emergencydepartments,coronarycareunits,andcatheterizationlaboratorieshave
I C
awrittenupdatedSTEMImanagementprotocol,preferablysharedwithingeographicalnetworks.
ItisrecommendedthatprimaryPCI-capablecentresdelivera24h/7dayserviceandensurethatprimaryPCIisper-
I B
formedasfastaspossible.242–244
ItisrecommendedthatpatientstransferredtoaPCI-capablecentreforprimaryPCIbypasstheemergencydepart-
I B
mentandCCU/ICCU,andaretransferreddirectlytothecatheterizationlaboratory.245–247
CCU=coronarycareunit;EMS=emergencymedicalservices;ICCU=intensivecoronarycareunit;MI=myocardialinfarction;PCI=percutaneouscoronaryintervention;
STEMI=ST-segmentelevationmyocardialinfarction.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 30 ---
116 ESC/EACTSGuidelines
PrimarypercutaneouscoronaryinterventionformyocardialreperfusioninST-elevationmyocardialinfarction:proce-
duralaspects(strategyandtechnique)
Recommendations Classa Levelb
Strategy
Routinerevascularizationofnon-IRAlesionsshouldbeconsideredinpatientswithmultivesseldiseasebeforehospital
IIa A
discharge.211–214
CABGshouldbeconsideredinpatientswithongoingischaemiaandlargeareasofjeopardizedmyocardiumifPCIofthe
IIa C
IRAcannotbeperformed.
Incardiogenicshock,routinerevascularizationofnon-IRAlesionsisnotrecommendedduringprimaryPCI.190 III B
Technique
Routineuseofthrombusaspirationisnotrecommended.223–226,228 III A
CABG=coronaryarterybypassgrafting;IRA=infarct-relatedartery;PCI=percutaneouscoronaryintervention;STEMI=ST-segmentelevationmyocardialinfarction.
aClassofrecommendation.
bLevelofevidence.
.
8 Myocardial revascularization in .. revascularizationwithmedicaltherapyinpatientswithanEF<_40%
.
.
patients with heart failure .. showedthattherewasasignificantmortalityreductionwithCABG
.
. (HR 0.66,95% CI0.61–0.72, P <0.001) and PCI(HR 0.73, 95% CI
.
.
8.1 Chronic heart failure
.. 0.62–0.85, P <0.001) vs. medical therapy, though these finding are
.
.. limited by the predominantly observational nature of the included
8.1.1Recommendationsformyocardialrevascularization .
.. studies and missing information on the completeness of
inpatientswithchronicheartfailure .
.. revascularization.248
Whencomparedwithmedicaltherapyalone,coronaryrevasculariza- .
.. ArecentobservationalstudyinvestigatedoutcomeswithPCIor
tionissuperiorinimprovingsurvivalinpatientswithHFofischaemic .
.. CABGformultivesselCADandLVdysfunctionin1738propensity-
origin and is recommended in clinical practice.81,248 However, the ...
matchedpatientswithdiabetesmellitus.251Similartothefindingsin
optimalrevascularizationstrategyisnotdefined.Thechoicebetween ...
theabsenceofLVdysfunction,whenCABGwascomparedwithPCI
CABGandPCIshouldbemadebytheHeartTeamaftercarefuleval- ...
it was associated with a significantly lower risk of MACE, which
uationofthepatient’sclinicalstatusandcoronaryanatomy,expected ...
includedasignificantreductioninmortality.Eventcurvesseparated
completeness of revascularization (see section 5.3.1.3), myocardial ...
earlyduringthefirstyearandcontinuedtoseparateoutto12years.
viability, coexisting valvular disease, and comorbidities. ..
. PCI should be considered in older patients without diabetes in
Considerationsrelatingtotheneedforviabilitytestingpriortorevas- ..
. whomcompleterevascularizationcanbeachieved,whereasCABGis
cularizationarediscussedinsection3. ..
. preferred in younger patients with more extensive CAD or those
Randomized clinical trial data comparing revascularization with ..
. withdiabetes.InpatientswithdiabetesandLVmoderateorsevere
medical therapy exists only for CABG in the settingofthe STICH ..
. dysfunction (EF <50%), CABG is associated with better long-term
trial.81OneanalysisfromthistrialshowedthatCABGcanbeper- ...
survivalandreducedincidenceofMACCE.250,251
formedwithacceptable30daymortalityrates(5.1%)inpatientswith ..
.
LVdysfunction (LVEF <_35%).249 Extended follow-up in theSTICH ..
.
.
ExtensionStudy(STICHES)supportsasignificantsurvivalbenefitof . 8.1.2Ventricularreconstructionandaneurysmresection
. .
CABGcombinedwithmedicaltherapyvs.medicaltherapyaloneina . The aim of surgical ventricular reconstruction (SVR) is to restore
.
10yearobservationperiod.81 .. physiologicalvolume,andachieveanellipticalshapeoftheLV,byscar
.
.
Therearecurrentlynodedicatedrandomizedclinicaltrialscom- . resectionandLVwallreconstructiononamannequinofpredefined
.
.
paringPCIvs.medicaltherapyinpatientswithHFwithreducedEF . size. The aim of ventricular aneurysmectomy is to remove fibrous
.
.
(HFrEF).Inaddition,CABGvs.PCIrandomizedtrialshaveexcluded . scarsincasesofseveredilatation,thrombusformation,orasasource
.
.
patientswithsevereHF.Inoneprospectiveregistryincluding4616 . oflife-threateningventriculararrhythmias.
.
.
patients with multivessel disease and severe HFrEF, propensity .. The STICH trial revealed no difference in the primary outcome
.
score-matchedcomparisonrevealedsimilarsurvival(meanfollow-up .. (total mortality or cardiac hospitalization) between patients ran-
.
2.9years)withPCI(usingEES)vs.CABG.250PCIwasassociatedwith .. domly allocated to CABG vs. combined CABG and SVR.252
.
ahigherriskofMI,particularlyinpatientswithincompleterevascula- .. SubgroupanalysesofpatientswithalessdilatedLVandbetterLVEF
.
rization, and repeatrevascularization.CABGwasassociatedwitha .. showedbenefitfromSVR.253IntheSTICHtrial,apost-operativeLV
.
higherriskofstroke.Theconclusionofthestudywasthatmultivessel .. end-systolic volume index <_70 mL/m2, after CABG plus SVR,
.
PCIcanbeavaluableoptioninHFpatientsifcompleterevasculariza- .. resultedinimprovedsurvivalcomparedwithCABGalone.252,254In
.
tion is possible. A systematic review of studies comparing . experiencedcentres,SVRmaybedoneatthetimeofCABGifHF
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 31 ---
ESC/EACTSGuidelines 117
.
.
symptomsaremorepredominantthanangina,andifmyocardialscar . patientswithcardiogenicshockcomplicatingAMI,emergencyrevas-
.
.
andmoderateLVremodellingarepresent. . cularization with PCI or CABG improved long-term survival when
.
.
. comparedwithinitialintensivemedicaltherapy.All-causemortality
.
Recommendationsonrevascularizationsinpatients .. at 6 months was lower in the group assigned to revascularization
.
withchronicheartfailureandsystolicleftventricular .
. than in the medically treated patients (50.3 vs. 63.1%, respectively;
.
dysfunction(ejectionfraction(cid:4)35%) .. RR0.80,95%CI0.65–0.98,P=0.03).258
.
.
. Therevascularizationstrategyforpatientswithcardiogenicshock
.
Recommendations Classa Levelb .. andmultivesseldiseaseisaddressedinsection7.
.
.
InpatientswithsevereLVsystolicdysfunc-
... AsubanalysisoftheSHOCKtrialcomparingpatientstreatedwith
tionandcoronaryarterydiseasesuitablefor
... CABG orPCIshowedsimilar survivalrates between thetwo sub-
intervention,myocardialrevascularizationis
I B ... groups.259Thereweremorepatientswithdiabetes(48.9vs.26.9%;
recommended.81,250
... P=0.02),three-vesseldisease(80.4vs.60.3%;P=0.03),andLMcor-
.. onarydisease(41.3vs.13.0%;P= 0.001)intheCABGgroup.The
.
CABGisrecommendedasthefirstrevas- .. findings of this non-randomized comparison suggest that CABG
.
cularizationstrategychoiceinpatients
I B
... shouldbe consideredin patients with cardiogenic shock who have
withmultivesseldiseaseandacceptable .. suitableanatomy,particularlyifsuccessfulPCIisnotfeasible.
.
surgicalrisk.68,81,248,255 ..
.
.
.
Inpatientswithone-ortwo-vesseldis- . .
. 8.2.2Mechanicalcirculatorysupport
ease,PCIshouldbeconsideredasan .
IIa C .. Short-term MCS devices that are currently available are the intra-
alternativetoCABGwhencomplete .
.
. aorticballoonpump(IABP),veno-arterialextracorporealmembrane
revascularizationcanbeachieved. ..
. oxygenation(ECMO),andpercutaneousleftventricularassistdevi-
.
.
Inpatientswiththree-vesseldisease,PCI . ces(pLVADs).Short-termMCSmaybeconsideredinrefractorycar-
.
.
shouldbeconsideredbasedontheevalu- . diogenicshockdependingonpatientage,comorbidities,neurological
.
.
ationbytheHeartTeamofthepatient’s . function,andtheprospectsforlong-termsurvivalandqualityoflife.
IIa C ..
coronaryanatomy,theexpectedcom- .
.
.
pletenessofrevascularization,diabetes .. 8.2.2.1Intra-aorticballoonpump
.
status,andcomorbidities. .. IABPsarelow-costdevicesthatareeasytoinsertandremove.They
.
.. moderatelyincreasecardiacoutputandcoronaryandcerebralperfu-
LVaneurysmectomyduringCABGshould .
.. sion, while decreasing ventricular workload. In patients with cardio-
beconsideredinpatientswithNYHAclass .
.. genic shock complicating acute MI, the IABP-SHOCK II (Intraaortic
III/IV,largeLVaneurysm,largethrombus IIa C .
.. BalloonPumpinCardiogenicShockII)randomizedtrial(600patients)
formation,oriftheaneurysmistheoriginof .
.. showedthattheuseofIABPsdidnotreduce30daymortalityandthat
arrhythmias. .
.. therewasnoevidenceoflong-termbenefit.260,261ArecentCochrane
.
Surgicalventricularrestorationduring .. review of seven trials (790patients) showed thatIABPs may have a
.
CABGmaybeconsideredinselected .. beneficialeffectonsomehaemodynamicparametersbutdidnotresult
IIb B .
patientstreatedincentreswith .. insurvivalbenefits.262Thus,theroutineuseofIABPsinpatientswith .
expertise.252–254,256,257 .. cardiogenicshockcomplicatingacuteMIisnotrecommended.
.
.
.
.
.
CABG=coronaryarterybypassgrafting;LV=leftventricular;NYHA=New .. 8.2.2.2Extracorporealmembraneoxygenation
. YorkHeartAssociation;PCI=percutaneouscoronaryintervention. . Veno-arterialECMO(VA-ECMO),alsoknownasextracorporeallife
aClassofrecommendation. ..
. support(ECLS),initscurrentformisamodifiedformofcardiopul-
bLevelofevidence. ..
. monarybypass.Itdecompressesthevenoussystem;increasescoro-
. .
. nary, cerebral, and peripheral perfusion; and also provides
.
8.2 Acute heart failure and cardiogenic .. supplementary blood oxygenation. When performed percutane-
.
.
shock . ously,itdoesnotallowforLVdecompressionandleadstoincreasing
.
.
AcutemyocardialischaemiainthesettingofAMIistheantecedent .. LVafterload.
.
eventforthemajorityofpatientswithcardiogenicshockundergoing .. Inpatientswithcardiacarrest,evidencefromobservationaltrials
.
percutaneous revascularization. Mechanical complications—such as .. supports better survival in patients treated with VA-ECMO com-
.
papillarymusclerupturewithseveremitralvalveregurgitation,ven- .. pared with those without.263 When compared with IABP, VA-
.
tricularseptaldefect,orfreewallrupture—areadditionalprecipitat- .. ECMO provides superior circulatory support.264,265 Moreover, a
.
ingcauses. .. meta-analysisofobservationalstudiessuggestedthatinpatientswith
.
.. cardiogenic shock post-ACS, VA-ECMO showed a 33% higher 30
.
.. daysurvivalcomparedwithIABP[95%CI14–52%,P<0.001;number
.
8.2.1Revascularization .. neededtotreat(NNT)13].263However,thelownumberofpatients
.
The SHOCK (Should We Emergently Revascularize Occluded .. includedintheanalysedstudiesandthenon-randomtreatmentallo-
.
Coronaries for Cardiogenic Shock) trial demonstrated that in . cationareimportantlimitations.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 32 ---
118 ESC/EACTSGuidelines
.
8.2.2.3Percutaneousleftventricularassistdevices .. werenotedinanRCTofhigh-riskPCIinpatientswithimpairedLV
.
.
ThemajorityofclinicalexperiencewithcurrentlyavailablepLVADs . function.The30dayincidenceofmajoradverseeventswasnotdif-
.
is limited to two types ofdevice: (i) a transaortic microaxialpump .. ferentforpatientswithpLVADvs.IABP.267
.
.
(Impella)thatdirectlyunloadsthe LVproviding2.5-5L/minblood . Insummary, theevidence for pLVADis insufficienttoprovide a
.
.
flow and (ii) a transseptal centrifugal assist device (TandemHeart) . recommendationonitsclinicaluseincardiogenicshock.
.
.
that unloads the LV via a cannula introduced into the left atrium .
.
.
throughatransseptalpuncture. . 8.2.2.4Surgicallyimplantedleftventricularassistdevices
.
.
Arecentmeta-analysisonMCSincardiogenicshockincludedfour . There are limited data on surgically-implanted LV assist device
.
.
randomizedtrialsinvestigatingtheefficacyandsafetyofpLVADsvs. . (LVAD) therapy in patients with AMI and cardiogenic shock. One
.
.
IABP, and demonstrated similar short-term mortality despite initial . multicentreregistryshowedthatdespitebeingmorecriticallyillprior
.
.
beneficialeffectsonarterialbloodpressureandperipheralperfusion, .. toimplantation,patientswithacuteMImanagedwithLVADhadout-
.
measured by serum lactate levels.266 In all trials, a higher rate of .. comessimilartootherLVADpopulations.268
.
bleedingfromvascularaccesssitesandasignificantlyhigherincidence .. Asuggestedalgorithmforthemanagementofpatientswithcardio-
.
of limb ischaemia following pLVAD was noted. Similar outcomes .. genicshockisshowninFigure6.
.
Figure6Algorithmforthemanagementofpatientswithcardiogenicshock.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 33 ---
ESC/EACTSGuidelines 119
.
.
8.3 Gaps in the evidence . The anatomicalpatternof CADinpatientswithdiabetesclearly
.
.
. influences their prognosis and response to revascularization.
ThereisnoRCTcomparingrevascularizationwithPCIvs.CABGin .
.
. Angiographicstudieshavedemonstratedthatpatientswithdiabetes
patientswithHF. .
.
. aremorelikelytohaveLMdiseaseandmultivesselCAD,withmore
There is limited evidence on the role of active MCS in patients .
.. diffusediseaseinvolvingsmallervessels.273Inaddition,patientswith
withcardiogenicshockcomparedwithstandardtherapy. .
.
. diabetes have a greater atherosclerotic burden and an increased
.
.. numberoflipid-richplaques,whicharepronetorupture,274,275and
.
Recommendationsforthemanagementofpatientswith .
. thosewithunstableanginahavemorefissuredplaquesandintracoro-
cardiogenicshock ..
.. narythrombi.276Patientswithdiabetesundergoingrevascularization,
.
.. either with CABG orPCI, are atgreater riskofkidney injury than
Recommendations Classa Levelb ...
patientswithoutdiabetes.
.
.
Emergencycoronaryangiographyisindi- .
.
catedinpatientswithacuteheartfailureor I B .. 9.1 Evidence for myocardial
.
.
cardiogenicshockcomplicatingACS.258,269 . revascularization
.
.
.
. Inpatientswithdiabetes,theindicationsformyocardialrevasculariza-
EmergencyPCIoftheculpritlesionisindi- .
.
. tionarethesameasthoseinpatientswithoutdiabetes(seesections
catedforpatientswithcardiogenicshock .
.
. 5,6,and7).Ameta-analysisofnineRCTswith9904ACSpatientsdid
duetoSTEMIorNSTE-ACS,independent I B .
.
. notshowaninteractionbetweendiabeticstatusandthebenefitfrom oftimedelayofsymptomonset,ifcoronary .
anatomyisamenabletoPCI.258 ... invasive management and revascularization.277 Yet, absolute risk
.
. reductionswerelargerinthediabeticsubsetscomparedwithnon-
.
.
EmergencyCABGisrecommendedfor . diabeticsubsets.Consistentwiththefindingsintheabsenceofdiabe-
.
patientswithcardiogenicshockifthecoro- I B .. tes, the adverse impact of incomplete revascularization in patients
.
naryanatomyisnotamenabletoPCI.258 .. with diabetes was also demonstrated in the BARI-2D (Bypass
.
.
Incasesofhaemodynamicinstability,emer-
... AngioplastyRevascularizationInvestigation2Diabetes)trial.278
gencysurgicalorcatheter-basedrepairof
... Datafromrandomizedtrialsonrevascularizationinpatientswith
mechanicalcomplicationsofACSisindi-
I C ... diabetesaresummarizedinSupplementaryTable5.
.
cated,asdecidedbytheHeartTeam. ..
.. 9.2 Type of myocardial revascularization
.
InselectedpatientswithACSandcardio- ...
Theselectionoftheoptimalmyocardialrevascularizationstrategyfor
genicshock,short-termmechanicalcircula- ...
patientswithdiabetesandmultivesselCADrequiresparticularcon-
torysupportmaybeconsidered,depending
IIb C
...
sideration.Therecommendationsareprovidedinsection5.
onpatientage,comorbidities,neurological ..
.
function,andtheprospectsforlong-term ..
survivalandpredictedqualityoflife.
... 9.2.1.Randomizedclinicaltrials
.. TheFREEDOMtrialcomparedelectiverevascularizationwithCABG
.
RoutineuseofIABPsinpatientswithcar- .. orPCIwithfirst-generationDES(94%)in1900patientswithdiabetes
.
diogenicshockduetoACSisnot III B .. (6%ofthescreenedpopulation)withmultivesseldiseasebutwithout .
recommended.260–262 .. LMstenosis.150Theprimaryendpointofany-causedeath,non-fatal
.
.
. MI,orstrokeat5yearsoccurredin26.6% inthePCIgroup,com-
.
.
ACS=acutecoronarysyndrome;CABG=coronaryarterybypassgrafting;IABP . paredwith18.7%intheCABGgroup(absolutedifference7.9%,95%
.
=intra-aorticballoonpump;NSTE-ACS=non-ST-elevationacutecoronarysyn- .. CI3.3–12.5%,P=0.005).Theincidencesofdeath(16.3%inthePCI
drome;PCI=percutaneouscoronaryintervention;STEMI=ST-elevationmyo- ..
. groupvs.10.9%intheCABGgroup;absolutedifference5.4%,95%
cardialinfarction. .
.
aClassofrecommendation. . CI1.5–9.2%,P=0.049)andMI(13.9%inthePCIgroupvs.6.0%in
. bLevelofevidence ..
theCABGgroup,P<0.001)werehigherinthePCIgroup,butthe
.
.
. incidence of stroke was lower (2.4 vs. 5.2%; P =0.03). Within the
.
.
. FREEDOMtrialat5years,patientswithdiabetestreatedwithinsulin
9 Revascularization in patients ..
. had higher event rates, but there was no significant interaction of
.
with diabetes .. treatment and insulin requirement for the primary endpoint
.
.
. (P =0.40),evenafteradjustingforSYNTAXscore:theNNT
. interaction
.
Patients with diabetes mellitus have a higher prevalence of CAD, .. withCABGvs.PCItopreventoneeventwas12.7forinsulin-treated
.
whichoftenmanifestsearlierinlifeandconfersasubstantiallyworse .. patientsand13.2inthosenotrequiringinsulin.279
prognosisthanforpatientswithoutdiabetes.270Patientswithdiabe- ...
VACARDS (Veterans Affairs Coronary Artery Revascularization
.
tes who have suffered an MI have a worse prognosis, particularly .. inDiabetesStudy)comparedCABGwithPCIinpatientswithdiabe-
.
thoserequiringtreatmentwithinsulin,andthepresenceofdiabetes .. tesandextensiveCADintheUSA.154Only198patientswithdiabe-
amplifiestheriskofanycardiovascularevent.271Diabetesmellitusis ...
tes were randomized due to early termination of the study. The
.
presentin25–30%ofpatientsadmittedwithACSandinupto40% .. combinedriskofdeathornon-fatalMIwas18.4%fortheCABGarm
.
ofpatientsundergoingCABG.272 . and25.3%forthePCIarm(HR0.89,95%CI0.47–1.71,P<0.05).154
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 34 ---
120 ESC/EACTSGuidelines
.
In the CARDia (Coronary Artery Revascularization in Diabetes) .. highSYNTAXscore.Anetworkmeta-analysishadsuggestedthatthe
.
trial, 510patientswith diabetes and multivessel orcomplex single- .. survivalbenefitofCABGoverPCIinpatientswithdiabetesmightbe
.
vesselCAD wererandomlyassigned toeitherCABGorPCI,with .. lost when using EES,151 though this was not confirmed in a subse-
.
theuseofeitherBMSorDESandroutineuseofabciximab.156There .. quent meta-analysis that also included the direct comparison
.
werenodifferencesbetweenCABGand PCIfortheprimaryend- .. betweenEESandCABGinthesubsetofBEST.153
.
.
pointof1yearcompositeofdeath,MI,orstroke,butthetrialwas . Inacollaborative,individualpatientdatapooledanalysisof11518
.
.
underpoweredtodetectthesedifferences.However,repeatrevas- . patientswithmultivesselorLMdiseaserandomizedtoCABGorPCI
.
.
cularization was more likely to occur in patients treated with PCI . with stents, all-cause death was significantly different after CABG
.
(P<0.001).156 .. (9.2%)andPCI(11.2%)(P=0.0038),whichwasevidentinpatients
.
.
Inthesubsetof452patientswithdiabetesandmultivesselCAD . with diabetes (10.7 vs. 15.7%, respectively; P = 0.0001) but not in
.
.
whowereenrolledintheSYNTAXtrial,therewerenodifferences . patients without diabetes (8.4 vs. 8.7%, respectively; P = 0.81)
.
inthecompositesafetyendpointofall-causedeath,stroke,andMIat .. (P =0.0077).124Similarresultswerefoundinthesubgroupof
. interaction
.
5yearfollow-up.155However,theneedforrepeatrevascularization .. 7040patientswithmultivesseldisease(P interaction=0.0453),whilethe
.
(HR 2.01, 95% CI 1.04–3.88, P <0.001) was significantly more fre- .. interactionwithdiabeteswasnotsignificantinthe4478patientswith
.
quentinpatientswithdiabetestreatedwithPCIthaninthosewho ... LMdisease(P interaction=0.13).
underwentCABG.155,275Patientswithdiabeteshadahigherrateof .. A recent population-based analysis has confirmed the benefit of
.
repeatrevascularizationafterPCIwhencomparedwithCABGinthe .. CABG compared with PCIin patientswithdiabetes whenpatients
.
low(<_22)(38.5vs.18.5%,respectively,P=0.014)andintermediate .. presentwithanACS.196Consequently,overallcurrentevidencecon-
. (23-33)(27vs.13.4%,respectively,P=0.049)SYNTAXscoreter- .. tinues to favour CABG asthe revascularization modality of choice
.
tiles.Furtheranalysesaccordingtotreatmentwitheitheroralhypo- .. for patients with diabetes and multivessel disease. When patients
.
glycaemic agents or insulin showed that the MACCE rate was .. presentwithacomorbiditythatincreasessurgicalrisk,thechoiceof
.
significantly greater after PCI in both the oral hypoglycaemicagent .. revascularizationmethodisbestdecidedbymultidisciplinaryindividu-
.
group (PCI 40.4 vs. CABG 26.4%, P = 0.022) and the insulin- .. alizedriskassessment.
.
dependent group (PCI 56.2 vs. CABG 32.6%, P = 0.002). A higher ..
.
.
incidence of cardiac death was noted in the insulin-dependent .. 9.3 Revascularization with the use of
.
patientstreatedwithPCI(PCI18.8vs.CABG7.1%,P=0.023). .
. percutaneous coronary intervention
.
IntheSYNTAXtrial,diabeteswasnotanindependentpredictor .
.
. For the reasons discussed above, PCI in patients with diabetes is
ofoutcomesoncetheSYNTAXscorewasenteredintothemulti- .
.
variable model.127 Consequently, the SYNTAX 2 score does not .. often more complex than PCI in the absence of diabetes.
.
. Nevertheless, irrespective of diabetic status, the same principles
includediabetesasoneoftheeightvariablesthatimpactsonthepref- .
.
erential selection of revascularization modality.127 Conflicting data .. applyasdiscussedinsection16.Placementofanew-generationDES
.
wereseeninapatient-levelpooledanalysisof6081patientstreated
.. isthedefaultstrategy.
.
.
withstents(75%newergenerationDES),stratifiedaccordingtodia- .
.
betes status and SYNTAX score.157 After Cox regression adjust- .. 9.4 Antithrombotic pharmacotherapy
.
.
ment, SYNTAX score and diabetes were both associated with .
. InthecurrentcontextoftheuseoforalP2Y -inhibitors,thereisno
. 12
MACE(P<0.001andP=0.0028,respectively).At2years,patients ..
indication that antithrombotic pharmacotherapy should differ .
with diabetes had higher MACE (HR 1.25, 95% CI 1.03–1.53, P = ..
betweendiabeticsandpatientswithoutdiabeteswhoareundergoing
.
0.026)andTVR,andsimilardeathandMIrates.157 ..
revascularization.Fordetaileddiscussionrefertosection17.
.
In the BEST trial, patients with diabetes treated with PCI had a ..
.
higherrateoftheprimaryendpointofdeath,MI,orTVRcompared ..
. 9.5 Metformin
withCABG(EES:n=177;CABG:n=186)(19.2vs.9.1%,P=0.007) ..
.
(seesection5).105 .. There is a theoretical risk of lactic acidosis and deteriorating renal
.
. functioninpatientstreatedwithmetforminwhoareexposedtoiodi-
.
.. natedcontrastmedia.280Consequently,itisgenerallyrecommended
.
.
9.2.2Meta-analysisofcoronaryarterybypassgraftingvs. . thatinelectivecases,metforminshouldbewithheldbeforeangiogra-
.
percutaneouscoronaryinterventioninpatientswith .. phyorPCIfor48h,astheplasmahalf-lifeofmetforminis6.2h,280
.
.
diabetes . andreintroduced 48hlater.However, clinical experience suggests
.
.
A meta-analysis—restricted to four RCTs covering 3052 patients- .. thattheactualriskoflactateacidosisisverysmall,andthatchecking
.
compared PCI with the use of early-generation DES vs. CABG in .. renalfunctionafterangiographyinpatientsonmetforminandwith-
.
patientswithdiabetesandmultivesselCAD.Itsuggestedahigherrisk .. holdingthedrugwhenrenalfunctiondeterioratesappearstobean
.
ofdeathandMIwithrevascularizationbyearly-generationDES(RR .. acceptable alternative.280 In patients with renal failure, metformin
.
1.51,95%CI1.09–2.10;P<0.01),butalowerriskofstroke(2.3vs. .. should be stopped before the procedure. Accurate recognition of
.
3.8%;RR0.59,95%CI0.39– 0.90;P<0.01).152Asensitivityanalysis .. metformin-associated lactic acidosis based on arterial pH <7.35,
.
revealedthatthissuperiorityofCABGoverearly-generationDESfor .. bloodlactate>5mmol/L(45mg/dL),anddetectableplasmametfor-
.
theendpointMACCEwasmostpronouncedamongpatientswitha . minconcentrationshouldprompttheinitiationofhaemodialysis.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 35 ---
ESC/EACTSGuidelines 121
.
.
. 10.3 Gaps in the evidence
Recommendationforpatientsonmetformin ..
.. Thusfar,patientswithCKDhavebeenexcludedfromrandomized
.
.. trialsonmyocardialrevascularization,hencecurrentdataarebased
Recommendation Classa Levelb ..
. on observationalstudies only. A randomized trialonoptimal long-
.
.
Itisrecommendedtocheckrenalfunctionif . termrevascularizationstrategiesinpatientswithmoderate-to-severe
.
.
patientshavetakenmetforminimmediately . stress-induced ischaemia and severe CKD is currently ongoing
I C ..
beforeangiographyandwithholdmetformin .. (ISCHEMIA-CKD, https://clinicaltrials.gov/ct2/show/NCT01985360).
.
ifrenalfunctiondeteriorates. .. Moreover,additionalrandomizedevidenceonoptimalstrategiesfor
.
. CINpreventionisneeded.
aClassofrecommendation.
bLevelofevidence. Recommendationsforthepreventionofcontrast-
inducednephropathy
Recommendations Dose Classa Levelb
9.6 Gaps in the evidence PatientsundergoingcoronaryangiographyorMSCT
Following successful revascularization, the rate of events during Itisrecommendedthatall
follow-upremainshighinpatientswithdiabetes,independentofthe patientsareassessedfor
I C
mode of revascularization. Future research should be focused on theriskofcontrast-
identifyingnewdisease-modifyingtherapiestoinfluencetheprogres- inducednephropathy.
sionofvasculardiseaseinthishigh-riskcohort.
Adequatehydrationis
I C
recommended.
10 Revascularization in patients
PatientswithmoderateorsevereCKD(National
with chronic kidney disease KidneyFoundationstages3band4)
Useoflow-osmolaror
10.1 Evidence base for revascularization
iso-osmolarcontrast
and recommendations I A
mediais
Myocardialrevascularizationinpatientswithchronickidneydisease recommended.284–286
(CKD),specificallyNationalKidneyFoundationstage3orhigher,is
Itisrecommendedthat Totalcontrast
addressedbythe2014ESC/EACTSGuidelinesonmyocardialrevas-
thevolumeofcontrast volume/GFR
cularization. After reviewing the subsequent literature, the current I B
mediabe <3.7.c
TaskForcehasnotfoundanyevidencetosupportamajorupdate.A
minimized.287,288
recentposthocanalysisoftheSYNTAXtrialonpatientswithCKD
confirmstheprinciplesforallocatingpatientstoPCIorCABG,281as
Instatin-na¨ıvepatients, Rosuvastatin
discussedinsection5ofthisdocument. pre-treatmentwithhigh- 40/20mgor
IIa A
dosestatinsshouldbe atorvastatin80
10.2 Prevention of contrast-induced considered.293 mg.
nephropathy
Pre-andpost-hydration 1mL/kg/h12h
Theriskofcontrast-inducednephropathy(CIN)dependsonpatient- withisotonicsalineshould beforeandcon-
relatedfactors,suchasCKD,diabetesmellitus,congestiveHF,hae- beconsideredifthe tinuedfor24h
modynamicinstability,reducedplasmavolume,femalesex,advanced expectedcontrastvolume aftertheproce-
IIa C
age,anaemia,andperiproceduralbleeding,aswellasonthetypeand is>100mL. dure(0.5mL/
volumeofcontrastadministered.282–288Whentheratiooftotalcon-
kg/hifLVEF
trastvolume(inmL)toglomerularfiltrationrate(inmL/min)exceeds <_35%or
3.7,theriskofCINincreasessignificantly.287,288
NYHA>2).
Adequate hydration remains the mainstay of CIN pre-
vention.289–294High-dosestatins,asindicatedforsecondarypreven- Asanalternativetothe
tionirrespective oftheriskofCIN are also beneficial.293 All other pre-andpost-hydration
regimen,tailoredhydra- IIb B
strategiesforthepreventionofCINdonothavesufficientevidence
to justify a recommendation in favour or against.293,294 For more
tionregimensdmaybe
considered.295–297
detaileddiscussionrefertotheSupplementaryData.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 36 ---
122 ESC/EACTSGuidelines
.
.. 11.2 Primary indication for myocardial
PatientswithsevereCKD(NationalKidneyFoundation ..
. revascularization
stage4) ..
.
. 11.2.1Aorticvalvedisease
.
Prophylactichaemofiltra- Fluidreplace- .
. TherecommendationsforpatientsundergoingCABGfortheclini-
.
tion6hbeforecomplex mentrate1000 .
. callyleadingproblemofCAD,whoalsohavecoexistingsevereaortic
.
PCImaybe mL/hwithout .
. stenosisorregurgitation,remainunchangedfromthoseofthe2014
considered.298–300 negativeloss ... Guidelinesandsupportreplacementoftheaorticvalve.305However,
.
andsaline IIb B .
. in the current era of rapid developments in transcatheter valve
.
hydrationcon- .
.. implantation technologies, a decision regarding replacement of the
tinuedfor24h ...
aorticvalveformoderatestenosis/regurgitationshouldbe carefully
afterthe ...
considered on a case-by-case basis in discussion with the Heart
procedure. ...
Team. The patient’s age, type of prosthesis, pathogenesis of aortic
.
Haemodialysisisnotrec- .. stenosis/regurgitation,aorticannularsize,predictedsizeofimplanted
.
ommendedasapreven- III B .. valve, transcatheter aorticvalveimplantation (TAVI)accessroutes,
.
tivemeasure.300,301 .. andtechnicalfeasibilityofaTAVIprocedureinthefutureincaseof
.
.. diseaseprogressionshouldallbetakenintoaccount.306
.
.
.
CKD=chronickidneydisease;GFR=glomerularfiltrationrate;LVEF=leftven- .
.
tricularejectionfraction;MSCT=multi-slicecomputedtomography;NYHA= . . 11.2.2Mitralvalvedisease
NewYorkHeartAssociation;PCI=percutaneouscoronaryangiography. ..
aClassofrecommendation. .. Patientswithconcomitantsevereprimarymitralregurgitation(MR)
bLevelofevidence. .. shouldundergomitralvalverepairatthetimeofCABGinkeeping
.
cExample:370mLofcontrastmediuminapatientwithaGFRof100mL/minwill .. withguidanceforthesurgicalrepairofprimaryMR.305Thereisalso
yieldaratioof3.7. ..
dOptionsare:infusionofnormalsalineadjustedtocentralvenouspressure295or .. consensusbasedonexpertopiniononthesurgicalrepairofsevere
furosemide with matched infusion of normal saline296,297 (for details see the .. secondary MR at the time of CABG.305,307 However, considerable
.
SupplementaryData). ..
controversy exists about the treatment of moderatesecondary or
.
.
.. ischaemicMRinpatientsundergoingCABG.Untilthepublicationof
.
.. 2 year outcomes of the CTSN (Cardiothoracic Surgical Trials
.
11 Revascularization in .. Network) randomized trial on treatment of ‘moderate’ ischaemic
.
patients requiring valve
... MR, the literature in this field was limited to small single-centre
.. randomizedtrials,observationalstudies,andcaseseries,andfailedto
interventions ... providecleardirection.TheCTSNtrialshowedthatadditionofsur-
.
.. gicalmitralvalverepairtoCABGmadenosignificant differenceto
.
11.1 Primary indication for valve .. survival,overallreductionofadverseevents,orLVreverseremodel-
.
interventions .. lingat2years.308,309Increasedlengthofintensivecareandhospital
.
Myocardial revascularization in patients undergoing primary valve ... stay and perioperative morbidity, including neurological complica-
interventions,eitherbysurgeryortranscatheterroutes,isaddressed ... tionsandsupraventriculararrhythmias,werereportedintheCTSN
bythe2014ESC/EACTSGuidelinesonmyocardialrevascularization.
... andotherrandomizedtrialsinthisgroupofpatients.308–310Because
.
After reviewing the subsequent literature, the current Task Force .. theCTSNtrialusedaverybroaddefinitionofmoderateMR,includ-
endorsestherecommendationsofthe2014Guidelinesandhasnot
... inganeffectiveregurgitantorificearea(EROA)<_0.2cm2plusaddi-
.
foundanyevidencetosupportamajorupdate.Theserecommenda- .. tionalcriteria,nofirmconclusionscanbedrawnconcerningpatients
tionsareincludedbelowforeaseofreference.Ofnote,theavailable
... withanEROA>0.2cm2.Observationaldatasuggestthatinsecon-
evidence on invasive functional assessment of CAD (with FFR or
... daryMR,anEROA>0.2cm2andregurgitantvolume>30mLindi-
iwFR)inpatientswithsevereaorticstenosis(AS)islimitedtoafew ... cates greater risk of cardiovascular events.311,312 In the absence of
.
small-scaleobservationalstudies.Thesestudiessupportthefeasibility .. dedicatedtrialsinthissetting,thedecisiontocombinemitralvalve
ofFFRandiwFRinthissetting.302–304Notwithstanding,theavailable ... surgerywithCABGinpatientswithanEROA>0.2cm2andregurgi-
.
evidence is insufficient to support the use of invasive functional .. tantvolume>30mLneedstobemadeonacase-by-casebasisbythe
.
assessment of coronary lesions in patients with AS, particularly in .. HeartTeam.Foramoredetaileddiscussionofthisissue,pleaserefer
.
considerationofthealteredhaemodynamicconditionrelatedtothe .. totheSupplementaryData.
.
.
presenceofAS.Therefore,theTaskForceisinconsensusthatindica- .
.
tionsformyocardialrevascularizationbasedonangiographicassess- .. 11.3 Gaps in the evidence
.
.
mentofCADshouldbemaintained,consistentwiththe2014ESC/ .. Inpatientswithconcomitantvalvularandcoronarydisease,thepossi-
.
EACTS Guidelines on myocardial revascularization and the 2017 .. bilityoffuturetranscathetertherapyfortheaorticandmitralvalves
.
ESC/EACTS Guidelines for the management of valvular heart .. has made a significant impact on decision-making for patients with
.
disease.305 .. predominantly coronary disease with moderate valve lesions.
.
. However, thereiscurrentlylittle evidence onthistopic.Theneed
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 37 ---
ESC/EACTSGuidelines 123
.
.
forandtimingofPCIinpatientsundergoingTAVIisalsoanareawith .. 12 Associated peripheral artery
.
limitedevidence.Thelong-termoutcomesofpatientswithconcomi- ...
diseases
tantsurgicalrepairofischaemicMRarealsoawaited. ..
.
.
.. 12.1 Prevention of stroke associated with
.
.
.. carotid artery disease and myocardial
Recommendationsforcombinedvalvularandcoronary .
.
interventions .. revascularization
.
.. The earlyriskofstrokeaftermyocardialrevascularizationis higher
.
Recommendations Classa Levelb
... afterCABGthanafterPCI.313After30days,strokeratesbetween
.. revascularization techniques were similar in a recent individual
.
Primaryvalveinterventionandcoro- .. patientdatameta-analysisof11randomizedtrials.313
.
naryrevascularization .. IschaemicstrokeafterCABGismultifactorial:thrombo-embolism
.
.
. fromtheaorta,itsbranches,ortheheart;atrialarrhythmias;inflam-
CABGisrecommendedinpatientswitha .
.
. matorypro-thrombogenicmilieu;lowerlevelsofantiplatelettherapy
primaryindicationforaortic/mitralvalve .
I C .. perioperatively; and haemodynamic instability. However, the most
surgeryandcoronaryarterydiameter .
.
. consistent predictor of perioperative stroke is previous stroke or
stenosis>70%. .
.
. TIA.Thereisnostrongevidencethatcarotidarterystenosisisasig- .
.
CABGshouldbeconsideredinpatients . nificantcauseofperioperativestrokeexceptforbilateralseverecar-
.
withaprimaryindicationforaortic/mitral .. otid bifurcation stenosis.314 Therefore, indications for preoperative
IIa C ..
valvesurgeryandcoronaryarterydiameter . carotid bifurcation screening by duplex ultrasound are limited.315
.
.
stenosisof50–70%. .. Also,thereisnoevidencethatprophylacticrevascularizationofuni-
.
PCIshouldbeconsideredinpatientswitha
... lateralasymptomaticcarotidstenosesinCABGcandidatesreduces
primaryindicationtoundergoTAVIand
... theriskofperioperativestroke.Itmaybereasonabletorestrictpro-
IIa C .. phylacticcarotidrevascularizationtopatientsathighestriskofpost-
coronaryarterydiameterstenosis>70%in .
.. operativestroke,i.e.patientswithseverebilaterallesionsorahistory
proximalsegments. .
.. of prior stroke/TIA.316 Hence, the indication for revascularization,
.
PCIshouldbeconsideredinpatientswitha .. and the choice between carotid endarterectomy or carotid artery
.
primaryindicationtoundergotranscatheter .. stentinginthesepatients,shouldbemadebyamultidisciplinaryteam
.
mitralvalveinterventionsandcoronary IIa C .. includinganeurologist.
.
arterydiameterstenosis>70%inproximal .. The2017Guidelinesonthediagnosisandtreatmentofperipheral
.
segments. .. arterial diseases in collaboration with the European Society of
.
.. VascularSurgerycoverthescreeningforandmanagementofcarotid
Primarymyocardialrevascularization ..
. arterydiseaseinpatientsscheduledforCABG,includingscreening,
andvalveintervention ...
indications,andthetimingandtypeofcarotidrevascularization.317Its
.
.
SAVRisindicatedinpatientswith . recommendationsarereproducedhere.
.
.
severeASundergoingCABG,or . Particularlyforpatientsathighriskforperioperativestrokeafter
I C ..
surgeryoftheascendingaortaor . CABG,suchaselderlypatientsorpatientswithpreviousTIA/stroke,
.
.
anothervalve. .. specificpreventivemeasureshavebeensuggested.CTscanscreening
.
. oftheascendingaorta/archatheromahasbeenproposedtobetter .
Mitralvalvesurgeryisindicatedinpatients .
. assess risk stratification and guide the surgical strategy in elderly .
withseveresecondaryMRundergoing I C .. patients.318Itisrecommendedthatacetylsalicylicacidisrestarted6 .
CABGandLVEF>30%. .
. h,oratthelatest24h,aftersurgery,andthatclopidogrelorticagrelor
.
.
Mitralvalvesurgeryshouldbeconsideredin .. areaddedinpatientswithACS.New-onsetatrialfibrillation(AF)is
.
symptomaticpatientswithseveresecondary .. associated with a risk of stroke that increased two-to-three times
.
MRandLVEF<30%,butwithevidenceof IIa C .. afterCABG.Itsmanagementisdiscussedinsection14.
.
.
myocardialviabilityandanoptionforsurgi- .
.
. 12.2 Associated coronary and peripheral
calrevascularization. .
.
.. artery diseases
.
.
AS=aorticstenosis;CABG=coronaryarterybypassgrafting;LVEF=leftven- .. OfallpatientswithCAD,7–16%havelowerextremityarterydisease
.
tricularejectionfraction;MR=mitralregurgitation;PCI=percutaneouscoronary .. (LEAD),whichisassociatedwithaworseprognosis,evenifitremains
intervention; SAVR = surgical aortic valve replacement; TAVI = transcatheter .
aorticvalveimplantation.
... frequently asymptomatic, masked by cardiac symptoms. On the
aClassofrecommendation. .. otherhand,inpatientswithLEAD,CADispresentinupto70%of
bLevelofevidence. ... patients.317ThechoicebetweenCABGandPCIiscontroversialand,
.
. in the absence of solid data, it should follow a multidisciplinary
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 38 ---
124 ESC/EACTSGuidelines
approach.127 In patients undergoing CABG, the saphenous vein
Preoperativestrategiestoreducetheincidenceof
should be preserved or harvested guided by the results of clinical
strokeinpatientsundergoingcoronaryarterybypass
examinationincludingtheankle-brachialindex.Inaddition,inter-arm grafting
bloodpressureasymmetryshouldleadtotheinvestigationofsubcla-
vianarterystenosis.Furtherdetailsareprovidedinthe2017periph-
Recommendations Classa Levelb
eralarterialdiseasesGuidelines.317
InpatientsundergoingCABG,carotidDUS
Recommendationsonthemanagementofcarotid
isrecommendedinpatientswithrecent(<6 I B
stenosisinpatientsundergoingcoronaryarterybypass
months)historyofstroke/TIA.321,322
grafting
Inpatientswithnorecent(<6months)his-
Recommendations Classa Levelb toryofTIA/stroke,carotidDUSmaybe
consideredbeforeCABGinthefollowing
InpatientsscheduledforCABG,itisrecom- IIb B
cases:age>_70years,multivesselcoronary
mendedthattheindication(andifsothe
arterydisease,concomitantLEAD,orcaro-
methodandtiming)forcarotidrevasculari-
I C tidbruit.321,322
zationbeindividualizedafterdiscussion
withinamultidisciplinaryteam,includinga Screeningforcarotidstenosisisnotindi-
neurologist. catedinpatientsrequiringurgentCABG III C
withnorecentstroke/TIA.
InpatientsscheduledforCABG,withrecent
(<6months)historyofTIA/stroke:
CABG =coronaryarterybypassgrafting;DUS =duplexultrasound; LEAD =
• Carotidrevascularizationshouldbecon-
lowerextremityarterydisease;TIA=transientischaemicattack.
sideredinpatientswith50-99%carotid aClassofrecommendation.
stenosis.319,320 IIa B bLevelofevidence.
• CarotidrevascularizationwithCEA
shouldbeconsideredasfirstchoicein
patientswith50-99%carotid IIa B
.
stenosis.319,320 ..
13 Repeat revascularization
.
• Carotidrevascularizationisnotrecom- ..
.
mendedinpatientswithcarotidstenosis
III C
...
13.1 Early graft failure
<50%. ..
.. EarlygraftfailureafterCABGisreportedinupto12%ofgrafts,as
.
Inneurologicallyasymptomaticpatients .. evaluatedbyintraoperativeangiography.323However,onlyaminority
.
scheduledforCABG: .. (around3%)areclinicallyapparent.Graftfailurecanbeduetocon-
.
• Carotidrevascularizationmaybeconsid- .. duitdefects,anastomotictechnicalerrors,poornativevesselrun-off,
.
eredinpatientswithbilateral70-99% .. orcompetitiveflowwiththenativevessel.Whenclinicallyrelevant,
IIb C .
carotidstenosisor70-99%carotid .. acutegraftfailuremayresultinMIwithconsequentlyincreasedmor-
.
stenosisandcontralateralocclusion. .. tality and major cardiac events. The suspicion of early graft failure
.
• Carotidrevascularizationmaybeconsid- .. shouldarise inthe presence ofECGsignsofischaemia,ventricular
.
eredinpatientswitha70-99%carotid .. arrhythmias,biomarkerchanges,newwallmotionabnormalities,or
.
stenosis,inthepresenceofoneormore .. haemodynamicinstability.324,325OwingtothelowspecificityofECG
. characteristicsthatmaybeassociated IIb C .. changesandechocardiographicwallmotionabnormalitiesduringthe
.
withanincreasedriskofipsilateralstro- .. post-operativecourse,andthedelayintheappearanceofbiomarker
.
ke,cinordertoreducestrokerisk .. changes,acarefulassessmentofallvariableswillinfluencedecision- .
beyondtheperioperativeperiod. .. makingforangiographicevaluation.
.
• Routineprophylacticcarotidrevasculari- .. Perioperativeangiographyisrecommendedincasesofsuspected
.
.
zationinpatientswitha70-99%carotid III C .. severe myocardial ischaemia to detect its cause and aid decision-
stenosisisnotrecommended. .. makingonthemostappropriatetreatment.323,325,326Insymptomatic
.
.
. patients, early post-operative graft failure can be identified as the
.
CABG=coronaryarterybypassgrafting;CEA=carotidendarterectomy;TIA=
... causeofischaemiain40-80%ofcases.324,326–328Theoptimaltreat-
transientischaemicattack. .. mentstrategyinpatientswithacutegraftfailureshouldbedecidedby
aClassofrecommendation. ..
. ad hoc consultation between the cardiovascular surgeon and the
bLevelofevidence. ..
cContralateralTIA/stroke,ipsilateralsilentinfarctiononcerebralimaging,intraplaque .. interventionalcardiologist,onthebasisofthepatient’sclinicalcondi-
.
haemorrhageorlipid-richnecroticcoreonmagneticresonanceangiography,oranyof .. tionandtheextentofmyocardiumatrisk.Inthecaseofearlypost-
thefollowingultrasoundimagingfindings:stenosisprogression(>20%),spontaneous .
embolizationontranscranialDoppler,impairedcerebralvascularreserve,largepla-
... operativegraftfailure,emergencyadhocPCImaylimittheextentof
ques,echolucentplaques,orincreasedjuxta-luminalhypoechogenicarea.317 .. infarction,iftechnicallyfeasible.ThetargetforPCIisthenativevessel
.
.. or the internal mammary artery (IMA) graft, while the acutely
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 39 ---
ESC/EACTSGuidelines 125
.
.
occludedsaphenousveingraft(SVG)andanyanastomoticsiteshould . The IMA isthe conduitofchoice forrevascularizationduringredo
.
.
be avoided, if possible, due to concerns regarding embolization or . CABGifnotpreviouslyused,orcanbesalvagedandreusedinspe-
.
perforation. Redo surgery should be favoured if the anatomy is .. cificcases.344,345
.
.
unsuitableforPCI,ifseveralimportantgraftsareoccluded,orinthe .
.
.
case of clear anastomotic errors. In asymptomatic patients, repeat .
. 13.3.2Percutaneouscoronaryinterventionforsaphenous
.
revascularizationshouldbeconsideredifthearteryisofanappropri- .
. veingraftlesions
.
atesizeandsuppliesalargeterritoryofmyocardium. .
. PCIinSVGs is associated with anincreased riskofdistalcoronary
.
Furtherdetailsonthediagnosisandmanagementofperioperative .. embolization,frequentlyresultinginperiproceduralMI.346PCIofde
.
MIareprovidedinarecentESCpositionpaper.329 ..
novoSVGstenosisisconsideredahigh-riskinterventionbecauseSVG
.
.
.. atheroma is friable and more prone to distalembolization. Several
13.2 Acute percutaneous coronary .
.. differentapproacheshavebeenevaluatedtopreventthedistalembo-
intervention failure ... lization of particulate debris, including distal occlusion/aspiration,
.
TheneedforurgentsurgerytomanagePCI-relatedcomplicationsis .. proximalocclusion,suction,filterdevices,orcoveredstents.Distal
.
uncommon(<1%)andonlyrequiredinpatientswithmajorcomplica- .. protection devices using filters have shown the most encouraging
.
tions that cannot be adequately resolved by percutaneous techni- .. results.However,althoughasinglerandomizedtrialsupportstheuse
.
ques.330,331 The need for emergency CABG is mainly confined to .. of distal embolic protection during SVG PCI, observational studies
.
patientswithalarge,evolvingMIduetoiatrogenicvesselocclusion .. including data from large-scale registries are conflicting.347–349
.
thatcannotbesalvagedpercutaneously,orinpatientswithrecurrent .. OutcomesfromstudieswithotherdevicesusedforSVGPCIarenot
.
cardiac tamponade after pericardiocentesis following PCI-related .. sufficienttorecommenditsuse.350–353
.
vesselrupture.330,332,333 .. Basedondatafromasmallnumberofrandomizedtrials,implanta-
.
.
. tionofDESinSVGlesionsisassociatedwithalowerriskofrepeat
.
13.3 Disease progression and late graft .. revascularization than with BMS at 1 year follow-up.354–356 In the
.
.
failure .. onlytrialpoweredforaclinicalendpoint—theISAR-CABG(IsDrug-
.
. Eluting-Stenting Associated with Improved Results in Coronary
IschaemiaafterCABGmaybeduetotheprogressionofdiseasein ...
Artery Bypass Grafts) trial354—the primary endpoint of death, MI,
nativevesselsordenovodiseaseofbypassgrafts.334Repeatrevascula- ..
. andtargetlesionrevascularizationwassignificantlyreducedwithDES
rization in these patients is indicated in the presence of significant ..
. vs.BMS.However,at5yearfollow-up,theadvantageofDESover
symptomsdespitemedicaltreatment,andinasymptomaticpatients ..
. BMSwaslostduetoahigherincidenceoftargetlesionrevasculariza-
withobjectiveevidenceoflargemyocardialischaemia(>10%ofthe ...
tionbetweenyears1and5inpatientstreatedwithDES.357Longer-
LV).32,87 ..
. termfollow-upofthetwo smaller trialsis available; one suggested
.
.
. sustained superiority of DES over BMS, while the other suggested
.
13.3.1Redocoronaryarterybypassgraftingor ... lossoftheefficacyadvantageoftheDES.358,359
percutaneouscoronaryintervention ..
.
PCIinpatientswithpriorCABGhasworseacuteandlong-termout- ... 13.4 Repeat percutaneous coronary
comes than in patients without prior CABG.335,336 Likewise, redo ..
. intervention
CABG has a two- to four-fold increased mortality compared with ..
first-time CABG, and repeat CABG is generally performed
... RecurrenceofsymptomsorischaemiaafterPCIistheresultofreste-
infrequently.334,337–339Therearelimiteddatacomparingtheefficacy
... nosis,incompleteinitialrevascularization,ordiseaseprogression.334
.
. Patients may require repeat PCI due to late and very late stent
ofPCIvs.redoCABGinpatientswithpreviousCABG.Thepropor- .
.
. thrombosis.
tionofpatientsundergoingPCI,redoCABG,orconservativetreat- .
.
. ment differs significantly between studies; in one study, PCI was .
.
.
favouredin(cid:5)50%ofpatientswithonly22%undergoingredoCABG, . 13.4.1Restenosis
.
whileanotherstudyfavouredCABGin67%ofpatients.340,341Inthe .. Restenosisassociatedwithanginaorischaemiashouldbetreatedby
. .
AWESOME (Angina With Extremely Serious Operative Mortality . repeat revascularization, and repeat PCI remains the strategy of
.
.
Evaluation)RCTandregistry,overall3yearmortalitywascompara- . choiceformostofthesepatients.Inthissetting,theresultsfromDES
.
blebetweenredoCABGandPCI.341,342Amorerecentstudyalso .. aresuperiortothoseobtainedwithballoonangioplasty,BMSimplan-
.
foundcomparableratesofdeathandMIbetweenredoCABGand .. tation,orbrachytherapy.360–364
.
.
PCI,althoughthereweresignificantlymorerepeatrevascularizations . For restenosis within BMS, drug-coated balloon (DCB) proved
.
.
withPCI.341,343 . superiortoplainballoonangioplasty365–367andcomparabletofirst-
.
.
InviewofthehigherriskofproceduralmortalitywithredoCABG .. generationDES.365,366,368–372Onetrialshowedinferiorangiographic
.
andthesimilarlong-termoutcome,PCIisthepreferredrevasculari- .. outcomesincomparisontonew-generationDES,373whileasecond
.
zation strategy in patients with amenable anatomy.340 PCI via the .. trial showed comparable outcomes.374 For restenosis within DES,
.
bypassed native artery should be thepreferred approach. If PCI in .. DCBsalsoprovedsuperiortoplainballoonangioplasty367,369,371and
.
thenative vessel failsoris notanoption, PCIin the diseased SVG .. comparabletofirst-generationDES.371Inonestudy,DCBswereinfe-
.
shouldbeconsidered.CABGshouldbeconsideredforpatientswith .. riortonew-generationDESintermsoftheprimaryangiographicout-
.
extensivelydiseasedoroccludedbypassgraftsanddiffusenativeves- .. comemeasure.375Inamorerecentstudy,includingpatientswithany
.
sel disease, especially in the absence of patent arterial grafts.340 . type of in-stent restenosis, outcomes between DCB and repeat
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 40 ---
126 ESC/EACTSGuidelines
.
stenting with new-generation DES were comparable.376 A single .. associated multivessel disease, especially in the presence of other
.
randomized trial of patients undergoing DCB for restenosis within .. complexlesionssuchaschronictotalocclusions—CABGshouldbe
.
DESshowedsuperiorangiographicoutcomesinpatientswhounder- .. consideredbeforeanewPCIattempt.
.
went lesion preparation with scoring balloons vs. standard angio- ..
.
plastyballoons.377 ..
. 13.4.2Diseaseprogression
Network meta-analysis suggests that repeat stenting with new- ..
. PatientswithsymptomaticdiseaseprogressionafterPCIaccountfor
generationDES(withEES)andDCBarerankedfirstandsecondas ..
. upto50% ofreinterventions.383,384Theyshouldbemanagedusing
thehighestefficacytreatments.378,379Thesuperiorangiographicanti- ..
.. criteria similar to those applied to patients without previous
restenoticefficacyofnew-generationDESshouldbeweighedagainst .
.. revascularization.
a possible excessoflong-termadverse eventswith repeatstenting .
.
duringlonger-termfollow-upofthesetrials.380,381However,obser- ..
.
.
vationsinrelationtoclinicaleventsmustbeinterpretedwithcaution, . 13.4.3Stentthrombosis
.
.
asnoneofthetrialswaspoweredforclinicalendpointsandthecom- . Althoughstentthrombosisisveryrare,particularlysincetheadventof .
.
parator stent in studies with long-term follow-up was an early- . new-generation DES, it may have devastating clinical consequences.
.
.
generationDES. . StentthrombosisusuallypresentsasalargeMIandpatientsshouldbe
.
Theuseofintracoronaryimagingprovidesuniqueinsightsintothe .. treatedaccordingtotheprinciplesoutlinedinsection8.385Aggressive,
.
.
underlying mechanisms of in-stent restenosis (see section 16.2). . high-pressure balloon dilation should be used to correct underlying, .
OCTisabletodetectthepresenceofneoatherosclerosisinasignifi- .. stent-related,predisposingmechanicalproblems.386,387Liberaluseof
.
.
cant number of these patients. Underexpanded stents should be . intracoronary imaging in order to detect and modify underlying
.
.
aggressively tackled with high-pressure dilatations using non- .. mechanicalfactorsisrecommended(Figure7)(seesection16.2).
.
compliantballoons.Theoptimizationofthefinalresultsremainscru- .. Althoughrepeatstentinginpatientswithstentthrombosismaybe
.
cialduringreinterventionsforin-stentrestenosisand,inthisregard, .. avoidedwhensatisfactoryresultsareobtainedwithballoondilation,
.
the use of intracoronary imaging may be particularly helpful. .. anewstentmayberequiredtoovercomeedge-relateddissections
.
Outcomesofpatientswithin-stentrestenosisafterDESarepoorer .. andadjacentlesions,ortooptimizefinalresults.388
.
thanthoseinpatientswithBMSin-stentrestenosis,independentlyof .. Thereisnoevidencethatthepost-interventionalmanagementof
.
the therapeutic modality.382 In patients with recurrent episodes of .. patients with stent thrombosis should differ from that of patients
.
diffuse in-stent restenosis in large vessels—and in those with . withthrombosisofadenovolesionresultinginSTEMI.
Figure7Intracoronaryimagingfortheassessmentofstentfailure.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 41 ---
ESC/EACTSGuidelines 127
Recommendationsonrepeatrevascularization
Recommendations Classa Levelb
Earlypost-operativeischaemiaandgraftfailure
Coronaryangiographypost-CABGisrecommendedforpatientswith:
• symptomsofischaemiaand/orabnormalbiomarkerssuggestiveofperioperativeMI
• ischaemicECGchangesindicatinglargeareaofrisk I C
• newsignificantwallmotionabnormalities
• haemodynamicinstability.
ItisrecommendedthateitheremergencyreoperationorPCIisdecideduponbyadhocconsultationintheHeart
I C
Team,basedonthefeasibilityofrevascularization,areaatrisk,comorbidities,andclinicalstatus.
Diseaseprogressionandlategraftfailure
Repeatrevascularizationisindicatedinpatientswithalargeareaofischaemiaorseveresymptomsdespitemedical
I B
therapy.84,334
Ifconsideredsafe,PCIshouldbeconsideredasfirstchoiceoverCABG. IIa C
Proceduralaspectsoftherevascularizationmodalities
CABG
IMAistheconduitofchoiceforredoCABGinpatientsinwhomtheIMAwasnotusedpreviously.344 I B
RedoCABGshouldbeconsideredforpatientswithoutapatentIMAgrafttotheLAD.340,341,344 IIa B
PCI
DistalprotectiondevicesshouldbeconsideredforPCIofSVGlesions.348,350,351 IIa B
PCIofthebypassednativearteryshouldbeconsideredoverPCIofthebypassgraft. IIa C
Restenosis
DESarerecommendedforthetreatmentofin-stentrestenosisofBMSorDES.373,375,378,379 I A
Drug-coatedballoonsarerecommendedforthetreatmentofin-stentrestenosisofBMSorDES.373,375,378,379 I A
Inpatientswithrecurrentepisodesofdiffusein-stentrestenosis,CABGshouldbeconsideredbytheHeartTeamover
IIa C
anewPCIattempt.
IVUSand/orOCTshouldbeconsideredtodetectstent-relatedmechanicalproblemsleadingtorestenosis. IIa C
BMS=bare-metalstent;CABG=coronaryarterybypassgrafting;DES=drug-elutingstent;ECG=electrocardiogram;IMA=internalmammaryartery;IVUS=intravascular
ultrasound;LAD=leftanteriordescendingartery;MI=myocardialinfarction;OCT=opticalcoherencetomography;PCI=percutaneouscoronaryintervention;SVG=saphe-
nousveingraft.
aClassofrecommendation.
bLevelofevidence.
14 Arrhythmias ...
patientswithCADandLVEF<_35%.391Indirectevidenceforapro-
.
.
. tectiveeffectofrevascularizationwasdemonstratedintheMADITII
14.1 Ventricular arrhythmias ..
. (MulticenterAutomaticDefibrillatorImplantationTrialII)andSCD-
.
14.1.1Revascularizationforthepreventionofsudden .. HEFTstudies(SuddenCardiacDeathinHeartFailureTrial),where
.
cardiacdeathinpatientswithstablecoronaryartery .. the efficacy of implantation cardioverter defibrillators (ICDs) was
.
diseaseandreducedleftventricularfunction .. reduced if revascularization was performed prior to implanta-
.
Revascularizationplaysanimportantroleinreducingthefrequency .. tion.392,393 CABG in patients with reduced EF reduces cardiacand
.
ofventriculararrhythmiasinpatientswithnormalormildlyreduced .. overallmortalityforafollow-upof10years.78,81Inviewofthepro-
.
LV function,389,390 as well as the risk of sudden cardiac death in .. tectiveeffectofrevascularizationonventriculararrhythmias,patients
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 42 ---
128 ESC/EACTSGuidelines
.
.
withischaemicLVdysfunction(LVEF<_35%)whoareconsideredfor . impaired prognosis and a more than doubling of the risk of death,
.
primarypreventiveICDimplantationshouldbeevaluatedforischae- .. congestiveHF,andstroke.403
.
.
miaand/orforpotentialrevascularizationtargets. . The use of oral anticoagulation (OAC) for stroke prevention in
.
.
. patientswithAFoccurringduringorafterPCIshouldfollowtheESC
.
.
14.1.2Revascularizationforthetreatmentofelectrical .. GuidelinesonAtrialFibrillationforantithrombotictreatmentofAF
.
storm .. thatoccursoutsidethesettingofPCI,405althoughprospectivestud-
.
Electrical storm is a life-threatening syndrome related to incessant .. iesarescarce.Thecombinationanddurationofanticoagulationand
.
ventricular arrhythmias, which is most frequently observed in .. antiplatelettherapyshouldbeassessedaccordingtotheclinicalsitua-
.
patientswithischaemicheartdisease,advancedsystolicHF,valvedis- .. tion, as outlined in section 17 as well as in the ESC Guidelines on
.
ease,correctedcongenitalheartdisease,andgeneticdisorderssuch .. Atrial Fibrillation405 and the ESC Focused Update on Dual
.
as Brugada syndrome, early repolarization, and long QT syn-
.. AntiplateletTherapy.410
.
drome.394Urgentcoronaryangiographyandrevascularizationshould ..
.
.
bepartofthemanagementofpatientswithelectricalstorm,aswell . .
.
as antiarrhythmic drug therapy and/or ablation of ventricular . 14.2.2Atrialfibrillationcomplicatingcoronaryartery
.
.
tachycardia. .. bypassgrafting
.
.. Post-operative AF affects one-third of patients undergoing cardiac
.
14.1.3Revascularizationafterout-of-hospitalcardiac .. surgery.411–414Themainriskfactorforpost-operativeAFisage,and
.
arrest .. itisassociatedwithanincreasedimmediateriskofstroke,increased
.
Approximately 70% of survivors of out-of-hospital cardiac arrest .. morbidity, and 30 day mortality.415–417 In the long-term, patients
.
haveCAD,withacutevesselocclusionobservedin50%.395Multiple .. withanepisodeofpost-operativeAFhaveatwo-foldincreaseincar-
.
non-randomizedstudiessuggestthatemergencycoronaryangiogra- .. diovascularmortality,andasubstantiallyincreasedriskoffutureAF
.
phyand,ifappropriate,PCIafterout-of-hospitalcardiacarrestyielda .. andischaemicstrokecomparedwithpatientswhoremaininSRafter
.
favourable survival rate of <_60% at 1 year, which is considerably .. surgery.416,418–422
.
higherthanthe25%overallsurvivalrateinpatientswithabortedcar- .. Post-operativeAFisacommoncomplication,inwhichprophylac-
.
diacarrest.396,397Morerecentdatasuggestthatalmostone-quarter .. tic treatment has a moderate effect. Pre-operative anti-arrhythmic
.
.
ofpatients,resuscitatedfromcardiacarrestbutwithoutST-segment . drugtreatmentmaybeinitiatedbutwillhavetobeweighedagainst
.
.
elevation,showaculpritlesion(eithervesselocclusionorirregular . sideeffects.Beta-blockersdecreasetheincidenceofpost-operative
.
lesion).398–401 Recent large-scale observational studies have shown .. AFafterCABG.412,423–429
.
.
animpactonmortalityofearlyangiographyafterout-of-hospitalcar- .
.
diacarrest.402,403Thus,insurvivorsofout-of-hospitalcardiacarrest, ..
.
.
early coronary angiography and PCI, if appropriate, should be per- .. 14.2.3Post-operativeatrialfibrillationandstrokerisk
.
formed irrespective of the ECG pattern if no obvious non-cardiac .. Patientswithpost-operativeAFhaveanincreasedstrokeriskpost-
.
causeofthearrhythmiaispresent.404 .. operativelyaswellasduringfollow-up,419,430andwarfarinmedication
.
.
. atdischargehasbeenassociatedwithareducedlong-termmortal-
14.2 Atrial arrhythmias ...
ity.431Todate,therearenostudiesindicatingthatpost-operativeAF
.
The management of AF in patients with ischaemic heart disease is .. islessharmfulthananyotherformofAF,andgoodqualitydataare
.
addressed by the 2016 ESC Guidelines for the management of AF .. needed. Anticoagulation treatment with warfarin or non-vitamin K
.
developedincollaborationwithEACTS.405Afterreviewingthesub- ..
antagonist oral anticoagulants (NOACs) for stroke prevention in
.
sequentliterature,thecurrentTaskForceendorsestherecommen- .. patientswithpost-operativeAFshould thereforefollowtheguide-
.
dationsofthe2016Guidelinesandhasnotidentifiedaneedforany .. linesforthe antithrombotictreatmentofAFoccurringoutside the
. major update. Accordingly, the recommendation tables are taken .. setting of CABG using the CHA DS -VASc [Cardiac failure,
. 2 2
.
fromthe2016Guidelines.Foradetaileddiscussion,werefertothe . Hypertension, Age >_75 (Doubled), Diabetes, Stroke (Doubled) –
.
previousGuidelines.405 ..
Vasculardisease,Age65–74andSexcategory(Female)]score.The .
.
.. durationandtimingofOACinpost-operativeAFpatientsshouldbe
.
14.2.1Atrialfibrillationcomplicatingpercutaneous .. assessedindividually.
.
coronaryintervention .. Whetherornotsurgicalleftatrialappendage(LAA)obliteration
.
New-onsetAFinpatientsundergoingPCIoccursin2–6%ofproce- .. reduces stroke risk has been studied in smaller trials and registry
.
dures and increases with age, pre-existing HF, AMI, and arterial .. studieswithconflictingresults,432–434andiscurrentlyunderinvesti-
.
hypertension.406–409Notably,new-onsetAF[definedaschangefrom .. gationinalargerandomizedtrial.435RemovalorclosureoftheLAA
.
sinus rhythm (SR) at admission to AF during/after PCI] typically .. shouldbeconsideredasanadjuncttoanticoagulationandnotasan
.
occurs during the first 4 days after AMI, and is associated with . alternativeuntilmoredataareavailable.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 43 ---
ESC/EACTSGuidelines 129
Recommendationsforthepreventionofventriculararrhythmiasbyrevascularization
Recommendations Classa Levelb
AprimaryPCIstrategyisrecommendedinpatientswithresuscitatedcardiacarrestandanECGconsistentwith
I B
STEMI.395,397,436,437
Urgentangiography(andPCIifindicated)shouldbeconsideredinpatientswithresuscitatedcardiacarrestwithoutdiagnostic
IIa C
ST-segmentelevationbutwithahighsuspicionofongoingmyocardialischaemia.
Inpatientswithelectricalstorm,urgentcoronaryangiographyandrevascularization(asrequired)shouldbeconsidered. IIa C
ECG=electrocardiogram;STEMI=ST-elevationmyocardialinfarction;PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence.
Recommendationsforthepreventionandtreatmentofatrialfibrillationinthesettingofmyocardialrevascularization
Recommendations Classa Levelb
Perioperativeoralbeta-blockertherapyisrecommendedforthepreventionofpost-operativeAFafterCABGsurgery.412,438 I B
Restorationofsinusrhythmbyelectricalcardioversionorantiarrhythmicdrugsisrecommendedinpost-operativeAFwithhae-
I C
modynamicinstability.
PerioperativeamiodaroneshouldbeconsideredasprophylactictherapytopreventAFafterCABGsurgery.412,439 IIa A
Long-termanticoagulationshouldbeconsideredinpatientswithAFafterCABGorPCIwhoareatriskofstroke,considering
IIa B
theindividualstrokeandbleedingrisk.440,441
Ratecontrolandanticoagulationshouldbeconsideredastheinitialmanagementofasymptomaticpost-operativeAF.442 IIa B
Antiarrhythmicdrugsshouldbeconsideredforsymptomaticpost-operativeAFafterCABGorPCIinanattempttorestore
IIa C
sinusrhythm.
SurgicalocclusionorexclusionoftheLAAmaybeconsideredforstrokepreventioninpatientswithAFundergoingCABG
IIb B
surgery.432–434
AF=atrialfibrillation;CABG=coronaryarterybypassgrafting;LAA=leftatrialappendage;PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence.
.
.
14.3 Gaps in the evidence . Perioperativemedicationandbloodmanagementarecoveredinsep-
.
.. arateGuidelines.410,444
Thedurationofanticoagulationandtheircombinationwithantiplate- .
.
.
lettherapyinpatientswithnew-onsetAFafterPCIorCABGhasnot .
.
.
beenstudiedsufficiently.Likewise,theroleofroutineleftatrialexclu- .. 15.1 Surgical techniques
.
sionatsurgeryforthepreventionofstrokeiscurrentlyunclear. .
.. 15.1.1Completenessofrevascularization
.
.. Currentsurgicalpracticeislargelybasedonananatomicaldefinition
.
.. ofcompleterevascularization,andaimstobypassallepicardialvessels
15 Procedural aspects of coronary .
.. withadiameterexceeding>_1.5mmandaluminalreductionof>_50%
.
artery bypass grafting .. inatleastoneangiographicview.131Dependingonthedefinitionof
.
.. completeness of revascularization, the outcome after CABG in
.
CABG remains the most common cardiac surgical procedure, and .. patients with incomplete revascularization was either similar445–449
.
the techniques have been refined during 50 years of evolution.443 . or inferior131,132,449–451 to that of patients with complete
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 44 ---
130 ESC/EACTSGuidelines
.
.
revascularization.Certainly,insomepatientswithastenosisinsmall . grafting should be considered in patients with a reasonable life
.
.
vesselswithlittlemyocardiumatrisk,completerevascularizationmay . expectancyandalowriskofsternalwoundcomplications.
.
.
notbenecessary. . Theradialarteryconstitutesanalternativeasthesecondarterial
.
.
FFR-guided surgical revascularization has been associated with .. graftinpatientsinwhomBIMAgraftingisnotfeasible,patientswitha
.
improvedgraftpatency,butmorestudiesareneededtoinvestigate .. highriskofsternalwoundcomplications,orasathirdarterialgraft.
.
whether it improves clinical outcomes.28,452 Further discussion of .. There is a strong, adverse influence on radialartery patency when
.
FFR-guided revascularization is provided in sections 3.2.1.1 and .. the native coronary artery stenosis is <70%, and therefore its use
.
5.3.1.3. .. should be limited to coronary artery stenosis >70% and ideally
.
.. >90%.477Useoftheradialarteryasthesecondconduitofchoicehas
.
.. beenlinkedtoimprovedsurvivalinregistrystudies.478–480Available
.
15.1.2Conduitselection .. RCTs testing the radial artery vs. saphenous vein graft used angio-
.
Inadditiontopatient-relatedfactors,theoutcomefollowingCABG .. graphicpatencyastheprimaryendpoint,andnonewaspoweredto
.
isrelatedtothelong-termpatencyofgraftsandthereforeismaxi- .. detect differences in clinical outcomes.481 A recently published .
mized with the use of arterial grafts, specifically the IMA.453,454 .. patient-levelmeta-analysispoolingsixRCTscomparingradialartery
.
Exceptinrarecircumstances,allpatientsshouldreceiveatleastone .. vs.saphenousveingraftshowedthattheuseoftheradialarterywas
.
arterialgraft—theleftIMA(LIMA)—preferentiallytotheLAD.453,455 .. associatedwithalowerrateoftheprimaryendpoint(compositeof
.
.
SVGpatencyratesfornon-LADtargetshavebeenreported tobe . death, myocardial infarction, and repeat revascularization) at mean .
.
suboptimal.456 Bilateral IMA (BIMA)and radial artery fornon-LAD . follow-upof50months,mainlydrivenbyasignificantlystrongreduc-
.
.
targetshavebeenshowntoprovidebetterpatencyratesthanSVG, .. tionofneedforreinterventionandamoremodestreductioninsub-
particularlyfortheleftcoronaryarterysystem.457Therefore,asec- ... sequent MI.482 Despite a significantly lower risk of occlusion at
.
ondarterialgraftshouldbeconsidereddependingonthepatient’slife .. follow-upangiography,nodifferenceinall-causemortalitywasfound.
.
expectancy,riskfactors for sternalwound complications,coronary ..
.
anatomy,degreeoftargetvesselstenosis,graftquality,andsurgical .. 15.1.3Mammaryarteryharvesting
.
expertise. .. WhiletheskeletonizedtechniqueofharvestingtheIMAhasahigher
.
Whetherornottheuseofadditionalarterialgraftscantranslate .. theoreticalpotentialforinjury,thepotentialbenefitsincludealonger
.
into prolonged survival remains debatable. Data from non- .. conduit,moreversatility(sequentialanastomosis),higherbloodflow,
.
randomized studies suggest that the use of BIMA over single IMA .. andfewerwound-healingproblems.471,483–488Therefore,inpatients
.
(SIMA)useisassociatedwithimprovedlong-termsurvival,aswellas .. at higher risk of sternal wound complications, skeletonization is
.
fewernon-fataleventssuchasMI,recurrentangina,andtheneedfor .. recommended.
.
re-operation.458–465 However, observational studies are subject to ..
.
selection bias, despite propensity matching, and the effect of pro- .. 15.1.4Radialarteryharvesting
.
longedsurvivalwithadditionalarterialgraftshasnotbeenconfirmed .. Radialarteryharvestingisassociatedwithnegligiblemorbidityifpre-
.
inrandomizedtrials.466 .. cededbyassessmentofthehand’scollateralcirculation.Endoscopic
.
.
TheARTtrial(ArterialRevascularizationTrial)hasbeendesigned . radialharvestingispossible,butrobustevidenceconcerningitssafety
.
toanswerthequestionofwhetherBIMAcanimprove10yearsur- .. andefficacyisscarce.489,490Useoftheradialarteryafterrecentcoro-
.
.
vivalwhencomparedwithSIMA.Interimanalysisshowednodiffer- . nary angiography with radial access should be discouraged due to
.
enceat5yearsintherateofdeathorthecompositeofdeath,MI,or .. potentialendothelialdamage.491Harvestingofthewholeradialartery .
.
stroke, and 10 year results are warranted to draw final conclu- . pedicle,togetherwiththeintraluminalandsubadventitialinjectionof
.
sions.467 Limitations of the ART trial include a high crossover rate .. vasodilators,areusefulstepstopreventspasm.
.
.
fromtheBIMAarmtotheSIMAarmandahighrateofradialartery .
.
.
use in the SIMA arm that may have diluted the benefit of .. 15.1.5Saphenousveinharvesting
.
BIMA.468–470TheuseofBIMAgraftingisassociatedwithanincrease .. Saphenousveinharvestingcanbeaccomplishedusingopenandmini-
.
insternaldehiscence,andanincreasedrateofmediastinitisinobese .. mally invasive techniques, which include interrupted incisions and
.
patientsandpatientswithdiabetes.458,464,471–475IntheARTtrial,the .. partialorfullendoscopicprocedures.Endoscopicveingraftharvest-
.
useofBIMAwasassociatedwitha1.0-1.5%absoluteriskincreasein .. ing leads to a reduced rate ofleg woundcomplications,492–495 but
.
theneedforsternalwouldreconstruction,andasubsequentsubanal- .. the short- and long-term patency ofendoscopically harvested vein
.
ysishasfoundthatthisriskisminimizedwithskeletonizedharvest- .. grafts, compared with openly harvested grafts, has been
.
ing.476 While we await the 10 year data of the ART trial, BIMA . challenged.456,496–498 Although there is no unequivocal evidence
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 45 ---
ESC/EACTSGuidelines 131
.
concerning patency rates, most data from meta-analyses and .. 15.1.9Minimallyinvasiveandhybridprocedures
.
randomizedandnon-randomizedtrialsdonotdemonstrateinferior .. Minimally invasive coronary surgery with LIMA, harvested either
.
clinical outcomes with endoscopic vein harvest.492,493,499,500 If an .. directlyorunder video-assisted vision, may representanattractive
.
endoscopicveingraftharvestisperformed,itshouldbeundertaken .. alternativetoasternotomy.530Ithasasimilarsafetyandefficacypro-
.
by experienced surgeons or physician assistants with appropriate .. filetoconventionalon-pumpandoff-pumpprocedures,withamark-
.
trainingandreasonablecaseloads.501–503Ifanopentechniqueisused, .. edlyreducedpost-operativelengthofstayandanearlyqualityoflife
.
the‘no-touch’techniquehasshownsuperiorpatencyratesinmulti- .. benefit, although spreading of the ribs is associated with increased
.
ple randomized trials,504–507 with a patency rate >80% after 16 .. post-operativepain.531–533Ithasbeenshowntobesafeandeffective
.
years.507 .. inthetreatmentofproximalLADstenosisorchronicallyoccluded
.
.. LADarteries.144Moreover,whencomparedwithPCIinasettingof
.
.
. single-vesselproximalLADdisease,minimallyinvasivecoronarysur-
15.1.6Cross-Clamping ..
. gery was associated with less need for coronary reinterven-
Asinglecross-clamptechniquemaybepreferredtomultiplemanipu- ...
tion.143,534,535 When combined with PCI to non-LAD vessels, it lationsoftheaorta,withtheaimofreducingatheroembolicevents, ..
. providestheopportunityforhybridcoronaryrevascularizationtobe
butastrictno-touchtechniquemosteffectivelyreducesembolization ...
performedinselectedpatientswithmultivesseldisease.536
ofatheroscleroticmaterial.508–510Incasesofoff-pumpsurgery,devi- ..
. Hybrid revascularization can be performed consecutively in a
cesthatallowaclamplessproceduremayhelpreducetheincidence ..
. hybridoperatingroom,orsequentiallyonseparateoccasionsinthe ofcerebralvascularcomplications.511,512 ...
conventional surgical and PCI environments.537–540 In a small
.
.
. randomizedtrialof200patients,1yearand5yearratesofdeath,MI,
.
.
15.1.7Intraoperativequalitycontrol .. stroke,andmajorbleedingorrepeatrevascularizationwerenotsig-
.
BesidescontinuousECGmonitoringandtransoesophagealechocar- .. nificantly different between hybrid revascularization and
.
diographyimmediatelyafterrevascularization,intraoperativequality .. CABG.536,541HeartTeamdiscussionandtheprospectiveplanningof
.
control may also include graft flow measurement to confirm or .. ajointstrategyarecriticalforthesuccessofahybridrevascularization
.
excludeatechnicalgraftproblem.513Transit-timeflowmeasurement .. strategy.542
.
isthemostfrequentlyusedtechniqueforgraftassessmentandhas ..
.
been able to detect 2-4% of grafts that require revision.513,514 ..
.. 15.2 Reporting perioperative outcomes
In observational studies, the use of intraoperative graft assessment .
.
hasbeenshowntoreducetherateofadverseeventsandgraftfailure, .. PerioperativereportingofoutcomesafterCABGproceduresshould
.
althoughinterpretationcanbe challenging insequentialand T-graft .. bedoneonarisk-adjustedbasis.TheearlyriskperiodafterCABG
.
configurations.513,515–517 .. extendsupto3months,ismultifactorial,anddependsontheinter-
.
.. facebetweentechnicalvariabilityandpatientcomorbidity.543
.
.
.
.
15.1.8On-pumpandoff-pumpprocedures .
.
. 15.3 Gaps in the evidence
Twolarge,internationalrandomizedtrialshaveshownnodifference .
.
.
in30dayor1yearclinicaloutcomesbetweenon-andoff-pumpsur- . TheroleofFFRandiwFRinguidingsurgicalrevascularizationneeds
.
gerywhenperformedbyexperiencedsurgeons.518–520Thereisalso .. further investigation into whether it improves clinical outcomes.
.
.
evidencetoconcludethat,formostpatientsandsurgeons,on-pump . Likewise,thereareinsufficientdataontheimpactofintraoperative
.
surgeryprovidesexcellentshort-andlong-termoutcomes.518,520–523 .. assessmentofgraftflowonoutcomes.
.
.
Forsomesurgeons,off-pumpsurgeryisassociatedwithinferiorearly . InviewofthelimitationsofobservationalstudiescomparingBIMA
. .
and late graft patency rates, and possibly compromised long-term . with SIMA and the limitations of the ART trial, the ROMA
.
.
survival;however,aorticno-touch/clamplessoff-pumpproceduresin .. (RandomizationofSinglevs.MultipleArterialGrafts)trialisrecruiting
.
the hands of highly trained teams appear to be associated with a .. toanswerthequestionofwhethertheuseofadditionalarterialcon-
.
reduced risk of early morbidity, such as stroke, and fewer trans- .. duits (either BIMA or radial artery) translates into superior clinical
.
fusions.508–510,524–528 In the subgroup of patients with end-stage .. outcomeswhencomparedwithSIMAsupplementedbySVGonly.
.
CKD, there is some evidence that off-pump surgery is associated .. Hybrid procedures, which combine minimally invasive arterial
.
withlowerin-hospitalmortalityandlessneedfornewrenalreplace- .. grafting with PCI, proved feasible and safe. However, multicentre
.
menttherapy.529 .. studies are required to prove the efficacy and superiority of this
.
AsummaryofthesetechnicalaspectscanbefoundinFigure8. . approachinstable,multivesselcoronarydisease.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 46 ---
132 ESC/EACTSGuidelines
Recommendationsonproceduralaspectsofcoronaryarterybypassgrafting
Recommendations Classa Levelb
Generalconsiderations
Completemyocardialrevascularizationisrecommended.c131,132 I B
Minimizationofaorticmanipulationisrecommended.508,509,544,545 I B
Routineintraoperativegraftflowmeasurementshouldbeconsidered.516,517 IIa B
CTscansoftheascendingaortashouldbeconsideredinpatientsover70yearsofageand/orwithsignsofextensive
IIa C
generalizedatherosclerosis.
Priortoaorticmanipulation,epiaorticultrasoundshouldbeconsideredtoidentifyatheromatousplaquesandselectthe
IIa C
optimalsurgicalstrategy.
Conduitselection
ArterialgraftingwithIMAtotheLADsystemisrecommended.453,454,546 I B
Anadditionalarterialgraftshouldbeconsideredinappropriatepatients.467,482,547–551 IIa B
Theuseoftheradialarteryisrecommendedoverthesaphenousveininpatientswithhigh-gradecoronaryartery
I B
stenosis.d482,549,550,552,553
BIMAgraftingshouldbeconsideredinpatientswhodonothaveahighriskofsternalwoundinfection.e467,547,548,551 IIa B
Vesselharvesting
SkeletonizedIMAdissectionisrecommendedinpatientswithahighriskofsternalwoundinfection.471,484,485 I B
Endoscopicveinharvesting,ifperformedbyexperiencedsurgeons,shouldbeconsideredtoreducetheincidenceof
IIa A
woundcomplications.490,493,494,500,554
No-touchveinharvestingshouldbeconsideredwhenanopentechniqueisused.506,507,555,556 IIa B
Minimallyinvasivetechniques
Off-pumpCABGandpreferablyno-touchtechniquesontheascendingaorta,byexperiencedoperators,arerecom-
I B
mendedinpatientswithsignificantatheroscleroticaorticdisease.508,509,544,557–559
Off-pumpCABGshouldbeconsideredforsubgroupsofhigh-riskpatientsbyexperiencedoff-pumpteams.525,557–560 IIa B
Whereexpertiseexists,minimallyinvasiveCABGthroughlimitedthoracicaccessshouldbeconsideredinpatientswith
IIa B
isolatedLADlesionsorinthecontextofhybridrevascularization.143,534,535,561
Hybridprocedures,definedasconsecutiveorcombinedsurgicalandpercutaneousrevascularization,maybeconsid-
IIb B
eredinspecificpatientsubsetsatexperiencedcentres.536,561–563
BIMA=bilateralinternalmammaryartery;CABG=coronaryarterybypassgrafting;CT=computedtomography;IMA=internalmammaryartery;LAD=leftanterior
descendingcoronaryartery.
aClassofrecommendation.
bLevelofevidence.
cDefinitionsofcompleterevascularizationareprovidedinsection5.3.1.3.
dParticularlyinpatientswithpoorveingrafts.Theradialarteryshouldnotbeusedifpreviouslycatheterized,iftheAllentestispositiveorifcalcificdegenerationispresent.
ePatientswithdiabetesmellitus,chronicpulmonaryobstructivedisease,previousmediastinalradiation,andobesity,particularlywhenmultiplesofthesearepresent.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 47 ---
ESC/EACTSGuidelines 133
Minimize aortic manipulation IB
Off-pump if calcified aorta IB
Off-pump if high-risk IIaB
LIMA to LAD IB
BIMA if low risk of sternal
complications IIaB
Skeletonize if risk of
sternal complications IB
Complete revascularization IB
Graft flow measurement IIaB
ml/min 93ml/min PI 1.3
180
160
140
120
100
80
60
40 Radial artery
20
0 in high-grade
-20 LITA- LAD DF 74% stenosis IB
Endoscopic vein harvesting IIaA
No-touch vein harvesting IIaB
Figure8 TechnicalaspectsofCABG.BIMA=bilateralinternalmammaryartery;CABG=coronaryarterybypassgrafting;IMA=internalmam-
maryartery;LAD=leftanteriordescendingcoronaryartery.
.
.
16 Procedural aspects of .. selected patients in whom implantation of stents is not technically
.
percutaneous coronary
.. feasible,orinavesselthatisconsideredtobetoosmalltobestented.
.
.. BalloonangioplastyisnolongerpreferredtostentingwithDESfor
intervention ...
patients who require urgent non-cardiac surgery as short-duration
.
.. DAPTmaybereasonablewithbothstrategies.565,566
16.1 Percutaneous coronary intervention ..
.
.
devices .
.. 16.1.2Choiceofcoronarystents
.
16.1.1Balloonangioplasty .. StentingwithBMSresultsinanapproximately30%lowerrateofresteno-
.
Plainballoonangioplastyhasbeensupersededinthetreatmentofde .. sisincomparisonwithplainballoonangioplasty.564Althoughmanyefforts
.
novocoronarylesionsafterdemonstrationofthesuperiorityofstent- .. havebeenmadetofurtherreducerestenosisbythemodificationofstent
.
ing in terms of the requirement for repeat revascularization.564 .. designsandmaterials,reducingthethicknessofstentstrutshasbeenthe
.
Balloon angioplasty might be considered for the treatment of . onlyprovenmodificationcapableofreducingrestenosisofBMS.567,568
8102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 48 ---
134 ESC/EACTSGuidelines
.
.
Amajorreductionintheriskofrestenosishasbeenachievedwith . ofreducingoreliminatingstent-relatedadverseeventsatlong-term
.
DEStechnology.Early-generationDESreleasedsirolimus569orpacli- .. follow-up.Currentscaffoldplatformstohavereachedclinicaltesting
.
taxel570 from a permanent polymer matrix coating on a relatively .. are based on two different technologies: bioresorbable, polymer-
.
.
thick-strut (120–140 mm) stainless steel backbone. These devices . basedscaffolds(resorptionupto3–4years)andresorbable,metallic
.
reduced angiographic and clinical restenosis by approximately .. (magnesium)scaffolds(resorptionupto1year).595Althoughanum-
.
.
50–70%,butincreasedtheriskofverylatestentthrombosiscom- . ber of devices have received approval for use in Europe (see
.
paredwithBMS.336,571 .. SupplementaryTable7),randomizedtrialdataareavailableonlywith
.
.
Early-generationDEShavenowbeensupplantedbynew-generation . theAbsorbbioresorbablevascularscaffold(BVS)(AbbottVascular).
.
.
DES.Thesestentsrepresentedaniterativedevelopmentofearlygener- .. ThesafetyandefficacyprofileoftheAbsorbBVShasbeencom-
.
ation technology, including polymers with enhanced biocompatibility .. paredwithcontemporaryDESinseveraltrials.Findingsofthesetrials
.
(permanent or biodegradable), exclusively sirolimus-analogue active .. aswellasmeta-analysesconsistentlyindicatetheinferiorefficacyand
.
drugs,andstentbackboneswiththinstruts(50–100mm)composedof .. safety of Absorb BVS compared with contemporary DES during
.
stainless steel, cobalt chromium,or platinum chromium.572–577 New- .. long-termfollow-up.Specifically,theAbsorbBVSisassociatedwitha
.
generationDEShavehigherefficacyandsafetyincomparisonwithboth .. significantly increased risk of target lesion revascularization and
.
early-generationDESandBMS.336,571,578Althoughstentingwithnew- .. device thrombosis, with numbers needed to harm of 40–60.596,597
.
generationDESconfersasimilarriskofdeathorMIatmid-tolong- .. Of note, commercial useofthe Absorb BVS wasstopped in 2017
.
termfollow-upincomparisonwithBMS,579theriskofsubacuteandlate .. (foradditionaldetailsseetheSupplementaryData).
.
stentthrombosisissignificantlylower.579,580Moreover,theriskofvery .. Available evidence on the magnesium scaffold is limited to small
. latestentthrombosisisatleastcomparabletothatofBMSandlower .. observational studies. Initial results appear encouraging, but further
.
than that of early-generation DES.336,571,579,580 These observations .. evaluationisneeded.Therefore,theTaskForceendorsestherecom-
.
.
wereconfirmedinarecenttrialenrollingpatientsaged75yearsorolder . mendationoftherecentESC/EuropeanAssociationforPercutaneous
.
.
anddemonstratingsuperioroutcomes(compositeofall-causemortal- . Cardiovascular Interventions (EAPCI) document on bioresorbable
.
.
ity,MI,stroke,orischaemia-driventargetlesionrevascularization)with . scaffoldsthatanyBRSshouldnotbeusedoutsidewell-controlledclin-
.
.
DESascomparedwithBMSwithsimilardurationofintendedDAPT(1 . icalstudies.InpatientswhohavebeentreatedwithBRS,prolonged-
.
monthor6months)inbothtreatmentarms.581Similarly,thereisno .. durationDAPTfor3yearsorlongermaybeconsidered.
.
.
clearevidenceofadifferencebetweenDESandBMSontheriskofstent .
.
thrombosis following unplanned disruption of DAPT.565 Accordingly, ..
. 16.1.4Drug-coatedballoons
.
new-generationDESshouldbepreferredtoBMSforroutineuse. .
. TherationaleforusingDCBsisbasedontheconceptthatwithhighly
.
A large number of new-generation DES have received approval .
. lipophilicdrugs,evenshortcontacttimesbetweentheballoonsurface
.
foruseandCEmarkinEurope.578SupplementaryTable6displaysa .
. andthevesselwallaresufficientforeffectivedrugdelivery.Thereare
.
list of new-generation DES with the CE mark and evidence from ..
varioustypesofDCBthatareapprovedforuseinEuropeandtheir
.
large-scaleclinicaltrialspoweredforclinicalprimaryendpoints. ...
maincharacteristicsarelistedinSupplementaryTable8.Althoughspe-
Biodegradablepolymerandpolymer-freeDESofferthepotentialto ...
cificallydesignedcomparativerandomizedtrialsarelacking,aclasseffect
reducelateadverseeventsafterPCIbyeliminatinginflammatoryreac- ... forallDCBscannotbeassumed.598Randomizedtrialdatasupporting
tions to permanent polymer coatings. A number of large-scale trials ...
the use of DCB angioplasty are limited to the treatment of in-stent
showedcomparableefficacyandsafetycomparedwithpermanentpoly- ...
restenosis(seesection13.4).IntermsoftheuseofDCBangioplastyfor
merstents.575,576,582–590However,atthemoment,thereisnoevidence ...
denovodisease,anumberofsmallrandomizedtrialshavebeenreported
ofdifferentialefficacywithnew-generationbiodegradablepolymerDES ... withsomewhatconflictingresults.599–601Atpresent,therearenocon-
incomparisonwithnew-generationpermanentpolymerDESinlarge- ... vincingdatatosupporttheuseofDCBangioplastyforthisindication.
scalerandomizedtrialswithfollow-upoutto5years.591–594 ..
.
Regarding polymer-free DES, two large-scale trials with different ..
devices showed comparable results with new-generation DES and
... 16.1.5Devicesforlesionpreparation
superiorresultstoBMS.173,577Long-termfollow-upfromrandomized ... LesionpreparationiscriticalforsuccessfulPCI.Inadditiontoplain
.. balloonangioplasty(withstandardornon-compliantballoons),cut-
trialsvs.new-generationpermanentpolymerDESisonlyavailablefora .
.
singledeviceandshowscomparableoutcomesbetweenthedevices.591 .. tingorscoringballoonangioplastyorrotationalatherectomymaybe
.
. required in selected lesions—particularly those with heavy
Thehighclinicalefficacyandsafetyofnew-generationDESsupport .
.
. calcification—in order to adequately dilate lesions prior to stent
their preferred use in patients with anindication for PCI, including .
.
. implantation. However, studies investigating the systematic use of
patientswithdiabetes,CKD,multivesselandLMSdisease,AMI,vein .
.
. theseadjunctivetechnologies,suchasrotationalatherectomy,have
grafts, restenotic lesions, and chronic total occlusions. New- .
.. failedtoshowclearclinicalbenefit.602
generationDESshouldthereforebeconsideredasthedefaultstent .
.
.
typeforPCIregardlessofclinicalpresentation,lesionsubtype,con- .
.
. 16.2 Invasive imaging tools for
comitanttherapies,orcomorbidities. .
.
.. procedural guidance
.
.
16.1.3Bioresorbablescaffolds .. 16.2.1Intravascularultrasound
.
Completelybioresorbablescaffolds(BRS),whichdegradetopredomi- .. ThemajorityoftheexistingclinicaltrialdatarelatetotheuseofIVUS
.
nantlyinertendproductsafterfulfillingtheirscaffoldfunctioninthe .. guidance during PCI. In the BMS era, several RCTs addressed the
.
lesionsiteofthecoronaryvessel,havebeendevelopedwiththegoal . potential of IVUS in reducing restenosis and adverse events after
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 49 ---
ESC/EACTSGuidelines 135
.
.
stenting, with somewhat conflicting results. Findings from one meta- . thisrule,whereupfrontsidebranchstentingmaybepreferable,include
.
.
analysis of randomized trials suggested better outcomes with IVUS . thepresenceofalargesidebranch(>_2.75mm)withalongostialside
.
.
guidanceintermsofacuteproceduralresultsandreducedangiographic . branchlesion(>5mm)oranticipateddifficultyinaccessinganimportant
.
.
restenosis, repeat revascularization, and MACE, with no effect on . sidebranchaftermainbranchstenting,andtruedistalLMbifurcations.
.
deathandMI.603,604IntheDESera,meta-analysisofrandomizedand .. Recently, a multicentre trial conducted in China directly compared a
.
.
observationalstudiesalsosuggestsbetterclinicaloutcomeswithIVUS- . double-kissingcrushtwo-stentstrategywithprovisionalstentingofthe
.
guidedvs.angiography-guidedPCI.605,606However,thecontributionof .. mainbranchin482patientswithdistalLMbifurcationdisease.Double-
.
.
findingsfromobservationalstudiesmustbeweighedagainstthelikeli- . kissingcrushresultedinalowerriskoftheprimaryendpointtargetlesion
.
.
hoodofconsiderableresidualconfoundingduetotreatmentselection .. failureat1yearcomparedwithprovisionalstenting.620
.
bias.Similarly,findingsofimprovedoutcomeinpatientsundergoingLM .. Whenatwo-stentstrategyisnecessary,whichtwo-stenttechnique
.
stemPCIwithIVUS-guidedPCIvs.angiography-guidedPCIfromapro- .. shouldbepreferredisdebated.Thethreemostwidelyusedcontem-
.
pensityscorematchedanalysismustbeinterpretedwithcaution.35 .. porary two-stent techniques are culotte, crush (classic or double-
.
Incasesofstentfailure,includingrestenosisandstentthrombosis, .. kissingcrush),andTandprotrusion(TAP).621,622SeveralRCTshave
.
theuseofIVUSshouldbeconsideredinordertoidentifyandcorrect .. comparedthesetechniques.Innon-LMbifurcationlesions,thereisno
.
underlyingmechanicalfactors(seesection13).386 .. compellingevidencethatonetechniqueissuperiortotheothersin
.
.. termsofmajorclinicalendpoints.621,622InLMtruebifurcationlesions,
.
.. double-kissingcrushhasthemostfavourableoutcomedata.623
16.2.2Opticalcoherencetomography ...
Final‘kissing’balloondilationisgenerallyrecommendedwhentwo
AnumberofstudieshaveassessedOCTimagingforPCIguidance.Two ...
stents are eventuallyrequired, withnoadvantagefromfinalkissing
observational studies show thatwhile OCTimaging changes operator ...
withtheone-stenttechnique.624,625Severalstents,designedspecifi-
behaviour,itsimpactonclinicaloutcomesisunclear.607,608Indeed,OCT ..
. callyforthetreatmentofbifurcationlesions,haveundergoneexten-
ismoreaccuratethanangiographyorIVUSindetectingsubtlemorpho- ..
. sive evaluation with promising angiographic and clinical results,
logicaldetailsincludingmalapposition,residualthrombus,plaqueprolapse, ...
thoughRCTsagainstcurrentrecommendedtherapyarelimited.626
andresidualdissections,althoughmanyoftheseadditionalfindingsmay ..
. FurthertechnicaldetailsrelatingtobifurcationPCIaredescribedin
haveabenigncourse.609,610AsinglerandomizedtrialcomparedOCT ...
theconsensusdocumentoftheEuropeanBifurcationClub.627
withIVUSandcoronaryangiography,andshowedthatOCT-guidedPCI ..
.
wassafeandresultedinasimilarminimumstentareatothatofIVUS- ..
guidedPCI.611However,OCTguidancewasnotsuperiortoeitherIVUS
... 16.3.2Chronictotalcoronaryocclusion
.. Dedicated RCTs examining the outcomes of patients with chronic
or angiography alone. An additional randomized trial that enrolled .
.. totalocclusion(CTO)allocatedtorevascularizationorconservative
patientswithNSTE-ACScomparedOCT-guidedPCIwithangiography- .
guidedPCIandfoundnosignalofimpactonclinicaloutcomes.612
... therapy are scarce. One trial randomized patients with STEMI and
.. CTOinanon-culpritvesseltoCTO-PCIvs.conservativetherapy,and
AnumberofobservationalstudieshaveshownthatOCTisfeasi- .
.. found no difference in the primary endpoint of LVEF and LV end-
bleandsafeintheassessmentofstentfailureduetothrombosis,and .
may yield information that may be clinically useful.386,387,613,614
... diastolic volume at 4 months.628 More recently, the prospective
.. randomizedEUROCTO(RandomizedMulticentreTrialtoCompare
Likewise,incasesofin-stentrestenosis,intrastentneointimaltissue .
.. RevascularizationWithOptimalMedicalTherapyfortheTreatment
maybecharacterizedbyOCT,enablingforexamplethedetectionof .
.. ofChronicTotalOcclusions)trialshowedsymptomaticimprovement
neoatherosclerosis.386,615,616Incasesofstentfailure,theuseofOCT .
.. by PCI of CTO.629 This trial included 396 patients who were ran- should be considered in order to identify and correct underlying .
.. domlyassignedtoPCIofCTOwithoptimalmedicaltherapy,oropti-
mechanicalfactors(seesection13). ..
. mal medical therapy alone. During the 12 month follow-up, the
.
.
. primaryendpoint-thechangeinhealthstatusassessedbytheSeattle
.
16.3 Specific lesion subsets . . angina questionnaire-showed significantly greater improvement of
.
.
16.3.1Bifurcationstenosis . anginafrequencyandqualityoflifewithCTOPCIascomparedwith
.
.
AnumberofRCTshaveinvestigatedtheoptimalinterventionstrategyin . optimalmedicaltherapyalone.Yet,MACEwerecomparablebetween
. .
patientswithbifurcationlesionsandshowednobenefitforthesystematic . the two groups. A systematic review of 25 observational studies
.
.
two-stentapproachvs.mainbranch-onlystentingwithprovisionalstent- . showedthatatmedianfollow-upof3years,successfulCTO-PCIwas
.
ingofthesidebranchintermsofclinicaloutcomes.617Arecentpooled .. associatedwithimprovedclinicaloutcomesincomparisonwithfailed
.
.
analysisoftwoRCTsshowedlower5yearsurvivalinpatientsrandom- . revascularization, including overall survival, angina burden, and the
.
izedtoasystematictwo-stentapproach.618Inaddition,proceduretime, .. requirementforbypasssurgery.630Broadlyspeaking,thetreatmentof
.
.
contrast volume, radiation exposure, and cost are higher with a two- . CTOsmaybeconsideredanalogoustothetreatmentofnon-CTO
.
.
stent approach.618 The EBC TWO (European Bifurcation Coronary .. lesions(seerecommendationsinsection5).Incasesofregionalwall
.
TWO)trialfoundnodifferencebetweenaprovisionalT-stentstrategy .. motionabnormalitiesintheterritoryoftheCTO,objectiveevidence
.
andasystematictwo-stentstrategy(culottetechnique)intermsofthe .. of viability should be sought. The decision to attempt CTO-PCI
.
composite endpointof death, MI, and TVRat 12 months among200 .. shouldbeconsideredagainsttheriskofgreatercontrastvolume,lon-
.
patientswithlarge-calibretruebifurcationlesions(sidebranchdiameter .. ger fluoroscopy time, and higher MACE rates in comparison with
.
>_2.5mm)andsignificantostialdiseaselength(>_5mm).619Thus,main .. non-CTOPCIpatients.631AdhocPCIisgenerallynotrecommended
.
branch-onlystentingwithprovisionalstentingofthesidebranchshould .. forCTOs,althoughitmaybenecessaryinselectedcases(e.g.acute
.
bethepreferredapproachformostbifurcationlesions.Exceptionsto . bypassgraftfailurenotamenabletorecanalizationofthebypassgraft).
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 50 ---
136 ESC/EACTSGuidelines
.
Recent developments in catheter and wire technology, and .. stroke,ornon-CABG-relatedmajorbleedingat30daysoccurredata
.
.
increasing operator expertise with both antegrade and retrograde . similarrateinradialvs.femoralaccess(HR0.92,95%CI0.72–1.17,P=
.
approachesaswellaswireescalationanddissection/re-entrytechni- .. 0.50).638IntheMATRIXtrial,8404ACSpatientswererandomlyallo-
.
ques,havetranslatedintoincreasingsuccessratesofCTO-PCIwith .. catedtoradialorfemoralaccess.172Intermsofthefirstco-primary
.
lowratesofMACE.631–633Successratesarestronglydependenton .. endpointof30dayMACE,therewasnosignificantdifferencebetween
.
.
operator skills, depending on experience with specific procedural . radial access and femoral access (RR 0.85, 95% CI 0.74–0.99, two-
.
.
techniques, and the availability of dedicated equipment, and vary . sidedP=0.031;non-significantatapre-specifiedaof0.025).Thesec-
.
from60–70%to>90%.631–633 .. ondco-primaryoutcomeof30daynetadverseclinicalevents[MACE
.
.
. or non-CABG BARC (Bleeding Academic Research Consortium
.
.
. (major bleeding] was significantly lower with radial access (RR 0.83,
16.3.3Ostiallesions ..
. 95%CI0.73–0.96;P=0.009).MajorBARC3or5bleedingwassignifi-
Inostialcoronarylesions,additionaljudgementandcautionisessen- ..
tialbeforeproceedingtoPCI.Inparticular,acatheter-inducedcoro-
... cantly reduced in the radial group (1.6 vs. 2.3%; RR 0.67, 95% CI
nary spasm must be rigorously excluded. Lesion assessment with
... 0.49–0.92;P=0.013),andradialaccesswasassociatedwithalower
.. risk of all-cause mortality (1.6 vs. 2.2%; RR 0.72, 95% CI 0.53–0.99,
IVUSmaybehelpful,particularlyinLMostialstenosis.FFRmeasure- .
.. P=0.045).However,thebenefitofradialoverfemoralaccessdepends
mentmayalsobevaluableintheassessmentofostiallesionsofbor- .
derlinesignificance,634takingspecialcaretoavoidawedgeposition
... upontheoperator’sexpertiseintheradialtechnique.639
.. Treatmentofrestenoticandsaphenousveingraftlesionsaredis-
of the guiding catheter and using i.v., rather than intracoronary, .
.. cussedinsection13.3.
adenosine. When performing an intervention, due to interaction .
betweentheguidecatheterandtheproximalstentedge,theriskof
Recommendationsonintravascularimagingforproce-
longitudinal stent deformation must be considered635 and avoided duraloptimization
with careful cathetermanipulation. The accurate positioning ofthe
stent,preciselyinthecoronaryostium,maybetechnicallychallenging
Recommendations Classa Levelb
and some specialized techniques that may help to achieve optimal
stentplacementhavebeendescribed.636,637 IVUSorOCTshouldbeconsideredin
selectedpatientstooptimizestent IIa B
16.4 Vascular access
implantation.603,612,651–653
AnumberofRCTshavecomparedradialaccesswithfemoralaccess IVUSshouldbeconsideredtooptimize
for diagnostic angiography and PCI. The two largest were RIVAL treatmentofunprotectedleftmain IIa B
(Radialversusfemoralaccessforcoronaryangiographyandinterven- lesions.35
tion in patients with acute coronary syndromes) and MATRIX
(MinimizingAdverseHaemorrhagicEventsbyTransradialaccessSite
IVUS=intravascularultrasound;OCT=opticalcoherencetomography.
and Systemic Implementation of AngioX).172,638 In the RIVAL trial, aClassofrecommendation.
which enrolled 7021 patients, the primary outcome of death, MI,
bLevelofevidence.
Recommendationsonchoiceofstentandaccesssite
Recommendations Classa Levelb Recommendationsonspecificlesionsubsets
DESarerecommendedoverBMSforany
Recommendations Classa Levelb
PCIirrespectiveof:
• clinicalpresentation Stentimplantationinthemainvesselonly,
• lesiontype followedbyprovisionalballoonangioplasty
I A
• plannednon-cardiacsurgery withorwithoutstentingofthesidebranch, I A
• anticipateddurationofDAPT isrecommendedforPCIofbifurcation
• concomitantanticoagulant lesions.654–658
therapy.100,578,579,640
PercutaneousrevascularizationofCTOs
Radialaccessisrecommendedasthestand- shouldbeconsideredinpatientswithangina
ardapproach,unlessthereareoverriding I A resistanttomedicaltherapyorwithalarge IIa B
proceduralconsiderations.172,638,641 areaofdocumentedischaemiaintheterri-
toryoftheoccludedvessel.629,659–663
BRSarecurrentlynotrecommendedfor
III C
clinicaluseoutsideofclinicalstudies.642–650 Intruebifurcationlesionsoftheleftmain,
thedouble-kissingcrushtechniquemaybe IIb B
BMS=bare-metalstents;BRS=bioresorbablescaffolds;DAPT=dualantiplatelet
preferredoverprovisionalT-stenting.620
therapy;DES=drug-elutingstents;PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence. CTO=chronictotalocclusion;PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 51 ---
ESC/EACTSGuidelines 137
.
17 Antithrombotic treatments .. ischaemic and bleeding events significantly influence the outcome
.
.
. of CAD patients and their overall mortality risk during and after
.
AntithrombotictreatmentismandatoryinCAD patientsundergoing .. myocardialrevascularization.664Thus,thechoiceoftreatmentshould
.
myocardialrevascularization.Thechoiceoftreatment,thecombination, .. reflect the ischaemic and bleeding risk. The recommended drugs
.
thetimepointofinitiation,andthedurationdependonthepatient’s .. (Figure 9) and doses (Table 7) for anticoagulant and antiplatelet
.
characteristics,comorbidities,theclinicalsetting(electiverevasculariza- .. drugs used in conjunction with myocardial revascularization are
.
tionvs.ACS),andthemode(PCIvs.CABG)ofrevascularization.Both .. summarizedbelow.
Figure9Antithrombotictreatmentformyocardialrevascularizationanditspharmacologicaltargets.
Table7 Dosesofantiplateletandanticoagulantdrugsusedduringandaftermyocardialrevascularization
Antiplateletdrugs
Aspirin Loadingdoseof150–300mgorallyor75–150mgi.v.iforalingestionisnotpossible,followedby
amaintenancedoseof75–100mg/day.
Clopidogrel Loadingdoseof600mgorally,followedbyamaintenancedoseof75mg/day.
Prasugrel Loadingdoseof60mgorally,followedbyamaintenancedoseof10mg/day.
Inpatientswithbodyweight<60kg,amaintenancedoseof5mgisrecommended.
Inpatientsaged>75years,prasugrelisgenerallynotrecommended,butadoseof5mgshould
beusediftreatmentisdeemednecessary.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 52 ---
138 ESC/EACTSGuidelines
Ticagrelor Loadingdoseof180mgorally,followedbyamaintenancedoseof90mgb.i.d.
Abciximab Bolusof0.25mg/kgi.v.and0.125lg/kg/mininfusion(maximum10lg/min)for12h.
Eptifibatide Doublebolusof180lg/kgi.v.(givenata10mininterval)followedbyaninfusionof2.0lg/kg/min
forupto18h.
Tirofiban Bolusof25lg/kgover3mini.v.,followedbyaninfusionof0.15lg/kg/minforupto18h.
Cangrelor Bolusof30mg/kgi.v.followedby4mg/kg/mininfusionforatleast2hordurationofprocedure,
whicheverislonger.
AnticoagulantdrugsforPCI
Unfractionatedheparin • 70–100U/kgi.v.boluswhennoGPIIb/IIIainhibitorisplanned.
• 50–70U/kgi.v.boluswithGPIIb/IIIainhibitors.
Enoxaparin 0.5mg/kgi.v.bolus.
Bivalirudin 0.75mg/kgi.v.bolusfollowedbyi.v.infusionof1.75mg/kg/hforupto4haftertheprocedure
asclinicallywarranted.
Oralanticoagulantdrugs(concomitanttreatmentafterPCI)
VitaminKantagonists(e.g.warfarin, DosingisbasedonINRvalueandtherespectiveclinicalindication.
phenprocoumon)
Apixaban Maintenancedosesof5and2.5amgb.i.d.
Dabigatran Maintenancedosesof150and110mgb.i.d.
Edoxaban Maintenancedosesof60and30amg/day
Rivaroxaban Maintenancedosesof20and15amg/day,and2.5mgb.i.d.(vasculardose).
aSpecificcriteriaforreduceddoseapply(seerecommendationtableonpage61).
b.i.d.=twicedaily;GP=glycoprotein;INR=internationalnormalizedratio;i.v.=intravenous;PCI=percutaneouscoronaryintervention.
.
.
17.1 Percutaneous coronary intervention .. andbivalirudin,havebeenevaluatedfortheiruseinclinicalpractice.
.
in stable coronaryartery disease .. TheREPLACE-2(RandomisedEvaluationinPCILinkingAngiomaxto
.
17.1.1Choiceoftreatmentandpre-treatment
... ReducedClinicalEvents2)trialdemonstratedthattheoutcomewith
.. bivalirudinandprovisionalglycoprotein(GP)IIb/IIIablockadeissimi-
tD hA eP cT orc no en rs si ts oti nn eg oo ff ta rs ep air tmin ea nn td inaP p2 atY ie1 n2 tr se uce np dt eo rr goin inh gib eit lo ecr tr ive epr Pe Cse I.n 66ts
5
.... lartothatofUFHplusplannedGPIIb/IIIainhibitionduringelective
.. PCI.669 The ISAR-REACT (Intracoronary Stenting and
TheP2Y receptorinhibitorclopidogrelisrecommendedforelec- .
12 .. Antithrombotic Regimen Rapid Early Action for Coronary
tive stenting procedures. For routine clopidogrel pre-treatment .
.. Treatment)3trialalsoshowedasimilaroutcomeforbivalirudinvs.
(administrationofthedrugwhenthecoronaryanatomyisunknown), .
.. UFHtreatment.670InISARREACT3A,671evaluatingalowerdoseof
there is no compelling evidence for a significant clinical benefit in .
SCADpatients.666–668Thus,pre-treatmentmayonlybeanoptionin
... 100U/kgUFH,thislowerdoseshowednetclinicalbenefitcompared
.. withthehistoricalcontrolcohortandthisbenefitwasmostlydriven
selected patientswithhighprobabilityofPCI orbefore staged PCI .
.
. by a reduction in bleedingevents.Inview ofthe primary endpoint
procedures.Figures9and10summarizethecommonlyusedantipla- .
.
. resultsoftheRCTsandinviewofatrendtowardsalowerriskofMI,
teletandanticoagulantdrugsinSCADpatientsundergoingPCI. .
.
. UFHremainsthestandardanticoagulantforelectivePCI.Basedon
.
.
. the results of the STEEPLE (Safety and Efficacy of Intravenous
.
.
17.1.2Peri-interventionaltreatment . Enoxaparin in Elective Percutaneous Coronary Intervention
.
.
Whileaspirinandclopidogrelareindicatedforelectivestentingpro- .. RandomisedEvaluation)trial,enoxaparinshouldbeconsideredasan
cedures,prasugrelorticagrelormayonlybeconsideredinselected ... alternativeanticoagulantdrug.672
.
patientsforspecifichigh-risksituationsofelectivestenting(e.g.com- .. Drugs for parenteral antiplatelet treatment include cangrelor
.
plexPCIproceduressuchasLMstentingandCTOprocedures)orin .. and GP IIb/IIIa inhibitors. Cangrelor is a direct reversible, short-
.
patientswithahistoryofstentthrombosisonclopidogreltreatment. .. acting P2Y 12-inhibitor that has been evaluated during PCI for
.
Inparallelwithantiplatelettreatment,theuseofanticoagulantsis .. SCAD and ACS in clinical trials comparing cangrelor with clopi-
.
standardofcareduringelectivePCItoinhibitthrombingeneration .. dogrel,administeredbeforePCI[CHAMPION(Cangrelorversus
.
andactivity.Differentagents,includingunfractionatedheparin(UFH) . Standard Therapy to Achieve Optimal Management of Platelet
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 53 ---
ESC/EACTSGuidelines 139
.
.
Inhibition) PCI] or after PCI (CHAMPION PLATFORM and . Analgorithmfortheuseofantithromboticdrugsinpatientsunder-
.
CHAMPION PHOENIX).673 A meta-analysis showed a benefit .. goingPCIisshowninFigure10.
.
.
with respect to major ischaemic endpoints that is counter- .
.
balanced by an increase in relevant bleeding.673 Moreover, the ... 17.1.3Post-interventionalandmaintenancetreatment
.
benefitofcangrelorwithrespecttoischaemicendpointswasatte- .. Followingelectivestenting,DAPTconsistingofclopidogrelinaddi-
.
nuated in CHAMPION PCI with upfront administration of clopi- .. tiontoaspirinisgenerallyrecommendedfor6months,irrespective
.
dogrel. Nevertheless, due to its proven efficacy in preventing .. of the stent type. In specific clinical scenarios, this standard DAPT
.
intraprocedural and post-procedural stent thrombosis in P2Y 12- .. duration can be shortened (<6 months) or extended (>6–12
.
inhibitor na¨ıve patients, cangrelor may be considered in P2Y 12- ... months).Foramoredetaileddescriptionofthepertinentclinicaltri-
inhibitorna¨ıvepatientsundergoingPCI(formoredetaileddiscus- .. alsinthefieldofDAPTduration,wereferthereadertothe2017
.
sionseetheSupplementaryData). .. ESC Focused Update on Dual Antiplatelet Therapy in Coronary
.
AvailableGPIIb/IIIainhibitorsincludeabciximab,eptifibatide,andtir- .. Artery Disease.410 Following DAPT, a life-long single antiplatelet
.
ofiban.InasettingofelectivePCI,clinicaltrialsdidnotdemonstratean .. therapy(usuallywithaspirin)isrecommended,andpatientsshould .
additional benefit of GP IIb/IIIa inhibitor administration in SCAD ... beadvisednottoprematurelydiscontinueoralantiplatelettherapy
patientsinasettingofDAPTtreatmentthatincludesloadingwithclo- ... after stenting due to the risks of stent thrombosis and recurrent
pidogrel.674,675Ameta-analysisonthistopicrevealednomortalityben- ... MI.677Recently,thevalueofavasculardoseofrivaroxaban(2.5mg
efit of GP IIb/IIIa treatment and while non-fatal MIs were reduced, ... b.i.d.)inconjunctionwithaspirinwasdemonstratedinthelarge-scale
(minor)bleedingeventsweresignificantlyhigherwhenutilizingthese ... COMPASS(RivaroxabanforthePreventionofMajorCardiovascular
agents.676Thus,GPIIb/IIIainhibitorsmayonlybeconsideredinspecific ... EventsinCoronaryorPeripheralArteryDisease)trial.678However,
.
‘bail-out’ situations including high intraprocedural thrombus burden, .. itsutilizationinSCADpatientsisamatterofsecondaryprevention
.
slowflow,orno-flowwithclosureofthestentedcoronaryvessel. . andisnotlinkedtomyocardialrevascularizationprocedures.
Figure10 Algorithmfortheuseofantithromboticdrugsinpatientsundergoingpercutaneouscoronaryintervention.Highbleedingriskisconsid-
eredasanincreasedriskofspontaneousbleedingduringDAPT(e.g.PRECISE-DAPTscore>_25).Colour-codingreferstotheESCclassesofrecom-
mendations(green=classI;yellow=classIIa;andorange=classIIb).
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 54 ---
140 ESC/EACTSGuidelines
Recommendationsforantithrombotictreatmentinstablecoronaryarterydiseasepatientsundergoingpercutaneous
coronaryintervention
Recommendations Classa Levelb
Pre-treatmentandantiplatelettherapy
Treatmentwith600mgclopidogrelisrecommendedinelectivePCIpatientsoncethecoronaryanatomyisknownand
I A
adecisionismadetoproceedwithPCI.667,679,680
Pre-treatmentwithclopidogrelmaybeconsiderediftheprobabilityofPCIishigh. IIb C
Inpatientsonamaintenancedoseof75mgclopidogrel,anewloadingdoseof600mgmaybeconsideredoncetheindi-
IIb C
cationforPCIisconfirmed.
Peri-interventionaltreatment
Aspirinisindicatedbeforeelectivestenting.681–683 I A
Anoralloadingdoseofaspirin(150–300mgp.o.or75–250mgi.v.)isrecommendedifthepatientisnotpre-treated. I C
Clopidogrel(600mgloadingdose,75mgdailymaintenancedose)isrecommendedforelectivestenting.684–688 I A
GlycoproteinIIb/IIIaantagonistsshouldbeconsideredonlyforbail-out. IIa C
Prasugrelorticagrelormaybeconsideredinspecifichigh-risksituationsofelectivestenting(e.g.historyofstentthrom-
IIb C
bosisorleftmainstenting).
Unfractionatedheparinisindicatedasthestandardanticoagulant(70–100U/kg).670,671 I B
Bivalirudin(0.75mg/kgbolus,followedby1.75mg/kg/hforupto4haftertheprocedure)isindicatedinthecaseofhep-
I C
arin-inducedthrombocytopenia.
Enoxaparin(i.v.0.5mg/kg)shouldbeconsideredasanalternativeagent.672,689 IIa B
CangrelormaybeconsideredinP2Y -inhibitorna¨ıvepatientsundergoingPCI.673 IIb A
12
Post-interventionalandmaintenancetreatment
Life-longsingleantiplatelettherapy,usuallyaspirin,isrecommended.681,683 I A
Instructionofpatientsabouttheimportanceofcomplyingwithantiplatelettherapyisrecommended. I C
InpatientswithSCADtreatedwithcoronarystentimplantation,DAPTconsistingofclopidogrelinadditiontoaspirinis
I A
generallyrecommendedfor6months,irrespectiveofthestenttype.c690–694
InpatientswithSCADtreatedwithBRS,DAPTshouldbeconsideredforatleast12monthsanduptothepresumed
IIa C
fullabsorptionoftheBRS,basedonanindividualassessmentofbleedingandischaemicrisk.
InpatientswithSCADtreatedwithDCB,DAPTshouldbeconsideredfor6months.369,371 IIa B
InpatientswithSCADconsideredathighbleedingrisk(e.g.PRECISE-DAPT>_25),DAPTshouldbeconsideredfor3
IIa A
months.d695,696
InpatientswithSCADwhohavetoleratedDAPTwithoutableedingcomplicationandwhoareatlowbleedingriskbut
highthromboticrisk,continuationofDAPTwithclopidogrelfor>6monthsandupto30monthsmaybe IIb A
considered.697–700
InpatientswithSCADinwhom3monthDAPTposessafetyconcerns,DAPTmaybeconsideredfor1month. IIb C
BRS=bioresorbablescaffold;CAD=coronaryarterydisease;DAPT=dualantiplatelettherapy;DCB=drug-coatedballoon;i.v.=intravenous;MI=myocardialinfarction;
PCI=percutaneouscoronaryintervention;p.o.=orally;PRECISE-DAPT=PREdictingbleedingComplicationsInpatientsundergoingStentimplantationandsubsEquentDual
AntiPlateletTherapy;SCAD=stablecoronaryarterydisease.
aClassofrecommendation.
bLevelofevidence.
cTheserecommendationsrefertostentsthataresupportedbylarge-scalerandomizedtrialswithclinicalendpointevaluationleadingtoanunconditionalCEmark.
dTheevidencesupportingthisrecommendationcomesfromtwostudieswherethezotarolimus-elutingEndeavourstentwasinvestigatedinconjunctionwitha3monthDAPT
regimen.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 55 ---
ESC/EACTSGuidelines 141
.
.
17.2 Non-ST-segment elevation acute . notconfirmedinVALIDATE-SWEDEHEARTandinacontemporary
.
.
coronary syndrome .. settingofpreferredradialaccessandselectiveuseofGPIIb/IIIainhibi-
.
. tors. More recently, a meta-analysis updated for the results of
Theactivationofbloodplateletsandthecoagulationcascadeplaysa ..
. VALIDATE-SWEDEHEART confirmed that bivalirudin compared
keyroleintheinitialphaseandevolutionofanACS.Hence,sufficient ..
. withheparinwasassociatedwithasimilarincidenceofall-causedeath
platelet inhibition and anticoagulation is essential during ACS, and ...
andischaemiceventsafterPCIforACS.710Asignificantassociationof
especiallyinACSpatientsundergoingPCI. ..
. bivalirudinwithdecreasedriskofbleedingwasonlyfoundwithunbal-
.
.
. anceduseofGPIIb/IIIainhibitorsinconjunctionwithheparin.Insum-
.
17.2.1Choiceoftreatmentandpre-treatment ...
mary and based on the above-mentioned trials, UFH is primarily
ForNSTE-ACSpatients,DAPTincludingaspirinandapotentP2Y
12
...
recommendedasananticoagulantforPCI.Duetoitsshorthalf-life
receptorinhibitor(prasugrelorticagrelor)isrecommended(seethe ...
andfavourableresultsinsomeofthestudies,bivalirudinmaybecon-
SupplementaryData).701,702Clopidogrelshouldonlybeusedwhen ...
sideredasanalternativetoUFHinselectedcases.
prasugrelorticagrelorarenotavailableorarecontraindicated.Based ...
Patientsmayundergocardiaccatheterizationafteraconservative
on the results of the ACCOAST (Comparison of Prasugrel at the ...
treatmentphaseandthesepatientsarecommonlytreatedwithfon-
TimeofPercutaneousCoronaryInterventionorasPretreatmentat ...
daparinuxduringtheconservativetreatmentphase.Thisregimenis
.
theTimeofDiagnosisinPatientswithNon-STElevationMyocardial .. based on the OASIS-5 (Optimal Antiplatelet Strategy for
Infarction)trial,165itisnotrecommendedthatprasugrelisadminis- ...
Interventions5)trial.711Ofnote,catheterthrombusformationwas
.
tered in patients in whom coronary anatomy is not known. .. an issue with fondaparinux and therefore full-dose UFH must be
. Nevertheless,pre-treatmentwithticagrelorwaspartofthePLATO .. addedtopreventthrombusformationwhenthepatientproceedsto
.
trial (Study of Platelet Inhibition and Patient Outcomes) and was .. PCI. Enoxaparin should be considered as anticoagulant for PCI in
associatedwithanearlybenefitoverclopidogrel.702Fortheserea- ..
. patients pre-treated with subcutaneous enoxaparin. A benefit of
.
sons,pre-treatmentwithticagrelorcanbeused,althoughthereisno .
. enoxaparinoverUFHinreducingmortalityandbleedingcomplica-
.
direct evidence from head-to-head comparisons between pre- .
. tionswasrecentlyreportedinameta-analysisincludingNSTE-ACS
.
treatmentstrategies. .. patients.689 Yet, this meta-analysis did not include a dedicated
.
.
. randomized study in NSTE-ACS and was largely based on non-
.
.
17.2.2Peri-interventionaltreatment . randomizedcomparisons.
.
.
Anticoagulationisrecommendedforallpatientsinadditiontoanti- .. Most of the trials evaluating GP IIb/IIIa inhibitors in PCI-treated
.
platelettherapyduringPCIforNSTE-ACS.703Ingeneral,acrossover .. patients pre-date the era of routine oral DAPT treatment. These
.
betweenanticoagulantsshouldbeavoided[especiallybetweenUFH .. earlytrialsdemonstrated a reductioninthe incidenceofischaemic
.
andlow-molecular-weightheparin(LMWH)],withtheexceptionof .. events in favour of GP IIb/IIIa treatment in combination with UFH
.
addingUFHtofondaparinuxwhenapatientproceedstoPCI.704,705 .. compared withUFHalone,primarily through a reductioninMI.712
.
Therespective agents shouldbe discontinued afterPCI except for .. However, coronary angiography and PCI were delayed compared
.
specificclinicalsettings,suchasthepresenceofanLVaneurysmwith .. withwhatisrecommendednow,andaconsistentmajorbleedingrisk
.
thrombusorAFrequiringanticoagulation. .. wasobserved.Overall,thereisnocompellingevidenceforanaddi-
.
A numberoftrials have compared bivalirudinwith UFHin ACS .. tional benefit of routine upstream use of GP IIb/IIIa inhibitors in
.
patients undergoing PCI (see the Supplementary Data). Some of .. NSTE-ACSpatientsscheduledforcoronaryangiographyandreceiv-
.
thesetrialspursuedabalanceduseofadjunctiveGPIIb/IIIainhibitors .. ing DAPTtreatment.713,714 Ina setting ofpotentplatelet inhibition .
withbothbivalirudinandheparin,whereasothers,predominantlythe .. with ticagrelor or prasugrel, where randomized data on GP IIb/IIIa
.
olderones,hadselectiveuseofGPIIb/IIIainhibitorsintheheparin .. inhibitoruseislimited,routineuseoftheseagentscannotberecom-
.
arm. These trials have been reviewed extensively in a number of .. mended.Nevertheless,itshouldbeconsideredforbail-outsituations
.
meta-analyses.706–708Ameta-analysisthatincludedtheMATRIXtrial .. or thrombotic complications,and may be used forhigh-riskPCIin
.
but not VALIDATE-SWEDEHEART (Bivalirudin versus Heparin in ... patientswithoutpre-treatmentwith P2Y 12-inhibitors.Theavailable
.
ST-SegmentandNon-ST-SegmentElevationMyocardialInfarctionin . evidenceoncangrelorsuggeststhatthepotentialbenefitisindepend-
. .
Patients on Modern Antiplatelet Therapy on the Swedish Web- . entoftheclinicalpresentation.Thus,similartoSCADpatients,can-
.
.
systemforEnhancementandDevelopmentofEvidence-basedcare . grelormaybeconsideredinspecificsettingsinP2Y -na¨ıvepatients
. 12
.
inHeartdiseaseEvaluatedAccordingtoRecommendedTherapies) . undergoingPCI.
.
.
showednosignificantbenefitofbivalirudincomparedwithUFHwith .
.
respect to death, MACE, and MI.708 Nevertheless, bivalirudin was ..
.
.
associatedwithasignificantincreaseintheriskofstentthrombosis . 17.2.3Post-interventionalandmaintenancetreatment
.
.
andasignificantdecreaseintheriskofbleeding.However,thereduc- .. FollowingPCIforNSTE-ACS,DAPTconsistingofaP2Y 12receptor
.
tionofbleedingriskwaslinkedtounbalanceduseofGPIIb/IIainhibi- .. inhibitor in addition to aspirin is generally recommended for 12
.
tors predominantly with UFH. Recently, the VALIDATE- .. months,irrespectiveofthestenttype.Recently,theSMART-DATE
.
SWEDEHEART study709 compared UFH vs. bivalirudin in a back- .. (Smart Angioplasty Research Team-safety of 6-month duration of
.
groundofradialaccessandlimiteduseofGPIIb/IIIainhibitors.The .. DualAntiplateletTherapyafterpercutaneouscoronaryintervention
.
study demonstrated similar risk patterns for both ischaemia and .. inpatientswithacutecoronarysyndromes)prospectivemulticentre
.
bleedingwhencomparingthetwodrugs.Ofnote,whilepriorstudies .. randomizedtrialsupportedthisnotioninthesettingofcontempo-
.
reportedareducedbleedingriskwithbivalirudinvs.UFH,thiswas . rary interventional practice. The study randomly assigned 2712
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 56 ---
142 ESC/EACTSGuidelines
.
.
patientsundergoingPCIforNSTE-ACSorSTEMItoeither6month . inhibitiononchronicantiplatelettreatmentforacutecoronarysyn-
.
DAPT or 12 month or longer DAPT. Although the primary .. dromes)trial717,anapproachofDAPTde-escalationguidedbyplate-
.
.
endpoint—a composite of all-cause death, MI, or stroke—did not . letfunctiontestingmaybeconsideredinACSpatients(NSTE-ACS
.
.
confirmthebenefitofprolongedDAPTover6monthDAPT(cumu- . andSTEMI)asanalternativeto12monthspotentplateletinhibition,
.
.
lativeeventrate4.7vs.4.2%;absoluteriskdifference0.5%;upperlimit . especiallyforpatientsdeemedunsuitableformaintainedpotentpla-
.
.
ofone-sided95%CI1.8%;P =0.03withapredefinednon- . teletinhibition.Foramoredetaileddescriptionofthepertinentclini-
non-inferiority .
.
inferiority margin of 2.0%), MI occurred more frequently in the 6 . cal trials in the field of DAPT duration and switching antiplatelet
.
.
monthDAPTgroupthanintheprolongedDAPTgroup(1.8vs.0.8%; . drugs, we refer the reader to the International Expert Consensus
.
.
P=0.02).TherateofBARCtype2-5bleedingwasnotsignificantly . document on Switching Platelet P2Y12 Receptor-Inhibiting
.
.
affectedbyprolongedDAPT(HR0.69,95%CI0.45–1.05,P=0.09). .. Therapies718andthe2017ESCFocusedUpdateonDualAntiplatelet
.
TheauthorsstatedthattheincreasedriskofMIwith6monthDAPT .. Therapy in Coronary Artery Disease.410 Following DAPT, lifelong
.
andthewidenon-inferioritymarginpreventedthemfromconcluding .. singleantiplatelettherapy(usuallywithaspirin)isrecommendedand
.
thatshort-termDAPTwassafeinthissetting,andsuggestedthatpro- .. patientsshouldbeadvisednottoprematurelydiscontinueoralanti-
.
longed DAPT should remain the standard of care in patients with .. platelettherapyafterstenting.677,719
.
ACSwithoutexcessiveriskofbleeding.715 .. Based on the results of the ATLAS-ACS 2–TIMI 51 (Anti-Xa
.
Inspecificclinicalscenarios,thisstandardDAPTdurationcanbe .. Therapy to Lower cardiovascular events in Addition to Standard
.
shortened (<12 months) or extended (>12 months). Further on, .. therapy insubjects withAcuteCoronarySyndrome–Thrombolysis
.
switching and especially a de-escalation of DAPT (switching from .. InMyocardialInfarction51)trialinNSTE-ACSandSTEMIpatients,720
. potentP2Y 12-inhibitorstoclopidogrel)wassubjecttoanumberof ... low-dose rivaroxaban may be considered after discontinuation of
randomized clinical trials.716,717 Triggers for DAPT de-escalation .. parenteralanticoagulationforpatientswithnopriorstroke/TIA,and
.
includeclinical(bleedingeventsorpresumedhighbleedingrisk)and .. at high ischaemic riskaswell aslow bleedingrisk, receiving aspirin
.
socio-economic factors.716 Based on recent results from the .. andclopidogrel.Ofnote,rivaroxabanhasnotbeeninvestigatedina
.
.
randomized TROPICAL-ACS (Testing responsiveness to platelet . backgroundofpotentP2Y -inhibitors.
12
Recommendationsforantithrombotictreatmentinpatientswithnon-ST-elevationacutecoronarysyndromesunder-
goingpercutaneouscoronaryintervention
Recommendations Classa Levelb
Pre-treatmentandantiplatelettherapy
Aspirinisrecommendedforallpatientswithoutcontraindicationsataninitialoralloadingdoseof150–300mg(or
I A
75–250mgi.v.),andatamaintenancedoseof75–100mgdailylong-term.681,683,721
AP2Y inhibitorisrecommendedinadditiontoaspirin,maintainedover12monthsunlesstherearecontraindica-
12 I A
tionssuchasanexcessiveriskofbleeding.701,702,722,723Optionsare:
(cid:2)PrasugrelinP2Y -inhibitorna¨ıvepatientswhoproceedtoPCI(60mgloadingdose,10mgdailydose).701 I B
12
(cid:2)TicagrelorirrespectiveoftheprecedingP2Y inhibitorregimen(180mgloadingdose,90mgb.i.d.).702
12 I B
(cid:2)Clopidogrel(600mgloadingdose,75mgdailydose)onlywhenprasugrelorticagrelorarenotavailableorare
contraindicated.722–724 I B
GPIIb/IIIaantagonistsshouldbeconsideredforbail-outifthereisevidenceofno-refloworathrombotic
IIa C
complication.
Forpre-treatmentinpatientswithNSTE-ACSundergoinginvasivemanagement,ticagreloradministration(180mg
loadingdose,90mgb.i.d.),orclopidogrel(600mgloadingdose,75mgdailydose)ifticagrelorisnotanoption, IIa C
shouldbeconsideredassoonasthediagnosisisestablished.
CangrelormaybeconsideredinP2Y -inhibitorna¨ıvepatientsundergoingPCI.673 IIb A
12
GPIIb/IIIaantagonistsmaybeconsideredinP2Y -inhibitorna¨ıvepatientsundergoingPCI. IIb C
12
Pre-treatmentwithGPIIb/IIIaantagonistsinpatientsinwhomcoronaryanatomyisnotknownisnot
III A
recommended.713,714,725
Administrationofprasugrelinpatientsinwhomcoronaryanatomyisnotknownisnotrecommended.165 III B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 57 ---
ESC/EACTSGuidelines 143
Peri-interventionaltherapy
Anticoagulationisrecommendedforallpatientsinadditiontoantiplatelettherapy.703,726 I A
Itisrecommendedthatanticoagulationisselectedaccordingtobothischaemicandbleedingrisks,andaccordingto
I C
theefficacy–safetyprofileofthechosenagent.
UFHisrecommended. I C
Inpatientsonfondaparinux,asinglebolusUFH(85IU/kg,or60IUinthecaseofconcomitantuseofGPIIb/IIIa
I B
receptorinhibitors)isindicated.727
Enoxaparinshouldbeconsideredinpatientspre-treatedwithsubcutaneousenoxaparin.689 IIa B
Discontinuationofparenteralanticoagulationshouldbeconsideredimmediatelyafteraninvasiveprocedure. IIa C
Bivalirudin(0.75mg/kgbolus,followedby1.75mg/kg/hforupto4haftertheprocedure)maybeconsideredasan
IIb A
alternativetoUFH.163,708,710,714,728
CrossoverofUFHandLMWHisnotrecommended.705 III B
b.i.d.=twicedaily;GP=glycoprotein;i.v.=intravenous;LMWH=low-molecular-weightheparin;NSTE-ACS=non-ST-segmentelevationacutecoronarysyndromes;PCI=
percutaneouscoronaryintervention;UFH=unfractionatedheparin.
aClassofrecommendation.
bLevelofevidence.
Recommendationsforpost-interventionalandmaintenancetreatmentinpatientswithnon-ST-elevationacutecoro-
narysyndromesandST-elevationmyocardialinfarctionundergoingpercutaneouscoronaryintervention
Recommendations Classa Levelb
InpatientswithACStreatedwithcoronarystentimplantation,DAPTwithaP2Y inhibitorontopofaspirinisrec-
12
ommendedfor12monthsunlesstherearecontraindicationssuchasanexcessiveriskofbleeding(e.g.PRECISE- I A
DAPT>_25).701,702,722,723
InpatientswithACSandstentimplantationwhoareathighriskofbleeding(e.g.PRECISE-DAPT>_25),discontinua-
IIa B
tionofP2Y inhibitortherapyafter6monthsshouldbeconsidered.729,730
12
InpatientswithACStreatedwithBRS,DAPTshouldbeconsideredforatleast12monthsanduptothepresumed
IIa C
fullabsorptionoftheBRS,basedonanindividualassessmentofbleedingandischaemicrisk.
De-escalationofP2Y inhibitortreatment(e.g.withaswitchfromprasugrelorticagrelortoclopidogrel)guidedby
12
plateletfunctiontestingmaybeconsideredasanalternativeDAPTstrategy,especiallyforACSpatientsdeemed IIb B
unsuitablefor12-monthpotentplateletinhibition.717
InpatientswithACSwhohavetoleratedDAPTwithoutableedingcomplication,continuationofDAPTforlonger
IIb A
than12monthsmaybeconsidered.700,731
InpatientswithMIandhighischaemicriskcwhohavetoleratedDAPTwithoutableedingcomplication,ticagrelor
IIb B
60mgb.i.d.forlongerthan12monthsontopofaspirinmaybepreferredoverclopidogrelorprasugrel.732–734
InACSpatientswithnopriorstroke/TIA,andathighischaemicriskaswellaslowbleedingrisk,receivingaspirin
andclopidogrel,low-doserivaroxaban(2.5mgb.i.d.forapproximately1year)maybeconsideredafterdiscontinua- IIb B
tionofparenteralanticoagulation.720
ACS=acutecoronarysyndrome;b.i.d.=twicedaily;BRS=bioresorbablescaffold;DAPT=dualantiplatelettherapy;MI=myocardialinfarction;PCI=percutaneouscoronary
intervention;PRECISE-DAPT=PREdictingbleedingComplicationsInpatientsundergoingStentimplantationandsubsEquentDualAntiPlateletTherapy;TIA=transientischae-
micattack.
aClassofrecommendation.
bLevelofevidence.
cDefinedas>_50yearsofageandhavingoneofthefollowingadditionalhigh-riskfeatures:age>_65yearsorolder,diabetesmellitusrequiringmedication,asecondpriorsponta-
neousMI,multivesselcoronaryarterydisease,orchronicrenaldysfunction,definedasanestimatedcreatinineclearance<60mL/min.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 58 ---
144 ESC/EACTSGuidelines
.
17.3 ST-segment elevation myocardial .. administration—regardlessofwhethertreatmentstartsupstreamor
.
infarction .. in the catheterization laboratory—cannot be recommended.
.
.
17.3.1Choiceoftreatmentandpre-treatment
.. EspeciallyinasettingwherepotentP2Y 12-inhibitorslikeprasugrelor
.
. ticagrelorareused,thevalueofGPIIb/IIIainhibitorsremainsuncer-
STEMIpatientsundergoingprimaryPCIshouldreceiveaspirinanda .
.
. tainastheseagentsexhibitafastonsetofaction(usually<1h).GP
P2Y receptorinhibitorassoonasthediagnosisofSTEMIisestab- .
12 .. IIb/IIIainhibitorsremainanoptionasbail-outtherapyorinhigh-risk
lished.InlinewiththetreatmentrecommendationsforNSTE-ACS ..
. PCIwithoutpre-treatmentwithP2Y -inhibitors.Ofnote,thebail-
patients,DAPTisthecornerstoneoftreatmentforSTEMIpatients .. 12
. outscenarioshaveneverbeenaddressedinrandomizedcontrolled
andincludesaspirinandapotentP2Y 12receptorinhibitor(prasugrel ...
trials.Forreasonsdiscussedabove(seesections17.1and17.2),can-
orticagrelor).701,702Forbothantiplateletdrugs,publishedsubgroup ..
. grelormaybeconsideredinspecificsettingsinP2Y -na¨ıvepatients
analyses on STEMI patients are available (see the Supplementary .. 12
. undergoingPCI.
Data).Randomizeddataonacomparisonofticagrelorvs.prasugrel ..
.
inSTEMIpatientsarelimited,buttherecentlypublishedrandomized ..
.
PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the ..
.
TreatmentofAcuteMyocardialInfarction)trial735withlimitedstatis- .. 17.3.3Post-interventionalandmaintenancetreatment
.
ticalpowerfoundsimilarsafetyandefficacyprofilesofticagrelorand ... FollowingPCIforSTEMI,DAPTconsistingofaP2Y 12receptorinhibi-
prasugrelinasettingofprimaryPCI.WhenpotentP2Y 12receptor ... torinadditiontoaspirinisgenerallyrecommendedfor12months.
inhibitorsarecontraindicatedorarenotavailable,clopidogrelshould .. Recommendations for maintenance DAPT treatment are generally
.
begivenforprimaryPCIinstead.724Thevalueofpre-treatmentwith .. consistentwiththoseforNSTE-ACSpatientsandaredetailedinsec-
.
ticagrelor was addressed in the ATLANTIC (Administration of . tion17.2.3.
Ticagrelor in the Cath Lab or in the Ambulance for New ST-
Elevation Myocardial Infarction to Open the Coronary Artery) RecommendationsforantithrombotictreatmentinST-
trial.736Nosignificantdifferenceswereobservedinthelevelsofthe elevationmyocardialinfarctionpatientsundergoingper-
cutaneouscoronaryintervention
twoco-primarysurrogateendpointsmeasuredbeforePCI(throm-
bolysis in Myocardial Infarction flow and ST-segment resolution).
Likewise,theincidenceofacombinedischaemicendpoint(death,MI, Recommendations Classa Levelb
stroke,stentthrombosis,andurgentrevascularization)didnotdiffer
Pre-treatmentandantiplatelettherapy
between the two treatment arms. Nevertheless, in both the
TRITON (TRial to Assess Improvement in Therapeutic Outcomes Aspirinisrecommendedforallpatients
by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In withoutcontraindicationsataninitial
MyocardialInfarction)andPLATOtrials,pre-treatmentwaspartof oralloadingdoseof150–300mg(or
thetherapeuticregimeninSTEMI. 75–250mgi.v.),andatamaintenance I A
doseof75–100mgdailylong-term
regardlessoftreatment
17.3.2Peri-interventionaltreatment
strategy.681,683,721
Immediateandsufficientanticoagulationismandatoryinthesetting
ofprimaryPCIforSTEMIandavailableoptionsincludeUFH,bivaliru- ApotentP2Y 12inhibitor(prasugrelor
din, and enoxaparin. A number of RCTs compared bivalirudin vs. ticagrelor),orclopidogreliftheseare
UFH indifferent settingsand withdifferent utilizationofGPIIb/IIIa notavailableorarecontraindicated,is
inhibitors(seetheSupplementaryData).Theprimaryrecommenda- recommendedbefore(oratlatestatthe
I A
tionofUFH,reservingbivalirudinforselectedcases,isessentiallythe timeof)PCIandmaintainedover12
sameforprimaryPCIasforPCIinNSTE-ACS,andismostlybased months,unlesstherearecontraindica-
onthesameclinicaltrials706,709(seesection17.2.2). tionssuchasexcessiveriskof
Enoxaparin was compared with UFH in the randomized open- bleeding.701,702,724,743
labelATOLL(Acute STEMITreated withprimaryPCIandintrave-
GPIIb/IIIainhibitorsshouldbeconsid-
nousenoxaparinOrUFHtoLowerischaemicandbleedingeventsat
eredforbail-outifthereisevidenceof
short- and Long-term follow-up) trial,737 and based on the trial IIa C
no-refloworathrombotic
results, enoxaparin should be considered as analternative to UFH
complication.
treatmentinSTEMIpatients.
A number of clinical trials, performed at a time when pre- CangrelormaybeconsideredinP2Y -
12
treatmentandpotentplateletinhibitionwasnotpartofroutineclini- inhibitorna¨ıvepatientsundergoing IIb A
calpractice,havedocumentedclinicalbenefitsofGPIIb/IIIainhibitors PCI.673
as an adjunct to primary PCI performed with UFH.738,739 A meta-
GPIIb/IIIaantagonistsmaybeconsid-
analysis showed a significant survival benefit, especially in high-risk
eredinP2Y -inhibitorna¨ıvepatients IIb C
STEMI patients, but also a higher risk of bleeding with GP IIb/IIIa 12
undergoingPCI.
administration.740 Dedicated trials have investigated the value of
upstreamtreatmentinthepast.741,742Basedupontheavailableevi- Continued
dence, the routine use of i.v. or intracoronary GP IIb/IIIa inhibitor
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 59 ---
ESC/EACTSGuidelines 145
Peri-interventionaltherapy InpatientswithACS(NSTE-ACSor
STEMI)treatedwithDAPTwhoare
Anticoagulationisrecommendedforall
undergoingCABGanddonotrequire
patientsinadditiontoantiplateletther- I A
long-termOACtherapy,resumptionof
apyduringPCI.703,726 I C
P2Y inhibitortherapyassoonas
12
RoutineuseofUFHisrecommended. I C deemedsafeaftersurgeryanditscontin-
uationupto12monthsis
Routineuseofenoxaparinshouldbe
IIa B recommended.
considered.737
InpatientsonP2Y inhibitorswho
12
Routineuseofbivalirudinmaybe
IIb A needtoundergonon-emergentcardiac
considered.708,710,728,744–746
surgery,postponingsurgeryforatleast
3daysafterdiscontinuationofticagre- IIa B
GP=glycoprotein;i.v.=intravenous;PCI=percutaneouscoronaryintervention; lor,atleast5daysafterclopidogrel,and
UFH=unfractionatedheparin.
aClassofrecommendation. atleast7daysafterprasugrelshouldbe
bLevelofevidence. considered.747–749
InCABGpatientswithpriorMIwhoare
athighriskofseverebleeding(e.g.
17.4 Coronaryartery bypass grafting
PRECISE-DAPT>_25),discontinuationof IIa C
Antithrombotic treatment before and after CABG is addressed in P2Y inhibitortherapyafter6months
12
the 2017 ESC Focused Update on Dual Antiplatelet Therapy in shouldbeconsidered.
CoronaryArteryDisease.410Afterreviewingthesubsequentlitera-
Plateletfunctiontestingmaybeconsid-
ture,thecurrentTaskForceendorsestherecommendationsofthe
eredtoguidethedecisiononthetiming
updateonDAPTanddoesnotidentifyaneedforanymajorupdate.
ofcardiacsurgeryinpatientswhohave IIb B
Accordingly, the recommendation tables in this section are taken
recentlyreceivedP2Y
from the Focused Update. For a detailed discussion, we refer the 12
inhibitors.193,750–752
readertotheFocusedUpdate.
Inpatientsperceivedtobeathigh
ischaemicriskwithpriorMIandCABG,
Dualantiplatelettherapyinpatientsundergoingcardiac
whohavetoleratedDAPTwithouta
surgery IIb C
bleedingcomplication,treatmentwith
DAPTforlongerthan12monthsandup
Recommendations Classa Levelb
to36monthsmaybeconsidered.
ItisrecommendedthattheHeartTeam
estimatestheindividualbleedingand ACS = acute coronary syndrome; CABG = coronary artery bypass grafting;
ischaemicrisks,andguidesthetimingof I C DAPT=dualantiplatelettherapy;MI=myocardialinfarction;NSTE-ACS=non-
ST-elevationacutecoronarysyndrome;OAC=oralanticoagulant;STEMI=ST-
CABGaswellastheanti-thrombotic
elevation myocardial infarction. PRECISE-DAPT = PREdicting bleeding
management. Complications In patients undergoing Stent implantation and subsEquent Dual
AntiPlateletTherapy.
Inpatientsonaspirinwhoneedto aClassofrecommendation.
undergonon-emergentcardiacsurgery,
bLevelofevidence.
itisrecommendedtocontinueaspirinat I C
alowdailyregimenthroughouttheperi-
operativeperiod.
.
.
. 17.5 Special conditions
InpatientstreatedwithDAPTaftercor- ..
.. 17.5.1Antithrombotictherapyafterpercutaneous
onarystentimplantationwhosubse- .
.
. coronaryinterventioninpatientsrequiringoral
quentlyundergocardiacsurgery,itis .
.
. anticoagulation
recommendedtoresumeP2Y 12inhibi-
I C
...
ComparedwithOACtherapyalone,theadditionofDAPTtoOAC
tortherapypost-operativelyassoonas .
.
. therapyresultsinatwo-tothree-foldincreaseinbleedingcomplica-
itisdeemedsafe,sothatDAPTcontin- .
.
. tions, suggesting that every effort should be undertaken to avoid
uesuntiltherecommendeddurationof .
.. bleeding(Table8).753Assessingthebalanceofischaemicandbleeding
therapyiscompleted. .
.
. risksofrelativelyshort(i.e.<_6months)tripletherapydurationcom-
.
Continued .
. pared with double therapy consisting of clopidogrel and an OAC
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 60 ---
146 ESC/EACTSGuidelines
.
.
requirespatient-by-patientdecisions.Ofnote,previousrandomized . relevantbleedingevents.However,ascomparedwithtripletherapy,
.
.
studies evaluating the duration of triple therapy or the benefit of . anincreaseinbothMI(4.5vs.3.0%,P=0.09)andstentthrombosis
.
.
NOACsvs.vitaminKantagonists(VKAs)werenotadequatelypow- . risk(1.5vs.0.8%,P= 0.15)wasreportedforthelowerdabigatran
.
.
eredtoassessischaemicevents,anddataarelackingontheefficacy . dose(110mgb.i.d.),butnotforthehigherdabigatrandose(150mg
.
.
of dual therapy in patients at high risk of stroke or recurrent . b.i.d.).Althoughstatisticalsignificancewasmissed,thesefindingsraise
.
ACS.754–757Inthemajortrials,therewasnointeractionbetweenthe .. concernabouttheefficacyofthelowerdabigatrandoseincombina-
.
.
durationoftripletherapyandclinicalpresentation(ACSvs.noACS). . tion with single antiplatelet therapy in preventing coronary events.
.
.
Therateofbleedingeventspeakedwithinthefirst30daysofinitia- . Thus,the150mgb.i.d.doseofdabigatranispreferred.Atpresent,
.
.
tionoftripletherapy,andwastwiceashighwhencomparedwiththe .. evidenceforadualtreatmentapproachisavailableforVKA,755rivar-
.
rate of acute coronary events including recurrent MI and stent .. oxaban,756anddabigatran,757butnoneofthesestudieswerepow-
.
thrombosis.Forthesereasons,thedurationoftripletherapyshould .. ered to assess the efficacy of preventing stent thrombosis or
.
beminimizeddependingonbleedingandischaemicrisks(seeTables8 .. thrombo-embolic events and only RE-DUAL used a NOAC dose
.
to 10 for guidance in decision-making). In stabilized event-free .. that was previously shown to be effective in the prevention of
.
patients,discontinuationofanyantiplateletagentat1yearafterstent- .. thrombo-embolic events. The ongoing AUGUSTUS trial
.
ing is encouraged, while dual therapy may be continued beyond 1 .. (ClinicalTrials.govIdentifier:NCT02415400)willaddressthevalueof
.
yearaccordingtothestent-drivenriskshowninTable9. .. apixabaninasimilarsetting,andwithandwithoutaspirin.Edoxaban
.
Basedonthefavourablebleedingriskinthelargephase3studies,a .. iscurrentlybeinginvestigatedinasettingoftripletreatmentinthe
.
NOAC should be preferred over a VKA. The PIONEER756 .. ENTRUST-AF-PCI(Evaluationofthesafetyandefficacyofanedoxa-
. (PreventionofbleedinginpatientswithAFundergoingPCI)trialand .. ban-based antithrombotic regimen in patients with atrial fibrillation
.
.
the more recent RE-DUAL (Randomised Evaluation of Dual . following successful percutaneous coronary intervention) trial
.
.
AntithromboticTherapywithDabigatranversusTripleTherapywith . (ClinicalTrials.govIdentifier:NCT02866175).
.
.
WarfarininPatientswithNonvalvularAtrialFibrillationUndergoing . Figure11illustratesapplicableDAPTalgorithmsinpatientswithan
.
Percutaneous Coronary Intervention)757 trial compared a NOAC .. indication for OAC undergoing PCI with the respective classes of
.
.
plus single antiplatelet therapy withtripletherapywith a VKA plus . recommendations for the different treatment regimens. For more
.
.
DAPTandconsistentlyshowedsignificantlylowerbleedingriskswith . detailsonthepertinentstudiesinthefieldoftripletreatment(DAPT
.
.
thedualantithromboticregimen.InRE-DUAL,bothdosingregimens . plusOAC)andtheassociatedissues,wereferthereadertothe2017
.
.
fordabigatran(150mgand110mgb.i.d.)vs.warfarintripletherapy . ESC Focused Update on Dual Antiplatelet Therapy in Coronary
.
were associated with a significant reduction of major or clinically .. ArteryDisease.410
.
.
Table8 Strategiestoavoidbleedingcomplicationsinoralanticoagulationpatients
Assessischaemicandbleedingrisksusingvalidatedriskpredictors(e.g.CHADS-VASc,ABC,andHAS-BLED)withafocusonmodifiablerisk
2 2
factors.
Keeptripletherapydurationasshortaspossible;dualtherapyafterPCI(OACandclopidogrel)tobeconsideredinsteadoftripletherapy.
OneshouldconsidertheuseofaNOACinsteadofaVKAwhenNOACsarenotcontraindicated.
ConsideratargetINRinthelowerpartoftherecommendedtargetrangeandmaximizetimeinthetherapeuticrange(i.e.>65%)
whenaVKAisused.
ClopidogrelistheP2Y inhibitorofchoice.
12
Uselow-dose(<_100mgdaily)aspirin.
RoutineuseofPPIs.
AdaptedfromValgimiglietal.410
ABC=Age,Biomarkers,Clinicalhistory;CHA2DS2-VASc=Congestiveheartfailure,Hypertension,Age>_75years(doubled),Diabetesmellitus,priorStrokeortransient
ischaemicattackorthromboembolism(doubled),Vasculardisease,Age65–74years,Sexcategory(female);HAS-BLED=Hypertension,Abnormalrenal/liverfunction,Stroke,
Bleedinghistoryorpredisposition,LabileINR,Elderly,Drugs/alcoholconcomitantly;INR=internationalnormalizedratio;NOAC=non-vitaminKantagonistOAC;OAC=
oralanticoagulant;PPIs=protonpumpinhibitors;VKA=vitaminKantagonist.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 61 ---
ESC/EACTSGuidelines 147
Table9 High-riskfeaturesforischaemicevents Dualantiplatelettherapydurationinpatientswithindi-
cationfororalanticoagulation
Priorstentthrombosisonadequateantiplatelettherapy
Recommendations Classa Levelb
Stentingofthelastremainingpatentcoronaryartery
Itisrecommendedthatperiproceduralaspirin
Diffusemultivesseldisease,especiallyindiabeticpatients andclopidogrelareadministeredtopatients I C
undergoingcoronarystentimplantation.
Chronickidneydisease(i.e.creatinineclearance<60mL/min)
Inpatientstreatedwithcoronarystentimplan-
Atleastthreestentsimplanted
tation,tripletherapywithaspirin,clopidogrel,
IIa B
andanOACshouldbeconsideredfor1month,
Atleastthreelesionstreated
irrespectiveofthetypeofstentused.755
Bifurcationwithtwostentsimplanted
Tripletherapywithaspirin,clopidogrel,and
Totalstentedlength>60mm anOACforlongerthan1monthandupto6
monthsshouldbeconsideredinpatients
IIa B
Treatmentofachronictotalocclusion withhighischaemicriskduetoACSorother
anatomical/proceduralcharacteristics,which
HistoryofSTEMI
outweighthebleedingrisk.755
Dualtherapywithclopidogrel75mg/dayand
STEMI=ST-elevationmyocardialinfarction.
anOACshouldbeconsideredasanalterna-
tiveto1-monthtripleantithromboticther- IIa A
apyinpatientsinwhomthebleedingrisk
outweighstheischaemicrisk.754,756,757
Inpatientswithnon-valvularAFrequiringanti-
coagulationandantiplatelettreatment,a IIa A
Table10 Unfavourablepatientprofileforacombina-
NOACshouldbepreferredoverVKAs.758–760
tionoforalanticoagulantandantiplatelettherapy
InpatientswithanindicationforaVKAincom-
Shortlifeexpectancy binationwithaspirinand/orclopidogrel,the
doseintensityoftheVKAshouldbecarefully
IIa B
Ongoingmalignancy regulatedwithatargetINRinthelowerpartof
therecommendedtargetrangeandtimeinthe
Poorexpectedadherence
therapeuticrange>65%.754,755
Poormentalstatus
Discontinuationofantiplatelettreatmentin
patientstreatedwithOACshouldbeconsid- IIa B
End-stagerenalfailure
eredat12months.753
Advancedage
WhenaNOACisusedincombinationwith
Priormajorbleeding/priorhaemorrhagicstroke aspirinand/orclopidogrel,thelowestapproved
IIa C
doseeffectiveforstrokepreventiontestedin
Chronicalcoholabuse AFtrialsshouldbeconsidered.c
Anaemia Whenrivaroxabanisusedincombinationwith
aspirinand/orclopidogrel,rivaroxaban15mgq.d. IIb B
Clinicallysignificantbleedingondualantithrombotictherapy
maybeusedinsteadofrivaroxaban20mgq.d.756
Whendabigatranisusedincombinationwith
aspirinorclopidogrel,adoseof150mgb.i.d. IIb B
maybepreferredoveradoseof110mgb.i.d.757
Theuseofticagrelororprasugrelisnotrec-
ommendedaspartoftripleantithrombotic III C
therapywithaspirinandanOAC.
ACS=acutecoronarysyndrome;AF=atrialfibrillation;b.i.d.=twicedaily;INR
=internationalnormalizedratio;OAC=oralanticoagulant;NOAC=non-vita-
minKoralanticoagulant;q.d.=oncedaily;VKA=vitaminKantagonist.
aClassofrecommendation.
bLevelofevidence.
cApixaban5mgb.i.d.orapixaban2.5mgb.i.d.ifatleasttwoofthefollowing:age
>_80years,bodyweight<_60kg,orserumcreatininelevel>_1.5mg/dL(133mmol/
L);dabigatran110mgor150mgb.i.d.;andedoxaban60mgq.d.oredoxaban30
mgq.d.ifanyofthefollowing:creatinineclearanceof30–50mL/min;bodyweight
<_60kg;concomitantuseofverapamil,quinidine,ordronedarone;andrivaroxa-
ban20mgq.d.orrivaroxaban15mgq.d.ifcreatinineclearance30–49mL/min.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 62 ---
148 ESC/EACTSGuidelines
Patients with an indication for oral anticoagulation1
undergoing PCI2
Concerns about
ischaemic risk3 Concerns about bleeding risk4 prevailing
prevailing
Time from
treatment
initiation
A C O A C O C O
1 month Triple Therapy 1 month Triple Therapy Dual Therapy
Class IIa B Class IIa B up to 12 months
1 month
Class IIa A
3 months A C O C O OR A O
Triple Therapy Dual Therapy
up to 6 months up to 12 months
Class IIa B Class IIa A
6 months
C O A O
Dual Therapy up to 12 months
Class IIa A
12 months
Beyond O
12 months OAC monotherapy
Class IIa B
A = Aspirin C = Clopidogrel O = Oral anticoagulation1
Colour-coding refers to the number of concomitant antithrombotic medication(s). Triple therapy denotes treatment with DAPT plus oral anticoagulant (OAC). Dual
therapy denotes treatment with a single antiplatelet agent (aspirin or clopidogrel) plus OAC.
ABC = Age, Biomarkers, Clinical history; AF = atrial fibrillation; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition,
Labile INR, Elderly, Drugs/alcohol concomitantly; VKA = vitamin K antagonist.
1Non-vitamin K antagonist oral anticoagulant (NOAC) preferred over VKA in patients with non-valvular AF. (Class IIaA).
2Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy.
3High ischaemic risk is considered as an acute clinical presentation or anatomical/procedural features which might increase the risk for myocardial infarction.
4Bleeding risk can be estimated by HAS-BLED or ABC score.
Figure 11 Algorithm for dual antiplatelet therapy in patients with an indication for oral anticoagulation undergoing percutaneous coronary
intervention.
.
17.5.2Revascularizationinpatientswithrenal .. 17.5.4Surgeryinpatientsondualantiplatelettherapy
.
failure .. See 2017 ESC Focused Update on Dual Antiplatelet Therapy in
.
SeetheSupplementaryData. .. CoronaryArteryDisease.410
.
.
.
.
17.5.3Monitoringofantiplateletdrugs(plateletfunction
... 17.6 Gaps in the evidence
.
testingandgenotyping) .. The value of pre-hospital pre-treatment with prasugrel in STEMI
.
SeetheSupplementaryData. . patients, as well as the safety and efficacy of ticagrelor given at
8102
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 63 ---
ESC/EACTSGuidelines 149
.
hospitaladmissioninNSTE-ACSpatients,hasnotbeenaddressedin .. hospitalsstronglypredictedmortality,irrespectiveofsurgeonorhos-
.
dedicatedrandomizedstudies. .. pitalcasevolumes.767Therefore,itisrecommendedthatsuchquality
.
Thesafetyandefficacyofshort-termpotentantiplatelettreatment .. measures (as an example see Supplementary Table 9) are
.
witheitherprasugrelorticagrelorinSCADpatientsisunknown,and .. adoptedandreportedtofacilitatefocusedqualityimprovement.768
.
.
is subject to ongoing clinical trials [the ALPHEUS (Assessment of .
.
LoadingWiththeP2Y InhibitorTicagrelororClopidogreltoHalt .. 18.2 Percutaneous coronary
12 .
IschemicEventsinPatientsUndergoingElectiveCoronaryStenting) .. intervention
.
.
trial: NCT02617290 and the SASSICAIA (Comparison of Loading .. Numerous studies have investigated the relationship between the
.
Strategies With Antiplatelet Drugs in Patients Undergoing Elective .. volume of procedures and outcomes of PCI, suggesting a
.
CoronaryIntervention)trial:NCT02548611]. .. volume–outcomerelationshipattheoperatorlevel,aswellasatthe
.
The clinical benefit of a short-term DAPT duration followed by .. institutionallevel.761,769–773Apopulation-basedstudyfromthePCI
.
long-term ticagrelor monotherapy (and stopping aspirin) remains .. reportingsystemofNewYorkindicatedthathospitalcasevolumes
.
unknown. The ongoing GLOBAL LEADERS (Long-term ticagrelor .. <400PCIsperyearandoperatorcasevolumes<75PCIsperyear
.
monotherapy versus standard dual antiplatelet therapy followed .. wereassociatedwithimpairedoutcomes.769
.
by aspirin monotherapy in patients undergoing biolimus-eluting .. AmongpatientswithACS,particularlySTEMI,operatorandhospi-
.
stent implantation) and TWILIGHT (Ticagrelor With Aspirin or .. talvolumesplayimportantroles.AlargestudyintheUSAreported
.
AloneinHigh-RiskPatientsAfterCoronaryIntervention)trialsaim .. that, in a cohort of 36 535 patients undergoing primary PCI, in-
.
to close this gap in our current knowledge (NCT01813435 and .. hospital mortality was significantly lower in institutions with higher
. NCT02270242,respectively). .. primary PCI volumes (5.7% in hospitals performing >33 primary
.
.. PCIs/yearvs.7.7%inhospitalsperforming<12primaryPCIs/year).774
.
.
. OperatorvolumehasalsobeenshowntoimpactoutcomesinLM
.
18 Volume outcome relationship .
.. PCI.Asingle-centrestudyof1948patientswhounderwentunpro-
.
for revascularization procedures .. tected LM PCI, performed by 25 operators over a 7 year period,
.
.. showedreduced30dayand3yearmortalityforpatientswhohad
.
Operator experience influences outcomes, particularly in critical, .. theirPCIperformedbyahigh-volumeoperator(definedas>_15LM
.
complex situations. Greater total experience of an entire hospital .. PCI/year; mean 25/year) vs. a low-volume operator (<15 LM PCI/
.
team—consistingofthesupportingmembersintheoperatingroom .. year).775
.
orcatheterizationlaboratoryand thoseresponsibleforpostopera- .. An example of quality measures for PCI is provided in
.
tivecare—resultsinmorefavourableoutcomes. .. SupplementaryTable10.
.
.
.
.
. 18.3 Training in cardiac surgeryand
18.1 Coronaryartery bypass grafting .
.
.. interventional cardiology for myocardial
StudieshavesuggestedthatthevolumeofCABGsurgeryinahos- .
.
. revascularization
pitalsignificantlyimpactsin-hospitalmortality,althoughnoconsis- .
.
tent cut-offs for volume were used in these studies.761–762 This .. A European training programme in interventional cardiology has
.
.
increaseinmortalityobservedinlowervolumecentresseemsto . beenproposedbytheEAPCIinordertoensurethehighqualityof
.
be attributable to so-called ‘failure to rescue’: although patients .. patient care and clinical excellence.776 The programme should last
.
.
operatedonatlow-volumecentresarenotatparticularlyhigher . 1–2yearsathigh-volumeinstitutionsthathandle>_800PCIsperyear
.
.
riskofsufferingamajorcomplication,theyaremorelikelytodie . andthathaveanestablished24h/7dayserviceforthetreatmentof
. .
fromsuchacomplicationshoulditoccur.763Therefore,consider- . patientswithACS.
. .
ation should be given to the performance of CABG in centres .. For CABG, no standardized European programme exists at
.
with an annual volume of at least 200 CABG cases. Apart from .. this time. However, the pace at which proficiency reaches certain
.
hospitalvolume,highersurgeonvolumealsoappearstobeinver- .. acceptable standards differs from trainee to trainee. Therefore,
.
selyrelatedtooperativemortality.Birkmeyeretal.providedevi- .. althoughitisrecommendedthattraineesperform>_200CABGpro-
.
dence suggesting that both hospitals and surgeons have some .. cedures under supervision before becoming completely independ-
.
impactonoutcomes.764 .. ent, a competency-driven residency programme with regular
.
Several studies suggest that quality measures are more .. evaluation of progress is recommended over a volume-driven
.
important than volume per se.765,766 Missing quality indicators in . programme.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 64 ---
150 ESC/EACTSGuidelines
Recommendationsforoperator/institutionalvolumeinmyocardialrevascularization
Recommendations Classa Levelb
CABG
ItshouldbeconsideredthatCABGbeperformedatinstitutionswithannualinstitutionalvolumesof>_200CABGcases. IIa C
PCI
ItshouldbeconsideredthatPCIforACSbeperformedbytrainedoperatorswithannualvolumesof>_75procedures
atinstitutionsperforming>_400PCIsperyearwithanestablished24h/7dayserviceforthetreatmentofpatientswith IIa C
ACS.
ItshouldbeconsideredthatPCIforSCADbeperformedbytrainedoperatorswithannualvolumesof>_75procedures
IIa C
atinstitutionsperforming>_200PCIsperyear.
Itshouldbeconsideredthatinstitutionswithannualvolumesof<400PCIscollaborateinnetworkswithhigher-volume
IIa C
institutions(>400PCIsperyear),withsharedwrittenprotocolsandexchangeofoperatorsandsupportstaff.
ItshouldbeconsideredthatPCIforLMbeperformedbytrainedoperatorswithanannualvolumeof>_25LMPCIcases
IIa C
peryear.
Itshouldbeconsideredthatnon-emergencyhigh-riskPCIprocedures—suchasforLMdisease,singleremainingpatent
coronaryartery,andcomplexchronictotalocclusions—areonlyperformedbyadequatelyexperiencedoperatorsat IIa C
centresthathaveaccesstocirculatorysupportandintensivecaretreatment.
ACS=acutecoronarysyndromes;CABG=coronaryarterybypassgrafting;LM=leftmain;PCI=percutaneouscoronaryintervention;SCAD=stablecoronaryartery
disease.
aClassofrecommendation.
bLevelofevidence.
Recommendationsfortraininginmyocardialrevascularization
Recommendations Classa Levelb
TraininginCABG
Itisrecommendedthattraineesincardiacsurgeryandinterventionalcardiologyfollowacompetency-drivenresidency
I C
programmewithregularevaluationofprogression.
Itshouldbeconsideredthattraineesincardiacsurgeryperform>_200CABGproceduresundersupervisionbefore
IIa C
beingindependent.
TraininginPCI
Itshouldbeconsideredthattraineesininterventionalcardiologyperform>_200PCIproceduresasfirstoperator,with
IIa C
one-thirdofPCIproceduresinemergencyorACSpatientsundersupervision,beforebeingindependent.
Itshouldbeconsideredthattraineesininterventionalcardiologycompleteformaltrainingaccordingtoa1–2yearcur-
riculumatinstitutionswith>_800PCIsperyearandanestablished24h/7dayserviceforthetreatmentofpatientswith IIa C
ACS.
ACS=acutecoronarysyndrome;CABG=coronaryarterybypassgrafting;PCI=percutaneouscoronaryintervention.
aClassofrecommendation.
bLevelofevidence.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 65 ---
ESC/EACTSGuidelines 151
Recommendationsforoutcomeregistration,monitor- Strategiesforfollow-upandmanagementinpatients
ing,andbenchmarking aftermyocardialrevascularization
Recommendations Classa Levelb Recommendations Classa Levelb
Itisrecommendedthatspecificqualityper- AfterCABGorPCIforAMI,participationin
formancemeasuresforCABGareadopted acardiacrehabilitationprogrammeisrec-
I C I A
atanationalleveltoallowoutcomemoni- ommendedtoimprovepatient
toringandbenchmarking. outcomes.777
Itisrecommendedthatnationalsocieties Itisrecommendedthatsecondarypreven-
establishnationaldatabasesonCABGprac- I C tionmeasures,includingmedicaltherapy
ticeandoutcomes. andlifestylechanges,arestartedandrein- I A
forcedaftermyocardial
ItisrecommendedthatCABGoutcome
revascularization.683,778–785
dataarereportedbyhospitalstonational I C
databases. Itisrecommendedthatpatientsarere-eval-
uatedaftermyocardialrevascularization
CABG=coronaryarterybypassgrafting. (e.g.at3monthsandthereafter,atleaston
aClassofrecommendation. anannualbasis)inordertoreassesssymp-
bLevelofevidence. I C
tomsandadherencetosecondarypreven-
tionmeasures,andreinforcemedical
therapyandlifestylechangeswhen
appropriate.
19 Medical therapy, secondary
Symptomaticpatients
prevention, and strategies for
Coronaryangiographyisrecommendedin
follow-up patientswithintermediate-tohigh-riskfin- I C
dingscatstresstesting.
Myocardialrevascularizationmustbeaccompaniedbymedicalther-
Animagingstresstestshouldbeconsidered
apyandothersecondarypreventionstrategiesforriskfactormodifi-
inpatientswithpriorrevascularizationover IIa B
cationandpermanentlifestylechanges.42Secondarypreventionand
stressECG.786
cardiacrehabilitationareanintegralpartofmanagementafterrevas-
cularization because such measures reduce future morbidity and Asymptomaticpatients
mortalityinacost-effectiveway,andcanfurtherimprovesymptoms.
Surveillancebynon-invasiveimaging-based
Thesemeasures are discussedindetailinthe EuropeanGuidelines
stresstestingmaybeconsideredinhigh-risk
onCardiovascularDiseasePreventionthatwerepublishedin2016.42 IIb C
patientsubsets6monthsafter
The need to detect restenosis has reduced in the DES era.
revascularization.
Likewise,thedurabilityofCABGresultshaveincreasedwiththeuse
ofarterialgrafts,andischaemiastemsmainlyfromSVGattritionand/ Afterhigh-riskPCI(e.g.unprotectedLM
or progression of CAD in native vessels. Nevertheless, the recur- stenosis),late(3–12months)surveillance
IIb C
renceofsymptomsorischaemiaduetodiseaseprogressionorreste- angiographymaybeconsidered,irrespective
nosisdeservesattention. ofsymptoms.
Routinenon-invasiveimaging-basedstress
testingmaybeconsidered1yearafterPCI IIb C
and>5yearsafterCABG.
AMI = acute myocardial infarction; CABG = coronary artery bypass grafting;
ECG = electrocardiogram; LM = left main; PCI = percutaneous coronary
intervention.
aClassofrecommendation.
bLevelofevidence.
cIntermediate-andhigh-riskfindingsatstressimagingareischaemiaatlowwork-
load with exercise stress testing, early-onset ischaemia with pharmacological
stress testing, an inducible wall motion abnormality, or a reversible perfusion
defectin>_10%ofLVmyocardium.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 66 ---
152 ESC/EACTSGuidelines
.
.
19.1 Gaps in the evidence . (5) Insomeinstances,bothPCIandCABGareequallyreasonable,or
.
.
. sometimes even equally problematic, options. This calls for the
Inallstudiestodateontheoptimalfollow-upafterPCI,thegainfrom .
.
. HeartTeamtobeconsultedtodevelopindividualizedtreatment
discovering patients with restenosis is obscured by the high rate .
.
. concepts,withrespectforthepreferencesofthepatientwhohas
offalsepositiveexerciseECGtestsindicatingischaemia.Therefore, .
.
. beeninformedaboutearlyandlateoutcomes.
simpleexerciseECGtestingisnotrecommendedforfollow-upand .
.
. (6) TimelyPCIoftheculpritlesionremainsthemainstayoftreatment
a non-invasive imaging approach is preferred. Specific studies to .
.
. ofACS.
clarifywhichsubsetofpatientsbenefitsmorefromaspecificfollow- .
.
. (7) AfterPCIoftheculpritlesioninACS,thechoiceoffurtherrevas-
upapproacharemissing.Morestudiesareneededtoassesstherole .
.
of CT angiography in patient surveillance after myocardial
.. cularizationmodalityshouldfollowthecriteriaappliedtopatients
.
revascularization.
.. withSCAD.
.
.. (8) RadialaccessispreferredforanyPCIirrespectiveofclinicalpre-
.
.. sentation,unlessthereareoverridingproceduralconsiderations.
.
20 Key messages .. (9) DESarerecommendedforanyPCIirrespectiveofclinicalpresen-
.
.. tation,lesiontype,anticipateddurationofDAPT,orconcomitant
.
(1) Myocardialrevascularizationisperformedforthereliefofsymp- .. anticoagulanttherapy.
.
tomsofmyocardialischaemiaandtheimprovementofprognosis. .. (10) Eventhough6monthsofDAPTisgenerallyrecommendedafter
.
In SCAD, the prognostic benefit is dependent on the extent of .. PCIinSCADand12monthsofDAPTafterACS,thetypeand
.
myocardiumsubjecttoischaemia. .. durationofDAPTshouldbeindividualizedaccordingtotheischae-
. (2) Theprognosticandsymptomaticbenefitsofmyocardialrevascula- .. micandbleedingrisks,andappropriatelyadaptedduringfollow-
.
.
rizationcriticallydependonthecompletenessofrevascularization. . up.Basedonthisjudgement,treatmentdurationsforDAPTafter
.
.
Therefore, the ability to achieve complete revascularization is a . DESthatareasshortas1monthorevenaslongaslifelongmaybe
.
.
keyissuewhenchoosingtheappropriatetreatmentstrategy. . reasonable.
.
.
(3) Apartfromissuesofindividualoperativeriskandtechnicalfeasibil- . (11) Off-pump surgery with no-touch aorta for high-risk patients
.
.
ity,diabetesmellitusandtheanatomicalcomplexityofCADdeter- . shouldbeconsideredwhenexpertiseexists.
.
.
minetherelativebenefitsofPCIandCABG. . (12) Multiple arterial grafting should be considered using the radial
.
.
(4) TheSYNTAXscoreistherecommendedtooltogaugetheana- .. artery for high-grade stenosis and/or BIMA grafting for patients
.
tomicalcomplexityofcoronarydisease. .. whodonothaveanincreasedriskofsternalwoundinfection.
.
.
.
21 Evidence-based ‘to do’ and ‘not to do’ messages from the Guidelines
Riskmodelstoassessshort-andlong-termoutcomesaftermyocardialrevascularization Classa Levelb
Whenevidenceofischaemiaisnotavailable,FFRoriwFRarerecommendedtoassessthehaemodynamicrelevance
I A
ofintermediate-gradestenosis.
ItisrecommendedthattheSTSscoreiscalculatedtoassessin-hospitalor30daymortality,andin-hospitalmorbidity,
I B
afterCABG.
InpatientswithLMormultivesseldisease,itisrecommendedthattheSYNTAXscoreiscalculatedtoassessthe
I B
anatomicalcomplexityofCADandthelong-termriskofmortalityandmorbidityafterPCI.
Indicationsforrevascularizationinpatientswithstableanginaorsilentischaemia
Forprognosis LMdiseasewithstenosis>50%.c I A
AnyproximalLADstenosis>50%.c I A
Two-orthree-vesseldiseasewithstenosis>50%cwithimpairedLVfunction(LVEF<_35%).c I A
Largeareaofischaemiadetectedbyfunctionaltesting(>10%LV)orabnormalinvasiveFFR.d I B
Forsymptoms Anyhaemodynamicallysignificantcoronarystenosisinthepresenceoflimitinganginaoranginaequivalent,
I A
withaninsufficientresponsetooptimizedmedicaltherapy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 67 ---
ESC/EACTSGuidelines 153
Typeofrevascularization(CABGorPCI)inpatientswithSCADwithsuitablecoronaryanatomyforboth
proceduresandlowpredictedsurgicalmortality
RecommendationsaccordingtotheextentofCAD CABG PCI
Classa Levelb Classa Levelb
One-vesselCAD
WithproximalLADstenosis I A I A
Two-vesselCAD
WithproximalLADstenosis I B
LMCAD
LMwithlowSYNTAXscore0-22 I A I A
LMwithintermediateSYNTAXscore>22and<_32 I A
LMwithhighSYNTAXscore>32.e I A III B
Three-vesselCADwithoutdiabetesmellitus
Three-vesseldiseasewithlowSYNTAXscore0-22 I A I A
Three-vesseldiseasewithintermediateorhighSYNTAXscore>22e I A III A
Three-vesselCADwithdiabetesmellitus
Three-vesseldiseasewithlowSYNTAXscore0-22 I A
Three-vesseldiseasewithintermediateorhighSYNTAXscore>22e I A III A
InvasiveevaluationandrevascularizationinNSTE-ACS
Anearlyinvasivestrategy(<24h)isrecommendedinpatientswithatleastonehigh-riskcriterion(Figure4). I A
Aninvasivestrategy(<72hafterfirstpresentation)isindicatedinpatientswithatleastoneintermediate-risk
I A
criterion(Figure4)orrecurrentsymptoms.
Itisrecommendedthattherevascularizationstrategy(adhocculprit-lesionPCI/multivesselPCI/CABG)isbased
onthepatient’sclinicalstatusandcomorbidities,aswellasthediseaseseverity,i.e.distributionand I B
angiographiclesioncharacteristics(e.g.SYNTAXscore),accordingtotheprinciplesforSCAD.
Incardiogenicshock,routinerevascularizationofnon-IRAlesionsisnotrecommendedduringprimaryPCI. III B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 68 ---
154 ESC/EACTSGuidelines
PrimaryPCIformyocardialreperfusioninSTEMI
Indication
Reperfusiontherapyisindicatedinallpatientswithtimefromsymptomonset<12hdurationandpersistentST-seg-
I A
mentelevation.
AprimaryPCIstrategyisrecommendedoverfibrinolysiswithinindicatedtimeframes. I A
Logistics
Itisrecommendedthatthepre-hospitalmanagementofSTEMIpatientsbebasedonregionalnetworksthatare
I B
designedtotimelyandeffectivelydeliverreperfusiontherapy,andtoofferprimaryPCItoasmanypatientsaspossible.
ItisrecommendedthatprimaryPCI-capablecentresdelivera24h/7dayserviceandensurethatprimaryPCIisper-
I B
formedasfastaspossible.
PatientstransferredtoaPCI-capablecentreforprimaryPCIshouldbypasstheemergencydepartmentandbetrans-
I B
ferreddirectlytothecatheterizationlaboratory.
Strategy/technique
Incardiogenicshock,routinerevascularizationofnon-IRAlesionsisnotrecommendedduringprimaryPCI. III B
Routineuseofthrombusaspirationisnotrecommended. III A
RecommendationsonrevascularizationsinpatientswithchronicheartfailureandsystolicLVdysfunction(EF(cid:4)35%)
InpatientswithsevereLVsystolicdysfunctionandcoronaryarterydiseasesuitableforintervention,myocardialrevas-
I B
cularizationisrecommended.
CABGisrecommendedasthefirstrevascularizationstrategychoiceinpatientswithmultivesseldiseaseandacceptable
I B
surgicalrisk.
Revascularizationsinpatientswithcardiogenicshock
EmergencyinvasiveevaluationisindicatedinpatientswithacuteheartfailureorcardiogenicshockcomplicatingACS. I B
EmergencyPCIisindicatedforpatientswithcardiogenicshockduetoSTEMIorNSTE-ACS,independentoftimedelay
I B
ofsymptomonset,ifcoronaryanatomyisamenable.
EmergencyCABGisrecommendedforpatientswithcardiogenicshockifthecoronaryanatomyisnotamenableto
I B
PCI.
RoutineuseofIABPinpatientswithcardiogenicshockduetoACSisnotrecommended. III B
Preventionofcontrast-inducednephropathy
Patientswithmoderate-to-severeCKD
Useoflow-oriso-osmolarcontrastmediaisrecommended. I A
Itisrecommendedthatthevolumeofcontrastmediaisminimized. I B
SevereCKD
Haemodialysistherapyisnotrecommendedasapreventativemeasure. III B
Pre-operativestrategiestoreducetheincidenceofstrokeinpatientsundergoingCABG
InpatientsundergoingCABG,carotidDUSisrecommendedinpatientswithrecent(<6months)historyofstroke/TIA. I B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 69 ---
ESC/EACTSGuidelines 155
Diseaseprogressionandlategraftfailure
Repeatrevascularizationisindicatedinpatientswithextensiveischaemiaorseveresymptomsdespitemedicaltherapy. I B
IMAistheconduitofchoiceforredoCABGinpatientsinwhomtheIMAwasnotusedpreviously. I B
DESarerecommendedforthetreatmentofin-stentrestenosiswithinBMSorDES. I A
Drug-coatedballoonsarerecommendedforthetreatmentofin-stentrestenosiswithinBMSorDES. I A
Preventionofventriculararrhythmiasbyrevascularization
AprimaryPCIstrategyisrecommendedinpatientswithresuscitatedcardiacarrestandanECGconsistentwithSTEMI. I B
Perioperativeoralb-blockertherapyisrecommendedforthepreventionofpost-operativeAFafterCABGsurgery. I B
ProceduralaspectsofCABG
ArterialgraftingwithanIMAtotheLADsystemisrecommended. I B
Useoftheradialarteryisrecommendedoverthesaphenousveininpatientswithhigh-degreestenosis. I A
SkeletonizedIMAdissectionisrecommendedinpatientswithhighriskofsternalwoundinfection. I B
Minimizationofaorticmanipulationisrecommended. I B
ProceduralaspectsofPCI
DESfarerecommendedoverBMSforanyPCIirrespectiveof:
• clinicalpresentation
• lesiontype
I A
• plannednon-cardiacsurgery
• anticipateddurationofDAPT
• concomitantanticoagulanttherapy.
Radialaccessisrecommendedasthestandardapproach,unlessthereareoverridingproceduralconsiderations. I A
Stentimplantationinthemainvesselonly,followedbyprovisionalballoonangioplastywithorwithoutstentingofthe
I A
sidebranch,isrecommendedforPCIofbifurcationlesions.
AntithrombotictreatmentinSCADpatientsundergoingPCI
Treatmentwith600mgclopidogrelisrecommendedinelectivePCIpatientsonceanatomyisknownandthedecision
I A
hasbeenmadetoproceedwithPCI.
Aspirinisindicatedbeforeelectivestenting. I A
Clopidogrel(600mgloadingdoseand75mgdailymaintenancedose)isrecommendedforelectivestenting. I A
UFHisindicatedasastandardanticoagulant(70–100U/kg). I B
Life-longsingleantiplatelettherapy,usuallyaspirin,isrecommended. I A
InpatientswithSCADtreatedwithcoronarystentimplantation,DAPTconsistingofclopidogrelinadditiontoaspirinis
I A
generallyrecommendedfor6months,irrespectiveofthestenttype.
AntithrombotictreatmentinNSTE-ACSpatientsundergoingPCI
Aspirinisrecommendedforallpatientswithoutcontraindicationsataninitialoralloadingdoseof150–300mg(or
I A
75–250mgi.v.)andatamaintenancedoseof75–100mgdailylong-term,regardlessoftreatmentstrategy.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 70 ---
156 ESC/EACTSGuidelines
AP2Y inhibitorisrecommendedinadditiontoaspirin,maintainedover12monthsunlesstherearecontraindications
12 I A
suchasanexcessiveriskofbleeding.Optionsare:
(cid:2)PrasugrelinP2Y -na¨ıvepatientswhoproceedtoPCI(60mgloadingdoseand10mgdailydose) I B
12
(cid:2)Ticagrelorirrespectiveofthepre-treatmentandrevascularizationstrategy(180mgloadingdose,90mgtwicedaily) I B
(cid:2)Clopidogrel(600mgloadingdoseand75mgdailydose),onlywhenprasugrelorticagrelorarenotavailableorare
I B
contraindicated.
Pre-treatmentwithGPIIb/IIIaantagonistsinpatientsinwhomcoronaryanatomyisnotknownisnotrecommended. III A
Administrationofprasugreltopatientsinwhomcoronaryanatomyisnotknownisnotrecommended. III B
Peri-interventionalanticoagulationisrecommendedforallpatientsinadditiontoantiplatelettherapy. I A
Inpatientsonfondaparinux(2.5mgdailys.c.),asinglebolusUFH(85IU/kg,or60IUinthecaseofconcomitantuseof
I B
GPIIb/IIIareceptorinhibitors)isindicated.
CrossoverofUFHandLMWHisnotrecommended. III B
InpatientswithACStreatedwithcoronarystentimplantation,DAPTwithaP2Y inhibitorontopofaspirinisrecom-
12
mendedfor12monthsunlesstherearecontraindicationssuchasanexcessiveriskofbleeding(e.g.PRECISE-DAPT I A
>_25).
AntithrombotictreatmentinSTEMIpatientsundergoingPCI
Aspirinisrecommendedforallpatientswithoutcontraindicationsataninitialoralloadingdoseof150–300mg(or
I A
75–250mgi.v.),andatamaintenancedoseof75–100mgdailylong-termregardlessoftreatmentstrategy.
ApotentP2Y inhibitor(prasugrelorticagrelor),orclopidogrelifthesearenotavailableorarecontraindicated,isrec-
12
ommendedbefore(oratthetimeofPCIatthelatest)PCIandshouldbemaintainedover12months,unlessthereare I A
contraindicationssuchasanexcessiveriskofbleeding.
Strategiesforfollow-upandmanagement
AfterCABGorPCIforAMI,participationinacardiacrehabilitationprogrammeisrecommendedtoimprovepatient
I A
outcomes.
Itisrecommendedthatsecondarypreventionmeasures,includingmedicaltherapyandlifestylechanges,arestartedand
I A
reinforcedaftermyocardialrevascularization.
ACS=acutecoronarysyndrome;AF=atrialfibrillation;AMI=acutemyocardialinfarction;BMS=bare-metalstent;CABG=coronaryarterybypassgrafting;CAD=coronary
arterydisease;CKD=chronickidneydisease;DAPT=dualantiplatelettherapy;DES=drugelutingstents;DUS=duplexultrasound;ECG=electrocardiogram;EF=ejection
fraction;FFR=fractionalflowreserve;GP=glycoprotein;IABP=intra-aorticballoonpump;iwFR=instantaneouswave-freeradio;IMA=internalmammaryartery;IRA=
infarct-relatedartery;i.v.=intravenous;LAD=leftanteriordescending;LM=leftmain;LMWH=low-molecular-weightheparin;LV=leftventricular;LVEF=leftventricular
ejectionfraction;NSTE-ACS=non-ST-elevationacutecoronarysyndrome;PCI=percutaneouscoronaryintervention;PRECISE-DAPT=PREdictingbleedingComplications
InpatientsundergoingStentimplantationandsubsEquentDualAntiPlateletTherapy;s.c.=subcutaneous;SCAD=stablecoronaryarterydisease;STEMI=ST-elevationmyo-
cardialinfarction;STS=SocietyofThoracicSurgeons;SYNTAX=SynergybetweenPercutaneousCoronaryInterventionwithTAXUSandCardiacSurgery;TIA=transient
ischaemicattack;UFH=unfractionatedheparin.
aClassofrecommendation.
bLevelofevidence.
cWithdocumentedischaemia,ahaemodynamicallyrelevantlesiondefinedbyFFR<_0.80oriwFR<_0.89,or>90%stenosisinamajorcoronaryvessel.
dBasedonFFR<0.75indicatingaprognosticallyrelevantlesion.
ePCIshouldbeconsidered,iftheHeartTeamisconcernedaboutthesurgicalriskorifthepatientrefusesCABGafteradequatecounsellingbytheHeartTeam.
fTheserecommendationsrefertostentsthataresupportedbylarge-scalerandomizedtrialswithclinicalendpointevaluationleadingtoanunconditionalCEmark.
.
22 Appendix .. Gaemperli (Switzerland), Gerhard Hindricks (Germany), Bernard
.
.
.. Iung (France), Peter Ju¨ni (Canada), Hugo A. Katus (Germany),
.
ESC Committee for Practice Guidelines (CPG): .. Juhani Knuuti (Finland), Patrizio Lancellotti (Belgium), Christophe
.
Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans .. Leclercq(France),TheresaA.McDonagh(UK),MassimoFrancesco
.
(France),StefanAgewall(Norway),EmanueleBarbato(Italy),He´ctor .. Piepoli (Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter
.
Bueno(Spain),AntonioCoca(Spain),Jean-PhilippeCollet(France), .. (Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russia),
.
Ioan Mircea Coman (Romania), Veronica Dean (France), Victoria .. Miguel Sousa-Uva (Portugal), Iain A. Simpson (UK), Jose Luis
.
Delgado (The Netherlands), Donna Fitzsimons (UK), Oliver .. Zamorano(Spain).
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 71 ---
ESC/EACTSGuidelines 157
.
EACTSCouncil:(OnbehalfoftheEACTSCouncil):Domenico .. 2. MinJK,LeipsicJ,PencinaMJ,BermanDS,KooBK,vanMieghemC,ErglisA,Lin
.
Pagano (Secretary General) (UK), Nick Freemantle (UK), Miguel .. FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB,
. Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic
Sousa-Uva(Portugal). ...
accuracy of fractional flow reserve from anatomic CT angiography. JAMA
ESC National Cardiac Societies actively involved in the .. 2012;308:1237–1245.
.
review process of the 2018 ESC/EACTS Guidelines on myocardial .. 3. NorgaardBL,LeipsicJ,GaurS,SeneviratneS,KoBS,ItoH,JensenJM,MauriL,
. De Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis A, Park SJ,
revascularization: Algeria: Algerian Society of Cardiology, ... ChristiansenEH,KaltoftA,LassenJF,BotkerHE,AchenbachS,GroupNXTTS.
MohamedChettibi;Armenia:ArmenianCardiologistsAssociation, .. Diagnosticperformanceofnoninvasivefractionalflowreservederivedfromcoro-
.
. nary computed tomography angiography in suspected coronary artery disease:
Hamayak Sisakian; Austria: Austrian Society of Cardiology, .
.. TheNXTtrial(AnalysisofCoronaryBloodFlowUsingCTAngiography:Next
Bernhard Metzler; Azerbaijan: Azerbaijan Society of Cardiology, .. Steps).JAmCollCardiol2014;63:1145–1155.
Firdovsi _Ibrahimov; Belarus: Belorussian Scientific Society of .. 4. DouglasPS,PontoneG,HlatkyMA,PatelMR,NorgaardBL,ByrneRA,CurzenN,
.
. PurcellI,GutberletM,RioufolG,HinkU,SchuchlenzHW,FeuchtnerG,Gilard
Cardiologists, Valeriy I. Stelmashok; Bulgaria: BulgarianSociety of .
.. M,AndreiniD,JensenJM,HadamitzkyM,ChiswellK,CyrD,WilkA,WangF,
Cardiology, Arman Postadzhiyan; Croatia: Croatian Cardiac .. RogersC,DeBruyneB,PLATFORMInvestigators.Clinicaloutcomesoffractional
.
Society, Bosko Skoric; Cyprus: Cyprus Society of Cardiology, . flowreservebycomputedtomographicangiography-guideddiagnosticstrategies
.
. vs.usualcareinpatientswithsuspectedcoronaryarterydisease:Theprospective
ChristosEftychiou;CzechRepublic:CzechSocietyofCardiology, .
.. longitudinaltrialofFFR(CT):Outcomeandresourceimpactsstudy.EurHeartJ
Petr Kala; Denmark: Danish Society of Cardiology, Christian Juhl .. 2015;36:3359–3367.
.
Terkelsen; Egypt: Egyptian Society of Cardiology, Ahmed Magdy; . 5. Ponikowski P,VoorsAA, Anker SD, Bueno H,Cleland JGF,Coats AJS, FalkV,
.
Estonia:EstonianSocietyofCardiology,JaanEha;Finland:Finnish
.. Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
.. Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM,
CardiacSociety,MattiNiemel€a;TheFormerYugoslavRepublic .. RuschitzkaF,RuttenFH,vanderMeerP;ESCScientificDocumentGroup.2016
. of Macedonia: Macedonian FYR Society of Cardiology, Sasko .. ESC Guidelines for the diagnosis and treatment of acute and chronic heart
Kedev; France: French Society of Cardiology, Pascal Motreff;
.... f fa ai il lu ur re e: oT fh te heTa Es uk roFo pr ec ae nf So or ct ih ee tyd oia fg Cno ars dis ioa ln od gytr (e Ea Stm C)e Dn et vo ef loa pc eu dte wa itn hd thc ehr so pn ecic iah le coa nrt
-
Georgia: Georgian Society of Cardiology, Alexander Aladashvili; .. tribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
.
Germany: German Cardiac Society, Julinda Mehilli; Greece: .. 2016;37:2129–2200.
Hellenic Society of Cardiology, Ioannis-Georgios Kanakakis;
... 6. BeanlandsRS,NicholG,HusztiE,HumenD,RacineN,FreemanM,Gulenchyn
. KY,GarrardL,deKempR,GuoA,RuddyTD,BenardF,LamyA,IwanochkoRM;
Hungary:HungarianSocietyofCardiology,DavidBecker;Iceland: .. PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography
.
IcelandicSocietyofCardiology,ThorarinnGudnason;Ireland:Irish .. imaging-assistedmanagementofpatientswithsevereleftventriculardysfunction
CardiacSociety,AaronPeace;Italy:ItalianFederationofCardiology,
... andsuspectedcoronarydisease:Arandomized,controlledtrial(PARR-2).JAm
. CollCardiol2007;50:2002–2012.
Francesco Romeo; Kosovo: Kosovo Society of Cardiology, Gani .. 7. MehraMR,CanterCE,HannanMM,SemigranMJ,UberPA,BaranDA,Danziger-
.
Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina .. IsakovL,KirklinJK,KirkR,KushwahaSS,LundLH,PotenaL,RossHJ,TaylorDO,
Kerimkulova;Latvia:LatvianSocietyofCardiology,Ain(cid:3)arsRudzıtis;
... Verschuuren EA, Zuckermann A, International Society for Heart Lung
. TransplantationInfectiousDiseasesCouncil,InternationalSocietyforHeartLung
.
Lebanon: Lebanese Society of Cardiology, Ziad Ghazzal; .. TransplantationPediatricTransplantationCouncil,InternationalSocietyforHeart
Lithuania:LithuanianSocietyofCardiology,AleksandrasKibarskis; .. Lung Transplantation Heart Failure, Transplantation Council. The 2016
.
. InternationalSocietyforHeartLungTransplantationlistingcriteriaforhearttrans-
Luxembourg:LuxembourgSociety ofCardiology, Bruno Pereira; .
. plantation:A10-yearupdate.JHeartLungTransplant2016;35:1–23.
.
Malta: Maltese Cardiac Society, Robert G. Xuereb; The .. 8. FeldmanD,PamboukianSV,TeutebergJJ,BirksE,LietzK,MooreSA,MorganJA,
Netherlands:NetherlandsSocietyofCardiology,SjoerdH.Hofma; .. ArabiaF,BaumanME,BuchholzHW,DengM,DicksteinML,El-BanayosyA,Elliot
.
. T,GoldsteinDJ,GradyKL,JonesK,HryniewiczK,JohnR,KaanA,KusneS,Loebe
Norway: Norwegian Society of Cardiology, Terje K. Steigen; .
.. M,MassicotteMP,MoazamiN,MohacsiP,MooneyM,NelsonT,PaganiF,Perry
Poland: Polish Cardiac Society, Adam Witkowski; Portugal: .. W,PotapovEV,EduardoRameJ,RussellSD,SorensenEN,SunB,StrueberM,
.
Portuguese Society of Cardiology, Eduardo Infante de Oliveira; . Mangi AA, Petty MG, Rogers J; International Society for Heart and
.
. Lung Transplantation. The 2013 International Society for Heart and Lung
Romania: Romanian Society of Cardiology, Stefan Mot; Russian .
.. Transplantation Guidelines for mechanical circulatory support: Executive sum-
Federation:RussianSocietyofCardiology,DmitryDuplyakov;San .. mary.JHeartLungTransplant2013;32:157–187.
.
Marino:SanMarinoSocietyofCardiology,MarcoZavatta;Serbia: .. 9. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P,
. DrozdzJ,FarskyPS,FeldmanAM,DoenstT,MichlerRE,BermanDS,Nicolau
Cardiology Society of Serbia, Branko Beleslin; Slovakia: Slovak ...
JC,PellikkaPA,WrobelK,AlottiN,AschFM,FavaloroLE,SheL,Velazquez
SocietyofCardiology,FrantisekKovar;Slovenia:SlovenianSociety .. EJ,JonesRH,PanzaJA;STICHTrialInvestigators.Myocardialviabilityandsur-
.
of Cardiology, Matja(cid:4)z Bunc; Spain: Spanish Society of Cardiology, .. vival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:
SoledadOjeda;Sweden:SwedishSocietyofCardiology,NilsWitt;
.... 10.1 A61 ll7 m– a1 n62 K5 C.
, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing
Switzerland: Swiss Society of Cardiology, Raban Jeger; Tunisia: .. andimpactofrevascularizationonprognosisinpatientswithcoronaryarterydis-
.
TunisianSocietyofCardiologyandCardio-VascularSurgery,Faouzi .. ease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol
Addad; Turkey: TurkishSociety ofCardiology, RamazanAkdemir;
....
11.
L2 i0 n0 g2;3 LF9 ,:1 M15 a1 rw–1 ic1 k58 T.
H, Flores DR, Jaber WA, Brunken RC, Cerqueira MD,
Ukraine: Ukrainian Association of Cardiology, Alexander .. Hachamovitch R. Identification of therapeutic benefit from revascularization in
.
Parkhomenko; United Kingdom: British Cardiovascular Society, .. patientswithleftventricularsystolicdysfunction:Inducibleischemiaversushiber-
RobertHenderson.
... natingmyocardium.CircCardiovascImaging2013;6:363–372.
. 12. AhnJM,ParkDW,ShinES,KooBK,NamCW,DohJH,KimJH,ChaeIH,Yoon
.
. JH,HerSH,SeungKB,ChungWY,YooSY,LeeJB,ChoiSW,ParkK,HongTJ,
.
23. References
.. LeeSY,HanM,LeePH,KangSJ,LeeSW,KimYH,LeeCW,ParkSW,ParkSJ;
.. IRIS-FFR Investigators. Fractional flow reserve and cardiac events in coronary
.
1. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, . artery disease: Data from a prospective IRIS-FFR Registry (Interventional Cardiology
.
Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, . Research Incooperation Society Fractional Flow Reserve). Circulation 2017;135:
.
Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, .. 2241–2251.
SeniorR,TaggartDP,vanderWallEE,VrintsCJ.2013ESCguidelinesonthe .. 13. BechGJ,DeBruyneB,BonnierHJ,BartunekJ,WijnsW,PeelsK,Heyndrickx
.
managementofstablecoronaryartery.EurHeartJ2013;34:2949–3003. GR,KoolenJJ,PijlsNH.Long-termfollow-upafterdeferralofpercutaneous
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 72 ---
158 ESC/EACTSGuidelines
.
transluminal coronary angioplasty of intermediate stenosis on the basis of .. 26. HamilosM,MullerO,CuissetT,NtalianisA,ChlouverakisG,SarnoG,NelisO,
.
coronarypressuremeasurement.JAmCollCardiol1998;31:841–847. . BartunekJ,VanderheydenM,WyffelsE,BarbatoE,HeyndrickxGR,WijnsW,
.
14. BechGJ,DeBruyneB,PijlsNH,deMuinckED,HoorntjeJC,EscanedJ,Stella . De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided
.
PR,BoersmaE,BartunekJ,KoolenJJ,WijnsW.Fractionalflowreservetodeter- .. treatmentinpatientswithangiographicallyequivocalleftmaincoronaryartery
mine the appropriateness of angioplasty in moderate coronary stenosis: A .. stenosis.Circulation2009;120:1505–1512.
.
randomizedtrial.Circulation2001;103:2928–2934. . 27. Yong AS, Daniels D, De Bruyne B, Kim HS, Ikeno F, Lyons J, Pijls NH,
.
15. PijlsNH,vanSchaardenburghP,ManoharanG,BoersmaE,BechJW,van’tVeer . FearonWF.Fractionalflowreserveassessmentofleftmainstenosisinthe
.
M,BarF,HoorntjeJ,KoolenJ,WijnsW,deBruyneB.Percutaneouscoronary .. presence of downstream coronary stenoses. Circ Cardiovasc Interv 2013;6:
intervention of functionally nonsignificant stenosis: 5-year follow-up of the .. 161–165.
.
DEFERStudy.JAmCollCardiol2007;49:2105–2111. . 28. TothG,DeBruyneB,CasselmanF,DeVroeyF,PyxarasS,DiSerafinoL,Van
.
16. AdjedjJ,DeBruyneB,FloreV,DiGioiaG,FerraraA,PellicanoM,TothGG, .. PraetF,VanMieghemC,StockmanB,WijnsW,DegrieckI,BarbatoE.Fractional
BartunekJ,VanderheydenM,HeyndrickxGR,WijnsW,BarbatoE.Significance .. flowreserve-guidedversusangiography-guidedcoronaryarterybypassgraftsur-
.
ofintermediatevaluesoffractionalflowreserveinpatientswithcoronaryartery . gery.Circulation2013;128:1405–1411.
.
disease.Circulation2016;133:502–508. . 29. ToninoPA,DeBruyneB,PijlsNH,SiebertU,IkenoF,van’tVeerM,Klauss
.
17. DaviesJE,SenS,DehbiHM,Al-LameeR,PetracoR,NijjerSS,BhindiR,Lehman .. V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA,
SJ,WaltersD,SapontisJ,JanssensL,VrintsCJ,KhashabaA,LaineM,VanBelleE, .. FearonWF;FAMEStudyInvestigators.Fractionalflowreserveversusangiog-
.
Krackhardt F, Bojara W, Going O, Harle T, Indolfi C, Niccoli G, Ribichini F, . raphy for guiding percutaneous coronary intervention. N Engl J Med 2009;
.
TanakaN,YokoiH,TakashimaH,KikutaY,ErglisA,VinhasH,CanasSilvaP, . 360:213–224.
.
BaptistaSB,AlghamdiA,HelligF,KooBK,NamCW,ShinES,DohJH,Brugaletta .. 30. PijlsNH,FearonWF,ToninoPA,SiebertU,IkenoF,BornscheinB,van’tVeerM,
.
S,Alegria-BarreroE,MeuwissenM,PiekJJ,vanRoyenN,SezerM,DiMarioC, . KlaussV,ManoharanG,EngstromT,OldroydKG,VerLeePN,MacCarthyPA,
.
GerberRT,MalikIS,SharpASP,TalwarS,TangK,SamadyH,AltmanJ,SetoAH, . DeBruyneB;FAMEStudyInvestigators.Fractionalflowreserveversusangiogra-
.
SinghJ,JeremiasA,MatsuoH,KharbandaRK,PatelMR,SerruysP,EscanedJ. .. phyforguidingpercutaneouscoronaryinterventioninpatientswithmultivessel
Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N .. coronaryarterydisease:2-yearfollow-upoftheFAME(FractionalFlowReserve
.
EnglJMed2017;376:1824–1834. . Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol
. 18. Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, . 2010;56:177–184.
.
JakobsenL,OlssonSE,OhagenP,OlssonH,OmerovicE,CalaisF,LindroosP, .. 31. vanNunenLX,ZimmermannFM,ToninoPA,BarbatoE,BaumbachA,Engstrom
MaengM,TodtT,VenetsanosD,JamesSK,KaregrenA,NilssonM,CarlssonJ, .. T,KlaussV,MacCarthyPA,ManoharanG,OldroydKG,VerLeePN,Van’tVeer
.
Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Frobert O, iFR- . M,FearonWF,DeBruyneB,PijlsNH;FAMEstudyInvestigators.Fractionalflow
.
SWEDEHEART Investigators. Instantaneous wave-free ratio versus fractional .. reserveversusangiographyforguidanceofPCIinpatientswithmultivesselcoro-
flowreservetoguidePCI.NEnglJMed2017;376:1813–1823. .. naryarterydisease(FAME):5-yearfollow-upofarandomisedcontrolledtrial.
.
19. VanBelleE,RioufolG,PouillotC,CuissetT,BougriniK,TeigerE,ChampagneS, . Lancet2015;386:1853–1860.
.
BelleL,BarreauD,HanssenM,BesnardC,DauphinR,DallongevilleJ,ElHahiY, . 32. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N,
.
SiderisG,BretelleC,LhoestN,BarnayP,LeborgneL,DupouyP,Investigatorsof .. Mobius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T,
theRegistreFrancaisdelaFFR–R3F.Outcomeimpactofcoronaryrevasculariza- .. Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N,
.
tion strategy reclassification with fractional flow reserve at time of diagnostic . Johnson JB, Juni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow
.
angiography: Insights from a large French multicenter fractional flow reserve . reserve-guidedPCIversusmedicaltherapyinstablecoronarydisease.NEnglJ
.
registry.Circulation2014;129:173–185. .. Med2012;367:991–1001.
20. CurzenN,RanaO,NicholasZ,GolledgeP,ZamanA,OldroydK,HanrattyC, .. 33. FearonWF,NishiT,DeBruyneB,BoothroydDB,BarbatoE,ToninoP,JuniP,
.
BanningA,WheatcroftS,HobsonA,ChitkaraK,Hildick-SmithD,McKenzieD, . PijlsNHJ,Hlatky MA; FAME2TrialInvestigators.Clinical outcomesandcost-
.
CalverA,DimitrovBD,CorbettS.Doesroutinepressurewireassessmentinflu- .. effectivenessoffractionalflowreserve-guidedpercutaneouscoronaryinterven-
encemanagementstrategyatcoronaryangiographyfordiagnosisofchestpain?: .. tioninpatientswithstablecoronaryarterydisease:Three-yearfollow-upofthe
.
theRIPCORDstudy.CircCardiovascInterv2014;7:248–255. . FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel
.
21. BaptistaSB,RaposoL,SantosL,RamosR,CaleR,JorgeE,MachadoC,CostaM, . Evaluation).Circulation2018;137:480–487.
.
InfantedeOliveiraE,CostaJ,PipaJ,FonsecaN,GuardadoJ,SilvaB,SousaMJ, .. 34. EscanedJ,ColletC,RyanN,DeMariaGL,WalshS,SabateM,DaviesJ,Lesiak
Silva JC, Rodrigues A, Seca L, Fernandes R. Impact of routine fractional flow .. M, Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West N, Piek JJ, Zaman A,
.
reserve evaluation during coronary angiography on management strategy and . Fath-OrdoubadiF,StablesRH,ApplebyC,vanMieghemN,vanGeunsRJ,Uren
.
clinical outcome: One-year results of the POST-IT. Circ Cardiovasc Interv .. N,ZuecoJ,BuszmanP,IniguezA,GoicoleaJ,Hildick-SmithD,OchalaA,Dudek
2016;9:e003288. .. D,HanrattyC,CavalcanteR,KappeteinAP,TaggartDP,vanEsGA,MorelMA,
.
22. VanBelleE,BaptistaSB,RaposoL,HendersonJ,RioufolG,SantosL,PouillotC, . deVriesT,OnumaY,FarooqV,SerruysPW,BanningAP.Clinicaloutcomesof
.
RamosR,CuissetT,CaleR,TeigerE,JorgeE,BelleL,MachadoC,BarreauD,Costa . state-of-the-art percutaneous coronary revascularization in patients with de
.
M, Hanssen M, Oliveira E, Besnard C, Costa J, Dallongeville J, Pipa J, Sideris G, .. novothreevesseldisease:1-yearresultsoftheSYNTAXIIstudy.EurHeart J
FonsecaN,BretelleC,GuardadoJ,LhoestN,SilvaB,BarnayP,SousaMJ,Leborgne .. 2017;38:3124–3134.
.
L,SilvaJC,VincentF,RodriguesA,SecaL,FernandesR,DupouyP,PRIMER-FFR . 34a.Waksman R, Legutko J, Singh J, Orlando Q, Marso S, Schloss T, Tugaoen J, .
StudyGroup.ImpactofRoutineFractionalFlowReserveonManagementDecision . DeVriesJ,PalmerN,HaudeM,SwymelarS,TorgusonR.FIRST:FractionalFlow
.
and1-YearClinicalOutcomeofPatientsWithAcuteCoronarySyndromes:PRIME- .. Reserve and Intravascular Ultrasound Relationship Study. J Am Coll Cardiol
FFR(InsightsFromthePOST-IT[PortugueseStudyontheEvaluationofFFR-Guided .. 2013;61:917–923.
.
Treatment of Coronary Disease] and R3F [French FFR Registry] Integrated . 35. ParkSJ,KimYH,ParkDW,LeeSW,KimWJ,SuhJ,YunSC,LeeCW,HongMK,
.
MulticenterRegistries-ImplementationofFFR[FractionalFlowReserve]inRoutine .. LeeJH,ParkSW;MAIN-COMPAREInvestigators.Impactofintravascularultra-
Practice).CircCardiovascInterv2017;10:e004296. .. soundguidanceonlong-termmortalityinstentingforunprotectedleftmaincor-
.
23. VanBelleE,DupouyP,RioufolG.Routinefractionalflowreservecombinedto . onaryarterystenosis.CircCardiovascInterv2009;2:167–177.
.
diagnostic coronary angiography as a one-stop procedure: Episode 3. Circ . 36. Fassa AA, Wagatsuma K, Higano ST, Mathew V, Barsness GW, Lennon RJ,
.
CardiovascInterv2016;9:e004137. .. HolmesDRJr,LermanA.Intravascularultrasound-guidedtreatmentforangio-
24. JohnsonNP,TothGG,LaiD,ZhuH,AcarG,AgostoniP,AppelmanY,Arslan .. graphicallyindeterminateleftmaincoronaryarterydisease:Along-termfollow-
.
F,BarbatoE,ChenSL,DiSerafinoL,Dominguez-FrancoAJ,DupouyP,Esen . upstudy.JAmCollCardiol2005;45:204–211.
.
AM,EsenOB,HamilosM,IwasakiK,JensenLO,Jimenez-NavarroMF,Katritsis . 37. delaTorreHernandezJM,HernandezHernandezF,AlfonsoF,Rumoroso
.
DG,KocamanSA,KooBK,Lopez-PalopR,LorinJD,MillerLH,MullerO,Nam .. JR,Lopez-PalopR,SadabaM,CarrilloP,RondanJ,LozanoI,RuizNodarJM,
.
CW, Oud N, Puymirat E, Rieber J, Rioufol G, Rodes-Cabau J, Sedlis SP, . Baz JA, Fernandez Nofrerias E, Pajin F, Garcia Camarero T, Gutierrez H,
.
Takeishi Y, Tonino PA, Van Belle E, Verna E, Werner GS, Fearon WF, Pijls . LITRO Study Group. Prospective application of pre-defined intravascular
.
NH, De Bruyne B, Gould KL. Prognostic value of fractional flow reserve: .. ultrasoundcriteriaforassessmentofintermediateleftmaincoronaryartery
Linking physiologic severity to clinical outcomes. J Am Coll Cardiol 2014; .. lesions results from the multicenter LITRO study. J Am Coll Cardiol 2011;
.
64:1641–1654. . 58:351–358.
.
25. MallidiJ,AtreyaAR,CookJ,GarbJ,JeremiasA,KleinLW,LotfiA.Long-term . 38. ParkSJ,AhnJM,KangSJ,YoonSH,KooBK,LeeJY,KimWJ,ParkDW,LeeSW,
.
outcomesfollowingfractionalflowreserve-guidedtreatmentofangiographically .. Kim YH, Lee CW, Park SW. Intravascular ultrasound-derived minimal lumen
ambiguous left main coronary artery disease: A meta-analysis of prospective .. areacriteriaforfunctionallysignificantleftmaincoronaryarterystenosis.JACC
.
cohortstudies.CatheterCardiovascInterv2015;86:12–18. CardiovascInterv2014;7:868–874.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 73 ---
ESC/EACTSGuidelines 159
.
39. PijlsNH,DeBruyneB,PeelsK,VanDerVoortPH,BonnierHJ,BartunekJKJJ, .. 56. HannanEL,SamadashviliZ,WalfordG,HolmesDR,JacobsA,SharmaS,KatzS,
.
Koolen JJ. Measurement of fractional flow reserve to assess the functional . KingSBIII.Predictorsandoutcomesofadhocversusnon-adhocpercutaneous
.
severityofcoronary-arterystenoses.NEnglJMed1996;334:1703–1708. . coronaryinterventions.JACCCardiovascInterv2009;2:350–356.
.
40. AytonDR,BarkerAL,PeetersG,BerkovicDE,LefkovitsJ,BrennanA,EvansS, .. 57. RITA-2TrialParticipantsCoronaryangioplastyversusmedicaltherapyforangina:
ZalcbergJ,ReidC,StoelwinderJJ,McNeilJ.Exploringpatient-reportedoutcomes .. ThesecondRandomisedInterventionTreatmentofAngina(RITA-2)trial.RITA-
.
followingpercutaneouscoronaryintervention:Aqualitativestudy.HealthExpect . 2trialparticipants.Lancet1997;350:461–468.
.
2018;21:457–465. . 58. TIME Investigators. Trial of invasive versus medical therapy in elderly patients
.
41. MylesPS.Meaningfuloutcomemeasuresincardiacsurgery.JExtraCorporTechnol .. with chronicsymptomaticcoronary-arterydisease(TIME): Arandomised trial.
2014;46:23–27. .. Lancet2001;358:951–957.
.
42. PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,Cooney . 59. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ,
.
MT,CorraU,CosynsB,DeatonC,GrahamI,HallMS,HobbsFDR,LochenML, .. KnudtsonM,DadaM,CaspersonP,HarrisCL,ChaitmanBR,ShawL,Gosselin
Lollgen H, Marques-Vidal P,Perk J,Prescott E, Redon J, Richter DJ,Sattar N, .. G,NawazS,TitleLM,GauG,BlausteinAS,BoothDC,BatesER,SpertusJA,
.
SmuldersY,TiberiM,vanderWorpHB,vanDisI,VerschurenWMM,BinnoS; . Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group.
.
Scientific Document ESC Group. 2016 European Guidelines on cardiovascular . OptimalmedicaltherapywithorwithoutPCIforstablecoronarydisease.NEngl
.
disease prevention in clinical practice: The Sixth Joint Task Force of the .. JMed2007;356:1503–1516.
EuropeanSocietyofCardiologyandOtherSocietiesonCardiovascularDisease .. 60. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT,
.
PreventioninClinicalPractice(constitutedbyrepresentativesof10societiesand . DubachP,ResinkTJ,PfistererM.Effectsofpercutaneouscoronaryinterventions
.
by invited experts)Developed with the special contribution of the European . in silent ischemia after myocardial infarction: The SWISSI II randomized con-
.
AssociationforCardiovascularPrevention&Rehabilitation(EACPR).EurHeartJ .. trolledtrial.JAMA2007;297:1985–1991.
.
2016;37:2315–2381. . 61. BARIStudyGroup2D,FryeRL,AugustP,BrooksMM,HardisonRM,KelseySF,
.
43. HeadSJ,KaulS,MackMJ,SerruysPW,TaggartDP,HolmesDRJr,LeonMB, . MacGregorJM,OrchardTJ,ChaitmanBR,GenuthSM,GoldbergSH,HlatkyMA,
.
MarcoJ,BogersAJ,KappeteinAP.TherationaleforHeartTeamdecision-making .. Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of
for patients with stable, complex coronary artery disease. Eur Heart J .. therapies for type 2 diabetes and coronary artery disease. N Engl J Med
.
2013;34:2510–2518. . 2009;360:2503–2515.
. 44. FilardoG,MaggioniAP,MuraG,ValagussaF,ValagussaL,SchweigerC,Ballard . 62. HuebW,LopesN,GershBJ,SoaresPR,RibeiroEE,PereiraAC,FavaratoD,
.
DJ, Liberati A. The consequences of under-use of coronary revascularization; .. RochaAS,HuebAC,RamiresJA.Ten-yearfollow-upsurvivaloftheMedicine,
ResultsofacohortstudyinNorthernItaly.EurHeartJ2001;22:654–662. .. Angioplasty,orSurgeryStudy(MASSII):Arandomizedcontrolledclinicaltrialof
.
45. YatesMT,Soppa GK,ValenciaO,JonesS,FirooziS,JahangiriM.Impactof . 3 therapeutic strategies for multivessel coronary artery disease. Circulation
.
European Society of Cardiology and European Association for .. 2010;122:949–957.
Cardiothoracic Surgery Guidelines on Myocardial Revascularization on the .. 63. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T,
.
activity of percutaneous coronary intervention and coronary artery bypass . MielewczikM,KaprielianR,MalikIS,NijjerSS,PetracoR,CookC,AhmadY,
.
graft surgery for stable coronary artery disease. J Thorac Cardiovasc Surg . HowardJ,BakerC,SharpA,GerberR,TalwarS,AssomullR,MayetJ,Wensel
.
2014;147:606–610. .. R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP, ORBITA
46. OrganisationforEconomicCo-operationandDevelopment.Healthataglance. .. Investigators.Percutaneouscoronaryinterventioninstableangina(ORBITA):A
.
http://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm . double-blind,randomisedcontrolledtrial.Lancet2018;391:31–40.
.
accessedJuly21,2018. . 64. Chaitman BR, Mori Brooks M, Fox K, Luscher TF. ORBITA revisited: what it
.
47. BradleySM,BohnCM,MalenkaDJ,GrahamMM,BrysonCL,McCabeJM,Curtis .. reallymeansandwhatitdoesnot?EurHeartJ2018;39:963–965.
JP,Lambert-KerznerA,MaynardC.Temporaltrendsinpercutaneouscoronary .. 65. Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-
.
intervention appropriateness: Insights from the clinical outcomes assessment . Yehuda O, van Es GA, Taggart DP, Morice MC, Lembo NJ, Brown WM III,
.
program.Circulation2015;132:20–26. .. Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW,
48. HannanEL,SamadashviliZ,CozzensK,GestenF,OsinagaA,FishDG,Donahue .. CohenDJ,EXCELInvestigators.Quality-of-lifeaftereverolimus-elutingstentsor
.
CL,BassRJ,WalfordG,JacobsAK,VendittiFJ,StamatoNJ,BergerPB,SharmaS, . bypass surgery for left-main disease: Results from the EXCEL trial. J Am Coll
.
KingSBIII.Changesinpercutaneouscoronaryinterventionsdeemed"inappropri- . Cardiol2017;70:3113–3122.
.
ate"byappropriateusecriteria.JAmCollCardiol2017;69:1234–1242. .. 66. Abdallah MS, Wang K, Magnuson EA, Osnabrugge RL, Kappetein AP, Morice
49. DenvirMA,PellJP,LeeAJ,RysdaleJ,PrescottRJ,EteibaH,WalkerA,MankadP, .. MC,MohrFA,SerruysPW,CohenDJ,SYNTAXTrialInvestigators.Qualityof
.
StarkeyIR.Variationsinclinicaldecision-makingbetweencardiologistsandcar- . lifeaftersurgeryorDESinpatientswith3-vesselorleftmaindisease.JAmColl
.
diacsurgeons;Acaseformanagementbymultidisciplinaryteams?JCardiothorac .. Cardiol2017;69:2039–2050.
Surg2006;1:2. .. 67. AbdallahMS,WangK,MagnusonEA,SpertusJA,FarkouhME,FusterV,Cohen
.
50. PavlidisAN,PereraD,KaramasisGV,BapatV,YoungC,ClappBR,BlauthC, . DJ; FREEDOM Trial Investigators. Quality of life after PCI vs CABG among
.
Roxburgh J, Thomas MR, Redwood SR. Implementation and consistency of . patients with diabetes and multivessel coronary artery disease: A randomized
.
HeartTeamdecision-makingincomplexcoronaryrevascularisation.IntJCardiol .. clinicaltrial.JAMA2013;310:1581–1590.
2016;206:37–41. .. 68. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K,
.
51. SanchezCE,DotaA,BadhwarV,KlinerD,SmithAJ,ChuD,TomaC,WeiL, . KillipT,PassamaniE,NorrisR,etal.Effectofcoronaryarterybypassgraft .
MarroquinOC,SchindlerJ,LeeJS,MulukutlaSR.Revascularizationheartteam . surgery on survival: Overview of 10-year results from randomised trials by
.
recommendationsasanadjuncttoappropriateusecriteriaforcoronaryrevascu- .. the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet
larizationinpatientswithcomplexcoronaryarterydisease.CatheterCardiovasc .. 1994;344:563–570.
.
Interv2016;88:E103–E112. . 69. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL, American College of
.
52. SobolevBG,FradetG,KuramotoL,RogulaB.Theoccurrenceofadverseevents .. Cardiology Foundation/American Heart Association Task Force on Practice
in relation to time after registration for coronary artery bypass surgery: A .. Guidelines.Bayesianmethodsaffirmtheuseofpercutaneouscoronaryinterven-
.
population-basedobservationalstudy.JCardiothoracSurg2013;8:74. . tiontoimprovesurvivalinpatientswithunprotectedleftmaincoronaryartery
.
53. Head SJ, da CostaBR,Beumer B, StefaniniGG,Alfonso F, Clemmensen PM, . disease.Circulation2013;127:2177–2185.
.
ColletJP,CremerJ,FalkV,FilippatosG,HammC,KappeteinAP,KastratiA, .. 70. DzavikV,GhaliWA,NorrisC,MitchellLB,KoshalA,SaundersLD,Galbraith
KnuutiJ,KolhP,LandmesserU,LauferG,NeumannFJ,RichterDJ,SchauerteP, .. PD,HuiW,Faris P,KnudtsonML,AlbertaforProvincialProject inOutcome
.
Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Windecker S, . AssessmentCoronaryHeartDiseaseInvestigators.Long-termsurvivalin11,661
.
JuniP, Sousa-Uva M. Adverse eventswhile awaitingmyocardial revasculariza- . patientswithmultivesselcoronaryarterydiseaseintheeraofstenting:Areport
.
tion: A systematic review and meta-analysis. Eur J Cardiothorac Surg 2017;52: .. fromtheAlbertaProvincialProjectforOutcomeAssessmentinCoronaryHeart
.
206–217. . Disease(APPROACH)Investigators.AmHeartJ2001;142:119–126.
.
54. Graham MM, Knudtson ML, O’Neill BJ, Ross DB, Canadian Cardiovascular . 71. LeePH,AhnJM,ChangM,BaekS,YoonSH,KangSJ,LeeSW,KimYH,Lee
.
SocietyAccesstoCareWorkingGroup.Treatingtherightpatientattheright .. CW, Park SW, Park DW, Park SJ. Left main coronary artery disease: Secular
time:Accesstocardiaccatheterization,percutaneouscoronaryinterventionand .. trends in patient characteristics, treatments, and outcomes. J Am Coll Cardiol
.
cardiacsurgery.CanJCardiol2006;22:679–683. . 2016;68:1233–1246.
.
55. TruffaMA,AlvesGM,BernardiF,EstevesFilhoA,RibeiroE,GalonMZ,Spadaro . 72. SmithPK,CaliffRM,TuttleRH,ShawLK,LeeKL,DelongER,LillyRE,Sketch
.
A,Kajita LJ, ArrietaR,LemosPA. Doesadhoccoronary intervention reduce .. MHJr,PetersonED,JonesRH.Selectionofsurgicalorpercutaneouscoronary
radiation exposure? - Analysis of 568 patients. Arq Bras Cardiol 2015; .. intervention provides differential longevity benefit. Ann Thorac Surg 2006;82:
.
105:487–492. 1420–1428;discussion1428–1429.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 74 ---
160 ESC/EACTSGuidelines
.
.
73. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, . withstablecoronaryheartdiseaseandobjectiveevidenceofmyocardialische-
.
CarlsonRE,JonesRH.Drug-elutingstentsvs.coronary-arterybypassgraftingin . mia.AmJCardiol2015;115:1194–1199.
.
multivesselcoronarydisease.NEnglJMed2008;358:331–341. .. 89. StergiopoulosK,BodenWE,HartiganP,Mobius-WinklerS,HambrechtR,Hueb
74. HannanEL,SamadashviliZ,CozzensK,WalfordG,JacobsAK,HolmesDRJr, .. W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention
.
StamatoNJ,GoldJP,SharmaS,VendittiFJ,PowellT,KingSBIII.Comparative . outcomesinpatientswithstableobstructivecoronaryarterydiseaseandmyo-
.
outcomes for patients who do and do not undergo percutaneous coronary .. cardialischemia:Acollaborativemeta-analysisofcontemporaryrandomizedclin-
intervention for stable coronary artery disease in New York. Circulation .. icaltrials.JAMAInternMed2014;174:232–240.
.
2012;125:1870–1879. . 90. NishigakiK,YamazakiT,KitabatakeA,YamaguchiT,KanmatsuseK,KodamaI,
.
75. CaraccioloEA,DavisKB,SopkoG,KaiserGC,CorleySD,SchaffH,TaylorHA, . TakekoshiN,TomoikeH,HoriM,MatsuzakiM,TakeshitaA,ShimboT,Fujiwara
.
ChaitmanBR.Comparisonofsurgicalandmedicalgroupsurvivalinpatientswith .. H;JapaneseStableAnginaPectorisStudyInvestigators.Percutaneouscoronary
left main equivalent coronary artery disease. Long-term CASS experience. .. interventionplusmedicaltherapyreducestheincidenceofacutecoronarysyn-
.
Circulation1995;91:2335–2344. . drome more effectively than initial medical therapy only among patients with
.
76. ChaitmanBR,HardisonRM,AdlerD,GebhartS,GroganM,OcampoS,Sopko . low-riskcoronaryarterydiseasearandomized,comparative,multicenterstudy.
.
G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization .. JACCCardiovascInterv2008;1:469–479.
.
Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization . 91. KatritsisDG,IoannidisJP.Percutaneouscoronaryinterventionversusconserva-
.
Investigation2Diabetesrandomizedtrialofdifferenttreatmentstrategiesintype . tive therapy in nonacute coronary artery disease: A meta-analysis. Circulation
.
2diabetesmellituswithstableischemicheartdisease:Impactoftreatmentstrat- .. 2005;111:2906–2912.
egy on cardiac mortality and myocardial infarction. Circulation .. 92.SchomigA,MehilliJ,deWahaA,SeyfarthM,PacheJ,KastratiA.Ameta-analysisof
.
2009;120:2529–2540. . 17 randomized trials of a percutaneous coronary intervention-based strategy in
.
77. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary . patientswithstablecoronaryarterydisease.JAmCollCardiol2008;52:894–904.
.
arterybypasssurgery.Survivalofpatientswithalowejectionfraction.NEnglJ .. 93. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM.
Med1985;312:1665–1671. .. Percutaneouscoronaryinterventionsfornon-acutecoronaryarterydisease:A
.
78. VelazquezEJ,LeeKL,DejaMA,JainA,SopkoG,MarchenkoA,AliIS,PohostG, . quantitative 20-year synopsis and a network meta-analysis. Lancet
.
Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie .. 2009;373:911–918.
MC,O’ConnorCM,PanchavinninP,SheL,BonowRO,RankinGR,JonesRH, .. 94. BangaloreS,PursnaniS,KumarS,BagosPG.Percutaneouscoronaryintervention
.
RouleauJL;STICHInvestigators.Coronary-arterybypasssurgeryinpatientswith . versusoptimalmedicaltherapyforpreventionofspontaneousmyocardialinfarc-
.
leftventriculardysfunction.NEnglJMed2011;364:1607–1616. . tioninsubjectswithstableischemicheartdisease.Circulation2013;127:769–781.
.
79. JonesRH,KeslerK,PhillipsHRIII,MarkDB,SmithPK,NelsonCL,NewmanMF, .. 95. PursnaniS,KorleyF,GopaulR,KanadeP,ChandraN,ShawRE,BangaloreS.
Reves JG, Anderson RW, Califf RM. Long-term survival benefits of coronary .. Percutaneous coronary intervention versus optimal medical therapy in stable
.
arterybypassgraftingandpercutaneoustransluminalangioplastyinpatientswith . coronaryarterydisease:Asystematicreviewandmeta-analysisofrandomized
.
coronaryarterydisease.JThoracCardiovascSurg1996;111:1013–1025. . clinicaltrials.CircCardiovascInterv2012;5:476–490.
.
80. BakerDW,JonesR,HodgesJ,MassieBM,KonstamMA,RoseEA.Management .. 96. ThomasS,GokhaleR,BodenWE,DevereauxPJ.Ameta-analysisofrandomized
.
ofheartfailure.III.Theroleofrevascularizationinthetreatmentofpatientswith . controlled trials comparing percutaneous coronary intervention with medical
.
moderate or severe left ventricular systolic dysfunction. JAMA . therapyinstableanginapectoris.CanJCardiol2013;29:472–482.
.
1994;272:1528–1534. .. 97. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N,
81. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, .. Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T,
.
BonowRO,DoenstT,PetrieMC,OhJK,SheL,MooreVL,Desvigne-NickensP, . Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N,
.
SopkoG,RouleauJL;STICHESInvestigators.Coronary-arterybypasssurgeryin . JohnsonJB,LimacherA,NueschE,JuniP; FAME-2TrialInvestigators.Fractional
.
patientswithischemiccardiomyopathy.NEnglJMed2016;374:1511–1520. .. flow reserve-guided PCI for stable coronary artery disease. N Engl J Med
82. PanzaJA,VelazquezEJ,SheL,SmithPK,NicolauJC,FavaloroRR,GradinacS, .. 2014;371:1208–1217.
.
Chrzanowski L, Prabhakaran D, Howlett JG, Jasinski M, Hill JA, Szwed H, . 98. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal
.
LarbalestierR,Desvigne-NickensP,JonesRH,LeeKL,RouleauJL.Extentofcor- .. coronaryangioplastyversusmedicaltreatmentfornon-acutecoronaryheartdis-
onaryandmyocardialdiseaseandbenefitfromsurgicalrevascularizationinische- .. ease:Meta-analysisofrandomisedcontrolledtrials.BMJ2000;321:73–77.
.
micLVdysfunction[Corrected].JAmCollCardiol2014;64:553–561. . 99. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical
.
83. PetrieMC,JhundPS,SheL,AdlbrechtC,DoenstT,PanzaJA,HillJA,LeeKL, . therapyvsmedicaltherapyaloneforstablecoronaryarterydisease:Meta-analy-
.
Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, .. sisofrandomizedcontrolledtrials.ArchInternMed2012;172:312–319.
ChrzanowskiL,RomanovA,MillerAB,VelazquezEJ,STICHTrialInvestigators. .. 100.WindeckerS,StorteckyS,StefaniniGG,daCostaBR,RutjesAW,DiNisioM,
.
Ten-year outcomes after coronary artery bypass grafting according to age in . SillettaMG,MaioneA,AlfonsoF,ClemmensenPM,ColletJP,CremerJ,FalkV, .
patientswithheartfailureandleftventricularsystolicdysfunction:Ananalysisof . FilippatosG,HammC,HeadS,KappeteinAP,KastratiA,KnuutiJ,Landmesser
. the extended follow-up of the STICH trial (Surgical Treatment for Ischemic .. U,LauferG,NeumannFJ,RichterD,SchauerteP,SousaUvaM,TaggartDP,
HeartFailure).Circulation2016;134:1314–1324. .. Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Juni P.
.
84. HachamovitchR,RozanskiA,ShawLJ,StoneGW,ThomsonLE,FriedmanJD, . Revascularisation versus medical treatment in patients with stable coronary
.
HayesSW,CohenI,GermanoG,BermanDS.Impactofischaemiaandscaron .. arterydisease:Networkmeta-analysis.BMJ2014;348:g3859.
the therapeutic benefit derived from myocardial revascularization vs. medical .. 101.JeremiasA,KaulS,RosengartTK,GrubergL,BrownDL.Theimpactofrevas-
.
therapyamongpatientsundergoingstress-restmyocardialperfusionscintigraphy. . cularizationonmortalityinpatientswithnonacutecoronaryarterydisease.Am
.
EurHeartJ2011;32:1012–1024. . JMed2009;122:152–161.
.
85. DaviesRF,GoldbergAD,FormanS,PepineCJ,KnatterudGL,GellerN,Sopko .. 102.Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ,
G,PrattC,DeanfieldJ,ContiCR.AsymptomaticCardiacIschemiaPilot(ACIP) .. Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K,
.
studytwo-yearfollow-up:Outcomesofpatientsrandomizedtoinitialstrategies . DawkinsKD,MohrFW;SYNTAXInvestigatorsS.Percutaneouscoronaryinter-
.
ofmedicaltherapyversusrevascularization.Circulation1997;95:2037–2043. .. ventionversuscoronary-arterybypassgraftingforseverecoronaryarterydis-
86. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, .. ease.NEnglJMed2009;360:961–972.
.
WeintraubWS,O’RourkeRA,DadaM,SpertusJA,ChaitmanBR,FriedmanJ, . 103.BoudriotE,ThieleH,WaltherT,LiebetrauC,BoeckstegersP,PohlT,Reichart
.
SlomkaP,HellerGV,GermanoG,GosselinG,BergerP,KostukWJ,Schwartz . B, Mudra H, Beier F, Gansera B, Neumann FJ, Gick M, Zietak T, Desch S,
.
RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; .. SchulerG,MohrFW.Randomizedcomparisonofpercutaneouscoronaryinter-
COURAGEInvestigators.Optimalmedicaltherapywithorwithoutpercutane- .. ventionwithsirolimus-elutingstentsversuscoronaryarterybypassgraftingin
.
ouscoronaryinterventiontoreduceischemicburden:ResultsfromtheClinical . unprotectedleftmainstemstenosis.JAmCollCardiol2011;57:538–545.
.
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation . 104.ParkSJ,KimYH,ParkDW,YunSC,AhnJM,SongHG,LeeJY,KimWJ,KangSJ,
.
(COURAGE)trialnuclearsubstudy.Circulation2008;117(10):1283–1291. .. LeeSW,LeeCW,ParkSW,ChungCH,LeeJW,LimDS,RhaSW,LeeSG,
87. HachamovitchR,HayesSW,FriedmanJD,CohenI,BermanDS.Comparisonof .. GwonHC,KimHS,ChaeIH,JangY,JeongMH,TahkSJ,SeungKB.Randomized
.
theshort-termsurvivalbenefitassociatedwithrevascularizationcomparedwith . trialof stents versus bypasssurgery forleftmaincoronaryartery disease. N
.
medical therapy in patients with no prior coronary artery disease undergoing .. EnglJMed2011;364:1718–1727.
stress myocardial perfusion single photon emission computed tomography. .. 105.ParkSJ,AhnJM,KimYH,ParkDW,YunSC,LeeJY,KangSJ,LeeSW,LeeCW,
.
Circulation2003;107:2900–2907. . ParkSW,ChooSJ,ChungCH,LeeJW,CohenDJ,YeungAC,HurSH,Seung
.
88. GadaH,KirtaneAJ,KereiakesDJ,BangaloreS,MosesJW,GenereuxP,Mehran . KB,AhnTH,KwonHM,LimDS,RhaSW,JeongMH,LeeBK,TresukosolD,Fu
.
R,DangasGD,LeonMB,StoneGW.Meta-analysisoftrialsonmortalityafter .. GS, Ong TK; BEST Trial Investigators. Trial of everolimus-eluting stents or
percutaneouscoronaryinterventioncomparedwithmedicaltherapyinpatients . bypasssurgeryforcoronarydisease.NEnglJMed2015;372:1204–1212.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 75 ---
ESC/EACTSGuidelines 161
.
.
106. MakikallioT,HolmNR,LindsayM,SpenceMS,ErglisA,MenownIB,TrovikT, . PW.Coronaryarterybypassgraftsurgeryversuspercutaneouscoronaryinter-
.
Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, . ventioninpatientswiththree-vesseldiseaseandleftmaincoronarydisease:5-
.
LinderRB,PentikainenM,HervoldA,BanningA,ZamanA,CottonJ,EriksenE, .. year follow-up of the randomised, clinical SYNTAX trial. Lancet
MargusS,SorensenHT,NielsenPH,NiemelaM,KervinenK,LassenJF,Maeng .. 2013;381:629–638.
.
M,OldroydK,BergG,WalshSJ,HanrattyCG,KumsarsI,StradinsP,Steigen . 122.Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A,
.
TK,FrobertO,GrahamAN,EndresenPC,CorbascioM,KajanderO,Trivedi .. MackMJ,HolmesDR,ChoiJW,RuzylloW,ReligaG,HuangJ,RoyK,Dawkins
U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; .. KD,MohrF.Five-yearoutcomesinpatientswithleftmaindiseasetreatedwith
.
NOBLE Study Investigators. Percutaneous coronary angioplasty versus coro- . eitherpercutaneouscoronaryinterventionorcoronaryarterybypassgrafting
.
nary artery bypass grafting in treatment of unprotected left main stenosis . inthesynergybetweenpercutaneouscoronaryinterventionwithtaxusandcar-
.
(NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet .. diacsurgerytrial.Circulation2014;129:2388–2394.
2016;388:2743–2752. .. 123.Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ,
.
107. StoneGW,SabikJF,SerruysPW,SimontonCA,GenereuxP,PuskasJ,Kandzari . MoriceMC,HolmesDRJr,FeldmanTE,StahleE,UnderwoodP,DawkinsKD,
.
DE,MoriceMC,LemboN,BrownWMIII,TaggartDP,BanningA,MerkelyB, . KappeteinAP,MohrFW.Coronaryarterybypassgraftingvs.percutaneouscor-
.
HorkayF,BoonstraPW,vanBovenAJ,UngiI,BogatsG,MansourS,Noiseux .. onaryinterventionforpatientswiththree-vesseldisease:Finalfive-yearfollow-
.
N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, . upoftheSYNTAXtrial.EurHeartJ2014;35:2821–2830.
.
SchampaertE,PageP,DresslerO,KosmidouI,MehranR,PocockSJ,Kappetein . 124.Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH,
.
AP;EXCELTrialInvestigators.Everolimus-elutingstentsorbypasssurgeryfor .. DomanskiMJ,FarkouhME,FlatherM,FusterV,HlatkyMA,HolmNR,Hueb
leftmaincoronaryarterydisease.NEnglJMed2016;375:2223–2235. .. WA,KamaleshM,KimYH,MakikallioT,MohrFW,PapageorgiouG,ParkSJ,
.
108. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, . RodriguezAE,SabikJFIII,StablesRH,StoneGW,SerruysPW,KappeteinAP.
.
LockowandtU.EuroSCOREII.EurJCardiothoracSurg2012;41:734–744;discus- . Mortalityaftercoronaryarterybypassgraftingversuspercutaneouscoronary
.
sion744–745. .. interventionwithstentingforcoronaryarterydisease:Apooledanalysisofindi-
109. ShahianDM,O’BrienSM,FilardoG,FerrarisVA,HaanCK,RichJB,Normand .. vidualpatientdata.Lancet2018;391:939–948.
.
SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, . 125.Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD,
.
AndersonRP,SocietyofThoracicSurgeonsQualityMeasurementTaskForce. .. Banning AP, Escaned J, de Vries T, Morel MA, Farooq V, Onuma Y, Garcia-
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part .. Garcia HM, Stone GW, Steyerberg EW, Mohr FW, Serruys PW. Prognostic
.
1–coronaryarterybypassgraftingsurgery.AnnThoracSurg2009;88:S2–S22. . valueofsiteSYNTAXscoreandrationaleforcombininganatomicandclinical
.
110. ShahianDM,O’BrienSM,FilardoG,FerrarisVA,HaanCK,RichJB,Normand . factors in decision making: Insights from the SYNTAX trial. J Am Coll Cardiol
.
SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, .. 2014;64:423–432.
AndersonRP;SocietyofThoracicSurgeonsQualityMeasurementTaskForce. .. 126.MedinaA,SuarezdeLezoJ,PanM.[Anewclassificationofcoronarybifurcation
.
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part . lesions].RevEspCardiol2006;59:183.
.
3–valve plus coronary artery bypass grafting surgery. Ann Thorac Surg . 127.FarooqV,vanKlaverenD,SteyerbergEW,MeligaE,VergouweY,ChieffoA,
.
2009;88:S43–S62. .. KappeteinAP,ColomboA,HolmesDRJr,MackM,FeldmanT,MoriceMC,
.
111. BiancariF,VasquesF,MikkolaR,MartinM,LahtinenJ,HeikkinenJ.Validationof . Stahle E,Onuma Y,MorelMA, Garcia-GarciaHM,vanEs GA, DawkinsKD,
.
EuroSCORE II in patients undergoing coronary artery bypass surgery. Ann . MohrFW,SerruysPW.Anatomicalandclinicalcharacteristicstoguidedecision
.
ThoracSurg2012;93:1930–1935. .. making between coronary artery bypass surgery and percutaneous coronary
112. OsnabruggeRL,SpeirAM,HeadSJ,FonnerCE,FonnerE,KappeteinAP,Rich .. intervention for individual patients: Development and validation of SYNTAX
.
JB.PerformanceofEuroSCOREIIinalargeUSdatabase:Implicationsfortrans- . scoreII.Lancet2013;381:639–650.
.
catheteraorticvalveimplantation.EurJCardiothoracSurg2014;46:400–408. . 128.Campos CM, Garcia-Garcia HM, van Klaveren D, Ishibashi Y, Cho YK,
.
113. SullivanPG,WallachJD,IoannidisJP.Meta-analysiscomparingestablishedrisk .. Valgimigli M, Raber L, JonkerH, Onuma Y, Farooq V, Garg S,WindeckerS,
predictionmodels(EuroSCOREII,STSScore,andACEFScore)forperiopera- .. MorelMA,SteyerbergEW,SerruysPW.ValidityofSYNTAXscoreIIforrisk
.
tivemortalityduringcardiacsurgery.AmJCardiol2016;118:1574–1582. . stratification of percutaneous coronary interventions: A patient-level pooled
.
114. KirmaniBH,MazharK,FabriBM,PullanDM.ComparisonoftheEuroSCOREII .. analysisof5,433patientsenrolledincontemporarycoronarystenttrials.IntJ
and Society of Thoracic Surgeons 2008 risk tools. Eur J Cardiothorac Surg .. Cardiol2015;187:111–115.
.
2013;44:999–1005. . 129.Sotomi Y, Cavalcante R, van Klaveren D, Ahn JM, Lee CW, de Winter RJ,
.
115. VelickiL,Cemerlic-AdjicN,PavlovicK,MihajlovicBB,BankovicD,MihajlovicB, . Wykrzykowska JJ, Onuma Y,SteyerbergEW, ParkSJ,Serruys PW. Individual
.
FabriM.ClinicalperformanceoftheEuroSCOREIIcomparedwiththeprevious .. long-termmortalitypredictionfollowingeithercoronarystentingorbypasssur-
EuroSCOREiterations.ThoracCardiovascSurg2014;62:288–297. .. gery in patients with multivessel and/or unprotected left main disease: An
.
116. SianosG,MorelMA,KappeteinAP,MoriceMC,ColomboA,DawkinsK,van . externalvalidationoftheSYNTAXScoreIImodelinthe1,480patientsofthe .
denBrandM,VanDyckN,RussellME,MohrFW,SerruysPW.TheSYNTAX . BEST and PRECOMBAT randomized controlled trials. JACC Cardiovasc Interv
. Score:Anangiographictoolgradingthecomplexityofcoronaryarterydisease. .. 2016;9:1564–1572.
EuroIntervention2005;1:219–227. .. 130.CamposCM,vanKlaverenD,FarooqV,SimontonCA,KappeteinAP,SabikJF
.
117. Wykrzykowska JJ, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, . III,SteyerbergEW,StoneGW,SerruysPW,InvestigatorsET.Long-termfore-
.
BuszmanP,LinkeA,IschingerT,KlaussV,CortiR,EberliF,WijnsW,Morice .. castingandcomparisonofmortalityintheEvaluationoftheXienceEverolimus
MC,diMarioC,vanGeunsRJ,JuniP,WindeckerS,SerruysPW.Valueofthe .. ElutingStentvs.CoronaryArteryBypassSurgeryforEffectivenessofLeftMain
.
SYNTAXscoreforriskassessmentintheall-comerspopulationoftherandom- . Revascularization(EXCEL)trial:ProspectivevalidationoftheSYNTAXScoreII.
.
ized multicenter LEADERS (Limus Eluted from A Durable versus ERodable . EurHeartJ2015;36:1231–1241.
.
Stentcoating)trial.JAmCollCardiol2010;56:272–277. .. 131.Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV, Holmes
118. Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, .. DR,MackM,FeldmanT,MoriceMC,StahleE,JamesS,ColomboA,DilettiR,
.
BuszmanPE,KelbaekH,vanBovenAJ,HofmaSH,LinkeA,KlaussV,WijnsW, . Papafaklis MI, de Vries T, Morel MA, van Es GA, Mohr FW, Dawkins KD,
.
Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, .. KappeteinAP,SianosG,BoersmaE.Thenegativeimpactofincompleteangio-
BartorelliA,VanRemortelE,RondenJ,WindeckerS.Theprognosticutilityof .. graphic revascularization on clinical outcomes and its association with total
.
theSYNTAXscoreon1-yearoutcomesafterrevascularizationwithzotaroli- . occlusions: The SYNTAX (Synergy Between Percutaneous Coronary
.
mus-andeverolimus-elutingstents:asubstudyoftheRESOLUTEAllComers . Intervention with Taxus and Cardiac Surgery) trial. J Am Coll Cardiol
.
Trial.JACCCardiovascInterv2011;4:432–441. .. 2013;61:282–294.
119. Zhao M, Stampf S, Valina C, Kienzle RP, Ferenc M, Gick M, Essang E, .. 132.Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D,
.
NuhrenbergT,ButtnerHJ,SchumacherM,NeumannFJ.RoleofeuroSCOREII . Brilakis ES. Outcomes after complete versus incomplete revascularization of
.
inpredictinglong-termoutcomeafterpercutaneouscatheterinterventionfor . patients with multivessel coronary artery disease: A meta-analysis of 89,883
.
coronary triple vessel disease or left main stenosis. Int J Cardiol .. patients enrolled in randomized clinical trials and observational studies. J Am
2013;168:3273–3279. .. CollCardiol2013;62:1421–1431.
.
120. CavalcanteR,SotomiY,ManconeM,WhanLeeC,AhnJM,OnumaY,Lemos . 133.ZimarinoM,RicciF,RomanelloM,DiNicolaM,CorazziniA,DeCaterinaR.
.
PA,vanGeunsRJ,ParkSJ,SerruysPW.ImpactoftheSYNTAXscoresIandII .. Complete myocardial revascularization confers a larger clinical benefit when
inpatientswithdiabetesandmultivesselcoronarydisease:Apooledanalysisof .. performedwithstate-of-the-arttechniquesinhigh-riskpatientswithmultivessel
.
patientleveldatafromtheSYNTAX,PRECOMBAT,andBESTtrials.EurHeart . coronaryarterydisease:Ameta-analysisofrandomizedandobservationalstud-
.
J2017;38:1969–1977. . ies.CatheterCardiovascInterv2016;87:3–12.
.
121. MohrFW,MoriceMC,KappeteinAP,FeldmanTE,StahleE,ColomboA,Mack .. 134.Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T,
MJ,HolmesDRJr,MorelMA,VanDyckN,HouleVM,DawkinsKD,Serruys . HolmesDR,MackM,MoriceMC,StahleE,ColomboA,deVriesT,MorelMA,
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 76 ---
162 ESC/EACTSGuidelines
.
.
DawkinsKD,KappeteinAP,MohrFW.Quantificationofincompleterevascula- . B, Buse J, Hueb W, Smith CR, Muratov V, BansilalS, King S III, Bertrand M,
.
rizationanditsassociationwithfive-yearmortalityinthesynergybetweenper- . FusterV;FREEDOMTrialInvestigators.Strategiesformultivesselrevasculariza-
.
cutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) .. tioninpatientswithdiabetes.NEnglJMed2012;367:2375–2384.
trialvalidationoftheresidualSYNTAXscore.Circulation2013;128:141–151. .. 151.Bangalore S,GuoY, Samadashvili Z, Blecker S,Xu J, Hannan EL.Everolimus
.
135. BangaloreS,GuoY,SamadashviliZ,BleckerS,XuJ,HannanEL.Everolimus- . elutingstentsversuscoronaryarterybypassgraftsurgeryforpatientswithdia-
.
elutingstentsorbypasssurgeryformultivesselcoronarydisease.NEnglJMed .. betesmellitusandmultivesseldisease.CircCardiovascInterv2015;8:e002626.
2015;372:1213–1222. .. 152.HakeemA,GargN,BhattiS,RajpurohitN,AhmedZ,UretskyBF.Effectiveness
.
136. Ahn JM, Park DW, Lee CW, Chang M, Cavalcante R, Sotomi Y, Onuma Y, . ofpercutaneouscoronaryinterventionwithdrug-elutingstentscomparedwith
.
TenekeciogluE,HanM,LeePH,KangSJ,LeeSW,KimYH,ParkSW,Serruys . bypasssurgeryindiabeticswithmultivesselcoronarydisease:Comprehensive
.
PW,ParkSJ.Comparisonofstenting versusbypasssurgeryaccordingtothe .. systematic review and meta-analysis of randomized clinical data. J Am Heart
completeness of revascularization in severe coronary artery disease: Patient- .. Assoc2013;2:e000354.
.
level pooled analysis of the SYNTAX, PRECOMBAT, and BEST Trials. JACC . 153.HerbisonP,WongCK.Hasthedifferenceinmortalitybetweenpercutaneous
.
CardiovascInterv2017;10:1415–1424. . coronaryinterventionandcoronaryarterybypassgraftinginpeoplewithheart
.
137. LaylandJ,OldroydKG,CurzenN,SoodA,BalachandranK,DasR,JunejoS, .. diseaseanddiabeteschangedovertheyears?Asystematicreviewandmeta-
.
AhmedN,LeeMM,ShaukatA,O’DonnellA,NamJ,BriggsA,HendersonR, . regression.BMJOpen2015;5:e010055.
.
McConnachie A, Berry C, FAMOUS-NSTEMI Investigators. Fractional flow . 154.Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King S III,
.
reservevs.angiographyinguidingmanagementtooptimizeoutcomesinnon- .. Colling C, Moritz T, Stroupe K, Reda D; CARDS Investigators VA.
ST-segment elevation myocardial infarction: The British Heart Foundation .. PercutaneouscoronaryinterventionversuscoronarybypasssurgeryinUnited
.
FAMOUS-NSTEMIrandomizedtrial.EurHeartJ2015;36:100–111. . Statesveteranswithdiabetes.JAmCollCardiol2013;61:808–816.
.
138. AdN,HolmesSD,PatelJ,PritchardG,ShumanDJ,HalpinL.Comparisonof . 155.Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW,
.
EuroSCORE II, original EuroSCORE, and The Society of Thoracic Surgeons .. DawkinsKD,MackMJ,InvestigatorsS.Treatmentofcomplexcoronaryartery
RiskScoreincardiacsurgerypatients.AnnThoracSurg2016;102:573–579. .. diseaseinpatientswithdiabetes:5-yearresultscomparingoutcomesofbypass
.
139. AzizO,RaoC,PanesarSS,JonesC,MorrisS,DarziA,AthanasiouT.Meta-anal- . surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J
.
ysisofminimally invasiveinternalthoracicarterybypassversuspercutaneous .. CardiothoracSurg2013;43:1006–1013.
revascularisationforisolatedlesionsoftheleftanteriordescendingartery.BMJ .. 156.Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A,
.
2007;334:617. . Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M,
.
140. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, . NihoyannopoulosP,BaggerJP,MorganK,BeattKJ.Randomizedcomparisonof
.
McDonald KM, Owens DK, Hlatky MA, Bravata DM. Isolated disease of the .. percutaneouscoronaryinterventionwithcoronaryarterybypassgraftingindia-
proximalleftanteriordescendingarterycomparingtheeffectivenessofpercuta- .. betic patients. 1-year results of the CARDia (Coronary Artery
.
neous coronary interventions and coronary artery bypass surgery. JACC . RevascularizationinDiabetes)trial.JAmCollCardiol2010;55:432–440.
.
CardiovascInterv2008;1:483–491. . 157.Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J,
.
141. Blazek S,HolzheyD, Jungert C,Borger MA, Fuernau G, Desch S,Eitel I,de .. SilberS,SerruysPW,PilgrimT,RaberL,HegD,JuniP,WindeckerS.Impactof
.
Waha S, Lurz P, Schuler G, Mohr FW, Thiele H. Comparison of bare-metal . diabeticstatusonoutcomesafterrevascularizationwithdrug-elutingstentsin
.
stentingwithminimallyinvasivebypasssurgeryforstenosisoftheleftanterior . relationtocoronaryarterydiseasecomplexity:Patient-levelpooledanalysisof
.
descending coronary artery: 10-year follow-up of a randomized trial. JACC .. 6081patients.CircCardiovascInterv2016;9:e003255.
CardiovascInterv2013;6:20–26. .. 158.Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
.
142. HannanEL,ZhongY,WalfordG,HolmesDRJr,VendittiFJ,BergerPB,Jacobs . Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,
.
AK,StamatoNJ,CurtisJP,SharmaS,KingSBIII.Coronaryarterybypassgraft . LancellottiP,LandmesserU,MehilliJ,MukherjeeD,StoreyRF,WindeckerS;
.
surgeryversusdrug-elutingstentsforpatientswithisolatedproximalleftante- .. ScientificDocumentESCGroup.2015ESCGuidelinesforthemanagementof
riordescendingdisease.JAmCollCardiol2014;64:2717–2126. .. acute coronary syndromes in patients presenting without persistent ST-
.
143. BlazekS,RossbachC,BorgerMA,FuernauG,DeschS,EitelI,StiermaierT, . segment elevation: Task Force for the Management of Acute Coronary
.
LurzP,HolzheyD,SchulerG,MohrFW,ThieleH.Comparisonofsirolimus- .. SyndromesinPatientsPresentingwithoutPersistentST-SegmentElevationof
elutingstentingwithminimallyinvasivebypasssurgeryforstenosisoftheleft .. theEuropeanSocietyofCardiology(ESC).EurHeartJ2016;37:267–315.
.
anterior descending coronary artery: 7-year follow-up of a randomized trial. . 159.Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW.
.
JACCCardiovascInterv2015;8:30–38. . Multiplecomplexcoronaryplaquesinpatientswithacutemyocardialinfarction.
.
144. Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr .. NEnglJMed2000;343:915–922.
FW, Schuler G, Falk V. Randomized comparison of minimally invasive direct .. 160.ShishehborMH,VenkatachalamS,SunZ,RajeswaranJ,KapadiaSR,BajzerC,
.
coronary artery bypass surgery versus sirolimus-eluting stenting in isolated . GornikHL,GrayBH,BartholomewJR,ClairDG,SabikJFIII,BlackstoneEH.A .
proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol . direct comparison of early and late outcomes with three approaches to
. 2009;53:2324–2331. .. carotid revascularization and open heart surgery. J Am Coll Cardiol
145. CapodannoD,StoneGW,MoriceMC,BassTA,TamburinoC.Percutaneous .. 2013;62:1948–1956.
.
coronaryinterventionversuscoronaryarterybypassgraftsurgeryinleftmain . 161.CheruvuPK,FinnAV,GardnerC,CaplanJ,GoldsteinJ,StoneGW,VirmaniR,
.
coronaryarterydisease:Ameta-analysisofrandomizedclinicaldata.JAmColl .. MullerJE.Frequencyanddistributionofthin-capfibroatheromaandruptured
Cardiol2011;58:1426–1432. .. plaques in human coronary arteries: A pathologic study. J Am Coll Cardiol
.
146. AhnJM,RohJH,KimYH,ParkDW,YunSC,LeePH,ChangM,ParkHW,Lee . 2007;50:940–949.
.
SW,LeeCW,ParkSW,ChooSJ,ChungC,LeeJ,LimDS,RhaSW,LeeSG, . 162.KerenskyRA,WadeM,DeedwaniaP,BodenWE,PepineCJ,VeteransAffairs
.
GwonHC,KimHS,ChaeIH,JangY,JeongMH,TahkSJ,SeungKB,ParkSJ. .. Non-Q-Wave Infarction Strategies in-Hospital (VANQWISH) Trial
Randomizedtrialofstentsversusbypasssurgeryforleftmaincoronaryartery .. Investigators.Revisitingtheculpritlesioninnon-Q-wavemyocardialinfarction.
.
disease: 5-Year outcomes of the PRECOMBAT study. J Am Coll Cardiol . Results from the VANQWISH trial angiographic core laboratory. J Am Coll
.
2015;65:2198–2206. .. Cardiol2002;39:1456–1463.
147. CavalcanteR,SotomiY,LeeCW,AhnJM,FarooqV,TateishiH,Tenekecioglu .. 163.KastratiA,NeumannFJ,SchulzS,MassbergS,ByrneRA,FerencM,Laugwitz
.
E, Zeng Y, Suwannasom P, Collet C, Albuquerque FN, Onuma Y, Park SJ, . KL,PacheJ,OttI,HausleiterJ,SeyfarthM,GickM,AntoniucciD,SchomigA,
.
Serruys PW. Outcomes after percutaneous coronary intervention or bypass . BergerPB,MehilliJ;ISAR-REACT4TrialInvestigators.Abciximabandheparin
.
surgery in patients with unprotected left main disease. J Am Coll Cardiol .. versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med
2016;68:999–1009. .. 2011;365:1980–1989.
.
148. GiacoppoD,ColleranR,CasseseS,FrangiehAH,WiebeJ,JonerM,Schunkert . 164.MehtaSR,GrangerCB,BodenWE,StegPG,BassandJP,FaxonDP,AfzalR,
.
H, Kastrati A, Byrne RA. Percutaneous coronary intervention vs coronary . Chrolavicius S,JollySS, Widimsky P,Avezum A, Rupprecht HJ, ZhuJ, ColJ,
.
arterybypassgraftinginpatientswithleftmaincoronaryarterystenosis:Asys- .. NatarajanMK,HorsmanC,FoxKA,YusufS;TIMACSInvestigators.Earlyversus
tematicreviewandmeta-analysis.JAMACardiol2017;2:1079–1088. .. delayed invasive intervention in acute coronary syndromes. N Engl J Med
.
149. ChangM,AhnJM,LeeCW,CavalcanteR,SotomiY,OnumaY,TenekeciogluE, . 2009;360:2165–2175.
.
HanM,ParkDW,KangSJ,LeeSW,KimYH,ParkSW,SerruysPW,ParkSJ. .. 165.MontalescotG,BologneseL,DudekD,GoldsteinP,HammC,TanguayJF,ten
Long-term mortality after coronary revascularization in nondiabetic patients .. Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J,
.
withmultivesseldisease.JAmCollCardiol2016;68:29–36. . Niethammer M, Motovska Z, Jakubowski JA, Cayla G,ViscontiLO, Vicaut E,
.
150. FarkouhME,DomanskiM,SleeperLA,SiamiFS,DangasG,MackM,YangM, . WidimskyP;ACCOASTInvestigators.Pretreatmentwithprasugrelinnon-ST-
.
Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, .. segment elevation acute coronary syndromes. N Engl J Med
LanskyA,BoineauR,WeinbergerJ,RamanathanK,SousaJE,RankinJ,Bhargava . 2013;369:999–1010.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 77 ---
ESC/EACTSGuidelines 163
.
.
166. ThieleH,RachJ,KleinN,PfeifferD,HartmannA,HambrechtR,SickP,EitelI, . 180.Thiele H, de Waha S, Zeymer U, Desch S, Scheller B, Lauer B, Geisler T,
.
Desch S, Schuler G; LIPSIA-NSTEMI Trial Group. Optimal timing of invasive . GawazM,GunkelO,BruchL,KleinN,PfeifferD,SchulerG,EitelI.Effectof
.
angiography in stable non-ST-elevation myocardial infarction: The Leipzig .. aspiration thrombectomy on microvascular obstruction in NSTEMI patients:
Immediate versus early and late PercutaneouS coronary Intervention triAl in .. TheTATORT-NSTEMItrial.JAmCollCardiol2014;64:1117–1124.
.
NSTEMI(LIPSIA-NSTEMITrial).EurHeartJ2012;33:2035–2043. . 181.Hakeem A, Edupuganti MM, Almomani A, Pothineni NV, Payne J, Abualsuod
.
167. TanakaA,ShimadaK,TearneyGJ,KitabataH,TaguchiH,FukudaS,Kashiwagi .. AM, Bhatti S, Ahmed Z, Uretsky BF. Long-term prognosis of deferred acute
M,KuboT,TakaradaS,HirataK,MizukoshiM,YoshikawaJ,BoumaBE,Akasaka .. coronarysyndromelesionsbasedonnonischemicfractionalflowreserve.JAm
.
T. Conformational change in coronary artery structure assessed by optical . CollCardiol2016;68:1181–1191.
.
coherence tomography in patients with vasospastic angina. J Am Coll Cardiol . 182.WallentinL,LagerqvistB,HustedS,KontnyF,StahleE,SwahnE.Outcomeat1
.
2011;58:1608–1613. .. year after an invasive compared with a non-invasive strategy in unstable
168. KatoM,DoteK,SasakiS,KagawaE,NakanoY,WatanabeY,HigashiA,Itakura .. coronary-artery disease: The FRISC II invasive randomised trial. FRISC II
.
K,OchiumiY,TakiguchiY.Presentationsofacutecoronarysyndromerelated . Investigators. Fast Revascularisation during Instability in Coronary artery dis-
.
to coronary lesion morphologies as assessed by intravascularultrasound and . ease.Lancet2000;3:9–16.
.
opticalcoherencetomography.IntJCardiol2013;165:506–511. .. 183.Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N,
.
169. MotreffP,MalclesG,CombaretN,Barber-ChamouxN,BouajilaS,PereiraB, . Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM,
.
AmonchotA,CitronB,LussonJR,EschalierR,SouteyrandG.Howandwhen . BraunwaldE,TACTICS(TreatAnginawithAggrastatandDetermineCostof
.
to suspect spontaneous coronary artery dissection: Novel insights from a .. Therapy with an Invasive or Conservative Strategy)–Thrombolysis in
single-centreseriesonprevalenceandangiographicappearance.EuroIntervention .. MyocardialInfarction18Investigators.Comparisonofearlyinvasiveandconser-
.
2017;12:e2236–e2243. . vativestrategiesinpatientswithunstablecoronarysyndromestreatedwiththe
.
170. BavryAA,KumbhaniDJ,RassiAN,BhattDL,AskariAT.Benefitofearlyinva- . glycoproteinIIb/IIIainhibitortirofiban.NEnglJMed2001;344:1879–1887.
.
sive therapy in acute coronary syndromes: A meta-analysis of contemporary .. 184.GenereuxP,PalmeriniT,CaixetaA,CristeaE,MehranR,SanchezR,LazarD,
randomizedclinicaltrials.JAmCollCardiol2006;48:1319–1325. .. JankovicI,CorralMD,DresslerO,FahyMP,PariseH,LanskyAJ,StoneGW.
.
171. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, . SYNTAXscorereproducibilityandvariabilitybetweeninterventionalcardiolo-
.
LagerqvistB,WallentinL,FIRCollaboration.Long-termoutcomeofaroutine .. gists,corelaboratorytechnicians,andquantitativecoronarymeasurements.Circ
versus selective invasive strategy in patients with non-ST-segment elevation .. CardiovascInterv2011;4:553–561.
.
acutecoronarysyndromeameta-analysisofindividualpatientdata.JAmColl . 185.SardellaG,LucisanoL,GarboR,PennacchiM,CavalloE,StioRE,CalcagnoS,
.
Cardiol2010;55:2435–2445. . UgoF,BoccuzziG,FedeleF,ManconeM.Single-stagedcomparedwithmulti-
.
172. ValgimigliM,GagnorA,CalabroP,FrigoliE,LeonardiS,ZaroT,RubartelliP, .. staged PCI in multivessel NSTEMI patients: The SMILE Trial. J Am Coll Cardiol
BriguoriC,AndoG,RepettoA,LimbrunoU,CorteseB,SganzerlaP,LupiA, .. 2016;67:264–272.
.
GalliM,ColangeloS,IernaS,AusielloA,PresbiteroP,SardellaG,VarbellaF, . 186.Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F,
.
Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, . WhiteHD,AylwardPE,WallentinL,ChenE,LokhnyginaY,PeiJ,LeonardiS,
.
RigattieriS,TosiP,PalmieriC,BrugalettaS,RaoSV,HegD,RothenbuhlerM, .. RorickTL,KilianAM,JenningsLH,AmbrosioG,BodeC,CequierA,CornelJH,
.
Vranckx P, Juni P; MATRIX Investigators. Radial versus femoral access in . DiazR,ErkanA,HuberK,HudsonMP,JiangL,JukemaJW,LewisBS,Lincoff
.
patients with acute coronary syndromes undergoing invasive management: A . AM,MontalescotG,NicolauJC,OgawaH,PfistererM,PrietoJC,RuzylloW,
.
randomisedmulticentretrial.Lancet2015;385:2465–2476. .. Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J,
173. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, .. Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor
.
RichardtG,IniguezA,BrunelP,Valdes-ChavarriM,GarotP,TalwarS,Berland . antagonist vorapaxar in acute coronary syndromes. N Engl J Med
.
J,AbdellaouiM,EberliF,OldroydK,ZambahariR,GregsonJ,GreeneS,Stoll . 2012;366:20–33.
.
HP,MoriceMC;LEADERSFREEInvestigators.Polymer-freedrug-coatedcoro- .. 187.LindholmD,VarenhorstC,CannonCP,HarringtonRA,HimmelmannA,Maya
narystentsinpatientsathighbleedingrisk.NEnglJMed2015;373:2038–2047. .. J,HustedS,StegPG,CornelJH,StoreyRF,StevensSR,WallentinL,JamesSK.
.
174. KatritsisDG,SiontisGC,KastratiA,van’tHofAW,NeumannFJ,SiontisKC, . Ticagrelorvs.clopidogrelinpatientswithnon-ST-elevationacutecoronarysyn-
.
IoannidisJP.Optimaltimingofcoronaryangiographyandpotentialintervention .. drome with or without revascularization: Results from the PLATO trial. Eur
innon-ST-elevationacutecoronarysyndromes.EurHeartJ2011;32:32–40. .. HeartJ2014;35:2083–2093.
.
175. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, . 188.CurtisJP,SchreinerG,WangY,ChenJ,SpertusJA,RumsfeldJS,BrindisRG,
.
Engstrom T, DiPasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW, . KrumholzHM.All-causereadmissionandrepeatrevascularizationafterpercu-
.
KubicaJ.Optimaltimingofcoronaryinvasivestrategyinnon-ST-segmenteleva- .. taneous coronary intervention in a cohort of medicare patients. J Am Coll
tion acute coronary syndromes: A systematic review and meta-analysis. Ann .. Cardiol2009;54:903–907.
.
InternMed2013;158:261–270. . 189.Meadows ES, Bae JP, Zagar A, Sugihara T, Ramaswamy K, McCracken R, .
176. Jobs A, Mehta SR, Montalescot G, Vicaut E, Van’t Hof AWJ, Badings EA, . Heiselman D.Rehospitalizationfollowing percutaneouscoronary intervention
. Neumann FJ, Kastrati A, Sciahbasi A, Reuter PG, Lapostolle F, Milosevic A, .. forcommerciallyinsuredpatientswithacutecoronarysyndrome:Aretrospec-
StankovicG,MilasinovicD,VontheinR,DeschS,ThieleH.Optimaltimingof .. tiveanalysis.BMCResNotes2012;5:342.
.
aninvasivestrategyinpatientswithnon-ST-elevationacutecoronarysyndrome: . 190.ThieleH,AkinI,SandriM,FuernauG,deWahaS,Meyer-SaraeiR,Nordbeck
.
Ameta-analysisofrandomisedtrials.Lancet2017;390:737–746. .. P,GeislerT,LandmesserU,SkurkC,FachA,LappH,PiekJJ,NocM,GoslarT,
177. RaberL,KelbaekH,OstojicM,BaumbachA,HegD,TullerD,vonBirgelenC, .. Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G,
.
Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, PedrazziniG, . Barthelemy O, HuberK, Windecker S,SavonittoS,Torremante P,Vrints C,
.
KornowskiR,WeberK,TrelleS,LuscherTF,TaniwakiM,MatterCM,MeierB, . Schneider S, Desch S, Zeymer U; CULPRIT-SHOCK Investigators. PCI strat-
.
Juni P, Windecker S; COMFORTABLE AMI Trial Investigators. Effect of .. egiesinpatientswithacutemyocardialinfarctionandcardiogenicshock.NEngl
biolimus-elutingstentswithbiodegradablepolymervsbare-metalstentsoncar- .. JMed2017;377:2419–2432.
.
diovascular events among patients with acute myocardial infarction: The . 191.Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT,
.
COMFORTABLEAMIrandomizedtrial.JAMA2012;308:777–787. .. Lopez-SendonJ,AvezumA,GoodmanSG,GrangerCB,BriegerD.Riskstratifi-
178. Sabate M, Raber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, .. cationinthesettingofnon-STelevationacutecoronarysyndromes1999-2007.
.
IniguezA,TullerD,SerraA,BaumbachA,vonBirgelenC,Hernandez-Antolin . AmJCardiol2011;108:617–624.
.
R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Juni P, Windecker S. . 192.FukuiT,TabataM,MoritaS,TakanashiS.Earlyandlong-termoutcomesofcor-
.
Comparison of newer-generation drug-eluting with bare-metal stents in .. onaryarterybypassgraftinginpatientswithacutecoronarysyndromeversus
patientswithacuteST-segmentelevationmyocardialinfarction:Apooledanaly- .. stableanginapectoris.JThoracCardiovascSurg2013;145:1577–1583.
.
sisoftheEXAMINATION(clinicalEvaluationoftheXience-VstentinAcute . 193.Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C,
.
MyocardialINfArcTION)andCOMFORTABLE-AMI(ComparisonofBiolimus . JeppssonA.Preoperativeplateletfunctionpredictsperioperativebleedingcom-
.
ElutedFromanErodibleStentCoatingWithBareMetalStentsinAcuteST- .. plicationsinticagrelor-treatedcardiacsurgerypatients:Aprospectiveobserva-
ElevationMyocardialInfarction)trials.JACCCardiovascInterv2014;7:55–63. .. tionalstudy.BrJAnaesth2016;117:309–315.
.
179. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, . 194.ChangM,LeeCW,AhnJM,CavalcanteR,SotomiY,OnumaY,HanM,Park
.
Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; .. DW,KangSJ,LeeSW,KimYH,ParkSW,SerruysPW,ParkSJ.Comparisonof
PRODIGYInvestigators.Two-yearoutcomesafterfirst-orsecond-generation .. outcomeofcoronaryarterybypassgraftingversusdrug-elutingstentimplanta-
.
drug-elutingorbare-metalstentimplantationinall-comerpatientsundergoing . tion for non-ST-elevation acute coronary syndrome. Am J Cardiol
.
percutaneous coronary intervention: A pre-specified analysis from the . 2017;120:380–386.
.
PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading .. 195.PalmeriniT,GenereuxP,CaixetaA,CristeaE,LanskyA,MehranR,DangasG,
stent-inducedIntimalhyperplasiastudY).JACCCardiovascInterv2014;7:20–28. . Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic value of the
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 78 ---
164 ESC/EACTSGuidelines
.
.
SYNTAXscoreinpatientswithacutecoronarysyndromesundergoingpercuta- . 210.DiMario,CMara,SFlavio,AImad,SAntonio,MAnna,PEmanuela,PStefano,
.
neous coronary intervention: Analysis from the ACUITY (Acute . DSAngelo,RStefania,CAnna,FCarmelo,CAntonio,CMonzini,N,Bonardi,
.
CatheterizationandUrgentInterventionTriageStrategY)trial.JAmCollCardiol .. MA.Singlevsmultivesseltreatmentduringprimaryangioplasty:Resultsofthe
2011;57:2389–2397. .. multicentrerandomisedHEpacoatforcuLPritormultivesselstentingforAcute
.
196. RamanathanK,AbelJG,ParkJE,FungA,MathewV,TaylorCM,ManciniGBJ, . Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent
.
GaoM,DingL,VermaS,HumphriesKH,FarkouhME.Surgicalversuspercuta- .. 2004;6:128–133.
neouscoronaryrevascularizationinpatientswithdiabetesandacutecoronary .. 211.Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C,
.
syndromes.JAmCollCardiol2017;70:2995–3006. . OldroydKG;PRAMIInvestigators.Randomizedtrialofpreventiveangioplasty
.
197. KolteD,KheraS,DabhadkarKC,AgarwalS,AronowWS,TimmermansR,Jain . inmyocardialinfarction.NEnglJMed2013;369:1115–1123.
.
D,CooperHA,FrishmanWH,MenonV,BhattDL,AbbottJD,FonarowGC, .. 212.Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N,
PanzaJA.Trendsincoronaryangiography,revascularization,andoutcomesof .. Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M,
.
cardiogenic shock complicating non-ST-elevation myocardial infarction. Am J . HetheringtonSL,KelionAD,TalwarS,GunningM,HallR,SwantonH,McCann
.
Cardiol2016;117:1–9. . GP. Randomized trial of complete versus lesion-only revascularization in
.
198. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, .. patients undergoing primary percutaneous coronary intervention for STEMI
.
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, . andmultivesseldisease:TheCvLPRITtrial.JAmCollCardiol2015;65:963–972.
.
Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, . 213.Engstrom T, Kelbaek H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L,
.
Widimsky P, ESC Scientific Document Group. 2017 ESC Guidelines for the .. JorgensenE,PedersenF,SaunamakiK,ClemmensenP,DeBackerO,RavkildeJ,
management of acute myocardial infarction in patients presenting with ST- .. TilstedHH,VilladsenAB,AaroeJ,JensenSE,RaungaardB,KoberL,DANAMI-
.
segment elevation: The Task Force for the management of acute myocardial . PRIMULTI Investigators. Complete revascularisation versus treatment of the
.
infarction in patients presenting with ST-segment elevation of the European . culpritlesiononlyinpatientswithST-segmentelevationmyocardialinfarction
.
SocietyofCardiology(ESC).EurHeartJ2018;39:119–177. .. and multivessel disease (DANAMI-3-PRIMULTI): An open-label, randomised
199. Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J, .. controlledtrial.Lancet2015;386:665–671.
.
FleischmannC,WernerGS,OlbrichHG,OttR,MudraH,SeidlK,SchulzePC, . 214.Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K,
.
WeissC,HaimerlJ,FriedeT,MeyerT.Impactoftreatmentdelayonmortality .. Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R,
inST-segmentelevationmyocardialinfarction(STEMI)patientspresentingwith .. AngerasO,RichardtG,OmerovicE,Compare-AcuteInvestigators.Fractional
.
andwithouthaemodynamicinstability:ResultsfromtheGermanprospective, . flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J
.
multicentreFITT-STEMItrial.EurHeartJ2018;39:1065–1074. . Med2017;376:1234–1244.
.
200. KeeleyEC,BouraJA,GrinesCL.Comparisonofprimaryandfacilitatedpercuta- .. 215.Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or
neous coronary interventions for ST-elevation myocardial infarction: .. culprit-onlyrevascularizationforpatientswithmultivesselcoronaryarterydis-
.
Quantitativereviewofrandomisedtrials.Lancet2006;367:579–588. . easeundergoingpercutaneouscoronaryintervention:Apairwiseandnetwork
.
201. BoersmaE,PrimaryCoronaryAngioplastyvs.ThrombolysisGroup.Doestime . meta-analysisofrandomizedtrials.JACCCardiovascInterv2017;10:315–324.
.
matter?Apooledanalysisofrandomizedclinicaltrialscomparingprimaryper- .. 216.Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di
.
cutaneouscoronaryinterventionandin-hospitalfibrinolysisinacutemyocardial . LorenzoE,KaiserC,TieralaI,MehilliJ,SeyfarthM,VarenneO,DirksenMT,
.
infarctionpatients.EurHeartJ2006;27:779–788. . PercocoG,VarricchioA,PittlU,SyvanneM,SuttorpMJ,VioliniR,SchomigA.
.
202. MorrisonLJ,VerbeekPR,McDonaldAC,SawadskyBV,CookDJ.Mortalityand .. Meta-analysisofrandomizedtrialsondrug-elutingstentsvs.bare-metalstents
prehospitalthrombolysisforacutemyocardialinfarction:Ameta-analysis.JAMA .. inpatientswithacutemyocardialinfarction.EurHeartJ2007;28:2706–2713.
.
2000;283:2686–2692. . 217.Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V,
.
203. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, . Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-
.
Cattan S, Boullenger E, Machecourt J, Lacroute JM, Cassagnes J, Dissait F, .. HospitalJA,BazJA,Martin-YusteV,vanGeunsRJ,AlfonsoF,BordesP,Tebaldi
TouboulP,ComparisonofAngioplastyandPrehospitalThromboysisinAcute .. M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW.
.
MyocardialInfarctionstudygroup.Primaryangioplastyversusprehospitalfibri- . Everolimus-elutingstentversusbare-metalstentinST-segmentelevationmyo-
.
nolysis in acute myocardial infarction: A randomised study. Lancet .. cardialinfarction(EXAMINATION):1yearresultsofarandomisedcontrolled
2002;360:825–829. .. trial.Lancet2012;380:1482–1490.
.
204. BonnefoyE,StegPG,BoutitieF,DubienPY,LapostolleF,RoncalliJ,DissaitF, . 218.Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Jimenez-Quevedo P,
.
Vanzetto G, Leizorowicz A, Kirkorian G, CAPTIM Investigators, Mercier C, . MainarV,CampoG,TespiliM,denHeijerP,BethencourtA,VazquezN,vanEs
.
McFaddenEP,TouboulP.Comparisonofprimaryangioplastyandpre-hospital .. GA,BackxB,ValgimigliM,SerruysPW.ClinicaloutcomesinpatientswithST-
fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. .. segmentelevationmyocardialinfarctiontreatedwitheverolimus-elutingstents
.
EurHeartJ2009;30:1598–1606. . versus bare-metal stents (EXAMINATION): 5-year results of a randomised .
205. PintoDS,FrederickPD,ChakrabartiAK,KirtaneAJ,UllmanE,DejamA,Miller . trial.Lancet2016;387:357–366.
. DP, Henry TD, Gibson CM; National Registry of Investigators Myocardial .. 219.BelleL,MotreffP,ManginL,RangeG,MarcaggiX,MarieA,FerrierN,Dubreuil
Infarction. Benefit of transferring ST-segment-elevation myocardial infarction .. O, Zemour G, Souteyrand G, Caussin C, Amabile N, Isaaz K, Dauphin R,
.
patientsforpercutaneouscoronaryinterventioncomparedwithadministration . Koning R, Robin C, Faurie B, Bonello L, Champin S, Delhaye C, Cuilleret F,
.
of onsite fibrinolytic declines as delays increase. Circulation .. Mewton N, Genty C, Viallon M, Bosson JL, Croisille P, MIMI Investigators.
2011;124:2512–2251. .. ComparisonofimmediatewithdelayedstentingusingtheMinimalistImmediate
.
206. ArmstrongPW,GershlickAH,GoldsteinP,WilcoxR,DanaysT,LambertY, . Mechanical Intervention approach in acute ST-segment-elevation myocardial
.
SulimovV,RosellOrtizF,OstojicM,WelshRC,CarvalhoAC,NanasJ,Arntz . infarction:TheMIMIstudy.CircCardiovascInterv2016;9:e003388.
.
HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, .. 220.CarrickD,OldroydKG,McEntegartM,HaigC,PetrieMC,EteibaH,HoodS,
Vandenberghe K, Bogaerts K, Van de Werf F; STZREAM Investigative Team. .. OwensC,WatkinsS,LaylandJ,LindsayM,PeatE,RaeA,BehanM,SoodA,
.
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N . Hillis WS,Mordi I,Mahrous A,Ahmed N, Wilson R, Lasalle L, Genereux P,
.
EnglJMed2013;368:1379–1387. .. FordI,BerryC.Arandomizedtrialofdeferredstentingversusimmediatestent-
207. ParkDW,ClareRM,SchultePJ,PieperKS,ShawLK,CaliffRM,OhmanEM, .. ing to prevent no- or slow-reflow in acute ST-segment elevation myocardial
.
VandeWerfF,HirjiS,HarringtonRA,ArmstrongPW,GrangerCB,JeongMH, . infarction(DEFER-STEMI).JAmCollCardiol2014;63:2088–2098.
.
PatelMR.Extent,location,andclinicalsignificanceofnon-infarct-relatedcoro- . 221.Kelbaek H, Hofsten DE, Kober L, Helqvist S, Klovgaard L, Holmvang L,
.
nary artery disease among patients with ST-elevation myocardial infarction. .. Jorgensen E, Pedersen F, Saunamaki K, De Backer O, Bang LE, Kofoed KF,
JAMA2014;312:2019–2027. .. Lonborg J, Ahtarovski K, Vejlstrup N, Botker HE, Terkelsen CJ, Christiansen
.
208. KornowskiR,MehranR,DangasG,NikolskyE,AssaliA,ClaessenBE,GershBJ, . EH, Ravkilde J, Tilsted HH, Villadsen AB, Aaroe J, Jensen SE, Raungaard B,
.
WongSC,WitzenbichlerB,GuagliumiG,DudekD,FahyM,LanskyAJ,Stone . JensenLO,ClemmensenP,GrandeP,MadsenJK,Torp-PedersenC,Engstrom
.
GW,HORIZONS-AMITrialInvestigators.Prognosticimpactofstagedversus .. T.DeferredversusconventionalstentimplantationinpatientswithST-segment
"one-time"multivesselpercutaneousinterventioninacutemyocardialinfarction: .. elevation myocardial infarction (DANAMI 3-DEFER): An open-label, rando-
.
AnalysisfromtheHORIZONS-AMI(harmonizingoutcomeswithrevasculariza- . misedcontrolledtrial.Lancet2016;387:2199–2206.
.
tion and stents in acute myocardial infarction) trial. J Am Coll Cardiol .. 222.DeLucaG,NavareseEP,SuryapranataH.Ameta-analyticoverviewofthrom-
2011;58:704–711. .. bectomyduringprimaryangioplasty.IntJCardiol2013;166:606–612.
.
209. PolitiL,SguraF,RossiR,MonopoliD,GuerriE,LeuzziC,BursiF,Sangiorgi . 223.FrobertO,LagerqvistB,OlivecronaGK,OmerovicE,GudnasonT,MaengM,
.
GM,ModenaMG.Arandomisedtrialoftarget-vesselversusmulti-vesselrevas- . AasaM,AngerasO,CalaisF,DanielewiczM,ErlingeD,HellstenL,JensenU,
.
cularisationinST-elevationmyocardialinfarction:Majoradversecardiacevents .. Johansson AC, Karegren A, Nilsson J, Robertson L, Sandhall L, Sjogren I,
duringlong-termfollow-up.Heart2010;96:662–667. . OstlundO,HarnekJ,JamesSK;TASTETrialInvestigators.Thrombusaspiration
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 79 ---
ESC/EACTSGuidelines 165
.
.
during ST-segment elevation myocardial infarction. N Engl J Med . DANAMI-2Investigators.Acomparisonofcoronaryangioplastywithfibrino-
.
2013;369:1587–1597. . lytictherapyinacutemyocardialinfarction.NEnglJMed2003;349:733–742.
.
224. Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, .. 238.DalbyM,BouzamondoA,LechatP,MontalescotG.Transferforprimaryangio-
AnderssonJ,CalaisF,CarlssonJ,CollsteO,GotbergM,HardhammarP,Ioanes .. plastyversusimmediatethrombolysisinacutemyocardialinfarction:Ameta-
.
D,KallrydA,LinderR,LundinA,OdenstedtJ,OmerovicE,PuskarV,TodtT, . analysis.Circulation2003;108:1809–1814.
.
ZellerothE,OstlundO,JamesSK.Outcomes1yearafterthrombusaspiration .. 239.Mehilli J,KastratiA,Schulz S,FrungelS,NekollaSG,MoshageW, DotzerF,
formyocardialinfarction.NEnglJMed2014;371:1111–1120. .. HuberK,PacheJ,DirschingerJ,SeyfarthM,MartinoffS,SchwaigerM,Schomig
.
225. JollySS,CairnsJA,YusufS,MeeksB,PogueJ,RokossMJ,KedevS,ThabaneL, . A,BavarianReperfusionAlternativesEvaluation-Study3I.Abciximabinpatients
.
StankovicG,MorenoR,GershlickA,ChowdharyS,LaviS,NiemelaK,StegPG, . withacuteST-segment-elevationmyocardialinfarctionundergoingprimaryper-
.
BernatI,XuY,CantorWJ,OvergaardCB,NaberCK,CheemaAN,WelshRC, .. cutaneous coronary intervention after clopidogrel loading: A randomized
BertrandOF,AvezumA,BhindiR,PancholyS,RaoSV,NatarajanMK,tenBerg .. double-blindtrial.Circulation2009;119:1933–1940.
.
JM, Shestakovska O, Gao P, Widimsky P, Dzavik V, TOTAL Investigators. . 240.Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, Schreiber W,
.
Randomized trial of primary PCI with or without routine manual thrombec- . UngerG,GlogarHD,KaffA,LaggnerAN,MaurerG,MlczochJ,SlanyJ,Weber
.
tomy.NEnglJMed2015;372(15):1389–1398. .. HS, Huber K, Vienna SRG. Implementation of guidelines improves the
.
226. JollySS,CairnsJA,YusufS,RokossMJ,GaoP,MeeksB,KedevS,StankovicG, . standard of care: The Viennese registry on reperfusion strategies in ST-
.
MorenoR,GershlickA,ChowdharyS,LaviS,NiemelaK,BernatI,CantorWJ, . elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:
.
CheemaAN,StegPG,WelshRC,ShethT,BertrandOF,AvezumA,BhindiR, .. 2398–2405.
NatarajanMK,HorakD,LeungRC,KassamS,RaoSV,El-OmarM,MehtaSR, .. 241.HenryTD,SharkeySW,BurkeMN,ChavezIJ,GrahamKJ,HenryCR,LipsDL,
.
Velianou JL, Pancholy S, Dzavik V; TOTAL Investigators. Outcomes after . Madison JD, Menssen KM, Mooney MR, Newell MC, Pedersen WR, Poulose
.
thrombusaspirationforSTelevationmyocardialinfarction:1-yearfollow-upof . AK,TraverseJH,UngerBT,WangYL,LarsonDM.Aregionalsystemtopro-
.
theprospectiverandomisedTOTALtrial.Lancet2016;387:127–135. .. vide timely access to percutaneous coronary intervention for ST-elevation
227. JollySS,CairnsJA,YusufS,MeeksB,GaoP,HartRG,KedevS,StankovicG, .. myocardialinfarction.Circulation2007;116:721–728.
.
MorenoR,HorakD,KassamS,RokossMJ,LeungRC,El-OmarM,Romppanen . 242.Nallamothu BK, Krumholz HM, Ko DT, LaBresh KA, Rathore S, Roe MT,
.
HO, Alazzoni A, Alak A, Fung A, Alexopoulos D, Schwalm JD, Valettas N, .. Schwamm L. Development of systems of care for ST-elevation myocardial
DzavikV,TOTALInvestigators.StrokeintheTOTALtrial:Arandomizedtrial .. infarction patients: Gaps, barriers, and implications. Circulation
.
ofroutinethrombectomyvs.percutaneouscoronaryinterventionaloneinST . 2007;116:e68–e72.
.
elevationmyocardialinfarction.EurHeartJ2015;36:2364–2372. . 243.Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L,
.
228. Jolly SS, James S, Dzavik V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S, .. AndrikopoulosG,BazJA,BetriuA,ClaeysM,DanchinN,DjambazovS,ErneP,
OlivecronaGK,RenlundH,GaoP,LagerqvistB,AlazzoniA,KedevS,Stankovic .. HartikainenJ,HuberK,KalaP,KlincevaM,KristensenSD,LudmanP,FerreJM,
.
G,MeeksB,FrobertO.ThrombusaspirationinST-segment-elevationmyocar- . MerkelyB,MilicicD,MoraisJ,NocM,OpolskiG,OstojicM,RadovanovicD,
.
dial infarction: An individual patient meta-analysis: Thrombectomy Trialists . DeServiS,StenestrandU,StudencanM,TubaroM,VasiljevicZ,WeidingerF,
.
Collaboration.Circulation2017;135(2):143–152. .. Witkowski A, Zeymer U, European Association for Percutaneous
.
229. Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and . CardiovascularInterventions.ReperfusiontherapyforSTelevationacutemyo-
.
safety of immediate angioplasty versus ischemia-guided management after . cardialinfarctioninEurope:Descriptionofthecurrentsituationin30countries.
.
thrombolysisinacutemyocardialinfarctioninareaswithverylongtransferdis- .. EurHeartJ2010;31:943–957.
tancesresultsoftheNORDISTEMI(NORwegianstudyonDIstricttreatment .. 244.Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van THA,
.
ofST-elevationmyocardialinfarction).JAmCollCardiol2010;55:102–110. . Weidinger F, Janzon M, Norgaard BL, Soerensen JT, van de Wetering H,
.
230. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, . ThygesenK,BergstenPA,DigerfeldtC,PotgieterA,TomerN,FajadetJ.How
.
MorrisonLJ,LangerA,DzavikV,MehtaSR,LazzamC,SchwartzB,CasanovaA, .. to set up an effective national primary angioplasty network: Lessons learned
Goodman SG; TRANSFER-AMI Investigators. Routine early angioplasty after .. fromfiveEuropeancountries.EuroIntervention2009;5:299,301–309.
.
fibrinolysisforacutemyocardialinfarction.NEnglJMed2009;360:2705–2718. . 245.BradleyEH,HerrinJ,WangY,BartonBA,WebsterTR,MatteraJA,Roumanis
.
231. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, .. SA,CurtisJP,NallamothuBK,MagidDJ,McNamaraRL,ParkosewichJ,LoebJM,
DimopoulosK,ManariA,GaspardoneA,OchalaA,ZmudkaK,BologneseL, .. KrumholzHM.Strategiesforreducingthedoor-to-balloontimeinacutemyo-
.
StegPG,FlatherM;CARES-in-AMIInvestigators.Immediateangioplastyversus . cardialinfarction.NEnglJMed2006;355:2308–2320.
.
standardtherapywithrescueangioplastyafterthrombolysisintheCombined . 246.PintoDS,KirtaneAJ,NallamothuBK,MurphySA,CohenDJ,LahamRJ,Cutlip
.
AbciximabREteplaseStentStudyinAcuteMyocardialInfarction(CARESS-in- .. DE,BatesER,FrederickPD,MillerDP,CarrozzaJPJr,AntmanEM,CannonCP,
AMI): An open, prospective, randomised, multicentre trial. Lancet .. GibsonCM.HospitaldelaysinreperfusionforST-elevationmyocardialinfarc-
.
2008;371:559–568. . tion: Implications when selecting a reperfusion strategy. Circulation .
232. GershlickAH,Stephens-LloydA,HughesS,AbramsKR,StevensSE,UrenNG, . 2006;114:2019–2025.
. de Belder A, Davis J, Pitt M, Banning A, Baumbach A, Shiu MF, Schofield P, .. 247.StegPG,CambouJP,GoldsteinP,DurandE,SauvalP,KadriZ,BlanchardD,
Dawkins KD, Henderson RA, Oldroyd KG, Wilcox R; REACT Trial .. LablancheJM,GueretP,CottinY,JuliardJM,HananiaG,VaurL,DanchinN;
.
Investigators. Rescue angioplasty after failed thrombolytic therapy for acute . USIC 2000 Investigators. Bypassing the emergency room reduces delays and
.
myocardialinfarction.NEnglJMed2005;353:2758–2768. .. mortalityinSTelevationmyocardialinfarction:TheUSIC2000registry.Heart
233. Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, .. 2006;92:1378–1383.
.
Nekolla SG, Schlotterbeck K, Schuhlen H, Pache J, Seyfarth M, Martinoff S, . 248.WolffG,DimitroulisD,Andreotti F, KolodziejczakM, JungC,ScicchitanoP,
.
BenzerW,SchmittC,DirschingerJ,SchwaigerM,KastratiA;Beyond12hours . DevitoF,Zito A,OcchipintiM,Castiglioni B,CalveriG, Maisano F,Ciccone
.
ReperfusionAlternatiVeEvaluationTrial Investigators.Mechanicalreperfusion .. MM,DeServiS,NavareseEP.Survivalbenefitsofinvasiveversusconservative
in patients with acute myocardial infarction presenting more than 12 hours .. strategiesinheartfailureinpatientswithreducedejectionfractionandcoro-
.
from symptom onset: A randomized controlled trial. JAMA . naryarterydisease:Ameta-analysis.CircHeartFail2017;10:e003255.
.
2005;293:2865–2872. .. 249.WrobelK,StevensSR,JonesRH,SelzmanCH,LamyA,BeaverTM,Djokovic
234. BuskM,KaltoftA,NielsenSS,BottcherM,RehlingM,ThuesenL,BotkerHE, .. LT,WangN,VelazquezEJ,SopkoG,KronIL,DiMaioJM,MichlerRE,LeeKL,
.
LassenJF,ChristiansenEH,KrusellLR,AndersenHR,NielsenTT,Kristensen . YiiM,LengCY,ZembalaM,RouleauJL,DalyRC,Al-KhalidiHR.Influenceof
.
SD.Infarctsizeandmyocardialsalvageafterprimaryangioplastyinpatientspre- . baselinecharacteristics,operativeconduct,andpostoperativecourseon30-day
.
sentingwithsymptomsfor<12hvs.12-72h.EurHeartJ2009;30:1322–1330. .. outcomesofcoronaryarterybypassgraftingamongpatientswithleftventricu-
235. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, .. lardysfunction:ResultsfromtheSurgicalTreatmentforIschemicHeartFailure
.
FormanS,RuzylloW,MaggioniAP,WhiteH,SadowskiZ,CarvalhoAC,Rankin . (STICH)Trial.Circulation2015;132:720–730.
.
JM,RenkinJP,StegPG,MascetteAM,SopkoG,PfistererME,LeorJ,FridrichV, . 250.BangaloreS,GuoY,SamadashviliZ,BleckerS,HannanEL.Revascularizationin
.
MarkDB,KnatterudGL;OccludedArteryTrialInvestigators.Coronaryinter- .. patientswithmultivesselcoronaryarterydiseaseandsevereleftventricularsys-
vention for persistent occlusion after myocardial infarction. N Engl J Med .. tolicdysfunction:Everolimus-elutingstentsversuscoronaryarterybypassgraft
.
2006;355:2395–2407. . surgery.Circulation2016;133:2132–2140.
.
236. BoersmaE,MaasAC,DeckersJW,SimoonsML.Earlythrombolytictreatment .. 251.NagendranJ,BozsoSJ,NorrisCM,McAlisterFA,AppooJJ,MoonMC,Freed
in acute myocardial infarction: Reappraisal of the golden hour. Lancet .. DH, Nagendran J. Coronary artery bypass surgery improves outcomes in
.
1996;348:771–775. . patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol
.
237. AndersenHR,NielsenTT,RasmussenK,ThuesenL,KelbaekH,ThayssenP, . 2018;71:819–827.
.
Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, .. 252.JonesRH,VelazquezEJ,MichlerRE,SopkoG,OhJK,O’ConnorCM,HillJA,
Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS; . Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL, STICH
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 80 ---
165a ESC/EACTSGuidelines
.
.
Hypothesis2Investigators.Coronarybypasssurgerywithorwithoutsurgical . 269.Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J,
.
ventricularreconstruction.NEnglJMed2009;360:1705–1717. . WhiteHD;SHOCKInvestigators.Earlyrevascularizationandlong-termsurvival
.
253. OhJK,VelazquezEJ,MenicantiL,PohostGM,BonowRO,LinG,HellkampAS, .. in cardiogenic shock complicating acute myocardial infarction. JAMA
FerrazziP,WosS,RaoV,BermanD,BochenekA,CherniavskyA,RogowskiJ, .. 2006;295:2511–2515.
.
RouleauJL,LeeKL,STICHInvestigators.Influenceofbaselineleftventricular . 270.HammoudT,TanguayJF,BourassaMG.Managementofcoronaryarterydis-
.
function on the clinical outcome of surgical ventricular reconstruction in .. ease: Therapeutic options in patients with diabetes. J Am Coll Cardiol
patientswithischaemiccardiomyopathy.EurHeartJ2013;34:39–47. .. 2000;36:355–365.
.
254. DorV,CivaiaF,AlexandrescuC,SabatierM,MontiglioF.Favorableeffectsof . 271.HaffnerSM,LehtoS,RonnemaaT,PyoralaK,LaaksoM.Mortalityfromcoro-
.
left ventricular reconstruction in patients excluded from the Surgical . naryheartdiseaseinsubjectswithtype2diabetesandinnon-diabeticsubjects
.
Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg .. withandwithoutpriormyocardialinfarction.NEnglJMed1998;339:229–234.
2011;141:905–916,916e1–e4. .. 272.LuscherTF,CreagerMA,BeckmanJA,CosentinoF.Diabetesandvasculardis-
.
255. Killip T, Passamani E, Davis K. Coronary artery surgery study (CASS): A . ease: Pathophysiology, clinical consequences, and medical therapy: Part II.
.
randomizedtrialofcoronarybypasssurgery.Eightyearsfollow-upandsurvival . Circulation2003;108:1655–1661.
.
inpatientswithreducedejectionfraction.Circulation1985;72:V102–V109. .. 273.Ledru F, Ducimetiere P, Battaglia S, Courbon D, Beverelli F, Guize L,
.
256. DiDonatoM,CastelvecchioS,MenicantiL.End-systolicvolumefollowingsurgi- . GuermonprezJL,DieboldB.Newdiagnosticcriteriafordiabetesandcoronary
.
calventricularreconstructionimpactssurvivalinpatientswithischaemicdilated . artery disease: Insights from an angiographic study. J Am Coll Cardiol
.
cardiomyopathy.EurJHeartFail2010;12:375–381. .. 2001;37:1543–1550.
257. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, .. 274.MorenoPR,MurciaAM,PalaciosIF,LeonMN,BernardiVH,FusterV,FallonJT.
.
Holly TA, Oh JK, Dagenais F, Milano C, Wrobel K, Pirk J, Ali IS, Jones RH, . Coronarycompositionandmacrophageinfiltrationinatherectomyspecimens
.
VelazquezEJ,LeeKL,DiDonatoM,STICHTrialInvestigators.Insightsfromthe . frompatientswithdiabetesmellitus.Circulation2000;102:2180–2184.
.
STICHtrial:Changeinleftventricularsizeaftercoronaryarterybypassgrafting .. 275.MarsoSP,MercadoN,MaeharaA,WeiszG,MintzGS,McPhersonJ,SchieleF,
with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg .. DudekD,FahyM,XuK,LanskyA,TemplinB,ZhangZ,deBruyneB,Serruys
.
2013;146:1139–1145.e6. . PW,StoneGW.Plaquecompositionandclinicaloutcomesinacutecoronary
.
258. HochmanJS,SleeperLA,WebbJG,SanbornTA,WhiteHD,TalleyJD,Buller .. syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc
CE,JacobsAK,SlaterJN,ColJ,McKinlaySM,LeJemtelTH.Earlyrevasculariza- .. Imaging2012;5:S42–S52.
.
tioninacutemyocardialinfarctioncomplicatedbycardiogenicshock.SHOCK . 276.SilvaJA,EscobarA,CollinsTJ,RameeSR,WhiteCJ.Unstableangina.Acom-
.
Investigators. Should We Emergently Revascularize Occluded Coronaries for . parison of angioscopic findings between diabetic and nondiabetic patients.
.
CardiogenicShock.NEnglJMed1999;341:625–634. .. Circulation1995;92:1731–1736
259. WhiteHD,AssmannSF,SanbornTA,JacobsAK,WebbJG,SleeperLA,Wong .. 277.O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E,
.
CK,StewartJT,AylwardPE,WongSC,HochmanJS.Comparisonofpercutane- . CannonCP,ClaytonTC,deWinterRJ,FoxKA,LagerqvistB,McCulloughPA,
.
ouscoronaryinterventionandcoronaryarterybypassgraftingafteracutemyo- . Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or
.
cardial infarction complicated by cardiogenic shock: Results from the Should .. conservative strategy in patients with diabetes mellitus and non-ST-segment
.
We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock . elevationacutecoronarysyndromes:Acollaborativemeta-analysisofrandomized
.
(SHOCK)trial.Circulation2005;112:1992–2001. . trials.JAmCollCardiol2012;60:106–111.
.
260. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de .. 278.Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ,
WahaA,RichardtG,HennersdorfM,EmpenK,FuernauG,DeschS,EitelI, .. IkenoF,KingSBIII.Impactofcompletenessofrevascularizationonlong-term
.
HambrechtR,LauerB,BohmM,EbeltH,SchneiderS,WerdanK,SchulerG; . cardiovascularoutcomesinpatientswithtype2diabetesmellitus:Resultsfrom
.
Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) Trial . the Bypass Angioplasty Revascularization Investigation 2Diabetes (BARI 2D).
.
Investigators.Intra-aorticballooncounterpulsationinacutemyocardialinfarc- .. CircCardiovascInterv2012;5:166–173.
tioncomplicatedbycardiogenicshock(IABP-SHOCKII):Final12monthresults .. 279.DangasGD,FarkouhME,SleeperLA,YangM,SchoosMM,MacayaC,Abizaid
.
ofarandomised,open-labeltrial.Lancet2013;382:1638–1645. . A,BullerCE,DevlinG,RodriguezAE,LanskyAJ,SiamiFS,DomanskiM,Fuster
.
261. ThieleH,ZeymerU,NeumannFJ,FerencM,OlbrichHG,HausleiterJ,Richardt .. V;FREEDOMInvestigators.Long-termoutcomeofPCIversusCABGininsulin
G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, .. andnon-insulin-treateddiabeticpatients:ResultsfromtheFREEDOMtrial.JAm
.
Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP- . CollCardiol2014;64:1189–1197.
.
SHOCKIITrialInvestigatorsI-SIT.Intraaorticballoonsupportformyocardial . 280.GoergenSK,RumboldG,ComptonG,HarrisC.Systematicreviewofcurrent
.
infarctionwithcardiogenicshock.NEnglJMed2012;367:1287–1296. .. guidelines,andtheirevidencebase,onriskoflacticacidosisafteradministration
262. UnverzagtS,BuerkeM,deWahaA,HaertingJ,PietznerD,SeyfarthM,Thiele .. of contrast medium for patients receiving metformin. Radiology
.
H,WerdanK,ZeymerU,ProndzinskyR.Intra-aorticballoonpumpcounterpul- . 2010;254:261–269. .
sation (IABP) for myocardial infarction complicated by cardiogenic shock. . 281.MilojevicM,HeadSJ,MackMJ,MohrFW,MoriceMC,DawkinsKD,Holmes
. CochraneDatabaseSystRev2015;3:CD007398. .. DRJr,SerruysPW,KappeteinAP.Theimpactofchronickidneydiseaseonout-
263. Ouweneel DM, Schotborgh JV, Limpens J, Sjauw KD, Engstrom AE, Lagrand .. comes following percutaneous coronary intervention versus coronary artery
.
WK, Cherpanath TGV, Driessen AHG, de Mol B, Henriques JPS. . bypassgraftinginpatientswithcomplexcoronaryarterydisease:Five-yearfol-
.
Extracorporeallifesupportduringcardiacarrestandcardiogenicshock:asys- .. low-upoftheSYNTAXtrial.EuroIntervention2018;14:102–111.
tematicreviewandmeta-analysis.IntensiveCareMed2016;42:1922–1934. .. 282.Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS,
.
264. Burkhoff D, Cohen H, Brunckhorst C, O’Neill WW; TandemHeart . LanskyAJ,MosesJW,StoneGW,LeonMB,DangasG.Asimpleriskscorefor
.
Investigators Group. A randomized multicenter clinical study to evaluate the . predictionofcontrast-inducednephropathyafterpercutaneouscoronaryinter-
.
safetyandefficacyoftheTandemHeartpercutaneousventricularassistdevice .. vention: Development and initial validation. J Am Coll Cardiol
versusconventionaltherapywithintraaorticballoonpumpingfortreatmentof .. 2004;44:1393–1399.
.
cardiogenicshock.AmHeartJ2006;152:469.e1–469.e8. . 283.Ohno Y, Maekawa Y, Miyata H, Inoue S, Ishikawa S, Sueyoshi K, Noma S,
.
265. SeyfarthM,SibbingD,BauerI,FrohlichG,Bott-FlugelL,ByrneR,DirschingerJ, .. KawamuraA,KohsakaS,FukudaK.Impactofperiproceduralbleedingoninci-
KastratiA,SchomigA.Arandomizedclinicaltrialtoevaluatethesafetyandeffi- .. denceofcontrast-inducedacutekidneyinjuryinpatientstreatedwithpercuta-
.
cacyofapercutaneousleftventricularassistdeviceversusintra-aorticballoon . neouscoronaryintervention.JAmCollCardiol2013;62:1260–1266.
.
pumpingfortreatmentofcardiogenicshockcausedbymyocardialinfarction.J . 284.Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ,
.
AmCollCardiol2008;52:1584–1588. .. Nephrotoxicity in High-Risk Patients Study of I-O, Low-Osmolar Non-Ionic
266. ThieleH,JobsA,OuweneelDM,HenriquesJPS,SeyfarthM,DeschS,EitelI, .. Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients
.
PossJ,FuernauG,deWahaS.Percutaneousshort-termactivemechanicalsup- . undergoingangiography.NEnglJMed2003;348:491–499.
.
portdevicesincardiogenicshock:Asystematicreviewandcollaborativemeta- . 285.JoSH,YounTJ,KooBK,ParkJS,KangHJ,ChoYS,ChungWY,JooGW,Chae
.
analysisofrandomizedtrials.EurHeartJ2017;38:3523–3531. .. IH,ChoiDJ,OhBH,LeeMM,ParkYB,KimHS.Renaltoxicityevaluationand
267. O’NeillWW,KleimanNS,MosesJ,HenriquesJP,DixonS,MassaroJ,PalaciosI, .. comparisonbetweenvisipaque(iodixanol)andhexabrix(ioxaglate)inpatients
.
MainiB,MulukutlaS,DzavikV,PopmaJ,DouglasPS,OhmanM.Aprospective, . withrenalinsufficiencyundergoingcoronaryangiography:TheRECOVERstudy:
.
randomizedclinicaltrialofhemodynamicsupportwithImpella2.5versusintra- .. Arandomizedcontrolledtrial.JAmCollCardiol2006;48:924–930.
aortic balloon pump in patients undergoing high-risk percutaneous coronary .. 286.Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE,
.
intervention:ThePROTECTIIstudy.Circulation2012;126:1717–1727. . GelorminiJL,LabinazM,MoreyraAE;InvestigatorsoftheCAREStudy.Cardiac
.
268. AcharyaD,Loyaga-RendonRY,PamboukianSV,TallajJA,HolmanWL,Cantor . AngiographyinRenallyImpairedPatients(CARE)study:Arandomizeddouble-
.
RS,NaftelDC,KirklinJK.Ventricularassistdeviceinacutemyocardialinfarc- .. blindtrialofcontrast-inducednephropathyinpatientswithchronickidneydis-
tion.JAmCollCardiol2016;67:1871–1880. . ease.Circulation2007;115:3189–3196.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 81 ---
ESC/EACTSGuidelines 165b
.
.
287. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, . physiologic evaluation of coronary artery narrowings in patients with aortic
.
MoltrasioM,GraziM,RubinoM,VegliaF,FabbiocchiF,BartorelliAL.Contrast . valvestenosis.AmJCardiol2017;120:106–110.
.
volume during primary percutaneous coronary intervention and subsequent .. 305.Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B,
contrast-induced nephropathy and mortality. Ann Intern Med .. LancellottiP,LansacE,RodriguezMunozD,RosenhekR,SjogrenJ,TornosMas
.
2009;150:170–177. . P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC
.
288. LaskeyWK,JenkinsC,SelzerF,MarroquinOC,WilenskyRL,GlaserR,Cohen .. ScientificDocumentGroup.2017ESC/EACTSGuidelinesforthemanagement
HA,HolmesDRJr,InvestigatorsNDR.Volume-to-creatinineclearanceratio:A .. ofvalvularheartdisease.EurHeartJ2017;38:2739–2791.
.
pharmacokineticallybasedriskfactorforpredictionofearlycreatinineincrease . 306.YamashitaK,FujitaT,HataH,ShimaharaY,KumeY,MatsumotoY,KobayashiJ.
.
afterpercutaneouscoronaryintervention.JAmCollCardiol2007;50:584–590. . Long-term outcome of isolated off-pump coronary artery bypass grafting in
.
289. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, .. patientswithcoronaryarterydiseaseandmildtomoderateaorticstenosis.J
MarschS,RoskammH.Preventionofcontrastmedia-associatednephropathy: .. Cardiol2017;70:48–54.
.
Randomizedcomparisonof2hydrationregimensin1620patientsundergoing . 307.GoldsteinD,MoskowitzAJ,GelijnsAC,AilawadiG,ParidesMK,PerraultLP,
.
coronaryangioplasty.ArchInternMed2002;162:329–336. . Hung JW, Voisine P, Dagenais F, Gillinov AM, Thourani V, Argenziano M,
.
290. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, .. GammieJS,MackM,DemersP,AtluriP,RoseEA,O’SullivanK,WilliamsDL,
.
BersinRM,VanMooreA,SimontonCAIII,RittaseRA,NortonHJ,Kennedy . BagiellaE,MichlerRE,WeiselRD,MillerMA,GellerNL,Taddei-PetersWC,
.
TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: A . SmithPK,MoqueteE,OverbeyJR,KronIL,O’GaraPT,AckerMA,Ctsn.Two-
.
randomizedcontrolledtrial.JAMA2004;291:2328–2334. .. yearoutcomesofsurgicaltreatmentofsevereischemicmitralregurgitation.N
291. BrarSS,ShenAY,JorgensenMB,KotlewskiA,AharonianVJ,DesaiN,ReeM, .. EnglJMed2016;374:344–353.
.
ShahAI,BurchetteRJ.Sodiumbicarbonatevssodiumchlorideforthepreven- . 308.SmithPK,PuskasJD,AscheimDD,VoisineP,GelijnsAC,MoskowitzAJ,Hung
.
tionofcontrastmedium-inducednephropathyinpatientsundergoingcoronary . JW,ParidesMK,AilawadiG,PerraultLP,AckerMA,ArgenzianoM,ThouraniV,
.
angiography:Arandomizedtrial.JAMA2008;300:1038–1046. .. GammieJS,MillerMA,PageP,OverbeyJR,BagiellaE,DagenaisF,Blackstone
292. NijssenEC,RennenbergRJ,NelemansPJ,EssersBA,JanssenMM,Vermeeren .. EH, Kron IL, Goldstein DJ, Rose EA, Moquete EG, Jeffries N, Gardner TJ,
.
MA,OmmenVV,WildbergerJE.Prophylactichydrationtoprotectrenalfunc- . O’GaraPT,AlexanderJH,MichlerRE;CardiothoracicSurgicalTrialsNetwork
.
tion from intravascular iodinated contrast material in patients at high risk of .. Investigators.Surgicaltreatmentofmoderateischemicmitralregurgitation. N
contrast-inducednephropathy(AMACING):Aprospective,randomised,phase .. EnglJMed2014;371:2178–2188.
.
3,controlled,open-label,non-inferioritytrial.Lancet2017;389:1312–1322. . 309.Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ,
.
293. GiacoppoD,GargiuloG,BuccheriS,ArutaP,ByrneRA,CasseseS,DangasG, . Acker MA, Hung JW, Chang HL, Perrault LP, Gillinov AM, Argenziano M,
.
KastratiA,MehranR,TamburinoC,CapodannoD. Preventive strategies for .. BagiellaE,OverbeyJR,MoqueteEG,GuptaLN,MillerMA,Taddei-PetersWC,
contrast-inducedacutekidneyinjuryinpatientsundergoingpercutaneouscoro- .. JeffriesN,WeiselRD,RoseEA,GammieJS,DeRoseJJJr,PuskasJD,DagenaisF,
.
naryprocedures:EvidencefromahierarchicalBayesiannetworkmeta-analysis . BurksSG, El-HamamsyI, Milano CA, Atluri P,Voisine P, O’Gara PT, Gelijns
.
of124trialsand28240patients.CircCardiovascInterv2017;10:e004383. . AC, Ctsn. Two-year outcomes of surgical treatment of moderate ischemic
.
294. WeisbordSD,GallagherM,JneidH,GarciaS,CassA,ThwinSS,ConnerTA, .. mitralregurgitation.NEnglJMed2016;374:1932–1941.
.
ChertowGM,BhattDL,ShunkK,ParikhCR,McFallsEO,BrophyM,Ferguson . 310.Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, Rahman-
.
R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial . Haley S, Pennell DJ, Kilner PJ, Dreyfus GD, Pepper JR, Investigators R.
.
Group. Outcomes after angiography with sodium bicarbonate and acetylcys- .. Coronary artery bypass surgery with or without mitral valve annuloplasty in
teine.NEnglJMed2018;378:603–614. .. moderate functional ischemic mitral regurgitation: final results of the
.
295. QianG,FuZ,GuoJ,CaoF,ChenY.Preventionofcontrast-inducednephrop- . Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation
.
athybycentralvenouspressure-guidedfluidadministrationinchronickidney . 2012;126(21):2502–2510.
.
disease and congestive heart failure patients. JACC Cardiovasc Interv .. 311.LancellottiP,TribouilloyC,HagendorffA,PopescuBA,EdvardsenT,Pierard
2016;9:89–96. .. LA,BadanoL,ZamoranoJL,ScientificDocumentCommitteeoftheEuropean
.
296. BriguoriC,ViscontiG,FocaccioA,AiroldiF,ValgimigliM,SangiorgiGM,Golia . AssociationofCardiovascularImaging.Recommendationsfortheechocardio-
.
B,Ricciardelli B,CondorelliG; REMEDIAL II Investigators. Renal Insufficiency .. graphicassessmentofnativevalvularregurgitation:Anexecutivesummaryfrom
After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard .. the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc
.
Systeminhigh-riskpatientsforcontrast-inducedacutekidneyinjury.Circulation . Imaging2013;14:611–644.
.
2011;124:1260–1269. . 312.ZoghbiWA,AdamsD,BonowRO,Enriquez-SaranoM,FosterE,GrayburnPA,
.
297. Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, .. Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S,
PedrazziniG.Preventionofcontrast-inducedacutekidneyinjurybyfurosemide .. Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for
.
with matched hydration in patients undergoing interventional procedures: A . Noninvasive Evaluation of Native Valvular Regurgitation: A report from the .
systematicreviewandmeta-analysisofrandomizedtrials.JACCCardiovascInterv . American Society of Echocardiography developed in collaboration with the
. 2017;10:355–363. .. society for cardiovascular magnetic resonance. J Am Soc Echocardiogr
298. MarenziG,MaranaI,LauriG,AssanelliE,GraziM,CampodonicoJ,Trabattoni .. 2017;30:303–371.
.
D, Fabbiocchi F, Montorsi P, Bartorelli AL. The prevention of radiocontrast- . 313.Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH,
.
agent-induced nephropathy by hemofiltration. N Engl J Med .. DomanskiMJ,FarkouhME,FlatherM,FusterV,HlatkyMA,HolmNR,Hueb
2003;349:1333–1340. .. WA,KamaleshM,KimYH,M€akikallioT,MohrFW,PapageorgiouW,ParkSJ,
.
299. MarenziG,LauriG,CampodonicoJ,MaranaI,AssanelliE,DeMetrioM,Grazi . RodriguezAE,SabikIIIJF,StablesRH,StoneGW,SerruysPW,KappeteinAP.
.
M,VegliaF,FabbiocchiF,MontorsiP,BartorelliAL.Comparisonoftwohemo- . Strokeratesfollowingsurgicalversuspercutaneouscoronaryrevascularization.
.
filtrationprotocolsforpreventionofcontrast-inducednephropathyinhigh-risk .. JAmCollCardiol2018;72:386–398.
patients.AmJMed2006;119:155–162. .. 314.Naylor AR, Bown MJ. Stroke after cardiac surgery and its association with
.
300. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal . asymptomaticcarotiddisease:Anupdatedsystematicreviewandmeta-analysis.
.
replacementtherapiesforpreventionofradiocontrast-inducednephropathy:A .. EurJVascEndovascSurg2011;41:607–624.
systematicreview.AmJMed2012;125:66–78e3. .. 315.MasabniK,RazaS,BlackstoneEH,GornikHL,SabikJFIII.Doespreoperative
.
301. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, . carotidstenosisscreeningreduceperioperativestrokeinpatientsundergoing
.
CereghettiC,SerraA,Huynh-DoU,UehlingerD,FreyFJ.Prophylactichemo- . coronaryarterybypassgrafting?JThoracCardiovascSurg2015;149:1253–1260.
.
dialysisafterradiocontrastmediainpatientswithrenalinsufficiencyispoten- .. 316.NaylorAR.Doestheriskofpost-CABGstrokemeritstagedorsynchronous
tiallyharmful.AmJMed2001;111:692–698. .. reconstructioninpatientswithsymptomaticorasymptomaticcarotiddisease?J
.
302. ScarsiniR,PesariniG,ZivelonghiC,PiccoliA,FerreroV,LunardiM,Barbierato . CardiovascSurg(Torino)2009;50:71–81.
.
M,CaprioglioF,VassanelliC,RibichiniF.Coronaryphysiologyinpatientswith . 317.AboyansV,RiccoJB,BartelinkMEL,BjorckM,BrodmannM,CohnertT,Collet
.
severeaorticstenosis:Comparisonbetweenfractionalflowreserveandinstan- .. JP,CzernyM,DeCarloM,DebusS,Espinola-KleinC,KahanT,KownatorS,
taneouswave-freeratio.IntJCardiol2017;243:40–46. .. Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G,
.
303. ScarsiniR,PesariniG,ZivelonghiC,PiccoliA,FerreroV,LunardiM,GottinL, . Venermo M, Vlachopoulos C, Desormais I, ESC Scientific Document Group.
.
Zanetti C, Faggian G, Ribichini F. Physiologic evaluation of coronary lesions .. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial
usinginstantaneouswave-freeratio(iFR)inpatientswithsevereaorticstenosis .. Diseases, in collaboration with the European Society for Vascular Surgery
.
undergoing transcatheter aortic valve implantation. EuroIntervention . (ESVS):Documentcoveringatheroscleroticdiseaseofextracranialcarotidand
.
2018;13:1512–1519. . vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by:
.
304. DiGioiaG,ScarsiniR,StrisciuglioT,DeBiaseC,ZivelonghiC,FrancoD,De .. TheEuropeanStrokeOrganization(ESO)TheTaskForcefortheDiagnosisand
Bruyne B, Ribichini F, Barbato E. Correlation between angiographic and . Treatment of Peripheral Arterial Diseases of the European Society of
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 82 ---
165c ESC/EACTSGuidelines
.
.
Cardiology(ESC)andoftheEuropeanSocietyforVascularSurgery(ESVS).Eur . SYNTAXInvestigators.Incidence,characteristics,predictors,andoutcomesof
.
HeartJ2018;39:763–816. . repeatrevascularizationafterpercutaneouscoronaryinterventionandcoronary
.
318. Lee R, Matsutani N, Polimenakos AC, Levers LC, Lee M, Johnson RG. .. artery bypass grafting: The SYNTAX trial at 5 years. JACC Cardiovasc Interv
Preoperative noncontrast chest computed tomography identifies potential .. 2016;9:2493–2507.
.
aorticemboli.AnnThoracSurg2007;84:38–41. . 335.CasseseS,ByrneRA,TadaT,PinieckS,JonerM,IbrahimT,KingLA,FusaroM,
.
319. NaylorAR,CuffeRL,RothwellPM,BellPR.Asystematicreviewofoutcomes .. LaugwitzKL,KastratiA.Incidenceandpredictorsofrestenosisaftercoronary
followingstagedandsynchronouscarotidendarterectomyandcoronaryartery .. stenting in 10 004 patients with surveillance angiography. Heart
.
bypass.EurJVascEndovascSurg2003;25:380–389. . 2014;100:153–159.
.
320. ParaskevasKI,NduwayoS,SaratzisAN,NaylorAR.Carotidstentingpriorto . 336.Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M,
.
coronarybypasssurgery:Anupdatedsystematicreviewandmeta-analysis.EurJ .. SchneiderS,SchulzS,IbrahimT,Ott I,MassbergS,Laugwitz KL, KastratiA.
VascEndovascSurg2017;53:309–319. .. Riskofstentthrombosisamongbare-metalstents,first-generationdrug-eluting
.
321. LinJC,KabbaniLS,PetersonEL,MasabniK,MorganJA,BrooksS,WertellaKP, . stents, and second-generation drug-eluting stents: Results from a registry of
.
PaoneG.Clinicalutilityofcarotidduplexultrasoundpriortocardiacsurgery.J . 18,334patients.JACCCardiovascInterv2013;6:1267–1274.
.
VascSurg2016;63:710–714. .. 337.SabikJFIII,BlackstoneEH,HoughtalingPL,WaltsPA,LytleBW.Isreoperation
.
322. AboyansV,LacroixP.Indicationsforcarotidscreeninginpatientswithcoro- . still a risk factor in coronary artery bypass surgery? Ann Thorac Surg
.
naryarterydisease.PresseMed2009;38:977–986. . 2005;80:1719–1727.
.
323. ZhaoDX,LeaccheM,BalaguerJM,BoudoulasKD,DampJA,GreelishJP,Byrne .. 338.YapCH,SposatoL,AkowuahE,TheodoreS,DinhDT,ShardeyGC,Skillington
JG; Writing Group of the Cardiac Surgery, Cardiac Anesthesiology, and .. PD,TatoulisJ,YiiM,SmithJA,MohajeriM,PickA,SeevanayagamS,ReidCM.
.
Interventional Cardiology Groups at the Vanderbilt Heart and Vascular . Contemporaryresultsshowrepeatcoronaryarterybypassgraftingremainsa
.
Institute,AhmadRM,BallSK,CleatorJH,DeeganRJ,EagleSS,FongPP,FrediJL, . riskfactorforoperativemortality.AnnThoracSurg2009;87:1386–1391.
.
Hoff SJ, Jennings HS III, McPherson JA, Piana RN, Pretorius M, Robbins MA, .. 339.FosbolEL,ZhaoY,ShahianDM,GroverFL,EdwardsFH,PetersonED.Repeat
SloskyDA,ThompsonA.Routineintraoperativecompletionangiographyafter .. coronaryrevascularizationaftercoronaryarterybypasssurgeryinolderadults:
.
coronaryarterybypassgraftingand1-stophybridrevascularizationresultsfrom . TheSocietyofThoracicSurgeons’nationalexperience,1991-2007.Circulation
.
a fully integrated hybrid catheterization laboratory/operating room. J Am Coll .. 2013;127:1656–1663.
Cardiol2009;53:232–241. .. 340.Brener SJ,LytleBW,CasserlyIP,EllisSG,TopolEJ,LauerMS.Predictors of
.
324. ThielmannM,MassoudyP,JaegerBR,NeuhauserM,MarggrafG,SackS,Erbel . revascularization method and long-term outcome of percutaneous coronary
.
R,JakobH.Emergencyre-revascularizationwithpercutaneouscoronaryinter- . interventionorrepeatcoronarybypasssurgeryinpatientswithmultivesselcor-
.
vention,reoperation,orconservative treatment inpatients with acuteperio- .. onary disease and previous coronary bypass surgery. Eur Heart J
perativegraftfailurefollowingcoronaryarterybypasssurgery.EurJCardiothorac .. 2006;27:413–418.
.
Surg2006;30:117–125. . 341.MorrisonDA,SethiG,SacksJ,HendersonWG,GroverF,SedlisS,EspositoR;
.
325. ThygesenK,AlpertJS,JaffeAS,SimoonsML,ChaitmanBR,WhiteHD;Writing . InvestigatorsoftheDepartmentofVeteransAffairsCooperativeStudy#385.
.
Group on the Joint/ACCF/AHA/Task Force for the Universal Definition of .. AnginaWithExtremelySeriousOperativeMortalityEvaluation.Percutaneous
.
MyocardialInfactionWHF,ThygesenK,AlpertJS,WhiteHD,JaffeAS,Katus . coronaryinterventionversusrepeatbypasssurgeryforpatientswithmedically
.
HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, . refractorymyocardialischemia:AWESOMErandomizedtrialandregistryexpe-
.
JohansonP,HodH,UnderwoodR,BaxJJ,BonowRO,PintoF,GibbonsRJ,Fox .. riencewithpost-CABGpatients.JAmCollCardiol2002;40:1951–1954.
KA,AtarD,NewbyLK,GalvaniM,HammCW,UretskyBF,StegPG,WijnsW, .. 342.MorrisonDA,SethiG,SacksJ,HendersonW,GroverF,SedlisS,EspositoR,
.
Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, . RamanathanK,WeimanD,SaucedoJ,AntakliT,ParameshV,PettS,VernonS,
.
Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, . Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D,
.
Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, .. Barbiere C, Lewis D; Angina With Extremely Serious Operative Mortality
Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, .. Evaluation(AWESOME).Percutaneouscoronaryinterventionversuscoronary
.
Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, ESC Committee for . artery bypass graft surgery for patients with medically refractory myocardial
.
Practice Guidelines. Third universal definition of myocardial infarction. Eur .. ischemia and risk factors for adverse outcomes with bypass: A multicenter,
HeartJ2012;33:2551–2567. .. randomized trial. Investigators of the Department of Veterans Affairs
.
326. Davierwala PM, Verevkin A, Leontyev S, Misfeld M, Borger MA, Mohr FW. . Cooperative Study #385, the Angina With Extremely Serious Operative
.
Impact of expeditious management of perioperative myocardial ischemia in . MortalityEvaluation(AWESOME).JAmCollCardiol2001;38:143–149.
.
patients undergoing isolated coronary artery bypass surgery. Circulation .. 343.Harskamp RE, Beijk MA, Damman P, Kuijt WJ, Woudstra P, Grundeken MJ,
2013;128:S226–S234. .. KloekJJ,TijssenJG,deMolBA,deWinterRJ.Clinicaloutcomeaftersurgicalor
.
327. LaflammeM,DeMeyN,BouchardD,CarrierM,DemersP,PellerinM,Couture . percutaneousrevascularizationincoronarybypassgraftfailure.JCardiovascMed .
P,PerraultLP.Managementofearlypostoperativecoronaryarterybypassgraft . (Hagerstown)2013;14:438–445.
. failure.InteractCardiovascThoracSurg2012;14:452–456. .. 344.SabikJFIII,RazaS,BlackstoneEH,HoughtalingPL,LytleBW.Valueofinternal
328. Gaudino M, Nesta M, Burzotta F, Trani C, Coluccia V, Crea F, Massetti M. .. thoracicarterygraftingtotheleftanteriordescendingcoronaryarteryatcoro-
.
Resultsofemergencypostoperativere-angiographyaftercardiacsurgeryproce- . naryreoperation.JAmCollCardiol2013;61:302–310.
.
dures.AnnThoracSurg2015;99:1576–1582. .. 345.NwaejikeN,TennysonC,MoscaR,VenkateswaranR.Reusingthepatentinter-
329. ThielmannM,SharmaV,Al-AttarN,BulluckH,BisleriG,BungeJJH,CzernyM, .. nal mammary artery as a conduit in redo coronary artery bypass surgery.
.
FerdinandyP,FreyUH,HeuschG,HolfeldJ,KleinbongardP,KunstG,LangI, . InteractCardiovascThoracSurg2016;22:346–350.
.
LentiniS,MadonnaR,MeybohmP,MunerettoC,ObadiaJF,PerrinoC,Prunier . 346.CoolongA,BaimDS,KuntzRE,O’MalleyAJ,MarulkarS,CutlipDE,PopmaJJ,
.
F,SluijterJPG,VanLaakeLW,Sousa-UvaM,HausenloyDJ.ESCJointWorking .. MauriL.Saphenousveingraftstentingandmajoradversecardiacevents:Apre-
Groups on Cardiovascular Surgery and the Cellular Biology of the Heart .. dictive model derived from a pooled analysis of 3958 patients. Circulation
.
PositionPaper:Perioperativemyocardialinjuryandinfarctioninpatientsunder- . 2008;117:790–797.
.
goingcoronaryarterybypassgraftsurgery.EurHeartJ2017;38:2392–2407. .. 347.Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U,
330. SeshadriN,WhitlowPL,Acharya N,Houghtaling P,BlackstoneEH, EllisSG. .. PopmaJJ,HoKK,KuntzRE;SaphenousveingraftAngioplastyFreeofEmboli
.
Emergencycoronaryarterybypasssurgeryinthecontemporarypercutaneous . Randomized(SAFER)Trial Investigators.Randomizedtrialofadistalembolic
.
coronaryinterventionera.Circulation2002;106:2346–2350. . protectiondeviceduringpercutaneousinterventionofsaphenousveinaorto-
.
331. MattichakSJ,DixonSR,ShannonF,BouraJA,SafianRD.Failedpercutaneous .. coronarybypassgrafts.Circulation2002;105:1285–1290.
coronary intervention: A decade of experience in 21,000 patients. Catheter .. 348.Paul TK, Bhatheja S, Panchal HB, Zheng S, Banerjee S, Rao SV, Guzman L,
.
CardiovascInterv2008;71:131–137. . BeoharN,ZhaoD,MehranR,MukherjeeD.Outcomesofsaphenousveingraft
.
332. Davierwala PM, Leontyev S, Verevkin A, Rastan AJ, Mohr M, Bakhtiary F, . intervention with and without embolic protection device: A comprehensive
.
MisfeldM,MohrFW.Temporaltrendsinpredictorsofearlyandlatemortality .. reviewandmeta-analysis.CircCardiovascInterv2017;10:e005538.
afteremergencycoronaryarterybypassgraftingforcardiogenicshockcompli- .. 349.BrennanJM,Al-HejilyW,DaiD,ShawRE,TrilesskayaM,RaoSV,BrilakisES,
.
catingacutemyocardialinfarction.Circulation2016;134:1224–1237. . AnstromKJ,MessengerJC,PetersonED,DouglasPS,SketchMHJr.Three-year
.
333. AxelssonTA,MennanderA,MalmbergM,GunnJ,JeppssonA,GudbjartssonT. .. outcomesassociatedwithembolicprotectioninsaphenousveingraftinterven-
Isemergencyandsalvagecoronaryarterybypassgraftingjustified?TheNordic .. tion: Results in 49 325 senior patients in the Medicare-linked National
.
Emergency/Salvagecoronaryarterybypassgraftingstudy.EurJCardiothoracSurg . Cardiovascular Data Registry CathPCI Registry. Circ Cardiovasc Interv
.
2016;49:1451–1456. . 2015;8:e001403.
.
334. Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, Mohr .. 350.Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A,
FW, Feldman TE, Colombo A, Dawkins KD, Holmes DR Jr, Kappetein PA; . CambierP,CaputoRP,TurcoM,KovachR,BrodieB,HerrmannHC,KuntzRE,
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 83 ---
ESC/EACTSGuidelines 165d
.
.
Popma JJ, Ramee S, Cox DA; FilterWire EX Randomized Evaluation . Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol
.
Investigators. Randomized comparison of distal protection with a filter-based . 2006;47:2152–2160.
.
catheter and a balloon occlusion and aspiration system during percutaneous .. 363.AlfonsoF,ZuecoJ,CequierA,MantillaR,BethencourtA,Lopez-MinguezJR,
intervention of diseased saphenous vein aorto-coronary bypass grafts. .. AngelJ,AugeJM,Gomez-RecioM,MorisC,Seabra-GomesR,Perez-Vizcayno
.
Circulation2003;108:548–553. . MJ, Macaya C, Restenosis Intra-stent: Balloon Angioplasty Versus Elective
.
351. MauriL,CoxD,HermillerJ,MassaroJ,WahrJ,TaySW,JonasM,PopmaJJ, .. Stenting(RIBS)Investigators.Arandomizedcomparisonofrepeatstentingwith
PavliskaJ,WahrD,RogersC.ThePROXIMALtrial:Proximalprotectionduring .. balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol
.
saphenousveingraftinterventionusingtheProxisEmbolicProtectionSystem: . 2003;42:796–805.
.
A randomized, prospective, multicenter clinical trial. J Am Coll Cardiol . 364.Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J,
.
2007;50:1442–1449. .. SchomigA.Effectivenessofdrug-elutingstentsinpatientswithbare-metalin-
352. Sch€achingerV,HammCW,MunzelT,HaudeM,BaldusS,GrubeE,BonzelT, .. stent restenosis: Meta-analysis of randomized trials. J Am Coll Cardiol
.
KonorzaT,KosterR,ArnoldR,HaaseJ,ProbstP,vomDahlJ,NeumannFJ, . 2007;49:616–623.
.
Mudra H, Hennen B, Thiele L, Zeiher AM; STENTS (STents IN Grafts) . 365.SchellerB,CleverYP,KelschB,HehrleinC,BockschW,RutschW,HaghiD,
.
Investigators. A randomized trial of polytetrafluoroethylene-membrane- .. DietzU,SpeckU,BohmM,CremersB.Long-termfollow-upaftertreatmentof
.
coveredstentscomparedwithconventionalstentsinaortocoronarysaphenous . coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC
.
veingrafts.JAmCollCardiol2003;42:1360–1369. . CardiovascInterv2012;5:323–330.
.
353. Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, .. 366.Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M,
CernigliaroC,NiccoliL,BartorelliAL,RubartelliP,ReifartN,HeyndrickxGR, .. Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated
.
SaunamakiK,MoriceMC,SguraFA,DiMarioC;RandomizedEvaluationofpol- . ballooncatheter.NEnglJMed2006;355:2113–2124.
.
ytetrafluoroethylene COVERed stent in Saphenous vein grafts Investigators. . 367.HabaraS,Iwabuchi M,InoueN,NakamuraS,Asano R,NantoS,HayashiY,
.
Randomizedevaluationofpolytetrafluoroethylene-coveredstentinsaphenous .. Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J,
vein grafts: TheRandomizedEvaluationof polytetrafluoroethylene COVERed .. Kozuma K, Mitsudo K. A multicenter randomized comparison of paclitaxel-
.
stentinSaphenousveingrafts(RECOVERS)Trial.Circulation2003;108:37–42. . coatedballooncatheterwithconventionalballoonangioplastyinpatientswith
.
354. MehilliJ,PacheJ,Abdel-WahabM,SchulzS,ByrneRA,TirochK,HausleiterJ, .. bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J
SeyfarthM,OttI,IbrahimT,FusaroM,LaugwitzKL,MassbergS,NeumannFJ, .. 2013;166:527–533.
.
Richardt G, Schomig A, Kastrati A, Is Drug-Eluting-Stenting Associated with . 368.Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C,
.
Improved Results in Coronary Artery Bypass Grafts? (ISAR CABG) . Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M,
.
Investigators. Drug-eluting versus bare-metal stents in saphenous vein graft .. Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-
lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet .. coatedballooncatheterversuspaclitaxel-coatedstentforthetreatmentofcor-
.
2011;378:1071–1078. . onaryin-stentrestenosis.Circulation2009;119:2986–2994.
.
355. BrilakisES,LichtenwalterC,deLemosJA,RoesleM,ObelO,HaagenD,Saeed . 369.RittgerH,BrachmannJ,SinhaAM,WaliszewskiM,OhlowM,BruggerA,Thiele
.
B,GadiparthiC,BissettJK,SachdevaR,VoudrisVV,KaryofillisP,KarB,Rossen .. H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S,
.
J,FasseasP,BergerP,BanerjeeS.Arandomizedcontrolledtrialofapaclitaxel- . LonkeS,vonCranachM,NguyenTV,DanielWG,WohrleJ.Arandomized,
.
elutingstentversusasimilarbare-metalstentinsaphenousveingraftlesions . multicenter,single-blindedtrialcomparingpaclitaxel-coatedballoonangioplasty
.
the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol .. with plain balloon angioplasty in drug-eluting stent restenosis: ThePEPCAD-
2009;53:919–928. .. DESstudy.JAmCollCardiol2012;59:1377–1382.
.
356. VermeerschP,AgostoniP,VerheyeS,VandenHeuvelP,ConvensC,Bruining . 370.HabaraS,MitsudoK,KadotaK,GotoT,FujiiS,YamamotoH,KatohH,OkaN,
.
N, Van den Branden F, Van Langenhove G; DELAYED RRISC Investigators. . FukuY,HosogiS,HironoA,MaruoT,TanakaH,ShigemotoY,HasegawaD,
.
Randomized double-blind comparison of sirolimus-eluting stent versus bare- .. TasakaH,KusunoseM,OtsuruS,OkamotoY,SaitoN,TsujimotoY,EguchiH,
metal stent implantation in diseased saphenous vein grafts: Six-month angio- .. Miyake K, Yoshino M. Effectiveness of paclitaxel-eluting balloon catheter in
.
graphic,intravascularultrasound,andclinicalfollow-upoftheRRISCTrial.JAm . patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv
.
CollCardiol2006;48:2423–2431. .. 2011;4:149–154.
357. ColleranR,KufnerS,MehilliJ,RosenbeigerC,SchupkeS,HoppmannP,Joner .. 371.ByrneRA,NeumannFJ,MehilliJ,PinieckS,WolffB,TirochK,SchulzS,Fusaro
.
M,MankeriousN,FusaroM,CasseseS,Abdel-WahabM,NeumannFJ,Richardt . M,OttI,IbrahimT,HausleiterJ,ValinaC,PacheJ,LaugwitzKL,MassbergS,
.
G, Ibrahim T, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-CABG . KastratiA;ISAR-DESIRE3Investigators.Paclitaxel-elutingballoons,paclitaxel-
.
Investigators.Efficacyovertimewithdrug-elutingstentsinsaphenousveingraft .. elutingstents,andballoonangioplastyinpatientswithrestenosisafterimplanta-
lesions.JAmCollCardiol2018;71:1973–1982. .. tion of a drug-eluting stent (ISAR-DESIRE 3): Arandomised, open-label trial.
.
358. BrilakisES,LichtenwalterC,Abdel-karimAR,deLemosJA,ObelO,AddoT, . Lancet2013;381:461–467. .
RoesleM,HaagenD,RanganBV,SaeedB,BissettJK,SachdevaR,VoudrisVV, . 372.IndermuehleA,BahlR,LanskyAJ,FroehlichGM,KnappG,TimmisA,MeierP.
. KaryofillisP,KarB,RossenJ,FasseasP,BergerP,BanerjeeS.Continuedbenefit .. Drug-eluting balloon angioplasty for in-stent restenosis: A systematic
frompaclitaxel-elutingcomparedwithbare-metalstentimplantationinsaphe- .. review and meta-analysis of randomised controlled trials. Heart 2013;99:
.
nous vein graft lesions during long-term follow-up of the SOS (Stenting of . 327–333.
.
SaphenousVeinGrafts)trial.JACCCardiovascInterv2011;4:176–182. .. 373.AlfonsoF,Perez-VizcaynoMJ,CardenasA,GarciaDelBlancoB,Seidelberger
359. VermeerschP,AgostoniP,VerheyeS,VandenHeuvelP,ConvensC,Vanden .. B, Iniguez A, Gomez-Recio M, Masotti M, Velazquez MT, Sanchis J, Garcia-
.
BrandenF,VanLangenhoveG;DELAYEDRRISC(DeathandEventsatLong- . TouchardA,ZuecoJ,BethencourtA,MelgaresR,CequierA,DominguezA,
.
termfollow-upAnalYsis:ExtendedDurationoftheReductionofRestenosisin . MainarV,Lopez-MinguezJR,MoreuJ,MartiV,MorenoR,Jimenez-QuevedoP,
.
SaphenousveingraftswithCypherstent)Investigators.Increasedlatemortality .. GonzaloN,FernandezC,MacayaC;RIBSVStudyInvestigators,undertheaus-
after sirolimus-eluting stents versus bare-metal stents in diseased saphenous .. pices of the Working Group on Interventional Cardiology of the Spanish
.
vein grafts: Results from the randomized DELAYED RRISC Trial. J Am Coll . SocietyofCardiology.Arandomizedcomparisonofdrug-elutingballoonversus
.
Cardiol2007;50:261–267. .. everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis:
360. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, .. The RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents:
.
LaugwitzKL,SchomigA,KastratiA;ISAR-DESIRE2Investigators.Randomized . Paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol
.
trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary . 2014;63:1378–1386.
.
restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary .. 374.PlevaL,KuklaP,KusnierovaP,ZapletalovaJ,HlinomazO.Comparisonofthe
StentingandAngiographicResults:DrugElutingStentsforIn-StentRestenosis .. efficacyofpaclitaxel-elutingballooncathetersandeverolimus-elutingstentsin
.
2)study.JAmCollCardiol2010;55:2710–2716. . thetreatmentofcoronaryin-stentrestenosis:Thetreatmentofin-stentreste-
.
361. KastratiA,MehilliJ,vonBeckerathN,DibraA,HausleiterJ,PacheJ,Schuhlen . nosisstudy.CircCardiovascInterv2016;9:e003316.
.
H,SchmittC,DirschingerJ,SchomigA;ISAR-DESIREInvestigators.Sirolimus- .. 375.Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-
elutingstentorpaclitaxel-elutingstentvsballoonangioplastyforpreventionof .. Touchard A, Lopez-Minguez JR, Benedicto A, Masotti M, Zueco J, Iniguez A,
.
recurrencesinpatientswithcoronaryin-stentrestenosis:Arandomizedcon- . VelazquezM,MorenoR,MainarV,DominguezA,PomarF,MelgaresR,Rivero
.
trolledtrial.JAMA2005;293:165–171. .. F, Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C, RIBS IV
362. AlfonsoF,Perez-VizcaynoMJ, HernandezR,Bethencourt A,MartiV,Lopez- .. Investigators. A prospective randomized trial of drug-eluting balloons versus
.
Minguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabate M, Escaned J, . everolimus-eluting stents in patients with in-stent restenosis of drug-eluting
.
MorenoR,BanuelosC,SuarezA,MacayaC;RIBS-IIInvestigators.Arandomized . stents:TheRIBSIVrandomizedclinicaltrial.JAmCollCardiol2015;66:23–33.
.
comparisonofsirolimus-elutingstentwithballoonangioplastyinpatientswith .. 376.BaanJJr,ClaessenBE,DijkKB,VendrikJ,vanderSchaafRJ,MeuwissenM,van
in-stent restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty . RoyenN,GosselinkATM,vanWelyMH,DirkaliA,ArkenboutEK,deWinter
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 84 ---
165e ESC/EACTSGuidelines
.
.
RJ,KochKT,SjauwKD,BeijkMA,VisMM,WykrzykowskaJJ,PiekJJ,Tijssen . patientswithmyocardialinfarctionandreducedejectionfraction.NEnglJMed
.
JGP,HenriquesJPS.Arandomizedcomparisonofpaclitaxel-elutingballoonver- . 2002;346:877–883.
.
suseverolimus-elutingstentforthetreatmentofanyin-stentrestenosis:The .. 393.Al-KhatibSM,HellkampAS,LeeKL,AndersonJ,PooleJE,MarkDB,BardyGH;
DAREtrial.JACCCardiovascInterv2018;11:275–283. .. SCD-HeFT Investigators. Implantable cardioverter defibrillator therapy in
.
377. KufnerS,JonerM,SchneiderS,TolgR,ZrennerB,ReppJ,StarkmannA,Xhepa . patientswithpriorcoronaryrevascularizationintheSuddenCardiacDeathin
.
E,IbrahimT,CasseseS,FusaroM,OttI,HengstenbergC,SchunkertH,Abdel- .. HeartFailureTrial(SCD-HeFT).JCardiovascElectrophysiol2008;19:1059–1065.
Wahab M, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 4 Investigators. .. 394.SesselbergHW,MossAJ,McNittS,ZarebaW,DaubertJP,AndrewsML,Hall
.
Neointimalmodificationwithscoringballoonandefficacyofdrug-coatedbal- . WJ,McCliniticB,HuangDT;MADITIIResearchGroup.Ventriculararrhythmia
.
loon therapy in patients with restenosis in drug-eluting coronary stents: A . stormsinpostinfarctionpatientswithimplantabledefibrillatorsforprimarypre-
.
randomizedcontrolledtrial.JACCCardiovascInterv2017;10:1332–1340. .. ventionindications:AMADIT-IIsubstudy.HeartRhythm2007;4:1395–1402.
378. SiontisGC,StefaniniGG,MavridisD,SiontisKC,AlfonsoF,Perez-VizcaynoMJ, .. 395.SpauldingCM,JolyLM,RosenbergA,MonchiM,WeberSN,DhainautJF,Carli
.
ByrneRA, Kastrati A,MeierB,SalantiG,JuniP,WindeckerS.Percutaneous . P. Immediate coronary angiography in survivors of out-of-hospital cardiac
.
coronaryinterventionalstrategiesfortreatmentofin-stentrestenosis:Anet- . arrest.NEnglJMed1997;336:1629–1633.
.
workmeta-analysis.Lancet2015;386:655–664. .. 396.KernKB.Optimaltreatmentofpatientssurvivingout-of-hospitalcardiacarrest.
.
379. GiacoppoD,GargiuloG,ArutaP,CapranzanoP,TamburinoC,CapodannoD. . JACCCardiovascInterv2012;5:597–605.
.
Treatment strategies for coronary in-stent restenosis: Systematic review and . 397.GarotP,LefevreT,EltchaninoffH,MoriceMC,TamionF,AbryB,LesaultPF,
.
hierarchicalBayesiannetworkmeta-analysisof24randomisedtrialsand4880 .. LeTarnecJY,PougesC,MargenetA,MonchiM,LaurentI,DumasP,GarotJ,
patients.BMJ2015;351:h5392. .. LouvardY.Six-monthoutcomeofemergencypercutaneouscoronaryinterven-
.
380. KufnerS,CasseseS,ValeskiniM,NeumannFJ,Schulz-SchupkeS,HoppmannP, . tioninresuscitatedpatientsaftercardiacarrestcomplicatingST-elevationmyo-
.
Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 3 . cardialinfarction.Circulation2007;115:1354–1362.
.
Investigators.Long-termefficacyandsafetyofpaclitaxel-elutingballoonforthe .. 398.RadselP,KnafeljR,KocjancicS,NocM.Angiographiccharacteristicsofcoro-
treatmentofdrug-elutingstentrestenosis:3-yearresultsofarandomizedcon- .. narydiseaseandpostresuscitationelectrocardiogramsinpatientswithaborted
.
trolledtrial.JACCCardiovascInterv2015;8:877–884. . cardiacarrestoutsideahospital.AmJCardiol2011;108:634–638.
.
381. XuB,QianJ,GeJ,WangJ,ChenF,ChenJ,WeiM,ChenY,YangY,GaoR; .. 399.AnyfantakisZA,BaronG,AubryP,HimbertD,FeldmanLJ,JuliardJM,Ricard-
PEPCAD China ISR Investigators. Two-year results and subgroup analysesof .. HibonA,BurnodA,CokkinosDV,StegPG.Acutecoronaryangiographicfind-
.
the PEPCAD China in-stent restenosis trial: A prospective, multicenter, . ings in survivors of out-of-hospital cardiac arrest. Am Heart J
.
randomized trial for the treatment of drug-eluting stent in-stent restenosis. . 2009;157:312–318.
.
CatheterCardiovascInterv2016;87:624–629. .. 400.Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J,
382. ByrneRA,CasseseS,WindischT,KingLA,JonerM,TadaT,MehilliJ,PacheJ, .. Empana JP, Carli P, Mira JP, Jouven X, Spaulding C. Immediate percutaneous
.
KastratiA.Differentialrelativeefficacybetweendrug-elutingstentsinpatients . coronary intervention is associated with better survival after out-of-hospital
.
withbaremetalanddrug-elutingstentrestenosis;Evidenceinsupportofdrug . cardiac arrest: Insights from the PROCAT (Parisian Region Out of hospital
.
resistance: Insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. .. CardiacArresT)registry.CircCardiovascInterv2010;3:200–207.
.
EuroIntervention2013;9:797–802. . 401.Cronier P, Vignon P, Bouferrache K, Aegerter P, Charron C, Templier F,
.
383. Zellweger MJ, Kaiser C, Jeger R, Brunner-La Rocca HP, Buser P, Bader F, . Castro S, El Mahmoud R, Lory C, Pichon N, Dubourg O, Vieillard-Baron A.
.
Mueller-BrandJ,PfistererM.Coronaryarterydiseaseprogressionlateaftersuc- .. Impactofroutinepercutaneouscoronaryinterventionafterout-of-hospitalcar-
cessfulstentimplantation.JAmCollCardiol2012;59:793–799. .. diacarrestduetoventricularfibrillation.CritCare2011;15:R122.
.
384. StoneGW,MaeharaA,LanskyAJ,deBruyneB,CristeaE,MintzGS,MehranR, . 402.Geri G, Dumas F, Bougouin W, Varenne O, Daviaud F, Pene F, Lamhaut L,
.
McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, . ChicheJD,SpauldingC,MiraJP,EmpanaJP,CariouA.Immediatepercutaneous
.
SerruysPW;PROSPECTInvestigators.Aprospectivenatural-historystudyof .. coronaryinterventionisassociatedwithimprovedshort-andlong-termsurvival
coronaryatherosclerosis.NEnglJMed2011;364:226–235. .. afterout-of-hospitalcardiacarrest.CircCardiovascInterv2015;8:e002303.
.
385. Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, Consoli L, . 403.VyasA,ChanPS,CramP,NallamothuBK,McNallyB,GirotraS.Earlycoronary
.
BaldereschiG,Biondi-ZoccaiGG,SheibanI,MargheriM.ST-segmentelevation .. angiography and survival after out-of-hospital cardiac arrest. Circ Cardiovasc
myocardialinfarctionduetoearlyandlatestentthrombosisanewgroupof .. Interv2015;8:e002321.
.
high-riskpatients.JAmCollCardiol2008;51:2396–23402. . 404.NocM,FajadetJ,LassenJF,KalaP,MacCarthyP,OlivecronaGK,WindeckerS,
.
386. AlfonsoF,DutaryJ,PauloM,GonzaloN,Perez-VizcaynoMJ,Jimenez-Quevedo . SpauldingC.Invasivecoronarytreatmentstrategiesforout-of-hospitalcardiac
.
P, Escaned J, Banuelos C, Hernandez R, Macaya C. Combined use of .. arrest: A consensus statement from the European Association for
opticalcoherencetomographyandintravascularultrasoundimaginginpatients .. PercutaneousCardiovascularInterventions(EAPCI)/StentforLife(SFL)groups.
.
undergoing coronary interventions for stent thrombosis. Heart 2012;98: . EuroIntervention2014;10:31–37. .
1213–1220. . 405.KirchhofP,BenussiS,KotechaD,AhlssonA,AtarD,CasadeiB,CastellaM,
. 387. AdriaenssensT,JonerM,GodschalkTC,MalikN,AlfonsoF,XhepaE,DeCock .. Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J,
D,KomukaiK,TadaT,CuestaJ,SirbuV,FeldmanLJ,NeumannFJ,GoodallAH, .. Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document
.
HeestermansT,BuysschaertI,HlinomazO,BelmansA,DesmetW,TenBerg . Group.2016ESCGuidelinesforthemanagementofatrialfibrillationdeveloped
.
JM,GershlickAH,MassbergS,KastratiA,GuagliumiG,ByrneRA;Prevention .. incollaborationwithEACTS.EurHeartJ2016;37:2893–2962.
of Late Stent Thrombosis by an Interdisciplinary Global European Effort .. 406.ChanW,AjaniAE,ClarkDJ,StubD,AndrianopoulosN,BrennanAL,NewG,
.
(PRESTIGE) Investigators. Optical coherence tomography findings in patients . SebastianM,JohnstonR,WaltonA,ReidCM,DartAM,DuffySJ,Melbourne
.
with coronary stent thrombosis: A report of the PRESTIGE Consortium . Interventional Group Investigators. Impact of periprocedural atrial fibrillation
.
(PreventionofLateStentThrombosisbyanInterdisciplinaryGlobalEuropean .. onshort-termclinicaloutcomesfollowingpercutaneouscoronaryintervention.
Effort).Circulation2017;136:1007–1021. .. AmJCardiol2012;109:471–477.
.
388. Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo KK, Wong SC, . 407.LopesRD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D,
.
Spertus J, Shaw RE, Minutello RM, Moussa I, Ho KK, Rogers JH, Shunk KA. .. Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB.
Clinical presentation, management, and outcomes of angiographically docu- .. Antithrombotictherapyandoutcomesofpatientswithatrialfibrillationfollow-
.
mented early, late, and very late stent thrombosis. JACC Cardiovasc Interv . ingprimarypercutaneouscoronaryintervention:ResultsfromtheAPEX-AMI
.
2012;5:131–140. . trial.EurHeartJ2009;30:2019–2028.
.
389. HolmesDRJr,DavisKB,MockMB,FisherLD,GershBJ,KillipTIII,PettingerM. .. 408.MrdovicI,SavicL,KrljanacG,PerunicicJ,AsaninM,LasicaR,AntonijevicN,
The effect of medical and surgical treatment on subsequent sudden cardiac .. KocevN,MarinkovicJ,VasiljevicZ,OstojicM.Incidence,predictors,and30-
.
death in patients with coronary arterydisease: Areport from the Coronary . dayoutcomesofnew-onsetatrialfibrillationafterprimarypercutaneouscoro-
.
ArterySurgeryStudy.Circulation1986;73:1254–1263. . naryintervention:InsightintotheRISK-PCItrial.CoronArteryDis2012;23:1–8.
.
390. Long-termresultsofprospectiverandomisedstudyofcoronaryarterybypass .. 409.Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H, Carrel T,
surgery in stable angina pectoris. European Coronary Surgery Study Group. .. MoschovitisA,StorteckyS,WenaweserP,StefaniniGG,RaberL,MeierB,Juni
.
Lancet1982;2:1173–80. . P,WindeckerS.Impactofatrialfibrillationonclinicaloutcomesamongpatients
.
391. VeenhuyzenGD,SinghSN,McAreaveyD,SheltonBJ,ExnerDV.Priorcoro- .. with coronary artery disease undergoing revascularisation with drug-eluting
naryarterybypasssurgeryandriskofdeathamongpatientswithischemicleft .. stents.EuroIntervention2013;8:1061–1071.
.
ventriculardysfunction.Circulation2001;104:1489–1493. . 410.ValgimigliM,BuenoH,ByrneRA,ColletJP,CostaF,JeppssonA,JuniP,Kastrati
.
392. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, . A,KolhP,MauriL,MontalescotG,NeumannFJ,PetricevicM,RoffiM,StegPG,
.
Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator .. WindeckerS,ZamoranoJL,LevineGN;ESCScientificDocumentGroup;ESC
ImplantationTrialIIInvestigators.Prophylacticimplantationofadefibrillatorin . Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 85 ---
ESC/EACTSGuidelines 165f
.
.
2017ESCfocusedupdateondualantiplatelettherapyincoronaryarterydis- . 431.El-ChamiMF,KilgoP,ThouraniV,LattoufOM,DelurgioDB,GuytonRA,Leon
.
easedevelopedincollaborationwithEACTS:TheTaskForcefordualantiplate- . AR,PuskasJD.New-onsetatrialfibrillationpredictslong-termmortalityafter
.
lettherapyincoronaryarterydiseaseoftheEuropeanSocietyofCardiology(ESC) .. coronaryarterybypassgraft.JAmCollCardiol2010;55:1370–1376.
and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J .. 432.Melduni RM, Schaff HV, Lee HC, Gersh BJ, Noseworthy PA, Bailey KR,
.
2018;39:213–260. . AmmashNM,ChaSS,FatemaK,WysokinskiWE,SewardJB,PackerDL,Rihal
.
411. AhlssonAJ,BodinL,LundbladOH,EnglundAG.Postoperativeatrialfibrilla- .. CS,AsirvathamSJ.Impactofleftatrialappendageclosureduringcardiacsurgery
tion is not correlated to C-reactive protein. Ann Thorac Surg 2007;83: .. ontheoccurrenceofearlypostoperativeatrialfibrillation,stroke,andmortality:
.
1332–1337. . A propensity score-matched analysis of 10 633 patients. Circulation
.
412. ArsenaultKA,YusufAM,CrystalE,HealeyJS,MorilloCA,NairGM,Whitlock . 2017;135:366–378.
.
RP. Interventions for preventing post-operative atrial fibrillation in patients .. 433.TsaiYC,PhanK,Munkholm-LarsenS,TianDH,LaMeirM,YanTD.Surgical
undergoingheartsurgery.CochraneDatabaseSystRev2013;1:CD003611. .. left atrial appendage occlusion during cardiac surgery for patients with atrial
.
413. MathewJP,FontesML,TudorIC,RamsayJ,DukeP,MazerCD,BarashPG,Hsu . fibrillation:Ameta-analysis.EurJCardiothoracSurg2015;47:847–854.
.
PH, Mangano DT; Investigators of the Ischemia Research and Education . 434.FriedmanDJ,PicciniJP,WangT,ZhengJ,MalaisrieSC,HolmesDR,SuriRM,
.
Foundation; Multicenter Study of Perioperative Ischemia Research Group. A .. MackMJ,BadhwarV,JacobsJP,GacaJG,ChowSC,PetersonED,BrennanJM.
.
multicenter risk index for atrial fibrillation after cardiac surgery. JAMA . Associationbetweenleftatrialappendageocclusionandreadmissionforthrom-
.
2004;291:1720–1729. . boembolismamongpatientswithatrialfibrillationundergoingconcomitantcar-
.
414. ShenJ,LallS,ZhengV,BuckleyP,DamianoRJJr,SchuesslerRB.Thepersistent .. diacsurgery.JAMA2018;319:365–374.
problemofnew-onsetpostoperativeatrialfibrillation:Asingle-institutionexpe- .. 435.Whitlock R, Healey J, Vincent J,Brady K, Teoh K, Royse A, Shah P,Guo Y,
.
rienceovertwodecades.JThoracCardiovascSurg2011;141:559–570. . AlingsM,FolkeringaRJ,PaparellaD,ColliA,MeyerSR,LegareJF,Lamontagne
.
415. LaParDJ,SpeirAM,CrosbyIK,FonnerEJr,BrownM,RichJB,QuaderM,Kern . F, Reents W, Boning A, Connolly S. Rationale and design of the Left Atrial
.
JA,KronIL,AilawadiG,InvestigatorsfortheVirginiaCardiacSurgeryQuality .. AppendageOcclusionStudy(LAAOS)III.AnnCardiothoracSurg2014;3:45–54.
Initiative.Postoperativeatrialfibrillationsignificantlyincreasesmortality,hospital .. 436.KernKB,RahmanO.Emergentpercutaneouscoronaryinterventionforresusci-
.
readmission,andhospitalcosts.AnnThoracSurg2014;98:527–533. . tated victims of out-of-hospital cardiac arrest. Catheter Cardiovasc Interv
.
416. SaxenaA,DinhDT,SmithJA,ShardeyGC,ReidCM,NewcombAE.Usefulness .. 2010;75:616–624.
ofpostoperativeatrialfibrillationasanindependentpredictorforworseearly .. 437.Garcia-Tejada J, Jurado-Roman A, Rodriguez J, Velazquez M, Hernandez F,
.
andlateoutcomesafterisolatedcoronaryarterybypassgrafting(multicenter . Albarran A, Martin-Asenjo R, Granda-Nistal C, Coma R, Tascon J. Post-
.
Australianstudyof19,497patients).AmJCardiol2012;109:219–225. . resuscitationelectrocardiograms,acutecoronaryfindingsandin-hospitalprog-
.
417. SteinbergBA,ZhaoY,HeX,HernandezAF,FullertonDA,ThomasKL,MillsR, .. nosis of survivors of out-of-hospital cardiac arrest. Resuscitation 2014;85:
KlaskalaW,PetersonED,PicciniJP.Managementofpostoperativeatrialfibrilla- .. 1245–1250.
.
tion and subsequent outcomes in contemporary patients undergoing cardiac . 438.KhanMF,WendelCS,MovahedMR.Preventionofpost-coronaryarterybypass
.
surgery: Insights from the Society of Thoracic Surgeons CAPS-Care Atrial . grafting(CABG)atrialfibrillation:Efficacyofprophylacticbeta-blockersinthe
.
FibrillationRegistry.ClinCardiol2014;37:7–13. .. modern era: A meta-analysis of latest randomized controlled trials. Ann
.
418. AhlssonA,BodinL,FengsrudE,EnglundA.Patientswithpostoperativeatrial . NoninvasiveElectrocardiol2013;18:58–68.
.
fibrillation have a doubled cardiovascular mortality. Scand Cardiovasc J . 439.ChatterjeeS,SardarP,MukherjeeD,LichsteinE,AikatS.Timingandrouteof
.
2009;43:330–336. .. amiodaroneforpreventionofpostoperativeatrialfibrillationaftercardiacsur-
419. AhlssonA,FengsrudE,BodinL,EnglundA.Postoperativeatrialfibrillationin .. gery: A network regression meta-analysis. Pacing Clin Electrophysiol
.
patientsundergoingaortocoronarybypasssurgerycarriesaneightfold riskof . 2013;36:1017–1023.
.
futureatrialfibrillationandadoubledcardiovascularmortality.EurJCardiothorac . 440.Friberg L,Rosenqvist M, Lip GY. Evaluationof risk stratification schemes for
.
Surg2010;37:1353–1359. .. ischaemicstrokeandbleedingin182678patientswith atrialfibrillation:The
420. GialdiniG,NearingK,BhavePD,BonuccelliU,IadecolaC,HealeyJS,KamelH. .. SwedishAtrialFibrillationcohortstudy.EurHeartJ2012;33:1500–1510.
.
Perioperativeatrialfibrillationandthelong-termriskofischemicstroke.JAMA . 441.LipGY,NieuwlaatR,PistersR,LaneDA,CrijnsHJ.Refiningclinicalriskstratifi-
.
2014;312:616–622. .. cationforpredictingstrokeandthromboembolisminatrialfibrillationusinga
421. MariscalcoG,KlersyC,ZanobiniM,BanachM,FerrareseS,BorsaniP,Cantore .. novelriskfactor-based approach:Theeuroheartsurveyonatrialfibrillation.
.
C,BiglioliP,SalaA.Atrialfibrillationafterisolatedcoronarysurgeryaffectslate . Chest2010;137:263–272.
.
survival.Circulation2008;118:1612–1618. . 442.Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME,
.
422. VillarealRP,HariharanR,LiuBC,KarB,LeeVV,ElaydaM,LopezJA,RasekhA, .. Ailawadi G, Kirkwood KA, Perrault LP, Parides MK, Smith RL II, Kern JA,
WilsonJM,MassumiA.Postoperativeatrialfibrillationandmortalityaftercoro- .. DussaultG,HackmannAE,JeffriesNO,Miller MA,Taddei-PetersWC, Rose
.
naryarterybypasssurgery.JAmCollCardiol2004;43:742–748. . EA, Weisel RD, Williams DL, Mangusan RF, Argenziano M, Moquete EG, .
423. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post- . O’SullivanKL,PellerinM,ShahKJ,GammieJS,MayerML,VoisineP,GelijnsAC,
. operativeatrialfibrillationanditscomplicationsaftercardiacsurgery:Ameta- .. O’Gara PT, Mack MJ, CTSN. Rate control versus rhythm control for atrial
analysis.EurHeartJ2006;27:2846–2857. .. fibrillationaftercardiacsurgery.NEnglJMed2016;374:1911–1921.
.
424. ConnollySJ,CybulskyI,LamyA,RobertsRS,O’BrienB,CarrollS,CrystalE, . 443.HeadSJ,MilojevicM,TaggartDP,PuskasJD.Currentpracticeofstate-of-the-
.
ThorpeKE,GentM,Beta-BlockerLengthOfStay(BLOS)study.Double-blind, .. artsurgicalcoronaryrevascularization.Circulation2017;136:1331–1345.
placebo-controlled,randomizedtrialofprophylacticmetoprololforreduction .. 444.Task Force on Patient Blood Management for Adult Cardiac Surgery of the
.
ofhospitallengthofstayafterheartsurgery:thebeta-BlockerLengthOfStay . EuropeanAssociationforCardio-ThoracicSurgery(EACTS)andtheEuropean
.
(BLOS)study.AmHeartJ2003;145:226–232. . AssociationofCardiothoracicAnaesthesiology(EACTA),BoerC,MeestersMI,
.
425. CrystalE,ConnollySJ,SleikK,GingerTJ,YusufS.Interventionsonprevention .. MilojevicM,BenedettoU,BolligerD,vonHeymannC,JeppssonA,KosterA,
ofpostoperativeatrialfibrillationinpatientsundergoingheartsurgery:Ameta- .. OsnabruggeRL,RanucciM,RavnHB,VonkABA,WahbaA,PaganoD.2017
.
analysis.Circulation2002;106:75–80. . EACTS/EACTAGuidelinesonpatientbloodmanagementforadultcardiacsur-
.
426. DunningJ,TreasureT,VersteeghM,NashefSA;EACTSAuditandGuidelines . gery.JCardiothoracVascAnesth2018;32:88–120.
.
Committee.Guidelinesonthepreventionandmanagementofdenovoatrial .. 445.Head SJ, Mack MJ, Holmes DR Jr, Mohr FW, Morice MC, Serruys PW,
.
fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg . KappeteinAP.Incidence,predictorsandoutcomesofincompleterevasculariza-
.
2006;30:852–872. . tionafterpercutaneouscoronaryinterventionandcoronaryarterybypassgraft-
.
427. Koniari I, Apostolakis E, Rogkakou C, Baikoussis NG, Dougenis D. .. ing: A subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg
Pharmacologicprophylaxisforatrialfibrillationfollowingcardiacsurgery:Asys- .. 2012;41:535–541.
.
tematicreview.JCardiothoracSurg2010;5:121. . 446.KimYH,ParkDW,LeeJY,KimWJ,YunSC,AhnJM,SongHG,OhJH,ParkJS,
.
428. Lucio Ede A, Flores A, Blacher C, Leaes PE, Lucchese FA, Ribeiro JP. . KangSJ,LeeSW,LeeCW,ParkSW,ParkSJ.Impactofangiographiccompleterevas-
.
Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the .. cularizationafterdrug-elutingstentimplantationorcoronaryarterybypassgraftsur-
postoperativeperiodofcoronaryarterybypassgraftsurgery.ArqBrasCardiol .. geryformultivesselcoronaryarterydisease.Circulation2011;123:2373–2381.
.
2004;82:42–46,37–41. . 447.Mohammadi S, Kalavrouziotis D, Dagenais F, Voisine P, Charbonneau E.
.
429. TsuboiJ,KawazoeK,IzumotoH,OkabayashiH.Postoperativetreatmentwith .. Completeness of revascularization and survival among octogenarians with
carvedilol,abeta-adrenergicblocker,preventsparoxysmalatrialfibrillationafter .. triple-vesseldisease.AnnThoracSurg2012;93:1432–1437.
.
coronaryarterybypassgrafting.CircJ2008;72:588–591. . 448.Rastan AJ, Walther T, Falk V, Kempfert J, Merk D, Lehmann S, Holzhey D,
.
430. AndersonE,DykeC,LevyJH.Anticoagulationstrategiesforthemanagement . MohrFW.Doesreasonableincompletesurgicalrevascularizationaffectearlyor
.
ofpostoperativeatrialfibrillation.ClinLabMed2014;34:537–561. .. long-termsurvivalinpatientswithmultivesselcoronaryarterydiseasereceiving
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 86 ---
165g ESC/EACTSGuidelines
.
.
left internal mammary artery bypass to left anterior descending artery? . 471.DeoSV,ShahIK,DunlaySM,ErwinPJ,LockerC,AltarabshehSE,BoilsonBA,
.
Circulation2009;120:S70–S77. . Park SJ, Joyce LD. Bilateral internal thoracic artery harvest and deep sternal
.
449. YiG,YounYN,JooHC,HongS,YooKJ.Associationofincompleterevasculari- .. woundinfectionindiabeticpatients.AnnThoracSurg2013;95:862–869.
zationwithlong-termsurvivalafteroff-pumpcoronaryarterybypassgrafting.J .. 472.ElmistekawyEM,GawadN,BourkeM,MesanaT,BoodhwaniM,RubensFD.Is
.
SurgRes2013;185:166–173. . bilateralinternalthoracicarteryusesafeintheelderly?JCardSurg2012;27:1–5.
.
450. Scott R, Blackstone EH, McCarthy PM, Lytle BW, Loop FD, White JA, .. 473.HemoE,MohrR,UretzkyG,KatzG,PopovitsN,PevniD,MedalionB.Long-
CosgroveDM.Isolatedbypassgraftingoftheleftinternalthoracicarterytothe .. term outcomes of patients with diabetes receiving bilateral internal thoracic
.
left anterior descending coronary artery: Late consequences of incomplete . arterygrafts.JThoracCardiovascSurg2013;146:586–592.
.
revascularization.JThoracCardiovascSurg2000;120:173–184. . 474.Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K; ART
.
451. MelbySJ,SaintLL,BalsaraK,ItohA,LawtonJS,ManiarH,PasqueMK,Damiano .. Investigators.ProtocolfortheArterialRevascularisationTrial(ART).Arando-
RJ Jr, Moon MR. Complete coronary revascularization improves survival in .. misedtrialtocomparesurvivalfollowingbilateralversussingleinternalmam-
.
octogenarians.AnnThoracSurg2016;102:505–511. . marygraftingincoronaryrevascularisation[ISRCTN46552265].Trials2006;7:7.
.
452. BotmanCJ,SchonbergerJ,KoolenS,PennO,BotmanH,DibN,EeckhoutE, . 475.ToumpoulisIK,TheakosN,DunningJ.Doesbilateralinternalthoracicartery
.
PijlsN.Doesstenosisseverityofnativevesselsinfluencebypassgraftpatency? .. harvest increase the risk of mediastinitis? Interact Cardiovasc Thorac Surg
.
A prospective fractional flow reserve-guided study. Ann Thorac Surg . 2007;6:787–791.
.
2007;83:2093–2097. . 476.BenedettoU,AltmanDG,GerryS,GrayA,LeesB,PawlaczykR,FlatherM,
.
453. BoylanMJ,LytleBW,LoopFD,TaylorPC,BorshJA,GoormasticM,Cosgrove .. Taggart DP; Arterial Revascularization Trial Investigators. Pedicled and ske-
DM.Surgicaltreatmentofisolatedleftanteriordescendingcoronarystenosis. .. letonizedsingleandbilateralinternalthoracicarterygraftsandtheincidenceof
.
Comparisonofleftinternalmammaryarteryandvenousautograftat18to20 . sternalwoundcomplications:InsightsfromtheArterialRevascularizationTrial.J
.
yearsoffollow-up.JThoracCardiovascSurg1994;107:657–662. . ThoracCardiovascSurg2016;152:270–276.
.
454. SabikJFIII,BlackstoneEH,GillinovAM,BanburyMK,SmediraNG,LytleBW. .. 477.Hayward PA, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A,
Influenceofpatientcharacteristicsandarterialgraftsonfreedomfromcoronary .. BuxtonBF.Comparablepatenciesoftheradialarteryandrightinternalthoracic
.
reoperation.JThoracCardiovascSurg2006;131:90–98. . artery or saphenous vein beyond 5 years: Results from the Radial Artery
.
455. SchmittoJD,RajabTK,CohnLH.Prevalenceandvariabilityofinternalmam- .. Patency and Clinical Outcomes trial. J Thorac Cardiovasc Surg 2010;139:60–5;
marygraftuseincontemporarymultivesselcoronaryarterybypassgraft.Curr .. discussion65–67.
.
OpinCardiol2010;25:609–612. . 478.SchwannTA,EngorenM,BonnellM,ClancyC,HabibRH.Comparisonoflate
.
456. HessCN,LopesRD,GibsonCM,HagerR,WojdylaDM,EnglumBR,MackMJ, . coronaryarterybypassgraftsurvivaleffectsofradialarteryversussaphenous
.
CaliffRM,KouchoukosNT,PetersonED,AlexanderJH.Saphenousveingraft .. veingraftinginmaleandfemalepatients.AnnThoracSurg2012;94:1485–1491.
failure after coronary artery bypass surgery: Insights from PREVENT IV. .. 479.Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P,
.
Circulation2014;130:1445–1451. . CohenB,HoffmanDM.Radialarteryconduitsimprovelong-termsurvivalafter
.
457. Benedetto U, Raja SG, Albanese A, Amrani M, Biondi-Zoccai G, Frati G. . coronaryarterybypassgrafting.AnnThoracSurg2010;90:1165–1172.
.
Searchingforthesecondbestgraftforcoronaryarterybypasssurgery:Anet- .. 480.Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P,
.
work meta-analysis of randomized controlled trials†. Eur J Cardiothorac Surg . Cohen BM, Ko W, DeCastro H, Lucido D, Hoffman DM. Coronary artery
.
2015;47:59–65. . bypassgraftingusingtheradialartery:Clinicaloutcomes,patency,andneedfor
.
458. DormanMJ,KurlanskyPA,TraadEA,GalbutDL,ZuckerM,EbraG.Bilateral .. reintervention.Circulation2012;126:S170–S175.
internalmammaryarterygraftingenhancessurvivalindiabeticpatients:A30- .. 481.CaoC,ManganasC,HortonM,BannonP,Munkholm-LarsenS,AngSC,Yan
.
year follow-up of propensity score-matched cohorts. Circulation . TD.Angiographicoutcomesofradialarteryversussaphenousveinincoronary
.
2012;126:2935–2942. . arterybypassgraftsurgery:Ameta-analysisofrandomizedcontrolledtrials.J
.
459. GalbutDL,KurlanskyPA,TraadEA,DormanMJ,ZuckerM,EbraG.Bilateral .. ThoracCardiovascSurg2013;146:255–261.
internal thoracic artery grafting improves long-term survival in patients with .. 482.GaudinoM,BenedettoU,FremesS,Biondi-ZoccaiG,SedrakyanA,PuskasJD,
.
reducedejectionfraction:Apropensity-matchedstudywith30-yearfollow-up. . AngeliniGD,BuxtonB,FratiG,HareDL,HaywardP,NassoG,MoatN,Peric
.
JThoracCardiovascSurg2012;143:844–853.e4. .. M,YooKJ,SpezialeG,GirardiLN,TaggartDP;RADIALInvestigators.Radial-
460.Grau JB, Ferrari G, Mak AW, Shaw RE, Brizzio ME, Mindich BP, Strobeck J, .. arteryorsaphenous-veingraftsincoronary-arterybypasssurgery.NEnglJMed
.
ZapolanskiA.Propensitymatchedanalysisofbilateralinternalmammaryarteryver- . 2018;378:2069–2077.
.
sussingleleftinternalmammaryarterygraftingat17-yearfollow-up:Validationofa . 483.LytleBW.Skeletonizedinternalthoracicarterygraftsandwoundcomplications.
.
contemporarysurgicalexperience.EurJCardiothoracSurg2012;41:770–775. .. JThoracCardiovascSurg2001;121:625–627.
461. Kurlansky PA,TraadEA,DormanMJ,GalbutDL,Zucker M,EbraG.Thirty- .. 484.SaMP,FerrazPE,EscobarRR,VasconcelosFP,FerrazAA,BraileDM,LimaRC.
.
yearfollow-updefinessurvivalbenefitforsecondinternalmammaryarteryin . Skeletonizedversuspedicledinternalthoracicarteryandriskofsternalwound .
propensity-matchedgroups.AnnThoracSurg2010;90:101–108. . infection aftercoronarybypasssurgery:Meta-analysisandmeta-regressionof
. 462. Lytle BW. Bilateral internal thoracic artery grafting. Ann Cardiothorac Surg .. 4817patients.InteractCardiovascThoracSurg2013;16:849–857.
2013;2:485–492. .. 485.Sakic A, Chevtchik O, Kilo J, Schistek R, Mueller LC, Ulmer H, Grimm M,
.
463. RuttmannE,FischlerN,SakicA,ChevtchikO,AlberH,SchistekR,UlmerH, . Ruttmann E. Simple adaptations of surgical technique to critically reduce the
.
Grimm M. Second internal thoracic artery versus radial artery in coronary .. riskofpostoperativesternalcomplicationsinpatientsreceivingbilateralinternal
arterybypassgrafting:Along-term,propensityscore-matchedfollow-upstudy. .. thoracicarteries.InteractCardiovascThoracSurg2013;17:378–382.
.
Circulation2011;124:1321–1329. . 486.WendlerO,HennenB,MarkwirthT,KonigJ,TschollD,HuangQ,ShahangiE,
.
464. TaggartDP,D’AmicoR,AltmanDG.Effectofarterialrevascularisationonsur- . SchafersHJ.Tgraftswiththerightinternalthoracicarterytoleftinternalthoracic
.
vival: A systematic review of studies comparing bilateral and single internal .. arteryversustheleftinternalthoracicarteryandradialartery:Flowdynamicsin
mammaryarteries.Lancet2001;358:870–875. .. theinternalthoracicarterymainstem.JThoracCardiovascSurg1999;118:841–848.
.
465. WeissAJ,ZhaoS,TianDH,TaggartDP,YanTD.Ameta-analysiscomparing . 487.KajimotoK,YamamotoT,AmanoA.Coronaryarterybypassrevascularization
.
bilateralinternalmammaryarterywithleftinternalmammaryarteryforcoro- . usingbilateralinternalthoracicarteriesindiabeticpatients:Asystematicreview
.
naryarterybypassgrafting.AnnCardiothoracSurg2013;2:390–400. .. andmeta-analysis.AnnThoracSurg2015;99:1097–1104.
.
466. Gaudino M, Di Franco A, Rahouma M, Tam DY, Iannaccone M, Deb S, . 488.SaMP,CavalcantiPE,SantosHJ,SoaresAF,MirandaRG,AraujoML,LimaRC.
.
D’AscenzoF,AbouarabAA,GirardiLN,TaggartDP,FremesSE.Unmeasured . Flowcapacityofskeletonizedversuspedicledinternalthoracicarteryincoro-
.
confoundersinobservationalstudiescomparingbilateralversussingleinternal .. nary artery bypass graft surgery: Systematic review, meta-analysis and meta-
thoracicarteryforcoronaryarterybypassgrafting:Ameta-analysis.JAmHeart .. regression.EurJCardiothoracSurg2015;48:25–31.
.
Assoc2018;7:e008010. . 489.Navia JL, Olivares G, Ehasz P, Gillinov AM, Svensson LG, Brozzi N, Lytle B.
.
467. TaggartDP,AltmanDG,GrayAM,LeesB,GerryS,BenedettoU,FlatherM; . Endoscopicradialarteryharvestingprocedureforcoronaryarterybypassgraft-
.
ArterialRevascularizationTrialInvestigators.Randomizedtrialofbilateralver- .. ing.AnnCardiothoracSurg2013;2:557–564.
sussingleinternal-thoracic-arterygrafts.NEnglJMed2016;375:2540–2549. .. 490.CaoC,TianDH,AngSC,PeeceeyenS,AllanJ,FuB,YanTD.Ameta-analysis
.
468. Gaudino M, Tranbaugh R, Fremes S. Bilateral versus single internal-thoracic- . ofendoscopicversusconventionalopenradialarteryharvestingforcoronary
.
arterygrafts.NEnglJMed2017;376:e37. .. arterybypassgraftsurgery.Innovations(Phila)2014;9:269–275.
469. Raza S, Blackstone EH, Sabik JF, III. Bilateral versus single internal-thoracic- .. 491.Gaudino M, Leone A, Lupascu A, Toesca A, Mazza A, Ponziani FR, Flore R,
.
arterygrafts.NEnglJMed2017;376:e37. . TondiP,MassettiM.Morphologicalandfunctionalconsequencesoftransradial
.
470. RoyseA,EcclestonD,RoyseC;iGRAFTCollaborators.Bilateralversussingle . coronaryangiographyontheradialartery:Implicationsforitsuseasabypass
.
internal-thoracic-arterygrafts.NEnglJMed2017;376:e37. .. conduit.EurJCardiothoracSurg2015;48:370–374.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 87 ---
ESC/EACTSGuidelines 165h
.
.
492. Ouzounian M, Hassan A, Buth KJ, MacPherson C, Ali IM, Hirsch GM, Ali IS. . Meta-analysis of 11,398 cases from 8 studies. J Thorac Cardiovasc Surg
.
Impactofendoscopicversusopensaphenousveinharvesttechniquesonout- . 2011;142:e11–e17.
.
comesaftercoronaryarterybypassgrafting.AnnThoracSurg2010;89:403–408. .. 511.GuerrieriWolfL,Abu-OmarY,ChoudharyBP,PigottD,TaggartDP.Gaseous
493. YunKL,WuY,AharonianV,MansukhaniP,PfefferTA,SintekCF,Kochamba .. and solid cerebral microembolization during proximal aortic anastomoses in
.
GS,GrunkemeierG,KhonsariS.Randomizedtrialofendoscopicversusopen . off-pumpcoronarysurgery:Theeffectofanaorticside-bitingclampandtwo
.
vein harvest for coronary artery bypass grafting: Six-month patency rates. J .. clamplessdevices.JThoracCardiovascSurg2007;133:485–493.
ThoracCardiovascSurg2005;129:496–503. .. 512.ElZayatH,PuskasJD,HwangS,ThouraniVH,LattoufOM,KilgoP,HalkosME.
.
494. ChernyavskiyA,VolkovA,LavrenyukO,TerekhovI,KarevaY.Comparative . Avoidingtheclampduringoff-pumpcoronaryarterybypassreducescerebral
.
resultsofendoscopicandopenmethodsofveinharvestingforcoronaryartery . embolic events: Results of a prospective randomized trial. Interact Cardiovasc
.
bypass grafting: A prospective randomized parallel-group trial. J Cardiothorac .. ThoracSurg2012;14:12–16.
Surg2015;10:163. .. 513.KieserTM,RoseS,KowalewskiR,BelenkieI.Transit-timeflowpredictsout-
.
495. KrishnamoorthyB,CritchleyWR,GloverAT,NairJ,JonesMT,Waterworth . comesincoronaryarterybypassgraftpatients:Aseriesof1000consecutive
.
PD,FildesJE,YonanN.Arandomizedstudycomparingthreegroupsofvein . arterialgrafts.EurJCardiothoracSurg2010;38:155–162.
.
harvestingmethodsforcoronaryarterybypassgrafting:endoscopicharvestver- .. 514.Mujanovic E, Kabil E, Bergsland J. Transit time flowmetry in coronary
.
sus standard bridging and open techniques. Interact Cardiovasc Thorac Surg . surgery–an important tool in graft verification. Bosn J Basic Med Sci
.
2012;15:224–228. . 2007;7:275–8.
.
496. Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, .. 515.JokinenJJ,WerkkalaK,VainikkaT,PerakylaT,Simpanen J,Ihlberg L.Clinical
Mehta RH, Gibson CM, Mack MJ, Kouchoukos NT, CaliffRM, Alexander JH. .. value of intra-operative transit-time flow measurement for coronary artery
.
Endoscopicversusopenvein-graftharvestingincoronary-arterybypasssurgery. . bypassgrafting:Aprospectiveangiography-controlledstudy.EurJCardiothorac
.
NEnglJMed2009;361:235–244. . Surg2011;39:918–923.
.
497. Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, Amidi M, .. 516.LehnertP,MollerCH,DamgaardS,GerdsTA,SteinbruchelDA.Transit-time
NovitzkyD,GroverFL,SonelAF.Impactofendoscopicversusopensaphenous .. flowmeasurementasapredictorofcoronarybypassgraftfailureatoneyear
.
veinharvesttechniqueonlatecoronaryarterybypassgraftingpatientoutcomes . angiographicfollow-up.JCardSurg2015;30:47–52.
.
in the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg .. 517.Niclauss L. Techniques and standards in intraoperative graft verification by
2011;141:338–434. .. transit time flow measurement after coronary artery bypass graft surgery: A
.
498. AndreasenJJ,VadmannH,OddershedeL,TilstedHH,FrokjaerJB,JensenSE. . criticalreview.EurJCardiothoracSurg2017;51:26–33.
.
Decreasedpatencyratesfollowingendoscopicveinharvestincoronaryartery . 518.DiegelerA,BorgermannJ,KappertU,BreuerM,BoningA,UrsulescuA,Rastan
.
bypasssurgery.ScandCardiovascJ2015;49:286–292. .. A,HolzheyD,TreedeH,RiessFC,VeeckmannP,AsfoorA,ReentsW,Zacher
499. Deppe AC, Liakopoulos OJ, Choi YH, Slottosch I, Kuhn EW, Scherner M, .. M, Hilker M, Group GS. Off-pump versus on-pump coronary-artery bypass
.
Stange S, Wahlers T. Endoscopic vein harvesting for coronary artery bypass . graftinginelderlypatients.NEnglJMed2013;368:1189–1198.
.
grafting:Asystematicreviewwithmeta-analysisof27,789patients.JSurgRes . 519.LamyA,DevereauxPJ,PrabhakaranD,TaggartDP,HuS,PaolassoE,StrakaZ,
.
2013;180:114–124. .. Piegas LS, Akar AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC,
.
500. WilliamsJB,PetersonED,BrennanJM,SedrakyanA,TavrisD,AlexanderJH, . Novick RJ, Vaijyanath P, Reddy S, Tao L, Olavegogeascoechea PA, Airan B,
.
Lopes RD, Dokholyan RS, Zhao Y, O’Brien SM, Michler RE, Thourani VH, . Sulling TA, Whitlock RP, Ou Y, Ng J, Chrolavicius S, Yusuf S, CORONARY
.
Edwards FH, Duggirala H, Gross T, Marinac-Dabic D, Smith PK. Association .. Investigators.Off-pumporon-pumpcoronary-arterybypassgraftingat30days.
betweenendoscopicvsopenvein-graftharvestingandmortality,woundcom- .. NEnglJMed2012;366:1489–1497.
.
plications, and cardiovascular events in patients undergoing CABG surgery. . 520.LamyA,DevereauxPJ,PrabhakaranD,TaggartDP,HuS,PaolassoE,StrakaZ,
.
JAMA2012;308:475–484. . Piegas LS, Akar AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC,
.
501. Brown EN, Kon ZN, Tran R, Burris NS, Gu J, Laird P, Brazio PS, Kallam S, .. Novick RJ, Vaijyanath P, Reddy SK, Tao L, Olavegogeascoechea PA, Airan B,
SchwartzK,BechtelL,JoshiA,ZhangS,PostonRS.Strategiestoreduceintralu- .. SullingTA,WhitlockRP,OuY,PogueJ,ChrolaviciusS,YusufS,CORONARY
.
minal clot formation in endoscopically harvested saphenous veins. J Thorac . Investigators.Effectsofoff-pumpandon-pumpcoronary-arterybypassgrafting
.
CardiovascSurg2007;134:1259–1265. .. at1year.NEnglJMed2013;368:1179–1188.
502. KhaleelMS,DorheimTA,DuryeeMJ,DurbinHEJr,BusseyWD,GarvinRP, .. 521.HattlerB,MessengerJC,ShroyerAL,CollinsJF,HaugenSJ,GarciaJA,BaltzJH,
.
Klassen LW, Thiele GM, Anderson DR. High-pressure distention of the . ClevelandJCJr,NovitzkyD,GroverFL,VeteransAffairsRandomizedOn/Off
.
saphenous vein during preparation results in increased markers of . Bypass (ROOBY) Study Group. Off-pump coronary artery bypass surgery is
.
inflammation: A potential mechanism for graft failure. Ann Thorac Surg .. associatedwithworsearterialandsaphenousveingraftpatencyandlesseffec-
2012;93:552–558. .. tive revascularization: Results from the Veterans Affairs Randomized On/Off
.
503. RousouLJ,TaylorKB,LuXG,HealeyN,CrittendenMD,KhuriSF,ThatteHS. . Bypass(ROOBY)trial.Circulation2012;125:2827–2835. .
Saphenousveinconduitsharvestedbyendoscopictechniqueexhibitstructural . 522.Houlind K, Kjeldsen BJ, Madsen SN, Rasmussen BS, Holme SJ, Nielsen PH,
. andfunctionaldamage.AnnThoracSurg2009;87:62–70. .. Mortensen PE; DOORS Group. On-pump versus off-pump coronary artery
504. JohanssonBL,SouzaDS,BodinL,FilbeyD,LoeschA,GeijerH,BojoL.Slower .. bypasssurgeryinelderlypatients:ResultsfromtheDanishon-pumpversusoff-
.
progressionofatherosclerosisinveingraftsharvestedwith0 touch0 technique . pumprandomizationstudy.Circulation2012;125:2431–2439.
.
compared with conventional harvesting technique in coronary artery bypass .. 523.ShroyerAL,GroverFL,HattlerB,CollinsJF,McDonaldGO,KozoraE,Lucke
grafting:Anangiographicandintravascularultrasoundstudy.EurJCardiothorac .. JC, Baltz JH, Novitzky D; Veterans Affairs Randomized On/Off Bypass
.
Surg2010;38:414–419. . (ROOBY)StudyGroup.On-pumpversusoff-pumpcoronary-arterybypasssur-
.
505. SouzaDS,DashwoodMR,TsuiJC,FilbeyD,BodinL,JohanssonB,BorowiecJ. . gery.NEnglJMed2009;361:1827–1837.
.
Improvedpatencyinveingraftsharvestedwithsurroundingtissue:Resultsofa .. 524.Keeling WB, Kilgo PD, Puskas JD, Halkos ME, Lattouf OM, Guyton RA,
randomized study using three harvesting techniques. Ann Thorac Surg .. ThouraniVH.Off-pumpcoronaryarterybypassgraftingattenuatesmorbidity
.
2002;73:1189–1195. . and mortality for patients with low and high body mass index. J Thorac
.
506. DreifaldtM,MannionJD,BodinL,OlssonH,ZagozdzonL,SouzaD.Theno- . CardiovascSurg2013;146:1442–1448.
.
touch saphenous vein as the preferred second conduit for coronary artery .. 525.PuskasJD,ThouraniVH,KilgoP,CooperW,VassiliadesT,VegaJD,MorrisC,
.
bypassgrafting.AnnThoracSurg2013;96:105–111. . Chen E, Schmotzer BJ, Guyton RA, Lattouf OM. Off-pump coronary artery
.
507. Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch . bypass disproportionately benefits high-risk patients. Ann Thorac Surg
.
saphenousveinforcoronaryarterybypassgraftingmaintainsapatency,after16 .. 2009;88:1142–1147.
years, comparable to the left internal thoracic artery: A randomized trial. J .. 526.Puskas JD, Williams WH, O’Donnell R, Patterson RE, Sigman SR, Smith AS,
.
ThoracCardiovascSurg2015;150:880–888. . BaioKT,KilgoPD,GuytonRA.Off-pumpandon-pumpcoronaryarterybypass
.
508. EmmertMY,SeifertB,WilhelmM,GrunenfelderJ,FalkV,SalzbergSP.Aortic . graftingareassociatedwithsimilargraftpatency,myocardialischemia,andfree-
.
no-touchtechniquemakesthedifferenceinoff-pumpcoronaryarterybypass .. dom from reintervention: Long-term follow-up of a randomized trial. Ann
grafting.JThoracCardiovascSurg2011;142:1499–1506. .. ThoracSurg2011;91:1836–1842;discussion1842–1843.
.
509. BorgermannJ,HakimK,RennerA,ParsaA,AboudA,BeckerT,MasshoffM, . 527.SedrakyanA,WuAW,ParasharA,BassEB,TreasureT.Off-pumpsurgeryis
.
ZittermannA,GummertJF,KussO.Clamplessoff-pumpversusconventional .. associated with reduced occurrence of stroke and other morbidity as com-
coronaryarteryrevascularization:Apropensityscoreanalysisof788patients. .. paredwithtraditionalcoronaryarterybypassgrafting:Ameta-analysisofsys-
.
Circulation2012;126:S176–S182. . tematicallyreviewedtrials.Stroke2006;37:2759–2769.
.
510. MisfeldM,BreretonRJ,SweetmanEA,DoigGS.Neurologiccomplicationsafter . 528.AltarabshehSE,DeoSV,Rababa’hAM,LimJY,ChoYH,SharmaV,JungSH,
.
off-pumpcoronaryarterybypassgraftingwithandwithoutaorticmanipulation: .. ShinE,MarkowitzAH,ParkSJ.Off-pumpcoronaryarterybypassreducesearly
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 88 ---
165i ESC/EACTSGuidelines
.
.
stroke in octogenarians: A meta-analysis of 18,000 patients. Ann Thorac Surg . addingaradialarterygrafttosingleandbilateralinternalthoracicarterygrafts
.
2015;99:1568–1575. . and outcomes: Insights from the Arterial Revascularization Trial. Circulation
.
529. ChawlaLS,ZhaoY,LoughFC,SchroederE,SeneffMG,BrennanJM.Off-pump .. 2017;136:454–463.
versuson-pumpcoronaryarterybypassgraftingoutcomesstratifiedbypreop- .. 550.YamasakiM,DebS,TsubotaH,MoussaF,KissA,CohenEA,RadhakrishnanS,
.
erativerenalfunction.JAmSocNephrol2012;23:1389–1397. . Dubbin J, Ko D, Schwartz L, Fremes SE, Radial Artery Patency Study
.
530. HeadSJ,BorgermannJ,OsnabruggeRL,KieserTM,FalkV,TaggartDP,Puskas .. Investigators. Comparison of radial artery and saphenous vein graft stenosis
JD, Gummert JF, Kappetein AP. Coronary artery bypass grafting: Part .. more than 5 years after coronary artery bypass grafting. Ann Thorac Surg
.
2–optimizingoutcomesandfutureprospects.EurHeartJ2013;34:2873–2886. . 2016;102:712–719.
.
531. Diegeler A, Walther T, Metz S, Falk V, Krakor R, Autschbach R, Mohr FW. . 551.BenedettoU,AmraniM,RajaSG,HarefieldCardiacOutcomesResearchGroup.
.
ComparisonofMIDCAPversusconventionalCABGsurgeryregardingpainand .. Guidancefortheuseofbilateralinternalthoracicarteriesaccordingtosurvivalbene-
qualityoflife.HeartSurgForum1999;2:290–5;discussion295–296. .. fitacrossagegroups.JThoracCardiovascSurg2014;148:2706–2711.
.
532. GrohMA,SutherlandSE,BurtonHGIII,JohnsonAM,ElySW.Port-accesscor- . 552.Desai ND, Cohen EA, Naylor CD, Fremes SE, Radial Artery Patency Study
.
onary artery bypass grafting: Technique and comparative results. Ann Thorac . Investigators. A randomized comparison of radial-artery and saphenous-vein
.
Surg1999;68:1506–1508. .. coronarybypassgrafts.NEnglJMed2004;351:2302–2309.
.
533. LapierreH,ChanV,SohmerB,MesanaTG,RuelM.Minimallyinvasivecoronary . 553.GaudinoM,TondiP,BenedettoU,MilazzoV,FloreR,GliecaF,PonzianiFR,
.
arterybypassgraftingviaasmallthoracotomyversusoff-pump:Acase-matched . LucianiN,GirardiLN,CreaF,MassettiM.Radialarteryasacoronaryartery
.
study.EurJCardiothoracSurg2011;40:804–810. .. bypassconduit:20-yearresults.JAmCollCardiol2016;68:603–610.
534. Deppe AC, Liakopoulos OJ, Kuhn EW, Slottosch I, Scherner M, Choi YH, .. 554.DaceyLJ,BraxtonJHJr,KramerRS,SchmokerJD,CharlesworthDC,HelmRE,
.
Rahmanian PB, Wahlers T. Minimally invasive direct coronary bypass grafting . Frumiento C, Sardella GL, Clough RA, Jones SR, Malenka DJ, Olmstead EM,
.
versus percutaneous coronary intervention for single-vessel disease: A meta- . RossCS,O’ConnorGT, Likosky DS; NorthernNew England Cardiovascular
.
analysisof2885patients.EurJCardiothoracSurg2015;47:397–406. .. DiseaseStudyGroup.Long-termoutcomesofendoscopicveinharvestingafter
535. WangXW,QuC,HuangC,XiangXY,LuZQ.Minimallyinvasivedirectcoro- .. coronaryarterybypassgrafting.Circulation2011;123:147–153.
.
narybypasscomparedwithpercutaneouscoronaryinterventionforleftante- . 555.Sen O,GoncaS,Solakoglu S,DalcikH,DalcikC,OzkaraA.Comparisonof
.
riordescendingarterydisease:Ameta-analysis.JCardiothoracSurg2016;11:125. .. conventionalandno-touchtechniquesinharvestingsaphenousveinforcoro-
536. Gasior M, Zembala MO, Tajstra M, Filipiak K, Gierlotka M, Hrapkowicz T, .. nary artery bypass grafting in view of endothelial damage. Heart Surg Forum
.
Hawranek M, Polonski L, Zembala M; POL-MIDES (HYBRID) Investigators. . 2013;16:E177–E183.
.
Hybrid revascularization for multivessel coronary artery disease. JACC . 556.KimYH,OhHC,ChoiJW,HwangHY,KimKB.No-touchsaphenousveinhar-
.
CardiovascInterv2014;7:1277–1283. .. vestingmayimprovefurtherthepatencyofsaphenousveincompositegrafts:
537. Bonatti JO, Zimrin D, Lehr EJ, Vesely M, Kon ZN, Wehman B, de Biasi AR, .. Early outcomes and 1-year angiographic results. Ann Thorac Surg
.
HofauerB,WeidingerF,SchachnerT,BonarosN,FriedrichG.Hybridcoronary . 2017;103:1489–1497.
.
revascularization using robotic totally endoscopic surgery: Perioperative out- . 557.BenedettoU,LauC,CaputoM,KimL,FeldmanDN,OhmesLB,DiFrancoA,
.
comesand5-yearresults.AnnThoracSurg2012;94:1920–1926. .. SolettiG,AngeliniGD,GirardiLN,GaudinoM.Comparisonofoutcomesfor
.
538. ShenL,HuS,WangH,XiongH,ZhengZ,LiL,XuB,YanH,GaoR.One-stop . off-pumpversuson-pumpcoronaryarterybypassgraftinginlow-volumeand
.
hybrid coronary revascularization versus coronary artery bypass grafting and . high-volumecentersandbylow-volumeandhigh-volumesurgeons.AmJCardiol
.
percutaneouscoronaryinterventionforthetreatmentofmultivesselcoronary .. 2018;121:552–557.
arterydisease:3-yearfollow-upresultsfromasingleinstitution.JAmCollCardiol .. 558.LaparDJ,MeryCM,KozowerBD,KernJA,KronIL,StukenborgGJ,AilawadiG.
.
2013;61:2525–2533. . Theeffectofsurgeonvolumeonmortalityforoff-pumpcoronaryarterybypass
.
539. HarskampRE,BonattiJO,ZhaoDX,PuskasJD,deWinterRJ,AlexanderJH, . grafting.JThoracCardiovascSurg2012;143:854–863.
.
Halkos ME. Standardizing definitions for hybrid coronary revascularization. J .. 559.AfilaloJ,RastiM,OhayonSM,ShimonyA,EisenbergMJ.Off-pumpvs.on-pump
ThoracCardiovascSurg2014;147:556–560. .. coronaryarterybypasssurgery:Anupdatedmeta-analysisandmeta-regression
.
540. Zembala M, Tajstra M, Zembala M, Filipiak K, Knapik P, Hrapkowicz T, . ofrandomizedtrials.EurHeartJ2012;33:1257–1267.
.
GierlotkaM,HawranekM,PolonskiL,GasiorM.ProspectiverandomisedpilOt .. 560.LemmaMG,CoscioniE,TrittoFP,CentofantiP,FondaconeC,SalicaA,Rossi
study evaLuating the safety and efficacy of hybrid revascularisation in MultI- .. A,DeSantoT,DiBenedettoG,PiazzaL,RinaldiM,SchinosaAL,DePaulisR,
.
vessel coronary artery DisEaSe (POLMIDES) - study design. Kardiol Pol . ContinoM,GenoniM.On-pumpversusoff-pumpcoronaryarterybypasssur-
.
2011;69:460–466. . geryinhigh-riskpatients:Operativeresultsofaprospectiverandomizedtrial
.
541. TajstraM,HrapkowiczT,HawranekM,FilipiakK,GierlotkaM,ZembalaM,Ga˛sior .. (on-offstudy).JThoracCardiovascSurg2012;143:625–631.
M,ZembalaMO;POL-MIDESStudyInvestigators.Hybridcoronaryrevascularization .. 561.Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de
.
inselectedpatientswithmultivesseldisease:5-yearclinicaloutcomesoftheprospec- . WinterRJ,VassiliadesTA,PuskasJD,HalkosME.Hybridcoronaryrevasculari- .
tiverandomizedpilotstudy.JACCCardiovascInterv2018;11:847–852 . zation versus coronary artery bypass surgery with bilateral or single internal
. 542. PanoulasVF,ColomboA,MargonatoA,MaisanoF.Hybridcoronaryrevascula- .. mammaryarterygrafts.JThoracCardiovascSurg2016;151:1081–1099.
rization:Promising,butyettotakeoff.JAmCollCardiol2015;65:85–97. .. 562.Harskamp RE, Brennan JM, Xian Y, Halkos ME, Puskas JD, Thourani VH,
.
543. Siregar S, Groenwold RH, de Mol BA, Speekenbrink RG, Versteegh MI, . GammieJS,TaylorBS,deWinterRJ,KimS,O’BrienS,PetersonED,GacaJG.
.
Brandon Bravo BruinsmaGJ, BotsML, vander Graaf Y, vanHerwerden LA. .. Practicepatternsandclinicaloutcomesafterhybridcoronaryrevascularization
Evaluationofcardiacsurgerymortalityrates:30-daymortalityorlongerfollow- .. intheUnitedStates:Ananalysisfromthesocietyofthoracicsurgeonsadult
.
up?EurJCardiothoracSurg2013;44:875–883. . cardiacdatabase.Circulation2014;130:872–879.
.
544. ZhaoDF,EdelmanJJ,SecoM,BannonPG,WilsonMK,ByromMJ,ThouraniV, . 563.PuskasJD,HalkosME,DeRoseJJ,BagiellaE,MillerMA,OverbeyJ,BonattiJ,
.
Lamy A, Taggart DP, Puskas JD, Vallely MP. Coronary artery bypass grafting .. SrinivasVS,VeselyM,SutterF,LynchJ,KirkwoodK,ShapiroTA,Boudoulas
withandwithoutmanipulationoftheascendingaorta:Anetworkmeta-analysis. .. KD,CrestanelloJ,GehrigT,SmithP,RagostaM,HoffSJ,ZhaoD,GelijnsAC,
.
JAmCollCardiol2017;69:924–936. . Szeto WY, Weisz G, Argenziano M, Vassiliades T, Liberman H, Matthai W,
.
545. Moss E, Puskas JD, Thourani VH, Kilgo P, Chen EP, Leshnower BG, Lattouf . AscheimDD.Hybridcoronaryrevascularizationforthetreatmentofmultives-
.
OM,GuytonRA,GlasKE,HalkosME.Avoidingaorticclampingduringcoronary .. sel coronary artery disease: A multicenter observational study. J Am Coll Cardiol
.
artery bypass grafting reduces postoperative stroke. J Thorac Cardiovasc Surg . 2016;68:356–365.
.
2015;149:175–180. . 564.BrophyJM,BelisleP,JosephL.Evidenceforuseofcoronarystents.Ahierarchi-
.
546. HlatkyMA,BoothroydDB,ReitzBA,ShilaneDA,BakerLC,GoAS.Adoption .. calbayesianmeta-analysis.AnnInternMed2003;138:7777–7786.
andeffectivenessofinternalmammaryarterygraftingincoronaryarterybypass .. 565.MehranR,BaberU,StegPG,AritiC,WeiszG,WitzenbichlerB,HenryTD,
.
surgeryamongMedicarebeneficiaries.JAmCollCardiol2014;63:33–39. . KiniAS,StuckeyT,CohenDJ,BergerPB,IakovouI,DangasG,WaksmanR,
.
547. KieserTM,LewinAM,GrahamMM,MartinBJ,GalbraithPD,RabiDM,Norris . Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM,
.
CM,FarisPD,KnudtsonML,GhaliWA;APPROACHInvestigators.Outcomes .. ChieffoA,AluM,MoliternoDJ,ColomboA,PocockS.Cessationofdualanti-
associated with bilateral internal thoracic artery grafting: The importance of .. platelettreatmentandcardiaceventsafterpercutaneouscoronaryintervention
.
age.AnnThoracSurg2011;92:1269–1275;discussion1275–1276. . (PARIS): 2 year results from a prospective observational study. Lancet
.
548. YiG,ShineB,RehmanSM,AltmanDG,TaggartDP.Effectofbilateralinternal .. 2013;382:1714–1722.
mammary artery grafts on long-term survival: A meta-analysis approach. .. 566.SilberS,KirtaneAJ,BelardiJA,LiuM,BrarS,RothmanM,WindeckerS.Lackof
.
Circulation2014;130:539–545. . association between dual antiplatelet therapy use and stent thrombosis
.
549. Taggart DP, Altman DG, Flather M, Gerry S, Gray A, Lees B, Benedetto U, . between1and12monthsfollowingresolutezotarolimus-elutingstentimplan-
.
ART (Arterial Revascularization Trial) Investigators. Associations between .. tation.EurHeartJ2014;35:1949–1956.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 89 ---
ESC/EACTSGuidelines 165j
.
.
567. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, . 581.VarenneO,CookS,SiderisG,KedevS,CuissetT,CarrieD,HovasseT,Garot
.
FleckensteinM,PfafferottC,SeyfarthM,SchomigA.Intracoronarystentingand . P,ElMahmoudR,SpauldingC,HelftG,DiazFernandezJF,BrugalettaS,Pinar-
.
angiographic results: Strut thickness effect on restenosis outcome (ISAR- .. Bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M,
STEREO)trial.Circulation2001;103:2816–2821. .. MoriceMC,SinnaevePR;SENIORInvestigators.Drug-elutingstentsinelderly
.
568. PacheJ,KastratiA,MehilliJ,SchuhlenH,DotzerF,HausleiterJ,FleckensteinM, . patientswithcoronaryarterydisease(SENIOR):Arandomisedsingle-blindtrial.
.
Neumann FJ,Sattelberger U, Schmitt C, Muller M, Dirschinger J, SchomigA. .. Lancet2018;391:41–50.
Intracoronary stenting and angiographic results: Strut thickness effect on .. 582.KangSH,ParkKW,KangDY,LimWH,ParkKT,HanJK,KangHJ,KooBK,Oh
.
restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41: . BH,ParkYB,KandzariDE,CohenDJ,HwangSS,KimHS.Biodegradable-poly-
.
1283–1288. . merdrug-elutingstentsvs.baremetalstentsvs.durable-polymerdrug-eluting
.
569. KastratiA,MehilliJ,PacheJ,KaiserC,ValgimigliM,KelbaekH,MenichelliM, .. stents:AsystematicreviewandBayesianapproachnetworkmeta-analysis.Eur
Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. .. HeartJ2014;35:1147–1158.
.
Analysisof14trialscomparingsirolimus-elutingstentswithbare-metalstents. . 583.Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, Cook S,
.
NEnglJMed2007;356:1030–1039. . WeilenmannD,KaiserC,JamshidiP,FahrniT,MoschovitisA,NobleS,Eberli
.
570. StoneGW,MosesJW,EllisSG,SchoferJ,DawkinsKD,MoriceMC,Colombo .. FR,WenaweserP,JuniP,WindeckerS.Ultrathinstrutbiodegradablepolymer
.
A,SchampaertE,GrubeE,KirtaneAJ,CutlipDE,FahyM,PocockSJ,MehranR, . sirolimus-elutingstentversusdurablepolymereverolimus-elutingstentforper-
.
LeonMB.Safetyandefficacyofsirolimus-andpaclitaxel-elutingcoronarystents. . cutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-
.
NEnglJMed2007;356:998–1008. .. blind,non-inferioritytrial.Lancet2014;384:2111–2122.
571. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, .. 584.Kaiser C, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H,
.
WenaweserP,DaemenJ,MeierB,JuniP,SerruysPW,WindeckerS.Verylate . Wanitschek M, Eberli F, Kurz DJ, Pedrazzini G, Moccetti T, Rickli H,
.
coronary stent thrombosis of a newer-generation everolimus-eluting stent . Weilenmann D, Vuillomenet A, Steiner M, Von Felten S, Vogt DR, Wadt
.
compared with early-generation drug-eluting stents: A prospective cohort .. HansenK,RickenbacherP,ConenD,MullerC,BuserP,HoffmannA,Pfisterer
study.Circulation2012;125:1110–1121. .. M BASKET-PROVE II Study Group. Long-term efficacy and safety of
.
572. StoneGW,RizviA,NewmanW,MastaliK,WangJC,CaputoR,DoostzadehJ, . biodegradable-polymerbiolimus-elutingstents:MainresultsoftheBaselStent
.
CaoS,SimontonCA,SudhirK,LanskyAJ,CutlipDE,KereiakesDJ;SPIRITIV .. Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-
Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary .. PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
.
arterydisease.NEnglJMed2010;362:1663–1674. . Circulation2015;131:74–81.
.
573. SerruysPW,SilberS,GargS,vanGeunsRJ,RichardtG,BuszmanPE,Kelbaek . 585.RaungaardB,JensenLO,TilstedHH,ChristiansenEH,MaengM,TerkelsenCJ,
.
H,vanBovenAJ,HofmaSH,LinkeA,KlaussV,WijnsW,MacayaC,GarotP, .. KrusellLR,KaltoftA,KristensenSD,BotkerHE,ThuesenL,AaroeJ,JensenSE,
DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, .. VilladsenAB,ThayssenP,VeienKT,HansenKN,JunkerA,MadsenM,Ravkilde
.
BressersM,GobbensP,NegoitaM,vanLeeuwenF,WindeckerS.Comparison . J, Lassen JF, Scandinavian Organization for Randomized Trials with Clinical
.
of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med . Outcome (SORT OUT). Zotarolimus-eluting durable-polymer-coated stent
.
2010;363:136–146. .. versus a biolimus-eluting biodegradable-polymer-coated stent in unselected
.
574. ChristiansenEH,JensenLO,ThayssenP,TilstedHH,KrusellLR,HansenKN, . patients undergoing percutaneous coronary intervention (SORT OUT VI): A
.
Kaltoft A, Maeng M, Kristensen SD, Botker HE, Terkelsen CJ, Villadsen AB, . randomisednon-inferioritytrial.Lancet2015;385:1527–1535.
.
RavkildeJ,AaroeJ,MadsenM,ThuesenL,LassenJF;ScandinavianOrganization .. 586.von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE,
for Randomized Trials with Clinical Outcome (SORT OUT) V Investigators. .. Scholte M, Gin R, Somi S, van Houwelingen KG, Stoel MG, de Man F,
.
Biolimus-elutingbiodegradablepolymer-coatedstentversusdurablepolymer- . Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J,
.
coated sirolimus-eluting stent in unselected patients receiving percutaneous . Doggen CJM, Lowik MM.Very thin strut biodegradable polymer everolimus-
.
coronary intervention (SORT OUT V): A randomised non-inferiority trial. .. elutingandsirolimus-elutingstentsversusdurablepolymerzotarolimus-eluting
Lancet2013;381:661–669. .. stentsinallcomerswithcoronaryarterydisease(BIO-RESORT):Athree-arm,
.
575. ByrneRA,KastratiA,KufnerS,MassbergS,BirkmeierKA,LaugwitzKL,Schulz . randomised,non-inferioritytrial.Lancet2016;388:2607–2617.
.
S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J, Intracoronary S, .. 587.KereiakesDJ,MeredithIT,WindeckerS,LeeJobeR,MehtaSR,SarembockIJ,
Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) .. FeldmanRL,SteinB,DuboisC,GradyT,SaitoS,KimuraT,ChristenT,Allocco
.
Investigators. Randomized, non-inferiority trial of three limus agent-eluting . DJ,DawkinsKD.Efficacyandsafetyofanovelbioabsorbablepolymer-coated,
.
stents with different polymer coatings: The Intracoronary Stenting and . everolimus-eluting coronary stent: The EVOLVE II Randomized Trial. Circ
.
Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) .. CardiovascInterv2015;8:e002372.
Trial.EurHeartJ2009;30:2441–2449. .. 588.Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y,
.
576. SmitsPC,HofmaS,TogniM,VazquezN,ValdesM,VoudrisV,SlagboomT, . AkasakaT,IgarashiK,TanabeK,MorinoY,IshikawaT,NishikawaH,AwataM, .
Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. . Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y,
. Abluminalbiodegradablepolymerbiolimus-elutingstentversusdurablepolymer .. Shiode N, Kimura T; NEXT Investigators. Biodegradable polymer biolimus-
everolimus-eluting stent (COMPARE II): A randomised, controlled, non- .. elutingstent versus durablepolymereverolimus-eluting stent: Arandomized,
.
inferioritytrial.Lancet2013;381:651–660. . controlled,noninferioritytrial.JAmCollCardiol2013;62:181–190.
.
577. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, Ibrahim T, .. 589.SaitoS,Valdes-ChavarriM,RichardtG,MorenoR,IniguezRomoA,BarbatoE,
FusaroM,OttI,SchomigA,LaugwitzKL,MehilliJ;IntracoronaryStentingand .. CarrieD,AndoK,MerkelyB,KornowskiR,EltchaninoffH,JamesS,WijnsW;
.
Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus . CENTURYIIInvestigators.Arandomized,prospective,intercontinentalevalua-
.
Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators. Polymer-free siroli- . tionofabioresorbablepolymersirolimus-elutingcoronarystentsystem:The
.
mus-andprobucol-elutingversusnewgenerationzotarolimus-elutingstentsin .. CENTURYII(ClinicalEvaluationofNewTerumoDrug-ElutingCoronaryStent
coronaryarterydisease:theIntracoronaryStentingandAngiographicResults: .. SystemintheTreatmentofPatientswithCoronaryArteryDisease)trial.Eur
.
Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting . HeartJ2014;35:2021–2031.
.
Stents(ISAR-TEST5)trial.Circulation2011;124:624–632. .. 590.Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM,
578. Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, .. Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW
.
Oktay S, Juni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S. . InvestigatorsV.Ultrathin,bioresorbablepolymersirolimus-elutingstentsversus
.
Report of a European Society of Cardiology-European Association of . thin,durablepolymereverolimus-elutingstentsinpatientsundergoingcoronary
.
PercutaneousCardiovascularInterventionstaskforceontheevaluationofcor- .. revascularisation (BIOFLOW V): A randomised trial. Lancet
onarystentsinEurope:Executivesummary.EurHeartJ2015;36:2608–2620. .. 2017;390:1843–1852.
.
579. Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, Nilsen . 591.KufnerS,SorgesJ,MehilliJ,CasseseS,ReppJ,WiebeJ,LohausR,LahmannA,
.
DW,KlowNE,UchtoM,TrovikT,BendzB,StavnesS,BjornerheimR,Larsen . Rheude T, Ibrahim T, Massberg S, Laugwitz KL, Kastrati A, Byrne RA; ISAR-
.
AI, Slette M, SteigenT, Jakobsen OJ,Bleie O, Fossum E, Hanssen TA, Dahl- .. TEST-5 Investigators. Randomized trial of polymer-free sirolimus- and
EriksenO,NjolstadI,RasmussenK,WilsgaardT,NordrehaugJE;NORSTENT .. probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-
.
Investigators.Drug-elutingorbare-metalstentsforcoronaryarterydisease.N . yearresultsoftheISAR-TEST-5trial.JACCCardiovascInterv2016;9:784–792.
.
EnglJMed2016;375:1242–1252. .. 592.KufnerS,ByrneRA,ValeskiniM,SchulzS,IbrahimT,HoppmannP,SchneiderS,
580. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, .. LaugwitzKL,SchunkertH,KastratiA;IntracoronaryStentingandAngiographic
.
SmitsPC,VlachojannisGJ,JensenLO,ChristiansenEH,BerencsiK,ValgimigliM, . Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST 4) Investigators.
.
OrlandiC,PetrouM,RapezziC,StoneGW.Long-termsafetyofdrug-eluting . Five-yearoutcomesfromatrialofthreelimus-elutingstentswithdifferentpoly-
.
andbare-metalstents:Evidencefromacomprehensivenetworkmeta-analysis.J .. mer coatings in patients with coronary artery disease: Final results from the
AmCollCardiol2015;65:2496–2507. . ISAR-TEST4randomisedtrial.EuroIntervention2016;11:1372–1379.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 90 ---
165k ESC/EACTSGuidelines
.
.
593. VlachojannisGJ,SmitsPC,HofmaSH,TogniM,VazquezN,ValdesM,Voudris . percutaneous coronary intervention impacts physician decision-making:
.
V,SlagboomT, GoyJJ,den Heijer P,vanderEntM.Biodegradable polymer . ILUMIENIstudy.EurHeartJ2015;36:3346–3355.
.
biolimus-eluting stents versus durable polymer everolimus-eluting stents in .. 609.PratiF,GuagliumiG,MintzGS,CostaM,RegarE,AkasakaT,BarlisP,Tearney
patientswithcoronaryarterydisease:Final5-yearreportfromtheCOMPARE .. GJ,JangIK,ArbustiniE,BezerraHG,OzakiY,BruiningN,DudekD,RaduM,
.
IITrial(abluminalbiodegradablepolymerbiolimus-elutingstentversusdurable . Erglis A, Motreff P, Alfonso F, Toutouzas K, Gonzalo N, Tamburino C,
.
polymereverolimus-elutingstent).JACCCardiovascInterv2017;10:1215–1221. .. Adriaenssens T, Pinto F, Serruys PW, Di Mario C; Expert’s OCT Review
594. Vlachojannis GJ, Puricel S, Natsuaki M, Morimoto T, Smits PC, Kimura T. .. Document. Expert review document part 2: Methodology, terminology and
.
Biolimus-elutingversuseverolimus-elutingstentsincoronaryarterydisease:a . clinical applications of optical coherence tomography for the assessment of
.
pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/ . interventionalprocedures.EurHeartJ2012;33:2513–2520.
.
PROMUSeverolimus-elutingstent)andCOMPAREII(Abluminalbiodegradable .. 610.RaduMD,RaberL,HeoJ,GogasBD,JorgensenE,KelbaekH,MuramatsuT,
polymer biolimus-eluting stent versus durable polymer everolimus-eluting .. FarooqV,HelqvistS,Garcia-GarciaHM,WindeckerS,SaunamakiK,Serruys
.
stent)randomisedtrials.EuroIntervention2017;12:1970–1977. . PW.Naturalhistoryofopticalcoherencetomography-detectednon-flow-limit-
.
595. WiebeJ,NefHM,HammCW.Currentstatusofbioresorbablescaffoldsinthe . ing edge dissections following drug-eluting stent implantation. EuroIntervention
.
treatmentofcoronaryarterydisease.JAmCollCardiol2014;64:2541–2551. .. 2014;9:1085–1094.
.
596. SorrentinoS,GiustinoG,MehranR,KiniAS,SharmaSK,FaggioniM,FarhanS, . 611.Ali ZA, Maehara A, Genereux P, Shlofmitz RA, Fabbiocchi F, Nazif TM,
.
VogelB,IndolfiC,DangasGD.Everolimus-elutingbioresorbablescaffoldsver- . GuagliumiG,MerajPM,AlfonsoF,SamadyH,AkasakaT,CarlsonEB,Leesar
.
suseverolimus-elutingmetallicstents.JAmCollCardiol2017;69:3055–3066. .. MA,MatsumuraM,OzanMO,MintzGS,Ben-YehudaO,StoneGW;ILUMIEN
597. MontoneRA,NiccoliG,DeMarcoF,MinelliS,D’AscenzoF,TestaL,Bedogni .. III:OPTIMIZEPCIInvestigators.Opticalcoherencetomographycomparedwith
.
F, Crea F. Temporal trends in adverse eventsafter everolimus-eluting biore- . intravascularultrasoundandwithangiographytoguidecoronarystentimplanta-
.
sorbablevascularscaffoldversuseverolimus-elutingmetallicstentimplantation: . tion (ILUMIEN III: OPTIMIZE PCI): A randomised controlled trial. Lancet
.
A meta-analysis of randomized controlled trials. Circulation 2017;135: .. 2016;388:2618–2628.
2145–2154. .. 612.Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P,
.
598. BondessonP,LagerqvistB,JamesSK,OlivecronaGK,VenetsanosD,HarnekJ. . Morel O, Lefrancois Y, Descotes-Genon V, Silvain J, Braik N, Chopard R,
.
Comparisonoftwodrug-elutingballoons:AreportfromtheSCAARregistry. .. ChatotM,EcarnotF,TauzinH,VanBelleE,BelleL,SchieleF.Opticalcoher-
EuroIntervention2012;8:444–449. .. encetomographytooptimizeresultsofpercutaneouscoronaryinterventionin
.
599. Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, . patientswithnon-ST-elevationacutecoronarysyndrome:Resultsofthemulti-
.
Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, . center,randomizedDOCTORSstudy(DoesOpticalCoherenceTomography
.
VarbellaF,MenozziA.Arandomizedmulticenterstudycomparingapaclitaxel .. OptimizeResultsofStenting).Circulation2016;134:906–917.
drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: .. 613.Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K,
.
The BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll . Jorgensen E, Kelbaek H, Pilgrim T, Caussin C, Zanchin T, Veugeois A,
.
Cardiol2012;60:2473–2480. . AbildgaardU,JuniP,CookS,KoskinasKC,WindeckerS,RaberL.Mechanisms
.
600. CorteseB,MicheliA,PicchiA,CoppolaroA,BandinelliL,SeveriS,Limbruno .. of very late drug-eluting stent thrombosis assessed by optical coherence
.
U.Paclitaxel-coatedballoonversusdrug-elutingstentduringPCIofsmallcoro- . tomography.Circulation2016;133:650–660.
.
nary vessels, a prospective randomised clinical trial. The PICCOLETO study. . 614.Souteyrand G, Amabile N, Mangin L, Chabin X, Meneveau N, Cayla G,
.
Heart2010;96:1291–1296. .. VanzettoG,BarnayP,TrouilletC,RioufolG,RangeG,TeigerE,DelaunayR,
601. StellaPR,BelkacemiA,DuboisC,NathoeH,DensJ,NaberC,AdriaenssensT, .. DubreuilO,LhermusierT,MulliezA,LevesqueS,BelleL,CaussinC,MotreffP;
.
vanBelleE,DoevendansP,AgostoniP.Amulticenterrandomizedcomparison . PESTO Investigators. Mechanisms of stent thrombosis analysed by optical
.
of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus . coherencetomography:InsightsfromthenationalPESTOFrenchregistry.Eur
.
drug-elutingstentinbifurcationlesionstreatedwithasingle-stentingtechnique: .. HeartJ2016;37:1208–1216.
Six-month angiographic and 12-month clinical results of the drug-eluting bal- .. 615.KangSJ,MintzGS,AkasakaT,ParkDW,LeeJY,KimWJ,LeeSW,KimYH,
.
looninbifurcationstrial.CatheterCardiovascInterv2012;80:1138–1146. . WhanLeeC,ParkSW,ParkSJ.Opticalcoherencetomographicanalysisofin-
.
602. Abdel-WahabM,RichardtG,JoachimButtnerHToelg,RGeist,VMeinertz,T .. stent neoatherosclerosis after drug-eluting stent implantation. Circulation
Schofer,JKing,LNeumann,FJKhattab,AA.High-speedrotationalatherectomy .. 2011;123:2954–2963.
.
before paclitaxel-eluting stent implantation in complex calcified coronary . 616.MalleC,TadaT,SteigerwaldK,UghiGJ,SchusterT,NakanoM,MassbergS,
.
lesions:TherandomizedROTAXUS(RotationalAtherectomyPriortoTaxus . JehleJ,GuagliumiG,KastratiA,VirmaniR,ByrneRA,JonerM.Tissuecharacter-
.
Stent Treatment for Complex Native Coronary Artery Disease) trial. JACC .. izationafterdrug-elutingstentimplantationusingopticalcoherencetomogra-
CardiovascInterv2013;6:10–19. .. phy.ArteriosclerThrombVascBiol2013;33:1376–1383.
.
603. PariseH,MaeharaA,StoneGW,LeonMB,MintzGS.Meta-analysisofrandom- . 617.GaoXF,ZhangYJ,TianNL,WuW,LiMH,BourantasCV,JiangXM,Wang .
izedstudiescomparingintravascularultrasoundversusangiographicguidanceof . ZM,LiB,MaoWX,ZhangJJ,ChenSL.Stentingstrategyforcoronaryartery
. percutaneouscoronaryinterventioninpre-drug-elutingstentera.AmJCardiol .. bifurcationwithdrug-elutingstents:Ameta-analysisofninerandomisedtrials
2011;107:374–382. .. andsystematicreview.EuroIntervention2014;10:561–569.
.
604. Lodi-JunqueiraL,deSousaMR,daPaixaoLC,KellesSM,AmaralCF,Ribeiro . 618.BehanMW,HolmNR,deBelderAJ,CockburnJ,ErglisA,CurzenNP,Niemela
.
AL. Does intravascular ultrasound provide clinical benefits for percutaneous .. M, Oldroyd KG, Kervinen K, Kumsars I, Gunnes P, Stables RH, Maeng M,
coronary intervention with bare-metal stent implantation? A meta-analysis of .. Ravkilde J, Jensen JS, Christiansen EH, Cooter N, Steigen TK, Vikman S,
.
randomizedcontrolledtrials.SystRev2012;1:42. . Thuesen L, Lassen JF, Hildick-Smith D. Coronary bifurcation lesions treated
.
605. NerlekarN,CheshireCJ,VermaKP,IhdayhidAR,McCormickLM,Cameron . withsimpleorcomplexstenting:5-yearsurvivalfrompatient-levelpooledanal-
.
JD,BennettMR,MalaiapanY,MeredithIT,BrownAJ.Intravascularultrasound .. ysisoftheNordicBifurcationStudyandtheBritishBifurcationCoronaryStudy.
guidance improves clinical outcomes during implantation of both first- and .. EurHeartJ2016;37:1923–1928.
.
second-generation drug-eluting stents: A meta-analysis. EuroIntervention . 619.Hildick-Smith D, Behan MW, Lassen JF, Chieffo A, Lefevre T, Stankovic G,
.
2017;12:1632–1642. .. Burzotta F, PanM, Ferenc M, Bennett L, Hovasse T, Spence MJ, Oldroyd K,
606. BuccheriS,FranchinaG,RomanoS,PuglisiS,VenutiG,D’ArrigoP,Francaviglia .. BrunelP,CarrieD,BaumbachA,MaengM,SkipperN,LouvardY.TheEBC
.
B,ScaliaM,CondorelliA,BarbantiM,CapranzanoP,TamburinoC,Capodanno . TWOStudy(EuropeanBifurcationCoronaryTWO):Arandomizedcompari-
.
D. Clinical outcomes following intravascular imaging-guided versus coronary . son of provisional T-stenting versus a systematic 2 stent culotte strategy in
.
angiography-guided percutaneous coronary intervention with stent implanta- .. largecalibertruebifurcations.CircCardiovascInterv2016;9:e003643.
tion:AsystematicreviewandBayesiannetworkmeta-analysisof31studiesand .. 620.ChenSL,ZhangJJ,HanY,KanJ,ChenL,QiuC,JiangT,TaoL,ZengH,LiL,
.
17,882patients.JACCCardiovascInterv2017;10:2488–2498. . XiaY,GaoC,SantosoT,PaiboonC,WangY,KwanTW,YeF,TianN,LiuZ,
.
607. PratiF,DiVitoL,Biondi-ZoccaiG,OcchipintiM,LaMannaA,TamburinoC, . LinS,LuC,WenS,HongL,ZhangQ,SheibanI,XuY,WangL,RabTS,LiZ,
.
Burzotta F, Trani C, Porto I, Ramazzotti V, Imola F, Manzoli A, Materia L, .. ChengG,CuiL,LeonMB,StoneGW.Doublekissingcrushversusprovisional
CremonesiA,AlbertucciM.Angiographyaloneversusangiographyplusoptical .. stentingforleftmaindistalbifurcationlesions:DKCRUSH-Vrandomizedtrial.J
.
coherencetomographytoguidedecision-makingduringpercutaneouscoronary . AmCollCardiol2017;70:2605–2617.
.
intervention: The Centro per la Lotta contro l’Infarto-Optimisation of .. 621.Erglis A, Kumsars I, Niemela M, Kervinen K, Maeng M, Lassen JF, Gunnes P,
Percutaneous Coronary Intervention (CLI-OPCI) study. EuroIntervention .. StavnesS,JensenJS,GalloeA,NarbuteI,SondoreD,MakikallioT,YlitaloK,
.
2012;8:823–829. . ChristiansenEH,RavkildeJ,SteigenTK,MannsverkJ,ThayssenP,HansenKN,
.
608. WijnsW,ShiteJ,JonesMR,LeeSW,PriceMJ,FabbiocchiF,BarbatoE,Akasaka . Syvanne M, Helqvist S, Kjell N, Wiseth R, Aaroe J, Puhakka M, Thuesen L;
.
T, Bezerra H, Holmes D. Optical coherence tomography imaging during .. Nordic PCI Study Group. Randomized comparison of coronary bifurcation
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 91 ---
ESC/EACTSGuidelines 165l
.
.
stenting with the crush versus the culotte technique using sirolimus eluting . 635.Arnous S, Shakhshir N, Wiper A, Ordoubadi FF, Williams P, Clarke B,
.
stents:TheNordicstenttechniquestudy.CircCardiovascInterv2009;2:27–34. . MahadavanV,El-OmarM,MamasM,FraserD.Incidenceandmechanismsof
.
622. ZhengXW,ZhaoDH,PengHY,FanQ,MaQ,XuZY,FanC,LiuLY,LiuJH. .. longitudinal stent deformation associated with Biomatrix, Resolute, Element,
Randomizedcomparisonofthecrushversustheculottestentingforcoronary .. and Xience stents: Angiographic and case-by-case review of 1,800 PCIs.
.
arterybifurcationlesions.ChinMedJ(Engl)2016;129:505–510. . CatheterCardiovascInterv2015;86:1002–1011.
.
623. ChenSL,XuB,HanYL,SheibanI,ZhangJJ,YeF,KwanTW,PaiboonC,Zhou .. 636.SzaboS,AbramowitzB,VaitkusP.Newtechniqueofaorto-ostialstentplace-
YJ,LvSZ,DangasGD,XuYW,WenSY,HongL,ZhangRY,WangHC,Jiang .. ment.AmJCardiol2005;96:212H.
.
TM,WangY,ChenF,YuanZY,LiWM,LeonMB.Comparisonofdoublekiss- . 637.Gutierrez-Chico JL, Villanueva-Benito I, Villanueva-Montoto L, Vazquez-
.
ing crush versus Culotte stenting for unprotected distal left main bifurcation . FernandezS,KleineckeC,GielenS,Iniguez-RomoA.Szabotechniqueversus
.
lesions: Results from a multicenter, randomized, prospective DKCRUSH-III .. conventionalangiographicplacementinbifurcations010-001ofMedinaandin
study.JAmCollCardiol2013;61:1482–1488. .. aorto-ostial stenting: Angiographic and procedural results. EuroIntervention
.
624. Niemela M, Kervinen K, Erglis A, Holm NR, Maeng M, Christiansen EH, . 2010;5:801–808.
.
KumsarsI,JegereS,DombrovskisA,GunnesP,StavnesS,SteigenTK,TrovikT, . 638.JollySS,YusufS,CairnsJ,NiemelaK,XavierD,WidimskyP,BudajA,Niemela
.
Eskola M, Vikman S, Romppanen H, Makikallio T, Hansen KN, Thayssen P, .. M,ValentinV,LewisBS,AvezumA,StegPG,RaoSV,GaoP,AfzalR,Joyner
.
AbergeL,JensenLO,HervoldA,AiraksinenJ,PietilaM,FrobertO,KellerthT, . CD,ChrolaviciusS,MehtaSR;RIVALtrialgroup.Radialversusfemoralaccess
.
RavkildeJ,AaroeJ,JensenJS,HelqvistS,SjogrenI,JamesS,MiettinenH,Lassen . forcoronaryangiographyandinterventioninpatientswithacutecoronarysyn-
.
JF,ThuesenL;Nordic-BalticPCIStudyGroup.Randomizedcomparisonoffinal .. dromes (RIVAL): A randomised, parallel group, multicentre trial. Lancet
kissing balloon dilatation versus no final kissing balloon dilatation in patients .. 2011;377:1409–1420.
.
with coronary bifurcation lesions treated with main vessel stenting: The . 639.HamonM,PristipinoC,DiMarioC,NolanJ,LudwigJ,TubaroM,SabateM,
.
Nordic-BalticBifurcationStudyIII.Circulation2011;123:79–86. . Mauri-FerreJ,HuberK,NiemelaK,HaudeM,WijnsW,DudekD,FajadetJ,
.
625. GwonHC,HahnJY,KooBK,SongYB,ChoiSH,ChoiJH,LeeSH,JeongMH, .. Kiemeneij F; European Association of Percutaneous Cardiovascular
KimHS,SeongIW,YangJY,RhaSW,JangY,YoonJH,TahkSJ,SeungKB,Park .. Interventions;WorkingGrouponAcuteCardiacCareoftheEuropeanSociety
.
SJ.Finalkissingballooningandlong-termclinicaloutcomesincoronarybifurca- . of Cardiology; Working Group on Thrombosis on the European Society of
.
tionlesionstreatedwith1-stenttechnique:ResultsfromtheCOBISregistry. .. Cardiology.Consensusdocumentontheradialapproachinpercutaneouscar-
Heart2012;98:225–231. .. diovascular interventions: Position paper by the European Association of
.
626. Genereux P, Kumsars I, Lesiak M, Kini A, Fontos G, Slagboom T, Ungi I, . Percutaneous Cardiovascular Interventions and Working Groups on Acute
.
MetzgerDC,WykrzykowskaJJ,StellaPR,BartorelliAL,FearonWF,LefevreT, . Cardiac Care** and Thrombosis of the European Society of Cardiology.
.
FeldmanRL,LaSalleL,FranceseDP,OnumaY,GrundekenMJ,Garcia-Garcia .. EuroIntervention2013;8:1242–1251.
HM,LaakLL,CutlipDE,KaplanAV,SerruysPW,LeonMB.Arandomizedtrial .. 640.PalmeriniT,Biondi-ZoccaiG,DellaRivaD,StettlerC,SangiorgiD,D’Ascenzo
.
ofadedicatedbifurcationstentversusprovisionalstentinginthetreatmentof . F,KimuraT,BriguoriC,SabateM,KimHS,DeWahaA,KedhiE,SmitsPC,
.
coronarybifurcationlesions.JAmCollCardiol2015;65:533–543. . KaiserC,SardellaG,MarulloA,KirtaneAJ,LeonMB,StoneGW.Stentthrom-
.
627. LassenJF,HolmNR,BanningA,BurzottaF,LefevreT,ChieffoA,Hildick-Smith .. bosiswithdrug-elutingandbare-metalstents:Evidencefromacomprehensive
.
D,LouvardY,StankovicG.Percutaneouscoronaryinterventionforcoronary . networkmeta-analysis.Lancet2012;379:1393–1402.
.
bifurcationdisease: 11thconsensus documentfrom theEuropeanBifurcation . 641.FerranteG,RaoSV,JuniP,DaCostaBR,ReimersB,CondorelliG,AnzuiniA,
.
Club.EuroIntervention2016;12:38–46. .. JollySS,BertrandOF,KrucoffMW,WindeckerS,ValgimigliM.Radialversus
628. HenriquesJP,HoebersLP,RamunddalT,LaanmetsP,EriksenE,BaxM,Ioanes .. femoral access for coronary interventions across the entire spectrum of
.
D,SuttorpMJ,StraussBH,BarbatoE,NijveldtR,vanRossumAC,MarquesKM, . patients with coronary artery disease: A meta-analysis of randomized trials.
.
EliasJ,vanDongenIM,ClaessenBE,TijssenJG,vanderSchaafRJ;EXPLORE . JACCCardiovascInterv2016;9:1419–1434.
.
Investigators Trial. Percutaneous intervention for concurrent chronic total .. 642.SabateM,WindeckerS,IniguezA,Okkels-JensenL,CequierA,BrugalettaS,
occlusions in patients with STEMI: The EXPLORE trial. J Am Coll Cardiol .. Hofma SH, Raber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G,
.
2016;68:1622–1632. . SotomiY,Garcia-GarciaHM,OnumaY,SerruysPW.Everolimus-elutingbiore-
.
629. WernerGS,Martin-YusteV,Hildick-SmithD,BoudouN,SianosG,GelevV, .. sorbablestentvs.durablepolymereverolimus-elutingmetallicstentinpatients
Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, .. with ST-segment elevation myocardial infarction: Results of the randomized
.
Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, . ABSORBST-segmentelevationmyocardialinfarction-TROFIIItrial.EurHeartJ
.
Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multi- . 2016;37:229–240.
.
centretrialtocomparerevascularizationwithoptimalmedicaltherapyforthe .. 643.CasseseS,ByrneRA,NdrepepaG,KufnerS,WiebeJ,ReppJ,SchunkertH,
treatment of chronic total coronary occlusions. Eur Heart J;doi:10.1093/ .. FusaroM,KimuraT,KastratiA.Everolimus-elutingbioresorbablevascularscaf-
.
eurheartj/ehy220.Publishedonlineaheadofprint2May2018. . foldsversuseverolimus-elutingmetallicstents:Ameta-analysisofrandomised .
630. Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, . controlledtrials.Lancet2016;387:537–544.
. Rangan BV, Abdullah S, Grodin J, Kumbhani DJ, Vo M, Luna M, Alaswad K, .. 644.SerruysPW,ChevalierB,DudekD,CequierA,CarrieD,IniguezA,Dominici
KarmpaliotisD,RinfretS,GarciaS,BanerjeeS,BrilakisES.Meta-analysisofclini- .. M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P,
.
caloutcomesofpatientswhounderwentpercutaneouscoronaryinterventions . Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable
.
forchronictotalocclusions.AmJCardiol2015;115:1367–1375. .. everolimus-elutingscaffoldversusametalliceverolimus-elutingstentforischae-
631. Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, .. micheartdiseasecausedbyde-novonativecoronaryarterylesions(ABSORB
.
KennedyKF,SpertusJA,HolmesDRJr,GranthamJA.Proceduraloutcomesof . II): An interim 1-yearanalysis of clinicaland proceduralsecondaryoutcomes
.
chronictotalocclusionpercutaneouscoronaryintervention:Areportfromthe . fromarandomisedcontrolledtrial.Lancet2015;385:43–54.
.
NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv .. 645.Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z,
2015;8:245–253. .. MullerO,AllardL,StaufferJC,TogniM,GoyJJ,CookS.Comparisonofeveroli-
.
632. MaeremansJ,WalshS,KnaapenP,SprattJC,AvranA,HanrattyCG,FaurieB, . mus- andbiolimus-eluting coronary stentswith everolimus-eluting bioresorb-
.
AgostoniP,BressolletteE,KayaertP,BagnallAJ,EgredM,SmithD,ChaseA, .. ablevascularscaffolds.JAmCollCardiol2015;65:791–801.
McEntegartMB,SmithWH,HarcombeA,KellyP,IrvingJ,SmithEJ,StrangeJW, .. 646.KimuraT,KozumaK,TanabeK,NakamuraS,YamaneM,MuramatsuT,SaitoS,
.
DensJ.ThehybridalgorithmfortreatingchronictotalocclusionsinEurope: . YajimaJ,HagiwaraN,MitsudoK,PopmaJJ,SerruysPW,OnumaY,YingS,Cao
.
TheRECHARGEregistry.JAmCollCardiol2016;68:1958–1970. . S,StaehrP,CheongWF,KusanoH,StoneGW;ABSORBJapanInvestigators.A
.
633. Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M, .. randomizedtrialevaluatingeverolimus-eluting Absorb bioresorbable scaffolds
CastaingM,ButtnerJH,BufeA,KalninsA,SprattJC,GarboR,Hildick-SmithD, .. vs.everolimus-elutingmetallicstentsinpatientswithcoronaryarterydisease:
.
ElhadadS,GagnorA,LauerB,BryniarskiL,ChristiansenEH,ThuesenL,Meyer- . ABSORBJapan.EurHeartJ2015;36:3332–3342.
.
GessnerM,GoktekinO,CarlinoM,LouvardY,LefevreT,LismanisA,Gelev . 647.GaoR,YangY,HanY,HuoY,ChenJ,YuB,SuX,LiL,KuoHC,YingSW,
.
VL, Serra A, Marza F, Di Mario C, Reifart N; Euro CTO Club. Retrograde .. Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW, Investigators
recanalizationofchronictotalocclusionsinEurope:Procedural,in-hospital,and .. AC. Bioresorbable vascular scaffolds versus metallic stents in patients with
.
long-term outcomes from the multicenter ERCTO registry. J Am Coll Cardiol . coronary artery disease: ABSORB China trial. J Am Coll Cardiol
.
2015;65:2388–400. .. 2015;66:2298–2309.
634. KohJS,KooBK,KimJH,YangHM,ParkKW,KangHJ,KimHS,OhBH,Park .. 648.EllisSG,KereiakesDJ,MetzgerDC,CaputoRP,RizikDG,TeirsteinPS,LittMR,
.
YB.Relationshipbetweenfractionalflowreserveandangiographicandintravas- . Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C,
.
cularultrasoundparametersinostiallesions:Majorepicardialvesselversusside . StoneGW;ABSORBIIIInvestigators.Everolimus-elutingbioresorbablescaffolds
.
branchostiallesions.JACCCardiovascInterv2012;5:409–415. .. forcoronaryarterydisease.NEnglJMed2015;373:1905–1915.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 92 ---
165m ESC/EACTSGuidelines
.
.
649. WykrzykowskaJJ,KraakRP,HofmaSH,vanderSchaafRJ,ArkenboutEK,AJIJ, . interventions:Appropriatenessofincludingbleedingasacomponentofaquad-
.
Elias,J,vanDongen,IM,Tijssen,RYG,Koch,KT,Baan, JJr,VisMM,deWinter . rupleendpoint.JAmCollCardiol2008;51:690–697.
.
RJ,PiekJJ,TijssenJGP,HenriquesJPS;AIDAInvestigators.Bioresorbablescaf- .. 665.Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M,
foldsversusmetallicstentsinroutinePCI.NEnglJMed2017;376:2319–2328. .. WalterH,Zitzmann-RothEM,RichardtG,AltE,SchmittC,UlmK.Arandom-
.
650. Cassese S, Byrne RA, Juni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, . izedcomparisonofantiplateletandanticoagulanttherapyaftertheplacement
.
Schunkert H, Fusaro M, Cook S, Kimura T, Henriques JPS, Serruys PW, .. ofcoronary-arterystents.NEnglJMed1996;334:1084–1089.
Windecker S, Kastrati A. Midterm clinical outcomes with everolimus-eluting .. 666.SibbingD,KastratiA,BergerPB.Pre-treatmentwithP2Y12inhibitorsinACS
.
bioresorbablescaffoldsversuseverolimus-elutingmetallicstentsforpercutane- . patients:Who,when,why,andwhichagent?EurHeartJ2016;37:1284–1295.
.
ous coronary interventions: A meta-analysis of randomised trials. . 667.SteinhublSR,BergerPB,MannJTIII,FryET,DeLagoA,WilmerC,TopolEJ;
.
EuroIntervention2018;13:1565–1573. .. CREDO Investigators. Clopidogrel fro the Reduction of Events During
651. CasellaG,KlaussV,OttaniF,SiebertU,SangiorgioP,BracchettiD.Impactof .. Observation.Earlyandsustaineddualoralantiplatelettherapyfollowingpercu-
.
intravascularultrasound-guidedstentingonlong-termclinicaloutcome:Ameta- . taneous coronary intervention: A randomized controlled trial. JAMA
.
analysis of available studies comparing intravascular ultrasound-guided and . 2002;288:2411–2420.
.
angiographicallyguidedstenting.CatheterCardiovascInterv2003;59:314–321. .. 668.Bellemain-AppaixA,O’ConnorSA,SilvainJ,CucheratM,BeyguiF,Barthelemy
.
652. WitzenbichlerB,MaeharaA,WeiszG,NeumannFJ,RinaldiMJ,MetzgerDC, . O,ColletJP,JacqL,BernasconiF,MontalescotG;ACTIONGroup.Association
.
HenryTD,CoxDA,DuffyPL,BrodieBR,StuckeyTD,MazzaferriELJr,XuK, . of clopidogrel pretreatment with mortality, cardiovascular events, and major
.
PariseH,MehranR,MintzGS,StoneGW.Relationshipbetweenintravascular .. bleeding among patients undergoing percutaneous coronary intervention: A
ultrasoundguidanceandclinicaloutcomesafterdrug-elutingstents:Theassess- .. systematicreviewandmeta-analysis.JAMA2012;308:2507–2516.
.
mentofdualantiplatelettherapywithdrug-elutingstents(ADAPT-DES)study. . 669.LincoffAM,KleimanNS,KereiakesDJ,FeitF,BittlJA,JackmanJD,SarembockIJ,
.
Circulation2014;129:463–470. . CohenDJ,SpriggsD,EbrahimiR,KerenG,CarrJ,CohenEA,BetriuA,Desmet
.
653. MaeharaA,Ben-YehudaO,AliZ,WijnsW,BezerraHG,ShiteJ,GenereuxP, .. W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2
NicholsM,JenkinsP,WitzenbichlerB,MintzGS,StoneGW.Comparisonof .. Investigators.Long-termefficacyofbivalirudinandprovisionalglycoproteinIIb/
.
stentexpansionguidedbyopticalcoherencetomographyversusintravascular . IIIablockadevsheparinandplannedglycoproteinIIb/IIIablockadeduringpercu-
.
ultrasound: The ILUMIEN II study (observational study of optical coherence .. taneous coronary revascularization: REPLACE-2 randomized trial. JAMA
tomography [OCT] in patients undergoing fractional flow reserve [FFR] and .. 2004;292:696–703.
.
percutaneouscoronaryintervention).JACCCardiovascInterv2015;8:1704–1714. . 670.KastratiA,NeumannFJ,MehilliJ,ByrneRA,IijimaR,ButtnerHJ,KhattabAA,
.
654. Maeng M, Holm NR, Erglis A, Kumsars I, Niemela M, Kervinen K, Jensen JS, . SchulzS,BlankenshipJC,PacheJ,MinnersJ,SeyfarthM,GrafI,SkeldingKA,
.
Galloe A, Steigen TK, Wiseth R, Narbute I, Gunnes P, Mannsverk J, .. Dirschinger J, Richardt G, Berger PB, Schomig A; ISAR-REACT 3 Trial
MeyerdierksO,RotevatnS,NikusK,VikmanS,RavkildeJ,JamesS,Aaroe J, .. Investigators. Bivalirudin versus unfractionated heparin during percutaneous
.
YlitaloA,HelqvistS,SjogrenI,ThayssenP,VirtanenK,PuhakkaM,AiraksinenJ, . coronaryintervention.NEnglJMed2008;359:688–696.
.
ChristiansenEH,LassenJF,Thuesen L;Nordic-Baltic PercutaneousCoronary . 671.SchulzS,MehilliJ,NeumannFJ,SchusterT,MassbergS,ValinaC,SeyfarthM,
.
InterventionStudyGroup.Long-termresultsaftersimpleversuscomplexstent- .. Pache J, Laugwitz KL, Buttner HJ, Ndrepepa G, Schomig A, Kastrati A,
.
ing of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year . Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for
.
follow-upresults.JAmCollCardiol2013;62:30–34. . CoronaryTreatment(ISAR-REACT)3ATrialInvestigators.ISAR-REACT3A:A
.
655. Hildick-Smith D,deBelder AJ,Cooter N,CurzenNP, ClaytonTC,Oldroyd .. studyofreduceddoseofunfractionatedheparininbiomarkernegativepatients
KG,BennettL,HolmbergS,CottonJM,GlennonPE,ThomasMR,Maccarthy .. undergoing percutaneous coronary intervention. Eur Heart J
.
PA, Baumbach A, Mulvihill NT, Henderson RA, Redwood SR, Starkey IR, . 2010;31:2482–2491.
.
StablesRH.Randomizedtrialofsimpleversuscomplexdrug-elutingstentingfor . 672.MontalescotG,WhiteHD,GalloR,CohenM,StegPG,AylwardPE,BodeC,
.
bifurcation lesions: The British Bifurcation Coronary Study: Old, new, and .. ChiarielloM,KingSBIII,HarringtonRA,DesmetWJ,MacayaC,SteinhublSR;
evolvingstrategies.Circulation2010;121:1235–1243. .. STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective
.
656. BehanMW,HolmNR,CurzenNP,ErglisA,StablesRH,deBelderAJ,Niemela . percutaneouscoronaryintervention.NEnglJMed2006;355:1006–1017.
.
M,CooterN,ChewDP,SteigenTK,OldroydKG,JensenJS,LassenJF,Thuesen .. 673.Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW,
L,Hildick-SmithD.Simpleorcomplexstentingforbifurcationcoronarylesions: .. Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS,
.
Apatient-levelpooled-analysisoftheNordicBifurcationStudyandtheBritish . GrubergL,FrenchWJ,WhiteHD,HarringtonRA;CHAMPIONInvestigators.
.
BifurcationCoronaryStudy.CircCardiovascInterv2011;4:57–64. . Effect of cangrelor on periprocedural outcomes in percutaneous coronary
.
657. ChenSL,SantosoT,ZhangJJ,YeF,XuYW,FuQ,KanJ,PaiboonC,ZhouY, .. interventions: A pooled analysis of patient-level data. Lancet
Ding SQ, Kwan TW. A randomized clinical study comparing double kissing .. 2013;382:1981–1992.
.
crush with provisional stenting for treatment of coronary bifurcation lesions: . 674.Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, .
Results from the DKCRUSH-II (Double Kissing Crush versus Provisional . SoukhomovskaiaO,FerrariR.Theadditivevalueoftirofibanadministeredwith
. StentingTechniqueforTreatmentofCoronaryBifurcationLesions)trial.JAm .. thehigh-dosebolusinthepreventionofischemiccomplications duringhigh-
CollCardiol2011;57:914–920. .. risk coronary angioplasty: The ADVANCE Trial. J Am Coll Cardiol
.
658. KatritsisDG,SiontisGC,IoannidisJP.Doubleversussinglestentingforcoro- . 2004;44:14–19.
.
narybifurcationlesions:Ameta-analysis.CircCardiovascInterv2009;2:409–415. .. 675.KastratiA,MehilliJ,SchuhlenH,DirschingerJ,DotzerF,tenBergJM,Neumann
659. MehranR,ClaessenBE,GodinoC,DangasGD,ObunaiK,KanwalS,CarlinoM, .. FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A; Intracoronary
.
HenriquesJP,DiMarioC,KimYH,ParkSJ,StoneGW,LeonMB,MosesJW, . Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary
.
Colombo A, Multinational Chronic Total Occlusion Registry. Long-term out- . TreatmentStudyInvestigators.Aclinicaltrialofabciximabinelectivepercuta-
.
comeofpercutaneouscoronaryinterventionforchronictotalocclusions.JACC .. neouscoronaryinterventionafterpretreatmentwithclopidogrel.NEnglJMed
CardiovascInterv2011;4:952–961. .. 2004;350:232–238.
.
660. ClaessenBE,DangasGD,GodinoC,LeeSW,ObunaiK,CarlinoM,SuhJW, . 676.Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA.
.
LeonMB,DiMarioC,ParkSJ,StoneGW,MosesJW,ColomboA,MehranR, .. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary
MultinationalCtoRegistry.Long-termclinicaloutcomesofpercutaneouscoro- .. revascularization:Ameta-analysisofrandomizedtrialsperformedintheeraof
.
naryinterventionforchronictotalocclusionsinpatientswithversuswithout . stentsandthienopyridines.JAmCollCardiol2011;57:1190–1199.
.
diabetesmellitus.AmJCardiol2011;108:924–931. . 677.IakovouI,SchmidtT,BonizzoniE,GeL,SangiorgiGM,StankovicG,AiroldiF,
.
661. JonesDA,WeerackodyR,RathodK,BeharJ,GallagherS,KnightCJ,KapurA, .. Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C,
JainAK,RothmanMT,ThompsonCA,MathurA,WraggA,SmithEJ.Successful .. Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of
.
recanalizationofchronictotalocclusionsisassociatedwithimprovedlong-term . thrombosis after successful implantation of drug-eluting stents. JAMA
.
survival.JACCCardiovascInterv2012;5:380–388. . 2005;293:2126–2130.
.
662. GranthamJA,JonesPG,CannonL,SpertusJA.Quantifyingtheearlyhealthsta- .. 678.EikelboomJW,ConnollySJ,BoschJ,DagenaisGR,HartRG,ShestakovskaO,
tus benefits of successful chronic total occlusion recanalization: Results from .. DiazR,AlingsM,LonnEM,AnandSS,WidimskyP,HoriM,AvezumA,Piegas
.
the FlowCardia’s Approach to Chronic Total Occlusion Recanalization . LS,BranchKRH,ProbstfieldJ,BhattDL,ZhuJ,LiangY,MaggioniAP,Lopez-
.
(FACTOR)Trial.CircCardiovascQualOutcomes2010;3:284–290. .. Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G,
663. JoyalD,AfilaloJ,RinfretS.Effectivenessofrecanalizationofchronictotalocclu- .. StorkS,KeltaiM,Ryden L, PogosovaN,DansAL, Lanas F,CommerfordPJ,
.
sions:Asystematicreviewandmeta-analysis.AmHeartJ2010;160:179–187. . Torp-PedersenC,GuzikTJ,VerhammePB,VinereanuD,KimJH,TonkinAM,
.
664. NdrepepaG,BergerPB,MehilliJ,SeyfarthM,NeumannFJ,SchomigA,Kastrati . LewisBS,FelixC,YusoffK,StegPG,MetsarinneKP,CookBrunsN,Misselwitz
.
A. Periproceduralbleedingand 1-year outcomeafter percutaneous coronary .. F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 93 ---
ESC/EACTSGuidelines 165n
.
.
without aspirin in stable cardiovascular disease. N Engl J Med . biodegradablepolymersirolimus-elutingstent:RandomizedsubstudyoftheI-
.
2017;377:1319–1330. . LOVE-IT2trial.CircCardiovascInterv2016;9:e003145.
.
679. DiSciascioG,PattiG,PasceriV,GattoL,ColonnaG,MontinaroA;ARMYDA- .. 693.HongSJ,ShinDH,KimJS,KimBK,KoYG,ChoiD,HerAY,KimYH,JangY,
5PRELOADInvestigators.Effectivenessofin-laboratoryhigh-doseclopidogrel .. HongMK,IVUS-InvestigatorsXPL.6-monthversus12-monthdual-antiplatelet
.
loadingversusroutinepre-loadinpatientsundergoingpercutaneouscoronary . therapy following long everolimus-eluting stent implantation: The IVUS-XPL
.
intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for .. randomizedclinicaltrial.JACCCardiovascInterv2016;9:1438–1446.
Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll .. 694. KereiakesDJ,YehRW,MassaroJM,Driscoll-ShemppP,CutlipDE,StegPG,
.
Cardiol2010;56:550–557. . GershlickAH,DariusH,MeredithIT,OrmistonJ,TanguayJF,WindeckerS,
.
680. WidimskyP,MotovskaZ,SimekS,KalaP,PudilR,HolmF,PetrR,BilkovaD, . GarrattKN,KandzariDE,LeeDP,SimonDI,IancuAC,TrebaczJ,MauriL;
.
Skalicka H, Kuchynka P, Poloczek M, Miklik R, Maly M, Aschermann M; .. Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet
PRAGUE-8TrialInvestigators.Clopidogrelpre-treatmentinstableangina:For .. therapydurationfollowingbaremetalordrug-elutingcoronarystents:The
.
allpatients>6hbeforeelectivecoronaryangiographyoronlyforangiographi- . dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113–
.
cally selected patients a few minutes before PCI? A randomized multicentre . 1121.
.
trialPRAGUE-8.EurHeartJ2008;29:1495–1503. .. 695.KimBK,HongMK,ShinDH,NamCM,KimJS,KoYG,ChoiD,KangTS,Park
.
681. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of rando- . BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y; RESET
.
misedtrialsofantiplatelettherapyforpreventionofdeath,myocardialinfarc- . Investigators. A new strategy for discontinuation of dual antiplatelet therapy:
.
tion,andstrokeinhighriskpatients.BMJ2002;324:71–86. .. TheRESETTrial(REalSafetyandEfficacyof3-monthdualantiplateletTherapy
682. AntiplateletTrialists’Collaboration.Collaborativeoverviewofrandomisedtri- .. following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol
.
als of antiplatelet therapy–I: Prevention of death, myocardial infarction, and . 2012;60:1340–1348.
.
strokebyprolongedantiplatelettherapyinvariouscategoriesofpatients.BMJ . 696.FeresF,CostaRA,AbizaidA,LeonMB,Marin-NetoJA,BotelhoRV,KingSBIII,
.
1994;308:81–106. .. Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr,
683. Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, .. NicolelaELJr, Perin MA, Devito FS, Labrunie A, SalvadoriD Jr, Gusmao M,
.
Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, . Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial
.
RoncaglioniMC,ZanchettiA.Aspirinintheprimaryandsecondaryprevention .. Investigators. Three vs twelve months of dual antiplatelet therapy after
of vascular disease: Collaborative meta-analysis of individual participant data .. zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA
.
fromrandomisedtrials.Lancet2009;373:1849–1860. . 2013;310:2510–2522.
.
684. BertrandME,RupprechtHJ,UrbanP,GershlickAH;CLASSICSInvestigators. . 697.Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G,
.
Double-blindstudyofthesafetyofclopidogrelwithandwithoutaloadingdose .. FeresF,AbizaidA,HongMK,KimBK,JangY,KimHS,ParkKW,GenereuxP,
in combination with aspirin compared with ticlopidine in combination with .. BhattDL,OrlandiC,DeServiS,PetrouM,RapezziC,StoneGW.Mortalityin
.
aspirinaftercoronarystenting:theclopidogrelaspirinstentinternationalcoop- . patients treated with extended duration dual antiplatelet therapy after drug-
.
erativestudy(CLASSICS).Circulation2000;102:624–629. . eluting stent implantation: A pairwise and Bayesian network meta-analysis of
.
685. TaniuchiM,KurzHI,LasalaJM.Randomizedcomparisonofticlopidineandclo- .. randomisedtrials.Lancet2015;385:2371–2382.
.
pidogrelafterintracoronarystentimplantationinabroadpatient population. . 698.Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma SK,
.
Circulation2001;104:539–543. . PocockSJ,DangasGD.Durationofdualantiplatelettherapyafterdrug-eluting
.
686. Muller C, Buttner HJ, PetersenJ, Roskamm H. Arandomized comparison of .. stentimplantation:Asystematicreviewandmeta-analysisofrandomizedcon-
clopidogrel and aspirin versus ticlopidine and aspirin after the placement of .. trolledtrials.JAmCollCardiol2015;65:1298–1310.
.
coronary-arterystents.Circulation2000;101:590–593. . 699.NavareseEP,AndreottiF,SchulzeV,KolodziejczakM,BuffonA,BrouwerM,
.
687. von Beckerath N, Taubert D, Pogatsa-Murray G, Scho¨mig E, Kastrati A, . CostaF,KowalewskiM,ParatiG,LipGY,KelmM,ValgimigliM.Optimaldura-
.
Scho¨migA.Absorption,metabolization,andantiplateleteffectsof300-,600-, .. tionofdualantiplatelettherapyafterpercutaneouscoronaryinterventionwith
and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE .. drug eluting stents: Meta-analysis of randomised controlled trials. BMJ
.
(IntracoronaryStentingandAntithromboticRegimen:ChooseBetween3High . 2015;350:h1618.
.
Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation .. 700.Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
2005;112:2946–2950. .. NormandSL,BraunwaldE,WiviottSD,CohenDJ,HolmesDRJr,KrucoffMW,
.
688. MontalescotG,SiderisG,MeulemanC,Bal-dit-SollierC,LelloucheN,StegPG, . HermillerJ,DauermanHL,SimonDI,KandzariDE,GarrattKN,LeeDP,Pow
.
SlamaM,MilleronO,ColletJP,HenryP,BeyguiF,DrouetL,InvestigatorsAT. . TK,VerLeeP,RinaldiMJ,MassaroJM;DAPTStudyInvestigators.Twelveor30
.
A randomized comparison of high clopidogrel loading doses in patients with .. months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med
non-ST-segment elevation acute coronary syndromes: The ALBION .. 2014;371:2155–2266.
.
(Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet . 701.WiviottSD,BraunwaldE,McCabeCH,MontalescotG,RuzylloW,GottliebS, .
Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol . NeumannFJ,ArdissinoD,DeServiS,MurphySA,RiesmeyerJ,WeerakkodyG,
. 2006;48:931–938. .. GibsonCM,AntmanEM;TRITONTIMI38Investigators.Prasugrelversusclopi-
689. SilvainJ,BeyguiF,BarthelemyO,PollackCJr,CohenM,ZeymerU,HuberK, .. dogrel in patients with acute coronary syndromes. N Engl J Med
.
GoldsteinP,CaylaG,ColletJP,VicautE,MontalescotG.Efficacyandsafetyof . 2007;357:2001–2015.
.
enoxaparinversusunfractionatedheparinduringpercutaneouscoronaryinter- .. 702.WallentinL,BeckerRC,BudajA,CannonCP,EmanuelssonH,HeldC,Horrow
vention:Systematicreviewandmeta-analysis.BMJ2012;344:e553. .. J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
.
690. ValgimigliM,CampoG,MontiM,VranckxP,PercocoG,TumscitzC,Castriota . StoreyRF,HarringtonRA;PLATOInvestigators,FreijA,ThorsenM.Ticagrelor
.
F,ColomboF,TebaldiM,FucaG,KubbajehM,CangianoE,MinarelliM,Scalone . versus clopidogrel in patients with acute coronary syndromes. N Engl J Med
.
A,CavazzaC,FrangioneA,BorghesiM,MarchesiniJ,ParrinelloG,FerrariR; .. 2009;361:1045–1057.
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal .. 703.Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S.
.
HyperplasiaStudy(PRODIGY)Investigators.Short-versuslong-termduration . Unfractionated heparin and low-molecular-weight heparin in acute coronary
.
ofdual-antiplatelettherapyaftercoronarystenting:Arandomizedmulticenter .. syndromewithoutSTelevation:Ameta-analysis.Lancet2000;355:1936–1942.
trial.Circulation2012;125:2015–2026. .. 704.Cohen M, Mahaffey KW, Pieper K, Pollack CV Jr, Antman EM, Hoekstra J,
.
691. Schulz-SchupkeS,ByrneRA,TenBergJM,NeumannFJ,HanY,AdriaenssensT, . GoodmanSG,LangerA,ColJJ,WhiteHD,CaliffRM,FergusonJJ;SYNERGY
.
Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von . Trial Investigators. A subgroup analysis of the impact of prerandomization
.
Hodenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, .. antithrombintherapyonoutcomesintheSYNERGY trial:Enoxaparinversus
MorathT,FeuchtenbergerA,IbrahimT,JanssenPW,ValinaC,LiY,Desmet .. unfractionatedheparininnon-ST-segmentelevationacutecoronarysyndromes.
.
W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, . JAmCollCardiol2006;48:1346–1354.
.
Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A; Intracoronary . 705.Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S,
.
StentingandAntithromboticRegimen:SafetyAndEFficacyof6MonthsDual .. KereiakesDJ,LangerA,MahaffeyKW,NesselCC,ArmstrongPW,AvezumA,
Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial .. AylwardP,BeckerRC,BiasucciL,BorzakS,ColJ,FreyMJ,FryE,GulbaDC,
.
Investigators.ISAR-SAFE:arandomized,double-blind, placebo-controlledtrial . Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB,
.
of6vs.12monthsofclopidogreltherapyafterdrug-elutingstenting.EurHeartJ .. Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-
2015;36:1252–1263. .. Figueroa L, White H; SYNERGY Trial Investigators. Enoxaparin vs unfractio-
.
692. HanY,XuB,XuK,GuanC,JingQ,ZhengQ,LiX,ZhaoX,WangH,ZhaoX, . natedheparininhigh-riskpatientswithnon-ST-segmentelevationacutecoro-
.
LiX,YuP,ZangH,WangZ,CaoX,ZhangJ,PangW,LiJ,YangY,DangasGD. . nary syndromes managed with an intended early invasive strategy: Primary
.
Six versus 12 months of dual antiplatelet therapy after implantation of .. resultsoftheSYNERGYrandomizedtrial.JAMA2004;292:45–54.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 94 ---
165o ESC/EACTSGuidelines
.
.
706. CavenderMA,SabatineMS.Bivalirudinversusheparininpatientsplannedfor . 720.Mega JL, Braunwald E, Wiviott SD,BassandJP, BhattDL,BodeC,BurtonP,
.
percutaneouscoronaryintervention:Ameta-analysisofrandomisedcontrolled . Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
.
trials.Lancet2014;384:599–606. .. Schneider D, Sun X, Verheugt FW, Gibson CM, ATLAS ACS 2–TIMI 51
707. Cassese S, Byrne RA, Laugwitz KL, Schunkert H, Berger PB, Kastrati A. .. Investigators.Rivaroxabaninpatientswitharecentacutecoronarysyndrome.
.
Bivalirudinversusheparininpatientstreatedwithpercutaneouscoronaryinter- . NEnglJMed2012;366:9–19.
.
vention:Ameta-analysisofrandomisedtrials.EuroIntervention2015;11:196–203. .. 721.Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De
708. ZhangS,GaoW,LiH,ZouM,SunS,BaY,LiuY,ChengG.Efficacyandsafety .. CaterinaR,GulbaD,HuberK,HustedS,KristensenSD,MoraisJ,NeumannFJ,
.
of bivalirudin versus heparin in patients undergoing percutaneous coronary . RasmussenLH,SiegbahnA,StegPG,StoreyRF,VandeWerfF,VerheugtF.
.
intervention: A meta-analysis of randomized controlled trials. Int J Cardiol . Antiplateletagentsforthetreatmentandpreventionofatherothrombosis.Eur
.
2016;209:87–95. .. HeartJ2011;32:2922–2932.
709. ErlingeD,OmerovicE,FrobertO,LinderR,DanielewiczM,HamidM,SwahnE, .. 722.MehtaSR,YusufS,PetersRJ,BertrandME,LewisBS,NatarajanMK,Malmberg
.
HenarehL,WagnerH,HardhammarP,SjogrenI,StewartJ,GrimfjardP,JensenJ, . K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in
.
AasaM,RobertssonL,LindroosP,HauptJ,WikstromH,UlvenstamA,Bhiladvala . UnstableanginatopreventRecurrentEventstrialInvestigators.Effectsofpre-
.
P,LindvallB,LundinA,TodtT,IoanesD,RamunddalT,KellerthT,ZagozdzonL, .. treatment with clopidogrel and aspirin followed by long-term therapy in
.
GotbergM,AnderssonJ,AngerasO,OstlundO,LagerqvistB,HeldC,Wallentin . patientsundergoingpercutaneouscoronaryintervention:ThePCI-CUREstudy.
.
L,ScherstenF,ErikssonP,KoulS,JamesS.Bivalirudinversusheparinmonother- . Lancet2001;358:527–533.
.
apyinmyocardialinfarction.NEnglJMed2017;377:1132–1142. .. 723.YusufS,ZhaoF,MehtaSR,ChrolaviciusS,TognoniG,FoxKK,Clopidogrelin
710. Nu¨hrenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. .. UnstableAnginatoPreventRecurrentEventsTrialInvestigators.Effectsofclo-
.
Efficacy and safety of bivalirudin for percutaneous coronary intervention in . pidogrelinadditiontoaspirininpatientswithacutecoronarysyndromeswith-
.
acute coronary syndromes: A meta-analysis of randomized-controlled trials. . outST-segmentelevation.NEnglJMed2001;345:494–502.
.
ClinResCardiol;doi:10.1007/s00392-018-1251-1.Publishedonlineaheadofprint .. 724.MehtaSR,TanguayJF,EikelboomJW,JollySS,JoynerCD,GrangerCB,Faxon
13April2018. .. DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP,
.
711. FifthOrganizationtoAssessStrategiesinAcuteIschemicSyndromesI,YusufS, . Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD,
.
Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, .. Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 Investigators.
BassandJP,WallentinL,JoynerC,FoxKA.Comparisonoffondaparinuxand .. Double-doseversusstandard-doseclopidogrelandhigh-doseversuslow-dose
.
enoxaparininacutecoronarysyndromes.NEnglJMed2006;354:1464–1476. . aspirininindividualsundergoingpercutaneouscoronaryinterventionforacute
.
712. BoersmaE,HarringtonRA,MoliternoDJ,WhiteH,TherouxP,VandeWerfF, . coronarysyndromes(CURRENT-OASIS7):Arandomisedfactorialtrial.Lancet
.
de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, .. 2010;376(9748):1233–1243.
TopolEJ,SimoonsML.PlateletglycoproteinIIb/IIIainhibitorsinacutecoronary .. 725.StoneGW,BertrandME,MosesJW,OhmanEM,LincoffAM,WareJH,Pocock
.
syndromes: A meta-analysis of all major randomised clinical trials. Lancet . SJ,McLaurinBT,CoxDA,JafarMZ,ChandnaH,HartmannF,LeischF,Strasser
.
2002;359:189–198. . RH,DesagaM,StuckeyTD,ZelmanRB,LieberIH,CohenDJ,MehranR,White
.
713. GiuglianoRP,WhiteJA,BodeC,ArmstrongPW,MontalescotG,LewisBS,van .. HD; ACUITY Investigators. Routine upstream initiation vs deferred selective
.
’tHofA,BerdanLG,LeeKL,StronyJT,HildemannS,VeltriE,VandeWerfF, . use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The
.
BraunwaldE,HarringtonRA,CaliffRM,NewbyLK;EARLYInvestigatorsACS. . ACUITYTimingtrial.JAMA2007;297:591–602.
.
Earlyversusdelayed,provisionaleptifibatideinacutecoronarysyndromes.N .. 726.OlerA,WhooleyMA,OlerJ,GradyD.Addingheparintoaspirinreducesthe
EnglJMed2009;360:2176–2190. .. incidenceofmyocardialinfarctionanddeathinpatientswithunstableangina.A
.
714. StoneGW,McLaurinBT,CoxDA,BertrandME,LincoffAM,MosesJW,White . meta-analysis.JAMA1996;276:811–815.
.
HD,PocockSJ,WareJH,FeitF,ColomboA,AylwardPE,CequierAR,Darius . 727.FUTURA/OASIS-TrialGroup8,StegPG,JollySS,MehtaSR,AfzalR,XavierD,
.
H,DesmetW,EbrahimiR,HamonM,RasmussenLH,RupprechtHJ,Hoekstra .. RupprechtHJ,Lopez-SendonJL,BudajA,DiazR,AvezumA,WidimskyP,Rao
J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with .. SV,ChrolaviciusS,MeeksB,JoynerC,PogueJ,YusufS.Low-dosevsstandard-
.
acutecoronarysyndromes.NEnglJMed2006;355:2203–2216. . doseunfractionatedheparinforpercutaneouscoronaryinterventioninacute
.
715. HahnJY,SongYB,OhJH,ChoDK,LeeJB,DohJH,KimSH,JeongJO,BaeJH, .. coronary syndromes treated with fondaparinux: The FUTURA/OASIS-8
KimBO,ChoJH,SuhIW,KimDI,ParkHK,ParkJS,ChoiWG,LeeWS,KimJ, .. randomizedtrial.JAMA2010;304:1339–1349.
.
ChoiKH,ParkTK,LeeJM,YangJH,ChoiJH,ChoiSH,GwonHC,SMART- . 728.Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P,
.
DATEInvestigators.6-monthversus12-monthorlongerdualantiplateletther- . GarducciS,RubartelliP,BriguoriC,AndoG,RepettoA,LimbrunoU,GarboR,
.
apyafterpercutaneouscoronaryinterventioninpatientswithacutecoronary .. Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G,
syndrome (SMART-DATE): A randomised, open-label, non-inferiority trial. .. Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N,
.
Lancet2018;391:1274–1284. . RigattieriS,ZingarelliA,TosiP,van’tHofA,BoccuzziG,OmerovicE,Sabate .
716. CuissetT,DeharoP,QuiliciJ,JohnsonTW,DeffargesS,BassezC,BonnetG, . M,HegD,JuniP,VranckxP; MATRIXInvestigators.Bivalirudinorunfractio-
. FourcadeL,MouretJP,LambertM,VerdierV,MorangePE,AlessiMC,Bonnet .. natedheparininacutecoronarysyndromes.NEnglJMed2015;373:997–1009.
JL.Benefitofswitchingdualantiplatelettherapyafteracutecoronarysyndrome: .. 729.PalmeriniT,DellaRivaD,BenedettoU,ReggianiLB,FeresF,AbizaidA,Gilard
.
The TOPIC (timing of platelet inhibition after acute coronary syndrome) . M,MoriceM,ValgimigliM,HongM,KimB,JangY,KimH,ParkKW,Colombo
.
randomizedstudy.EurHeartJ2017;38:3070–3078. .. A,ChieffoA,SangiorgiD,Biondi-ZoccaiG,GenereuxP,AngeliniGD,White,
717. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, .. BhattDL,StoneGW.Three,sixortwelvemonthsofdualantiplatelettherapy
.
HadamitzkyM,MerkelyB,KissRG,KomocsiA,DezsiCA,HoldtL,FelixSB, . afterdrug-elutingstentimplantationinpatientswithorwithoutacutecoronary
.
Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, . syndromes:Anindividualpatientdatapairwiseandnetworkmeta-analysisofsix
.
Koltowski L, Mehilli J, Huczek Z, Massberg S; TROPICAL-ACS Investigators. .. randomizedtrialsand11,473patients.EurHeartJ2017;38:1034–1043.
Guidedde-escalationofantiplatelettreatmentinpatientswithacutecoronary .. 730.CostaF,vanKlaverenD,JamesS,HegD,RaberL,FeresF,PilgrimT,HongMK,
.
syndromeundergoingpercutaneouscoronaryintervention(TROPICAL-ACS): . KimHS,ColomboA,StegPG,ZanchinT,PalmeriniT,WallentinL,BhattDL,
.
Arandomised,open-label,multicentretrial.Lancet2017;390:1747–1757. .. StoneGW,WindeckerS,SteyerbergEW,ValgimigliM;PRECISE-DAPTStudy
718. AngiolilloDJ,RolliniF,StoreyRF,BhattDL,JamesS,SchneiderDJ,SibbingD, .. Investigators.Derivationandvalidationofthepredictingbleedingcomplications
.
So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, . inpatientsundergoingstentimplantationandsubsequentdualantiplateletther-
.
BonelloL,AradiD,CuissetT,TantryUS,WangTY,ValgimigliM,WaksmanR, . apy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets
.
MehranR,MontalescotG,FranchiF,PriceMJ.Internationalexpertconsensus .. fromclinicaltrials.Lancet2017;389:1025–1034.
on switching platelet P2Y12 receptor-inhibiting therapies. Circulation .. 731.BonacaMP,BhattDL,StegPG,StoreyRF,CohenM,ImK,OudeOphuisT,
.
2017;136:1955–1975. . BudajA,GotoS,Lopez-SendonJ,DiazR,DalbyA,VandeWerfF,Ardissino
.
719. GrinesCL,BonowRO,CaseyDEJr,GardnerTJ,LockhartPB,MoliternoDJ, . D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E,
.
O’Gara P, Whitlow P; American Heart Association; American College of .. SabatineMS.Ischaemicriskandefficacyofticagrelorinrelationtotimefrom
Cardiology; Society for Cardiovascular Angiography and Interventions; .. P2Y12inhibitorwithdrawalinpatientswithpriormyocardialinfarction:Insights
.
American College of Surgeons; American Dental Association; American . fromPEGASUS-TIMI54.EurHeartJ2016;37:1133–1142.
.
CollegeofPhysicians.Preventionofprematurediscontinuationofdualantipla- .. 732.BonacaMP,BhattDL,CohenM,StegPG,StoreyRF,JensenEC,MagnaniG,
telettherapyinpatientswithcoronaryarterystents:Ascienceadvisoryfrom .. BansilalS,FishMP,ImK,BengtssonO,OudeOphuisT,BudajA,TherouxP,
.
theAmericanHeartAssociation,AmericanCollegeofCardiology,Societyfor . RudaM,HammC,GotoS,SpinarJ,NicolauJC,KissRG,MurphySA,Wiviott
.
CardiovascularAngiographyandInterventions,AmericanCollegeofSurgeons, . SD,HeldP,BraunwaldE,SabatineMS,PEGASUS-TIMI54SteeringCommittee
.
and American Dental Association, with representation from the American .. andInvestigators.Long-termuseofticagrelorinpatientswithpriormyocardial
CollegeofPhysicians.Circulation2007;115:813–818. . infarction.NEnglJMed2015;372:1791–1800.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 95 ---
ESC/EACTSGuidelines 165p
.
.
733.CostaF,AdamoM,AriottiS,NavareseEP,Biondi-ZoccaiG,ValgimigliM.Impactof . 747.HanssonEC,JideusL,AbergB,BjurstenH,DreifaldtM,HolmgrenA,IvertT,
.
greaterthan12-monthdualantiplatelettherapydurationonmortality:Drug-specific . Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A. Coronary artery bypass
.
oraclass-effect?Ameta-analysis.IntJCardiol2015;201:179–181. .. grafting-related bleeding complications in patients treated with ticagrelor or
734. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, .. clopidogrel:Anationwidestudy.EurHeartJ2016;37:189–197.
.
Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L; DAPT Study . 748.Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary
.
Investigators. Benefits and risks of extended dual antiplatelet therapy after .. artery bypass grafting-related bleeding complications in patients treated with
everolimus-elutingstents.JACCCardiovascInterv2016;9:138–147. .. dualantiplatelettreatment.EurJCardiothoracSurg2016;50:849–856.
.
735. MotovskaZ,HlinomazO,MiklikR,HromadkaM,VarvarovskyI,DusekJ,Knot . 749.GherliR,MariscalcoG,DalenM,OnoratiF,PerrottiA,ChocronS,VerhoyeJP,
.
J,JarkovskyJ,KalaP,RokytaR,TousekF,KramarikovaP,MajtanB,SimekS, . GulbinsH,ReichartD,SvenarudP,FaggianG,SantarpinoG,FischleinT,MaselliD,
.
BrannyM,MrozekJ,CervinkaP,OstranskyJ,WidimskyP;PRAGUE-18Study .. DominiciC,MusumeciF,RubinoAS,MignosaC,DeFeoM,BanconeC,GattiG,
Group.Prasugrelversusticagrelorinpatientswithacutemyocardialinfarction .. MaschiettoL,SantiniF,NicoliniF,GherliT,ZanobiniM,KinnunenEM,Ruggieri
.
treatedwithprimarypercutaneouscoronaryintervention:Multicenterrandom- . VG,RosatoS,BiancariF.Safetyofpreoperativeuseofticagrelorwithorwithout
.
izedPRAGUE-18study.Circulation2016;134:1603–1612. . aspirin compared with aspirin alone in patients with acutecoronary syndromes
.
736. MontalescotG,van’tHofAW,LapostolleF,SilvainJ,LassenJF,BologneseL, .. undergoingcoronaryarterybypassgrafting.JAMACardiol2016;1:921–928.
.
Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, . 750.KwakYL,KimJC,ChoiYS,YooKJ,SongY,ShimJK.Clopidogrelresponsiveness
.
JanzonM,MerkelyB,StoreyRF,ZeymerU,StibbeO,EcollanP,HeutzWM, . regardlessofthediscontinuationdatepredictsincreasedbloodlossandtransfu-
.
Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, .. sionrequirementafteroff-pumpcoronaryarterybypassgraftsurgery.JAmColl
HammCW;ATLANTICInvestigators.PrehospitalticagrelorinST-segmentele- .. Cardiol2010;56:1994–2002.
.
vationmyocardialinfarction.NEnglJMed2014;371:1016–1027. . 751.Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D;
.
737. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, . Surgical and Clinical Outcome Research (SCORE)Group. Multiple electrode
.
EcollanP,CombesX, HuberK,PollackC Jr, BenezetJF,Stibbe O,Filippi E, .. whole-blood aggregometry and bleeding in cardiac surgery patients receiving
TeigerE,CaylaG,ElhadadS,AdnetF,ChouihedT,GallulaS,GreffetA,Aout .. thienopyridines.AnnThoracSurg2011;91:123–129.
.
M,ColletJP,VicautE;ATOLLInvestigators.Intravenousenoxaparinorunfrac- . 752.Ranucci M, Colella D, Baryshnikova E, Di Dedda U; Surgical and Clinical
.
tionated heparin in primary percutaneous coronary intervention for ST- .. OutcomeResearch(SCORE)Group.EffectofpreoperativeP2Y12andthrom-
elevation myocardial infarction: The international randomised open-label .. binplateletreceptorinhibitiononbleedingaftercardiacsurgery.BrJAnaesth
.
ATOLLtrial.Lancet2011;378:693–703. . 2014;113:970–976.
.
738. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, . 753.Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM,
.
Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P; .. MikkelsenA,ChristensenCB,LipGY,KoberL,Torp-PedersenC,HansenML.
ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary .. Oralanticoagulationandantiplateletsinatrialfibrillationpatientsaftermyocar-
.
stentingforacutemyocardialinfarction.NEnglJMed2001;344:1895–1903. . dialinfarctionandcoronaryintervention.JAmCollCardiol2013;62:981–989.
.
739. StoneGW,GrinesCL,CoxDA,GarciaE,TchengJE,GriffinJJ,GuagliumiG, . 754.Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
.
Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ; Controlled .. AdriaenssensT,VrolixM,HeestermansAA,VisMM,TijsenJG,van’tHofAW,
.
AbciximabandDeviceInvestigationtoLowerLateAngioplastyComplications . tenBergJM:WOESTStudyInvestigators.Useofclopidogrelwithorwithout
.
(CADILLAC) Investigators. Comparison of angioplasty with stenting, with or . aspirininpatientstakingoralanticoagulanttherapyandundergoingpercutane-
.
without abciximab, in acute myocardial infarction. N Engl J Med .. ouscoronaryintervention:Anopen-label,randomised,controlledtrial.Lancet
2002;346:957–966. .. 2013;381:1107–1115.
.
740. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa . 755.Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D,
.
inhibitors among patients with ST-segment elevation myocardial infarction . HoppmannP,SchneiderS,FusaroM,OttI,KristensenSD,IbrahimT,Massberg
.
treatedwithprimaryangioplasty:Ameta-regressionanalysisofrandomizedtri- .. S,SchunkertH,LaugwitzKL,KastratiA,SarafoffN.Durationoftripletherapy
als.EurHeartJ2009;30:2705–2713. .. inpatientsrequiringoralanticoagulationafterdrug-elutingstentimplantation:
.
741. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, . TheISAR-TRIPLEtrial.JAmCollCardiol2015;65:1619–1629.
.
AndersenHR,BetriuA,SavonittoS,AdamusJ,PerugaJZ,KosmiderM,KatzO, .. 756.Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,
Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, .. BirminghamM,IanusJ,BurtonP,vanEickelsM,KorjianS,DaaboulY,LipGY,
.
HerrmannHC,MontalescotG,NeumannFJ,EffronMB,BarnathanES,TopolEJ; . CohenM,HustedS,PetersonED,FoxKA.Preventionofbleedinginpatients
.
FINESSEInvestigators.FacilitatedPCIinpatientswithST-elevationmyocardial . withatrialfibrillationundergoingPCI.NEnglJMed2016;375:2423–2434.
.
infarction.NEnglJMed2008;358:2205–2217. .. 757.Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M,
742. Van’tHofAW,TenBergJ,HeestermansT,DillT,FunckRC,vanWerkumW, .. MerkelyB,ZeymerU,GropperS,NordabyM,KleineE,HarperR,ManassieJ,
.
Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, . JanuzziJL,TenBergJM,StegPG,HohnloserSH;DUALRE-SteeringCommittee .
GiannitsisE,HammC;OngoingTirofibanInMyocardialinfarctionEvaluation2 . PCIandInvestigators.DualantithrombotictherapywithdabigatranafterPCIin
. Study Group. Prehospital initiation of tirofiban in patients with ST-elevation .. atrialfibrillation.NEnglJMed2017;377:1513–1524.
myocardial infarction undergoing primary angioplasty (On-TIME 2): A multi- .. 758.DansAL,ConnollySJ,WallentinL,YangS,NakamyaJ,BrueckmannM,Ezekowitz
.
centre,double-blind,randomisedcontrolledtrial.Lancet2008;372:537–546. . M,OldgrenJ,EikelboomJW,ReillyPA,YusufS.Concomitantuseofantiplatelet
.
743. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, .. therapywithdabigatranorwarfarinintheRandomizedEvaluationofLong-Term
EmanuelssonH,FinkelsteinA,HustedS,KatusH,KilhamnJ,OlofssonS,Storey .. AnticoagulationTherapy(RE-LY)trial.Circulation2013;127:634–640.
.
RF,WeaverWD,WallentinL;PLATOStudyGroup.Ticagrelorversusclopi- . 759.Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS,
.
dogrel in patients with ST-elevation acute coronary syndromes intended for . VerheugtFWA,VinereanuD,BahitMC,HalvorsenS,HuberK,Parkhomenko
.
reperfusion with primary percutaneous coronary intervention: A Platelet .. A,GrangerCB,LopesRD,AlexanderJH.Percutaneouscoronaryintervention
Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation .. andantiplatelettherapyinpatientswithatrialfibrillationreceivingapixabanor
.
2010;122:2131–2141. . warfarin:InsightsfromtheARISTOTLEtrial.AmHeartJ2018;197:133–141.
.
744. StegPG,van’tHofA,HammCW,ClemmensenP,LapostolleF,CosteP,Ten .. 760.RuffCT,GiuglianoRP,BraunwaldE,HoffmanEB,DeenadayaluN,Ezekowitz
BergJ,VanGrunsvenP,EgginkGJ,NibbeL,ZeymerU,Campodell’OrtoM, .. MD,CammAJ,WeitzJI,LewisBS,ParkhomenkoA,YamashitaT,AntmanEM.
.
NefH,SteinmetzJ,SoulatL,HuberK,DeliargyrisEN,BernsteinD,SchuetteD, . Comparisonoftheefficacyandsafetyofneworalanticoagulantswithwarfarin
.
PratsJ,ClaytonT,PocockS,HamonM,GoldsteinP;EUROMAXInvestigators. . in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet
.
BivalirudinstartedduringemergencytransportforprimaryPCI.NEnglJMed .. 2014;383:955–962.
2013;369:2207–2217. .. 761.PostPN,KuijpersM,EbelsT,ZijlstraF.Therelationbetweenvolumeandout-
.
745. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, . come of coronary interventions: a systematic review and meta-analysis. Eur
.
KornowskiR,HartmannF,GershBJ,PocockSJ,DangasG,WongSC,Kirtane . HeartJ2010;31:1985–1992.
.
AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin .. 762.KimLK,LooserP,FeldmanDN.Peri-andpostoperativecareaftercoronary
during primary PCI in acute myocardial infarction. N Engl J Med 2008;358: .. artery bypass grafting in low versus high volume centers. J Thorac Cardiovasc
.
2218–2230. . Surg2016;152:1205.
.
746. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, .. 763.Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the
ApplebyC,FisherM,KhandA,KunadianB,MillsJD,MorrisJL,MorrisonWL, .. volume-outcomeeffectincardiovascularsurgery:Theroleoffailuretorescue.
.
MunirS,PalmerND,PerryRA,RamsdaleDR,VelavanP,StablesRH;HEAT- . JAMASurg2014;149:119–123.
.
PPCI Trial Investigators. Unfractionated heparin versus bivalirudin in primary . 764.BirkmeyerJD,StukelTA,SiewersAE,GoodneyPP,WennbergDE,LucasFL.
.
percutaneouscoronaryintervention(HEAT-PPCI):Anopen-label,singlecentre, .. Surgeon volume and operative mortality in the United States. N Engl J Med
randomisedcontrolledtrial.Lancet2014;384:1849–1858. . 2003;349:2117–2127.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 96 ---
165q ESC/EACTSGuidelines
.
.
765. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A, Papadimos TJ, . outcomesafterleftmaincoronaryarterypercutaneouscoronaryintervention.
.
EngorenM,HabibRH.Ishospitalprocedurevolumeareliablemarkerofquality .. JACCCardiovascInterv2016;9:2086–2093.
for coronary artery bypass surgery? A comparison of risk and propensity .. 776.DiMarioC,DiSciascioG,Dubois-RandeJL,MichelsR,MillsP.Curriculumand
.
adjustedoperativeandmidtermoutcomes.AnnThoracSurg2005;79:1961–199. . syllabus for Interventional Cardiology subspecialty training in Europe.
.
766. KurlanskyPA,ArgenzianoM,DuntonR,LanceyR,NastE,StewartA,Williams . EuroIntervention2006;2:31–6.
.
T,ZapolanskiA,ChangH,TingleyJ,SmithCR.Quality,notvolume,determines .. 777.Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N,
outcome of coronary artery bypass surgery in a university-based community .. Taylor RS.Exercise-based cardiac rehabilitation for coronary heart disease:
.
hospitalnetwork.JThoracCardiovascSurg2012;143:287–293. . Cochrane systematic review and meta-analysis. J Am Coll Cardiol
.
767. Auerbach AD, Hilton JF, Maselli J, Pekow PS, Rothberg MB, Lindenauer PK. . 2016;67:1–12.
.
Shopforqualityorvolume?Volume,quality,andoutcomesofcoronaryartery .. 778.ClarkAM,HartlingL,VandermeerB,McAlister FA.Meta-analysis: Secondary
.
bypasssurgery.AnnInternMed2009;150:696–704. . preventionprogramsforpatientswithcoronaryarterydisease.AnnInternMed
.
768. PaganoD,KappeteinAP,Sousa-UvaM,BeyersdorfF,KlautzR,MohrF,FalkV; . 2005;143:659–72.
.
European Association for Cardio-Thoracic Surgery (EACTS) and the EACTS .. 779.CritchleyJA,CapewellS.Mortalityriskreductionassociatedwithsmokingces-
QualityImprovementProgramme.EACTSclinicalstatement:Guidanceforthe .. sation in patients with coronary heart disease: A systematic review. JAMA
.
provisionofadultcardiacsurgery.EurJCardiothoracSurg2016;50:1006–1009. . 2003;290:86–97.
.
769. HannanEL,WuC,WalfordG,KingSB,III,HolmesDR,Jr,AmbroseJA,Sharma . 780.EstruchR,RosE,Salas-SalvadoJ,CovasMI,CorellaD,ArosF,Gomez-Gracia
.
S,KatzS,ClarkLT,JonesRH.Volume-outcomerelationshipsforpercutaneous .. E,Ruiz-GutierrezV,FiolM,LapetraJ,Lamuela-RaventosRM,Serra-MajemL,
coronaryinterventionsinthestentera.Circulation2005;112:1171–1179. .. Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA,
.
770. McGrathPD,WennbergDE,DickensJDJr,SiewersAE,LucasFL,MalenkaDJ, . PREDIMED Study Investigators. Primary prevention of cardiovascular disease
.
KellettMAJr,RyanTJJr.Relationbetweenoperatorandhospitalvolumeand .. withaMediterraneandiet.NEnglJMed2013;368:1279–1290.
outcomesfollowingpercutaneouscoronaryinterventionsintheeraofthecor- .. 781.Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L,
.
onarystent.JAMA2000;284:3139–3144. . EmbersonJ,HollandLE,ReithC,BhalaN,PetoR,BarnesEH,KeechA,SimesJ,
.
771. NallamothuBK,WangY,MagidDJ,McNamaraRL,HerrinJ,BradleyEH,Bates . CollinsR.EfficacyandsafetyofmoreintensiveloweringofLDLcholesterol:A
.
ER, Pollack CV Jr, Krumholz HM; National Registry of Myocardial Infarction .. meta-analysisofdatafrom170,000participantsin26randomisedtrials.Lancet
Investigators.Relationbetweenhospitalspecializationwithprimarypercutane- .. 2010;376:1670–1681.
.
ouscoronaryinterventionandclinicaloutcomesinST-segmentelevationmyo- . 782.PatronoC,MoraisJ,BaigentC,ColletJP,FitzgeraldD,HalvorsenS,RoccaB,
.
cardial infarction: National Registry of Myocardial Infarction-4 analysis. . Siegbahn A, Storey RF, Vilahur G. Antiplatelet agents for the treatment and
.
Circulation2006;113:222–229. .. prevention of coronary atherothrombosis. J Am Coll Cardiol 2017;70:
772. SpauldingC,MoriceMC,LancelinB,ElHaddadS,LepageE,BatailleS,Tresca .. 1760–1776.
.
JP,MourancheX,FosseS,MonchiM,deVernejoulN;CARDIO-ARIFregistry . 783.Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J,
.
Investigators. Is the volume-outcome relation still an issue in the era of PCI .. ChalmersJ,RodgersA,RahimiK.Bloodpressureloweringforpreventionof
with systematic stenting? Results of the greater Paris area PCI registry. Eur .. cardiovasculardiseaseanddeath:Asystematicreviewandmeta-analysis.Lancet
.
HeartJ2006;27:1054–1060. . 2016;387:957–967.
.
773. VakiliBA, Kaplan R,Brown DL. Volume-outcome relation forphysicians and . 784.SelvinE,MarinopoulosS,BerkenblitG,RamiT,BrancatiFL,PoweNR,Golden
.
hospitalsperformingangioplastyforacutemyocardialinfarctioninNewYork .. SH.Meta-analysis:Glycosylatedhemoglobinandcardiovasculardiseaseindiabe-
state.Circulation2001;104:2171–2176. .. tesmellitus.AnnInternMed2004;141:421–431.
.
774.CantoJG,EveryNR,MagidDJ,RogersWJ,MalmgrenJA,FrederickPD,FrenchWJ, . 785.Effectofintensiveblood-glucosecontrolwithmetforminoncomplicationsin
.
TiefenbrunnAJ,MisraVK,KiefeCI,BarronHV.Thevolumeofprimaryangioplasty . overweight patients with type 2 diabetes (UKPDS 34). UK Prospective
.
procedures and survival after acute myocardial infarction. National Registry of .. DiabetesStudy(UKPDS)Group.Lancet1998;352:854–865.
.
MyocardialInfarction2Investigators.NEnglJMed2000;342:1573–1580. . 786.HarbSC,MarwickTH.Prognosticvalueofstressimagingafterrevasculariza-
.
775. XuB,RedforsB,YangY,QiaoS,WuY,ChenJ,LiuH,ChenJ,XuL,ZhaoY, . tion:Asystematicreviewofstressechocardiographyandstressnuclearimaging.
.
GuanC,GaoR,GenereuxP.Impactofoperatorexperienceandvolumeon . AmHeartJ2014;167:77–85.
Downloaded
from
https://academic.oup.com/eurheartj/article/40/2/87/5079120
by
guest
on
22
January
2026
--- Страница 97 ---
Delivering to 20+ European Countries.
To deliver the best
patient care, you
FREE CASE ANY LITTMANN® CARD IV
need the tools add code at the checkout to apply
FREECASE
to match.
SHOP NOW
™
Littmann® Cardiology IV
& Littmann® CORE Digital
Stethoscopes
LITTMANN
RATING
9/10
Keep your tools safe
with laser engraving.
LITTMANN
RATING
10+
♥☺♫★♠
FREE CASE ANY LITTMANN® CORE
add code at the checkout to apply
FREECASE
SHOP NOW
